

DEX-0257

CD

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
16 May 2002 (16.05.2002)

PCT

(10) International Publication Number  
WO 02/038606 A3

(51) International Patent Classification<sup>7</sup>: C07K 14/47, C12N 15/12, 15/10, C12Q 1/68, C07K 16/18, G01N 33/53, A61K 39/00

(74) Agents: LICATA, Jane, Massey et al.; Licata & Tyrell P.C., 66 E. Main Street, Marlton, NJ 08053 (US).

(21) International Application Number: PCT/US01/46459

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(22) International Filing Date:  
7 November 2001 (07.11.2001)

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(30) Priority Data:  
60/246,640 8 November 2000 (08.11.2000) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:  
US 60/246,640 (CIP)  
Filed on 8 November 2000 (08.11.2000)

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:  
15 May 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



A3

WO 02/038606 A3

(54) Title: COMPOSITIONS AND METHODS RELATING TO OVARY SPECIFIC GENES AND PROTEINS

(57) Abstract: The present invention relates to newly identified nucleic acids and polypeptides present in normal and neoplastic ovary cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions comprising the nucleic acids, polypeptides, antibodies, variants, derivatives, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating ovarian cancer and non-cancerous disease states in ovary tissue, identifying ovary tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered ovary tissue for treatment and research.

# INTERNATIONAL SEARCH REPORT

Internal Application No  
PCT/US 01/46459

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 7	C07K14/47	C12N15/12	C12N5/10	C12Q1/68	C07K16/18

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EMBL, EPO-Internal, SEQUENCE SEARCH, MEDLINE, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE EMBL [Online]  23 September 1998 (1998-09-23)  ADAMS, MD ET AL.: "RPCI11-43J8.TJ RPCI-11  Homo sapiens genomic clone RPCI-11-43J8,  genomic"  retrieved from EBI  Database accession no. AQ194904  XP002232022  abstract</p> <p>---</p> <p>WO 00 11014 A (ENDRESS GREGORY A ;FLORENCE  KIMBERLY A (US); HUMAN GENOME SCIENCES)  2 March 2000 (2000-03-02)  SEQ ID NO:49, 170  page 127 -page 128</p> <p>---</p> <p>-/-</p>	1-5,7,8
X		1-5,7-10

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the International search

20 February 2003

Date of mailing of the International search report

13.03.2003

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Schmitz, T

## INTERNATIONAL SEARCH REPORT

International Application No PCT/.. 01/46459
---

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE EMBL [Online] 29 June 2000 (2000-06-29) PHILLIMORE B.: "Human DNA sequence *** SEQUENCING IN PROGRESS *** from clone RP11-37015" retrieved from EBI Database accession no. AL360009 XP002217521 abstract ---	1-5
P,X	DATABASE EMBL [Online] 31 July 2001 (2001-07-31) KAUL RK ET AL.: "Homo sapiens chromosome 1 clone RP11-365016, complete sequence." retrieved from EBI Database accession no. AC092809 XP002232021 abstract ---	1-5,7,8
A	DATABASE SWALL [Online] 1 August 1998 (1998-08-01) MYLER P. ET AL.: "CAKC2" retrieved from EBI Database accession no. 060981 XP002217522 abstract ---	
A	WO 00 24755 A (Baylor College Medicine ;MATZUK MARTIN M (US); WANG PEI (US)) 4 May 2000 (2000-05-04) -----	

**INTERNATIONAL SEARCH REPORT**Int'l application No.  
PCT/US 01/46459**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  
**see FURTHER INFORMATION sheet PCT/ISA/210**
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

**see additional sheet**

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:  
**1-17 (all partially with respect to inventions 1 and 33)**
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

**Remark on Protest** The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

Invention 1: claims 1-17 (all partially)

Biosequence as defined by SEQ ID NO:1.  
Furthermore, as far as applicable, vectors, host cells, methods, antibodies, kits, vaccines, all referring to said biosequence.

Since no clear relationship between the amino acid- and nucleic acid sequences could be established, all SEQ ID NOs are regarded as individual inventions.

Invention 2: claims 1-17 (all partially)

As invention 1, but referring to SEQ ID NO:2.

⋮  
⋮

Invention 238: claims 1-17 (all partially)

As invention 1, but referring to SEQ ID NO:238.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claim 14 is directed to a diagnostic method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Although claim 16 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

**INTERNATIONAL SEARCH REPORT**

nation on patent family members

International Application No

PCT/US 01/46459

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 0011014	A 02-03-2000	AU 5583799 A		14-03-2000
		CA 2340884 A1		02-03-2000
		EP 1109821 A1		27-06-2001
		JP 2002523035 T		30-07-2002
		WO 0011014 A1		02-03-2000
		US 2001021700 A1		13-09-2001
		US 2002026040 A1		28-02-2002
-----	-----	-----	-----	-----
WO 0024755	A 04-05-2000	AU 1326200 A		15-05-2000
		EP 1124840 A1		22-08-2001
		WO 0024755 A1		04-05-2000
		US 2002042926 A1		11-04-2002
-----	-----	-----	-----	-----

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
16 May 2002 (16.05.2002)

PCT

(10) International Publication Number  
**WO 02/38606 A2**

(51) International Patent Classification<sup>7</sup>: **C07K 14/47**  
San Jose, CA 95136 (US). LIU, Chenghua [CN/US];  
1125 Rancho Way #14, San Jose, CA 95117 (US).

(21) International Application Number: PCT/US01/46459

(74) Agents: LICATA, Jane, Massey et al.; Licata & Tyrell  
P.C., 66 E. Main Street, Marlton, NJ 08053 (US).

(22) International Filing Date:  
7 November 2001 (07.11.2001)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,  
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,  
ZW.

(25) Filing Language: English

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG).

(26) Publication Language: English

**Published:**

— without international search report and to be republished  
upon receipt of that report

(30) Priority Data:  
60/246,640 8 November 2000 (08.11.2000) US

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier application:

US 60/246,640 (CIP)  
Filed on 8 November 2000 (08.11.2000)

(71) Applicant (*for all designated States except US*): DIADEXUS, INC. [US/US]; 343 Oyster Point Boulevard, South San Francisco, CA 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): SUN, Yongming [US/US]; 869 S. Winchester Boulevard, Apartment 260, San Jose, CA 95128 (US). RECIPON, Herve [FR/US]; 85 Fortuna Avenue, San Francisco, CA 94115 (US). SALCEDA, Susana [AR/US]; 4118 Crescendo Avenue,



A2

(54) Title: COMPOSITIONS AND METHODS RELATING TO OVARY SPECIFIC GENES AND PROTEINS

(57) Abstract: The present invention relates to newly identified nucleic acids and polypeptides present in normal and neoplastic ovary cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions comprising the nucleic acids, polypeptides, antibodies, variants, derivatives, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating ovarian cancer and non-cancerous disease states in ovary tissue, identifying ovary tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered ovary tissue for treatment and research.

WO 02/38606 A2

**COMPOSITIONS AND METHODS  
RELATING TO OVARY SPECIFIC GENES AND PROTEINS**

This application claims the benefit of priority from U.S. Provisional Application  
5 Serial No. 60/246,640 filed November 8, 2000, which is herein incorporated by reference  
in its entirety.

**FIELD OF THE INVENTION**

The present invention relates to newly identified nucleic acid molecules and  
10 polypeptides present in normal and neoplastic ovary cells, including fragments, variants  
and derivatives of the nucleic acids and polypeptides. The present invention also relates  
to antibodies to the polypeptides of the invention, as well as agonists and antagonists of  
the polypeptides of the invention. The invention also relates to compositions comprising  
the nucleic acids, polypeptides, antibodies, variants, derivatives, agonists and antagonists  
15 of the invention and methods for the use of these compositions. These uses include  
identifying, diagnosing, monitoring, staging, imaging and treating ovarian cancer and  
non-cancerous disease states in ovary tissue, identifying ovary tissue and monitoring and  
identifying and/or designing agonists and antagonists of polypeptides of the invention.  
The uses also include gene therapy, production of transgenic animals and cells, and  
20 production of engineered ovary tissue for treatment and research.

**BACKGROUND OF THE INVENTION**

Cancer of the ovaries is the fourth-most cause of cancer death in women in  
the United States, with more than 23,000 new cases and roughly 14,000 deaths  
predicted for the year 2001. Shridhar, V. et al., Cancer Res. 61(15):  
25 5895-904 (2001); Memarzadeh, S. & Berek, J. S., J. Reprod. Med. 46(7):  
621-29 (2001). The incidence of ovarian cancer is of serious concern  
worldwide, with an estimated 191,000 new cases predicted annually.  
Runnebaum, I. B. & Stickeler, E., J. Cancer Res. Clin. Oncol. 127(2): 73-79  
(2001). Because women with ovarian cancer are typically asymptomatic until  
30 the disease has metastasized, and because effective screening for ovarian  
cancer is not available, roughly 70% of women present with an advanced stage

-2-

of the cancer, with a five-year survival rate of ~25-30% at that stage.

Memarzadeh, S. & Berek, J. S., supra; Nunns, D. et al., *Obstet. Gynecol. Surv.* 55(12): 746-51. Conversely, women diagnosed with early stage ovarian

cancer enjoy considerably higher survival rates. Werness, B. A. &

- 5 Eltabbakh, G. H., *Int'l. J. Gynecol. Pathol.* 20(1): 48-63 (2001).

Although our understanding of the etiology of ovarian cancer is incomplete,

the results of extensive research in this area point to a combination of

age, genetics, reproductive, and dietary/environmental factors. Age is a

key risk factor in the development of ovarian cancer: while the risk for

- 10 developing ovarian cancer before the age of 30 is slim, the incidence of ovarian cancer rises linearly between ages 30 to 50, increasing at a slower rate thereafter, with the highest incidence being among septagenarian women.

Jeanne M. Schilder et al., *Hereditary Ovarian Cancer: Clinical Syndromes*

and Management, in *Ovarian Cancer* 182 (Stephen C. Rubin & Gregory P. Sutton

- 15 eds., 2d ed. 2001).

With respect to genetic factors, a family history of ovarian cancer is the most significant risk factor in the development of the disease, with that risk depending on the number of affected family members, the degree of their relationship to the woman, and which particular first degree relatives are

- 20 affected by the disease. Id. Mutations in several genes have been associated with ovarian cancer, including BRCA1 and BRCA2, both of which play a key role in the development of breast cancer, as well as hMSH2 and hMLH1, both of which are associated with hereditary non-polyposis ovary cancer. Katherine Y. Look, *Epidemiology, Etiology, and Screening of Ovarian*

- 25 *Cancer*, in *Ovarian Cancer* 169, 171-73 (Stephen C. Rubin & Gregory P. Sutton eds., 2d ed. 2001). BRCA1, located on chromosome 17, and BRCA2, located on chromosome 13, are tumor suppressor genes implicated in DNA repair; mutations in these genes are linked to roughly 10% of ovarian cancers. Id. at 171-72;

- Schilder et al., supra at 185-86. hMSH2 and hMLH1 are associated with DNA mismatch repair, and are located on chromosomes 2 and 3, respectively; it has been reported that roughly 3% of hereditary ovarian carcinomas are due to mutations in these genes. Look, supra at 173; Schilder et al., supra at

184, 188-89.

- Reproductive factors have also been associated with an increased or reduced risk of ovarian cancer. Late menopause, nulliparity, and early age at menarche have all been linked with an elevated risk of ovarian cancer.
- 5 Schilder et al., *supra* at 182. One theory hypothesizes that these factors increase the number of ovulatory cycles over the course of a woman's life, leading to "incessant ovulation," which is thought to be the primary cause of mutations to the ovarian epithelium. *Id.*; Laura J. Havrilesky & Andrew Berchuck, Molecular Alterations in Sporadic Ovarian Cancer, in *Ovarian*  
10 *Cancer* 25 (Stephen C. Rubin & Gregory P. Sutton eds., 2d ed. 2001). The mutations may be explained by the fact that ovulation results in the destruction and repair of that epithelium, necessitating increased cell division, thereby increasing the possibility that an undesired mutation will occur. *Id.* Support for this theory may be found in the fact pregnancy,  
15 lactation, and the use of oral contraceptives, all of which suppress ovulation, confer a protective effect with respect to developing ovarian cancer. *Id.*

- Among dietary/environmental factors, there would appear to be an association between high intake of animal fat or red meat and ovarian cancer, while the  
20 antioxidant Vitamin A, which prevents free radical formation and also assists in maintaining normal cellular differentiation, may offer a protective effect. Look, *supra* at 169. Reports have also associated asbestos and hydrous magnesium trisilicate (talc), the latter of which may be present in diaphragms and sanitary napkins. *Id.* at 169-70.
- 25 Current screening procedures for ovarian cancer, while of some utility, are quite limited in their diagnostic ability, a problem that is particularly acute at early stages of cancer progression when the disease is typically asymptomatic yet is most readily treated. Walter J. Burdette, *Cancer: Etiology, Diagnosis, and Treatment* 166 (1998); Memarzadeh & Berek, *supra*;  
30 Runnebaum & Stickeler, *supra*; Werness & Eltabakh, *supra*. Commonly used screening tests include bimanual rectovaginal pelvic examination, radioimmunoassay to detect the CA-125 serum tumor marker, and transvaginal

ultrasonography. Burdette, *supra* at 166.

Pelvic examination has failed to yield adequate numbers of early diagnoses, and the other methods are not sufficiently accurate. *Id.* One study reported that only 15% of patients who suffered from ovarian cancer were diagnosed

- 5 with the disease at the time of their pelvic examination. Look, *supra* at 174. Moreover, the CA-125 test is prone to giving false positives in pre-menopausal women and has been reported to be of low predictive value in post-menopausal women. *Id.* at 174-75. Although transvaginal ultrasonography is now the preferred procedure for screening for ovarian 10 cancer, it is unable to distinguish reliably between benign and malignant tumors, and also cannot locate primary peritoneal malignancies or ovarian cancer if the ovary size is normal. Schilder et al., *supra* at 194-95. While genetic testing for mutations of the BRCA1, BRCA2, hMSH2, and hMLH1 genes is now available, these tests may be too costly for some patients and 15 may also yield false negative or indeterminate results. Schilder et al., *supra* at 191-94.

The staging of ovarian cancer, which is accomplished through surgical exploration, is crucial in determining the course of treatment and management of the disease. AJCC Cancer Staging Handbook 187 (Irvin D.

- 20 Fleming et al. eds., 5th ed. 1998); Burdette, *supra* at 170; Memarzadeh & Berek, *supra*; Shridhar et al., *supra*. Staging is performed by reference to the classification system developed by the International Federation of Gynecology and Obstetrics. David H. Moore, Primary Surgical Management of Early Epithelial Ovarian Carcinoma, in Ovarian Cancer 203 (Stephen C. Rubin 25 & Gregory P. Sutton eds., 2d ed. 2001); Fleming et al. eds., *supra* at 188. Stage I ovarian cancer is characterized by tumor growth that is limited to the ovaries and is comprised of three substages. *Id.* In substage IA, tumor growth is limited to one ovary, there is no tumor on the external surface of the ovary, the ovarian capsule is intact, and no malignant cells are present 30 in ascites or peritoneal washings. *Id.* Substage IB is identical to A1, except that tumor growth is limited to both ovaries. *Id.* Substage IC refers to the presence of tumor growth limited to one or both ovaries, and

-5-

also includes one or more of the following characteristics: capsule rupture, tumor growth on the surface of one or both ovaries, and malignant cells present in ascites or peritoneal washings. Id.

- Stage II ovarian cancer refers to tumor growth involving one or both ovaries, along with pelvic extension. Id. Substage IIA involves extension and/or implants on the uterus and/or fallopian tubes, with no malignant cells in the ascites or peritoneal washings, while substage IIB involves extension into other pelvic organs and tissues, again with no malignant cells in the ascites or peritoneal washings. Id. Substage IIC involves pelvic extension as in IIA or IIB, but with malignant cells in the ascites or peritoneal washings. Id.

- Stage III ovarian cancer involves tumor growth in one or both ovaries, with peritoneal metastasis beyond the pelvis confirmed by microscope and/or metastasis in the regional lymph nodes. Id. Substage IIIA is characterized by microscopic peritoneal metastasis outside the pelvis, with substage IIIB involving macroscopic peritoneal metastasis outside the pelvis 2 cm or less in greatest dimension. Id. Substage IIIC is identical to IIIB, except that the metastasis is greater than 2 cm in greatest dimension and may include regional lymph node metastasis. Id. Lastly, Stage IV refers to the presence distant metastasis, excluding peritoneal metastasis. Id.

- While surgical staging is currently the benchmark for assessing the management and treatment of ovarian cancer, it suffers from considerable drawbacks, including the invasiveness of the procedure, the potential for complications, as well as the potential for inaccuracy. Moore, *supra* at 206-208, 213. In view of these limitations, attention has turned to developing alternative staging methodologies through understanding differential gene expression in various stages of ovarian cancer and by obtaining various biomarkers to help better assess the progression of the disease. Vartiainen, J. et al., *Int'l J. Cancer*, 95(5): 313-16 (2001); Shridhar et al. *supra*; Baekelandt, M. et al., *J. Clin. Oncol.* 18(22): 3775-81.

The treatment of ovarian cancer typically involves a multiprong attack, with

-6-

- surgical intervention serving as the foundation of treatment. Dennis S. Chi & William J. Hoskins, Primary Surgical Management of Advanced Epithelial Ovarian Cancer, in Ovarian Cancer 241 (Stephen C. Rubin & Gregory P. Sutton eds., 2d ed. 2001). For example, in the case of epithelial ovarian cancer,
- 5 which accounts for ~90% of cases of ovarian cancer, treatment typically consists of: (1) cytoreductive surgery, including total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and lymphadenectomy, followed by (2) adjuvant chemotherapy with paclitaxel and either cisplatin or carboplatin. Eltabbakh, G.H. & Awtrey, C.S., Expert Op.
- 10 Pharmacother. 2(10): 109-24. Despite a clinical response rate of 80% to the adjuvant therapy, most patients experience tumor recurrence within three years of treatment. Id. Certain patients may undergo a second cytoreductive surgery and/or second-line chemotherapy. Memarzadeh & Berek, supra.
- 15 From the foregoing, it is clear that procedures used for detecting, diagnosing, monitoring, staging, prognosticating, and preventing the recurrence of ovarian cancer are of critical importance to the outcome of the patient. Moreover, current procedures, while helpful in each of these analyses, are limited by their specificity, sensitivity, invasiveness,
- 20 and/or their cost. As such, highly specific and sensitive procedures that would operate by way of detecting novel markers in cells, tissues, or bodily fluids, with minimal invasiveness and at a reasonable cost, would be highly desirable.
- Accordingly, there is a great need for more sensitive and accurate methods
- 25 for predicting whether a person is likely to develop ovarian cancer, for diagnosing ovarian cancer, for monitoring the progression of the disease, for staging the ovarian cancer, for determining whether the ovarian cancer has metastasized, and for imaging the ovarian cancer. There is also a need for better treatment of ovarian cancer.

## SUMMARY OF THE INVENTION

The present invention solves these and other needs in the art by providing nucleic acid molecules and polypeptides as well as antibodies, agonists and antagonists, thereto that may be used to identify, diagnose, monitor, stage, image and treat ovarian cancer and

5 non-cancerous disease states in ovaries; identify and monitor ovary tissue; and identify and design agonists and antagonists of polypeptides of the invention. The invention also provides gene therapy, methods for producing transgenic animals and cells, and methods for producing engineered ovary tissue for treatment and research.

Accordingly, one object of the invention is to provide nucleic acid molecules that

10 are specific to ovary cells and/or ovary tissue. These ovary specific nucleic acids (OSNAs) may be a naturally-occurring cDNA, genomic DNA, RNA, or a fragment of one of these nucleic acids, or may be a non-naturally-occurring nucleic acid molecule. If the OSNA is genomic DNA, then the OSNA is an ovary specific gene (OSG). In a preferred embodiment, the nucleic acid molecule encodes a polypeptide that is specific to

15 ovary. In a more preferred embodiment, the nucleic acid molecule encodes a polypeptide that comprises an amino acid sequence of SEQ ID NO: 138 through 238. In another highly preferred embodiment, the nucleic acid molecule comprises a nucleic acid sequence of SEQ ID NO: 1 through 137. By nucleic acid molecule, it is also meant to be inclusive of sequences that selectively hybridize or exhibit substantial sequence

20 similarity to a nucleic acid molecule encoding an OSP, or that selectively hybridize or exhibit substantial sequence similarity to an OSNA, as well as allelic variants of a nucleic acid molecule encoding an OSP, and allelic variants of an OSNA. Nucleic acid molecules comprising a part of a nucleic acid sequence that encodes an OSP or that comprises a part of a nucleic acid sequence of an OSNA are also provided.

25 A related object of the present invention is to provide a nucleic acid molecule comprising one or more expression control sequences controlling the transcription and/or translation of all or a part of an OSNA. In a preferred embodiment, the nucleic acid molecule comprises one or more expression control sequences controlling the transcription and/or translation of a nucleic acid molecule that encodes all or a fragment

30 of an OSP.

Another object of the invention is to provide vectors and/or host cells comprising a nucleic acid molecule of the instant invention. In a preferred embodiment, the nucleic

acid molecule encodes all or a fragment of an OSP. In another preferred embodiment, the nucleic acid molecule comprises all or a part of an OSNA.

Another object of the invention is to provide methods for using the vectors and host cells comprising a nucleic acid molecule of the instant invention to recombinantly 5 produce polypeptides of the invention.

Another object of the invention is to provide a polypeptide encoded by a nucleic acid molecule of the invention. In a preferred embodiment, the polypeptide is an OSP. The polypeptide may comprise either a fragment or a full-length protein as well as a mutant protein (mutein), fusion protein, homologous protein or a polypeptide encoded by 10 an allelic variant of an OSP.

Another object of the invention is to provide an antibody that specifically binds to a polypeptide of the instant invention..

Another object of the invention is to provide agonists and antagonists of the nucleic acid molecules and polypeptides of the instant invention.

15 Another object of the invention is to provide methods for using the nucleic acid molecules to detect or amplify nucleic acid molecules that have similar or identical nucleic acid sequences compared to the nucleic acid molecules described herein. In a preferred embodiment, the invention provides methods of using the nucleic acid molecules of the invention for identifying, diagnosing, monitoring, staging, imaging and 20 treating ovarian cancer and non-cancerous disease states in ovaries. In another preferred embodiment, the invention provides methods of using the nucleic acid molecules of the invention for identifying and/or monitoring ovary tissue. The nucleic acid molecules of the instant invention may also be used in gene therapy, for producing transgenic animals and cells, and for producing engineered ovary tissue for treatment and research.

25 The polypeptides and/or antibodies of the instant invention may also be used to identify, diagnose, monitor, stage, image and treat ovarian cancer and non-cancerous disease states in ovaries. The invention provides methods of using the polypeptides of the invention to identify and/or monitor ovary tissue, and to produce engineered ovary tissue.

30 The agonists and antagonists of the instant invention may be used to treat ovarian cancer and non-cancerous disease states in ovaries and to produce engineered ovary tissue.

Yet another object of the invention is to provide a computer readable means of storing the nucleic acid and amino acid sequences of the invention. The records of the computer readable means can be accessed for reading and displaying of sequences for comparison, alignment and ordering of the sequences of the invention to other sequences.

## 5 DETAILED DESCRIPTION OF THE INVENTION

### Definitions and General Techniques

Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art. Further, unless otherwise required by context, singular 10 terms shall include pluralities and plural terms shall include the singular. Generally, nomenclatures used in connection with, and techniques of, cell and tissue culture, molecular biology, immunology, microbiology, genetics and protein and nucleic acid chemistry and hybridization described herein are those well-known and commonly used in the art. The methods and techniques of the present invention are generally performed 15 according to conventional methods well-known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. *See, e.g., Sambrook et al., Molecular Cloning: A Laboratory Manual*, 2d ed., Cold Spring Harbor Laboratory Press (1989) and Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 3d ed., Cold Spring Harbor 20 Press (2001); Ausubel et al., *Current Protocols in Molecular Biology*, Greene Publishing Associates (1992, and Supplements to 2000); Ausubel et al., *Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology – 4<sup>th</sup> Ed.*, Wiley & Sons (1999); Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press (1990); and Harlow and Lane, *Using Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press (1999); each of 25 which is incorporated herein by reference in its entirety.

Enzymatic reactions and purification techniques are performed according to manufacturer's specifications, as commonly accomplished in the art or as described herein. The nomenclatures used in connection with, and the laboratory procedures and 30 techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are those well-known and commonly used in

-10-

the art. Standard techniques are used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation, and delivery, and treatment of patients.

The following terms, unless otherwise indicated, shall be understood to have the following meanings:

- 5        A "nucleic acid molecule" of this invention refers to a polymeric form of nucleotides and includes both sense and antisense strands of RNA, cDNA, genomic DNA, and synthetic forms and mixed polymers of the above. A nucleotide refers to a ribonucleotide, deoxynucleotide or a modified form of either type of nucleotide. A "nucleic acid molecule" as used herein is synonymous with "nucleic acid" and
- 10      "polynucleotide." The term "nucleic acid molecule" usually refers to a molecule of at least 10 bases in length, unless otherwise specified. The term includes single- and double-stranded forms of DNA. In addition, a polynucleotide may include either or both naturally-occurring and modified nucleotides linked together by naturally-occurring and/or non-naturally occurring nucleotide linkages.
- 15      The nucleic acid molecules may be modified chemically or biochemically or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those of skill in the art. Such modifications include, for example, labels, methylation, substitution of one or more of the naturally occurring nucleotides with an analog, internucleotide modifications such as uncharged linkages (*e.g.*, methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), charged linkages (*e.g.*, phosphorothioates, phosphorodithioates, etc.), pendent moieties (*e.g.*, polypeptides), intercalators (*e.g.*, acridine, psoralen, etc.), chelators, alkylators, and modified linkages (*e.g.*, alpha anomeric nucleic acids, etc.) The term "nucleic acid molecule" also includes any topological conformation, including single-stranded, double-stranded, partially duplexed, triplexed, hairpinned, circular and padlocked conformations. Also included are synthetic molecules that mimic polynucleotides in their ability to bind to a designated sequence via hydrogen bonding and other chemical interactions. Such molecules are known in the art and include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule.
- 25      A "gene" is defined as a nucleic acid molecule that comprises a nucleic acid sequence that encodes a polypeptide and the expression control sequences that surround the nucleic acid sequence that encodes the polypeptide. For instance, a gene may

- comprise a promoter, one or more enhancers, a nucleic acid sequence that encodes a polypeptide, downstream regulatory sequences and, possibly, other nucleic acid sequences involved in regulation of the expression of an RNA. As is well-known in the art, eukaryotic genes usually contain both exons and introns. The term "exon" refers to a
- 5 nucleic acid sequence found in genomic DNA that is bioinformatically predicted and/or experimentally confirmed to contribute a contiguous sequence to a mature mRNA transcript. The term "intron" refers to a nucleic acid sequence found in genomic DNA that is predicted and/or confirmed to not contribute to a mature mRNA transcript, but rather to be "spliced out" during processing of the transcript.
- 10 A nucleic acid molecule or polypeptide is "derived" from a particular species if the nucleic acid molecule or polypeptide has been isolated from the particular species, or if the nucleic acid molecule or polypeptide is homologous to a nucleic acid molecule or polypeptide isolated from a particular species.
- An "isolated" or "substantially pure" nucleic acid or polynucleotide (*e.g.*, an
- 15 RNA, DNA or a mixed polymer) is one which is substantially separated from other cellular components that naturally accompany the native polynucleotide in its natural host cell, *e.g.*, ribosomes, polymerases, or genomic sequences with which it is naturally associated. The term embraces a nucleic acid or polynucleotide that (1) has been removed from its naturally occurring environment, (2) is not associated with all or a
- 20 portion of a polynucleotide in which the "isolated polynucleotide" is found in nature, (3) is operatively linked to a polynucleotide which it is not linked to in nature, (4) does not occur in nature as part of a larger sequence or (5) includes nucleotides or internucleoside bonds that are not found in nature. The term "isolated" or "substantially pure" also can be used in reference to recombinant or cloned DNA isolates, chemically synthesized
- 25 polynucleotide analogs, or polynucleotide analogs that are biologically synthesized by heterologous systems. The term "isolated nucleic acid molecule" includes nucleic acid molecules that are integrated into a host cell chromosome at a heterologous site, recombinant fusions of a native fragment to a heterologous sequence, recombinant vectors present as episomes or as integrated into a host cell chromosome.
- 30 A "part" of a nucleic acid molecule refers to a nucleic acid molecule that comprises a partial contiguous sequence of at least 10 bases of the reference nucleic acid molecule. Preferably, a part comprises at least 15 to 20 bases of a reference nucleic acid

-12-

molecule. In theory, a nucleic acid sequence of 17 nucleotides is of sufficient length to occur at random less frequently than once in the three gigabase human genome, and thus to provide a nucleic acid probe that can uniquely identify the reference sequence in a nucleic acid mixture of genomic complexity. A preferred part is one that comprises a

5 nucleic acid sequence that can encode at least 6 contiguous amino acid sequences (fragments of at least 18 nucleotides) because they are useful in directing the expression or synthesis of peptides that are useful in mapping the epitopes of the polypeptide encoded by the reference nucleic acid. *See, e.g., Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998-4002 (1984); and United States Patent Nos. 4,708,871 and 5,595,915, the*

10 disclosures of which are incorporated herein by reference in their entireties. A part may also comprise at least 25, 30, 35 or 40 nucleotides of a reference nucleic acid molecule, or at least 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400 or 500 nucleotides of a reference nucleic acid molecule. A part of a nucleic acid molecule may comprise no other nucleic acid sequences. Alternatively, a part of a nucleic acid may comprise other

15 nucleic acid sequences from other nucleic acid molecules.

The term "oligonucleotide" refers to a nucleic acid molecule generally comprising a length of 200 bases or fewer. The term often refers to single-stranded deoxyribonucleotides, but it can refer as well to single- or double-stranded ribonucleotides, RNA:DNA hybrids and double-stranded DNAs, among others.

20 Preferably, oligonucleotides are 10 to 60 bases in length and most preferably 12, 13, 14, 15, 16, 17, 18, 19 or 20 bases in length. Other preferred oligonucleotides are 25, 30, 35, 40, 45, 50, 55 or 60 bases in length. Oligonucleotides may be single-stranded, *e.g.* for use as probes or primers, or may be double-stranded, *e.g.* for use in the construction of a mutant gene. Oligonucleotides of the invention can be either sense or antisense

25 oligonucleotides. An oligonucleotide can be derivatized or modified as discussed above for nucleic acid molecules.

Oligonucleotides, such as single-stranded DNA probe oligonucleotides, often are synthesized by chemical methods, such as those implemented on automated oligonucleotide synthesizers. However, oligonucleotides can be made by a variety of

30 other methods, including *in vitro* recombinant DNA-mediated techniques and by expression of DNAs in cells and organisms. Initially, chemically synthesized DNAs typically are obtained without a 5' phosphate. The 5' ends of such oligonucleotides are

-13-

not substrates for phosphodiester bond formation by ligation reactions that employ DNA ligases typically used to form recombinant DNA molecules. Where ligation of such oligonucleotides is desired, a phosphate can be added by standard techniques, such as those that employ a kinase and ATP. The 3' end of a chemically synthesized

5 oligonucleotide generally has a free hydroxyl group and, in the presence of a ligase, such as T4 DNA ligase, readily will form a phosphodiester bond with a 5' phosphate of another polynucleotide, such as another oligonucleotide. As is well-known, this reaction can be prevented selectively, where desired, by removing the 5' phosphates of the other polynucleotide(s) prior to ligation.

10 The term "naturally-occurring nucleotide" referred to herein includes naturally- occurring deoxyribonucleotides and ribonucleotides. The term "modified nucleotides" referred to herein includes nucleotides with modified or substituted sugar groups and the like. The term "nucleotide linkages" referred to herein includes nucleotides linkages such as phosphorothioate, phosphorodithioate, phosphoroselenoate,

15 phosphorodiselenoate, phosphoroanilothioate, phosphoranylilate, phosphoroamidate, and the like. See e.g., LaPlanche *et al.* *Nucl. Acids Res.* 14:9081-9093 (1986); Stein *et al.* *Nucl. Acids Res.* 16:3209-3221 (1988); Zon *et al.* *Anti-Cancer Drug Design* 6:539-568 (1991); Zon *et al.*, in Eckstein (ed.) Oligonucleotides and Analogues: A Practical Approach, pp. 87-108, Oxford University Press (1991); United States Patent No.

20 5,151,510; Uhlmann and Peyman *Chemical Reviews* 90:543 (1990), the disclosures of which are hereby incorporated by reference.

Unless specified otherwise, the left hand end of a polynucleotide sequence in sense orientation is the 5' end and the right hand end of the sequence is the 3' end. In addition, the left hand direction of a polynucleotide sequence in sense orientation is 25 referred to as the 5' direction, while the right hand direction of the polynucleotide sequence is referred to as the 3' direction. Further, unless otherwise indicated, each nucleotide sequence is set forth herein as a sequence of deoxyribonucleotides. It is intended, however, that the given sequence be interpreted as would be appropriate to the polynucleotide composition: for example, if the isolated nucleic acid is composed of 30 RNA, the given sequence intends ribonucleotides, with uridine substituted for thymidine.

The term "allelic variant" refers to one of two or more alternative naturally- occurring forms of a gene, wherein each gene possesses a unique nucleotide sequence.

In a preferred embodiment, different alleles of a given gene have similar or identical biological properties.

The term "percent sequence identity" in the context of nucleic acid sequences refers to the residues in two sequences which are the same when aligned for maximum correspondence. The length of sequence identity comparison may be over a stretch of at least about nine nucleotides, usually at least about 20 nucleotides, more usually at least about 24 nucleotides, typically at least about 28 nucleotides, more typically at least about 32 nucleotides, and preferably at least about 36 or more nucleotides. There are a number of different algorithms known in the art which can be used to measure nucleotide sequence identity. For instance, polynucleotide sequences can be compared using FASTA, Gap or Bestfit, which are programs in Wisconsin Package Version 10.0, Genetics Computer Group (GCG), Madison, Wisconsin. FASTA, which includes, e.g., the programs FASTA2 and FASTA3, provides alignments and percent sequence identity of the regions of the best overlap between the query and search sequences (Pearson, 1990); Pearson, *Methods Enzymol.* 183: 63-98 (1990); Pearson, *Methods Mol. Biol.* 132: 185-219 (2000); Pearson, *Methods Enzymol.* 266: 227-258 (1996); Pearson, *J. Mol. Biol.* 276: 71-84 (1998); herein incorporated by reference). Unless otherwise specified, default parameters for a particular program or algorithm are used. For instance, percent sequence identity between nucleic acid sequences can be determined using FASTA with its default parameters (a word size of 6 and the NOPAM factor for the scoring matrix) or using Gap with its default parameters as provided in GCG Version 6.1, herein incorporated by reference.

A reference to a nucleic acid sequence encompasses its complement unless otherwise specified. Thus, a reference to a nucleic acid molecule having a particular sequence should be understood to encompass its complementary strand, with its complementary sequence. The complementary strand is also useful, e.g., for antisense therapy, hybridization probes and PCR primers.

In the molecular biology art, researchers use the terms "percent sequence identity", "percent sequence similarity" and "percent sequence homology" interchangeably. In this application, these terms shall have the same meaning with respect to nucleic acid sequences only.

-15-

The term "substantial similarity" or "substantial sequence similarity," when referring to a nucleic acid or fragment thereof, indicates that, when optimally aligned with appropriate nucleotide insertions or deletions with another nucleic acid (or its complementary strand), there is nucleotide sequence identity in at least about 50%, more 5 preferably 60% of the nucleotide bases, usually at least about 70%, more usually at least about 80%, preferably at least about 90%, and more preferably at least about 95-98% of the nucleotide bases, as measured by any well-known algorithm of sequence identity, such as FASTA, BLAST or Gap, as discussed above.

Alternatively, substantial similarity exists when a nucleic acid or fragment thereof 10 hybridizes to another nucleic acid, to a strand of another nucleic acid, or to the complementary strand thereof, under selective hybridization conditions. Typically, selective hybridization will occur when there is at least about 55% sequence identity, preferably at least about 65%, more preferably at least about 75%, and most preferably at least about 90% sequence identity, over a stretch of at least about 14 nucleotides, more 15 preferably at least 17 nucleotides, even more preferably at least 20, 25, 30, 35, 40, 50, 60, 70, 80, 90 or 100 nucleotides.

Nucleic acid hybridization will be affected by such conditions as salt concentration, temperature, solvents, the base composition of the hybridizing species, length of the complementary regions, and the number of nucleotide base mismatches 20 between the hybridizing nucleic acids, as will be readily appreciated by those skilled in the art. "Stringent hybridization conditions" and "stringent wash conditions" in the context of nucleic acid hybridization experiments depend upon a number of different physical parameters. The most important parameters include temperature of hybridization, base composition of the nucleic acids, salt concentration and length of the 25 nucleic acid. One having ordinary skill in the art knows how to vary these parameters to achieve a particular stringency of hybridization. In general, "stringent hybridization" is performed at about 25°C below the thermal melting point ( $T_m$ ) for the specific DNA hybrid under a particular set of conditions. "Stringent washing" is performed at temperatures about 5°C lower than the  $T_m$  for the specific DNA hybrid under a particular 30 set of conditions. The  $T_m$  is the temperature at which 50% of the target sequence hybridizes to a perfectly matched probe. See Sambrook (1989), *supra*, p. 9.51, hereby incorporated by reference.

-16-

The  $T_m$  for a particular DNA-DNA hybrid can be estimated by the formula:

$$T_m = 81.5^\circ\text{C} + 16.6 (\log_{10}[\text{Na}^+]) + 0.41 (\text{fraction G} + \text{C}) - 0.63 (\% \text{ formamide}) - (600/l)$$

where l is the length of the hybrid in base pairs.

The  $T_m$  for a particular RNA-RNA hybrid can be estimated by the formula:

- 5     $T_m = 79.8^\circ\text{C} + 18.5 (\log_{10}[\text{Na}^+]) + 0.58 (\text{fraction G} + \text{C}) + 11.8 (\text{fraction G} + \text{C})^2 - 0.35$   
    (% formamide) - (820/l).

The  $T_m$  for a particular RNA-DNA hybrid can be estimated by the formula:

$$T_m = 79.8^\circ\text{C} + 18.5(\log_{10}[\text{Na}^+]) + 0.58 (\text{fraction G} + \text{C}) + 11.8 (\text{fraction G} + \text{C})^2 - 0.50$$
  
    (% formamide) - (820/l).

- 10      In general, the  $T_m$  decreases by 1-1.5°C for each 1% of mismatch between two nucleic acid sequences. Thus, one having ordinary skill in the art can alter hybridization and/or washing conditions to obtain sequences that have higher or lower degrees of sequence identity to the target nucleic acid. For instance, to obtain hybridizing nucleic acids that contain up to 10% mismatch from the target nucleic acid sequence, 10-15°C  
15 would be subtracted from the calculated  $T_m$  of a perfectly matched hybrid, and then the hybridization and washing temperatures adjusted accordingly. Probe sequences may also hybridize specifically to duplex DNA under certain conditions to form triplex or other higher order DNA complexes. The preparation of such probes and suitable hybridization conditions are well-known in the art.

- 20      An example of stringent hybridization conditions for hybridization of complementary nucleic acid sequences having more than 100 complementary residues on a filter in a Southern or Northern blot or for screening a library is 50% formamide/6X SSC at 42°C for at least ten hours and preferably overnight (approximately 16 hours). Another example of stringent hybridization conditions is 6X SSC at 68°C without  
25 formamide for at least ten hours and preferably overnight. An example of moderate stringency hybridization conditions is 6X SSC at 55°C without formamide for at least ten hours and preferably overnight. An example of low stringency hybridization conditions for hybridization of complementary nucleic acid sequences having more than 100 complementary residues on a filter in a Southern or Northern blot or for screening a  
30 library is 6X SSC at 42°C for at least ten hours. Hybridization conditions to identify nucleic acid sequences that are similar but not identical can be identified by experimentally changing the hybridization temperature from 68°C to 42°C while keeping

the salt concentration constant (6X SSC), or keeping the hybridization temperature and salt concentration constant (e.g. 42°C and 6X SSC) and varying the formamide concentration from 50% to 0%. Hybridization buffers may also include blocking agents to lower background. These agents are well-known in the art. *See Sambrook et al.*

- 5 (1989), *supra*, pages 8.46 and 9.46-9.58, herein incorporated by reference. *See also* Ausubel (1992), *supra*, Ausubel (1999), *supra*, and Sambrook (2001), *supra*.

Wash conditions also can be altered to change stringency conditions. An example of stringent wash conditions is a 0.2x SSC wash at 65°C for 15 minutes (*see Sambrook* (1989), *supra*, for SSC buffer). Often the high stringency wash is preceded by a low  
10 stringency wash to remove excess probe. An exemplary medium stringency wash for duplex DNA of more than 100 base pairs is 1x SSC at 45°C for 15 minutes. An exemplary low stringency wash for such a duplex is 4x SSC at 40°C for 15 minutes. In general, signal-to-noise ratio of 2x or higher than that observed for an unrelated probe in the particular hybridization assay indicates detection of a specific hybridization.

15 As defined herein, nucleic acid molecules that do not hybridize to each other under stringent conditions are still substantially similar to one another if they encode polypeptides that are substantially identical to each other. This occurs, for example, when a nucleic acid molecule is created synthetically or recombinantly using high codon degeneracy as permitted by the redundancy of the genetic code.

20 Hybridization conditions for nucleic acid molecules that are shorter than 100 nucleotides in length (e.g., for oligonucleotide probes) may be calculated by the formula:  
 $T_m = 81.5^\circ\text{C} + 16.6(\log_{10}[\text{Na}^+]) + 0.41(\text{fraction G+C}) - (600/N)$ ,  
wherein N is change length and the  $[\text{Na}^+]$  is 1 M or less. *See Sambrook* (1989), *supra*, p. 11.46. For hybridization of probes shorter than 100 nucleotides, hybridization is usually  
25 performed under stringent conditions (5-10°C below the  $T_m$ ) using high concentrations (0.1-1.0 pmol/ml) of probe. *Id.* at p. 11.45. Determination of hybridization using mismatched probes, pools of degenerate probes or "guessmers," as well as hybridization solutions and methods for empirically determining hybridization conditions are well-known in the art. *See, e.g.*, Ausubel (1999), *supra*; Sambrook (1989), *supra*, pp. 11.45-  
30 11.57.

The term "digestion" or "digestion of DNA" refers to catalytic cleavage of the DNA with a restriction enzyme that acts only at certain sequences in the DNA. The

- various restriction enzymes referred to herein are commercially available and their reaction conditions, cofactors and other requirements for use are known and routine to the skilled artisan. For analytical purposes, typically, 1 µg of plasmid or DNA fragment is digested with about 2 units of enzyme in about 20 µl of reaction buffer. For the
- 5 purpose of isolating DNA fragments for plasmid construction, typically 5 to 50 µg of DNA are digested with 20 to 250 units of enzyme in proportionately larger volumes. Appropriate buffers and substrate amounts for particular restriction enzymes are described in standard laboratory manuals, such as those referenced below, and they are specified by commercial suppliers. Incubation times of about 1 hour at 37°C are
- 10 ordinarily used, but conditions may vary in accordance with standard procedures, the supplier's instructions and the particulars of the reaction. After digestion, reactions may be analyzed, and fragments may be purified by electrophoresis through an agarose or polyacrylamide gel, using well-known methods that are routine for those skilled in the art.
- 15 The term "ligation" refers to the process of forming phosphodiester bonds between two or more polynucleotides, which most often are double-stranded DNAs. Techniques for ligation are well-known to the art and protocols for ligation are described in standard laboratory manuals and references, such as, e.g., Sambrook (1989), *supra*.
- Genome-derived "single exon probes," are probes that comprise at least part of an
- 20 exon ("reference exon") and can hybridize detectably under high stringency conditions to transcript-derived nucleic acids that include the reference exon but do not hybridize detectably under high stringency conditions to nucleic acids that lack the reference exon. Single exon probes typically further comprise, contiguous to a first end of the exon portion, a first intronic and/or intergenic sequence that is identically contiguous to the
- 25 exon in the genome, and may contain a second intronic and/or intergenic sequence that is identically contiguous to the exon in the genome. The minimum length of genome-derived single exon probes is defined by the requirement that the exonic portion be of sufficient length to hybridize under high stringency conditions to transcript-derived nucleic acids, as discussed above. The maximum length of genome-derived single exon
- 30 probes is defined by the requirement that the probes contain portions of no more than one exon. The single exon probes may contain priming sequences not found in contiguity

with the rest of the probe sequence in the genome, which priming sequences are useful for PCR and other amplification-based technologies.

- The term "microarray" or "nucleic acid microarray" refers to a substrate-bound collection of plural nucleic acids, hybridization to each of the plurality of bound nucleic acids being separately detectable. The substrate can be solid or porous, planar or non-planar, unitary or distributed. Microarrays or nucleic acid microarrays include all the devices so called in Schena (ed.), DNA Microarrays: A Practical Approach (Practical Approach Series), Oxford University Press (1999); *Nature Genet.* 21(1)(suppl.):1 - 60 (1999); Schena (ed.), Microarray Biochip: Tools and Technology, Eaton Publishing Company/BioTechniques Books Division (2000). These microarrays include substrate-bound collections of plural nucleic acids in which the plurality of nucleic acids are disposed on a plurality of beads, rather than on a unitary planar substrate, as is described, *inter alia*, in Brenner *et al.*, *Proc. Natl. Acad. Sci. USA* 97(4):1665-1670 (2000).

- The term "mutated" when applied to nucleic acid molecules means that nucleotides in the nucleic acid sequence of the nucleic acid molecule may be inserted, deleted or changed compared to a reference nucleic acid sequence. A single alteration may be made at a locus (a point mutation) or multiple nucleotides may be inserted, deleted or changed at a single locus. In addition, one or more alterations may be made at any number of loci within a nucleic acid sequence. In a preferred embodiment, the nucleic acid molecule comprises the wild type nucleic acid sequence encoding an OSP or is an OSNA. The nucleic acid molecule may be mutated by any method known in the art including those mutagenesis techniques described *infra*.

- The term "error-prone PCR" refers to a process for performing PCR under conditions where the copying fidelity of the DNA polymerase is low, such that a high rate of point mutations is obtained along the entire length of the PCR product. *See, e.g.*, Leung *et al.*, *Technique* 1: 11-15 (1989) and Caldwell *et al.*, *PCR Methods Applic.* 2: 28-33 (1992).

- The term "oligonucleotide-directed mutagenesis" refers to a process which enables the generation of site-specific mutations in any cloned DNA segment of interest. *See, e.g.*, Reidhaar-Olson *et al.*, *Science* 241: 53-57 (1988).

The term "assembly PCR" refers to a process which involves the assembly of a PCR product from a mixture of small DNA fragments. A large number of different PCR

-20-

reactions occur in parallel in the same vial, with the products of one reaction priming the products of another reaction.

- The term “sexual PCR mutagenesis” or “DNA shuffling” refers to a method of error-prone PCR coupled with forced homologous recombination between DNA molecules of different but highly related DNA sequence *in vitro*, caused by random fragmentation of the DNA molecule based on sequence similarity, followed by fixation of the crossover by primer extension in an error-prone PCR reaction. *See, e.g., Stemmer, Proc. Natl. Acad. Sci. U.S.A. 91: 10747-10751 (1994).* DNA shuffling can be carried out between several related genes (“Family shuffling”).
- 10        The term “*in vivo* mutagenesis” refers to a process of generating random mutations in any cloned DNA of interest which involves the propagation of the DNA in a strain of bacteria such as *E. coli* that carries mutations in one or more of the DNA repair pathways. These “mutator” strains have a higher random mutation rate than that of a wild-type parent. Propagating the DNA in a mutator strain will eventually generate
- 15        random mutations within the DNA.
- The term “cassette mutagenesis” refers to any process for replacing a small region of a double-stranded DNA molecule with a synthetic oligonucleotide “cassette” that differs from the native sequence. The oligonucleotide often contains completely and/or partially randomized native sequence.
- 20        The term “recursive ensemble mutagenesis” refers to an algorithm for protein engineering (protein mutagenesis) developed to produce diverse populations of phenotypically related mutants whose members differ in amino acid sequence. This method uses a feedback mechanism to control successive rounds of combinatorial cassette mutagenesis. *See, e.g., Arkin et al., Proc. Natl. Acad. Sci. U.S.A. 89: 7811-7815 (1992).*
- The term “exponential ensemble mutagenesis” refers to a process for generating combinatorial libraries with a high percentage of unique and functional mutants, wherein small groups of residues are randomized in parallel to identify, at each altered position, amino acids which lead to functional proteins. *See, e.g., Delegrave et al., Biotechnology 30 Research 11: 1548-1552 (1993); Arnold, Current Opinion in Biotechnology 4: 450-455 (1993).* Each of the references mentioned above are hereby incorporated by reference in its entirety.

"Operatively linked" expression control sequences refers to a linkage in which the expression control sequence is contiguous with the gene of interest to control the gene of interest, as well as expression control sequences that act in *trans* or at a distance to control the gene of interest.

- 5       The term "expression control sequence" as used herein refers to polynucleotide sequences which are necessary to affect the expression of coding sequences to which they are operatively linked. Expression control sequences are sequences which control the transcription, post-transcriptional events and translation of nucleic acid sequences. Expression control sequences include appropriate transcription initiation, termination,  
10      promoter and enhancer sequences; efficient RNA processing signals such as splicing and polyadenylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (*e.g.*, ribosome binding sites); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion. The nature of such control sequences differs depending upon the host organism; in prokaryotes, such  
15      control sequences generally include the promoter, ribosomal binding site, and transcription termination sequence. The term "control sequences" is intended to include, at a minimum, all components whose presence is essential for expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences.
- 20       The term "vector," as used herein, is intended to refer to a nucleic acid molecule capable of transporting another nucleic acid to which it has been linked. One type of vector is a "plasmid", which refers to a circular double-stranded DNA loop into which additional DNA segments may be ligated. Other vectors include cosmids, bacterial artificial chromosomes (BAC) and yeast artificial chromosomes (YAC). Another type of  
25      vector is a viral vector, wherein additional DNA segments may be ligated into the viral genome. Viral vectors that infect bacterial cells are referred to as bacteriophages. Certain vectors are capable of autonomous replication in a host cell into which they are introduced (*e.g.*, bacterial vectors having a bacterial origin of replication). Other vectors can be integrated into the genome of a host cell upon introduction into the host cell, and  
30      thereby are replicated along with the host genome. Moreover, certain vectors are capable of directing the expression of genes to which they are operatively linked. Such vectors are referred to herein as "recombinant expression vectors" (or simply, "expression

vectors"). In general, expression vectors of utility in recombinant DNA techniques are often in the form of plasmids. In the present specification, "plasmid" and "vector" may be used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include other forms of expression vectors that 5 serve equivalent functions.

The term "recombinant host cell" (or simply "host cell"), as used herein, is intended to refer to a cell into which an expression vector has been introduced. It should be understood that such terms are intended to refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding 10 generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term "host cell" as used herein.

As used herein, the phrase "open reading frame" and the equivalent acronym "ORF" refer to that portion of a transcript-derived nucleic acid that can be translated in 15 its entirety into a sequence of contiguous amino acids. As so defined, an ORF has length, measured in nucleotides, exactly divisible by 3. As so defined, an ORF need not encode the entirety of a natural protein.

As used herein, the phrase "ORF-encoded peptide" refers to the predicted or actual translation of an ORF.

20 As used herein, the phrase "degenerate variant" of a reference nucleic acid sequence intends all nucleic acid sequences that can be directly translated, using the standard genetic code, to provide an amino acid sequence identical to that translated from the reference nucleic acid sequence.

The term "polypeptide" encompasses both naturally-occurring and non-naturally- 25 occurring proteins and polypeptides, polypeptide fragments and polypeptide mutants, derivatives and analogs. A polypeptide may be monomeric or polymeric. Further, a polypeptide may comprise a number of different modules within a single polypeptide each of which has one or more distinct activities. A preferred polypeptide in accordance with the invention comprises an OSP encoded by a nucleic acid molecule of the instant 30 invention, as well as a fragment, mutant, analog and derivative thereof.

The term "isolated protein" or "isolated polypeptide" is a protein or polypeptide that by virtue of its origin or source of derivation (1) is not associated with naturally

-23-

- associated components that accompany it in its native state, (2) is free of other proteins from the same species (3) is expressed by a cell from a different species, or (4) does not occur in nature. Thus, a polypeptide that is chemically synthesized or synthesized in a cellular system different from the cell from which it naturally originates will be
- 5    "isolated" from its naturally associated components. A polypeptide or protein may also be rendered substantially free of naturally associated components by isolation, using protein purification techniques well-known in the art.

A protein or polypeptide is "substantially pure," "substantially homogeneous" or "substantially purified" when at least about 60% to 75% of a sample exhibits a single

10   species of polypeptide. The polypeptide or protein may be monomeric or multimeric. A substantially pure polypeptide or protein will typically comprise about 50%, 60%, 70%, 80% or 90% W/W of a protein sample, more usually about 95%, and preferably will be over 99% pure. Protein purity or homogeneity may be indicated by a number of means well-known in the art, such as polyacrylamide gel electrophoresis of a protein sample,

15   followed by visualizing a single polypeptide band upon staining the gel with a stain well-known in the art. For certain purposes, higher resolution may be provided by using HPLC or other means well-known in the art for purification.

The term "polypeptide fragment" as used herein refers to a polypeptide of the instant invention that has an amino-terminal and/or carboxy-terminal deletion compared

20   to a full-length polypeptide. In a preferred embodiment, the polypeptide fragment is a contiguous sequence in which the amino acid sequence of the fragment is identical to the corresponding positions in the naturally-occurring sequence. Fragments typically are at least 5, 6, 7, 8, 9 or 10 amino acids long, preferably at least 12, 14, 16 or 18 amino acids long, more preferably at least 20 amino acids long, more preferably at least 25, 30, 35, 40

25   or 45, amino acids, even more preferably at least 50 or 60 amino acids long, and even more preferably at least 70 amino acids long.

A "derivative" refers to polypeptides or fragments thereof that are substantially similar in primary structural sequence but which include, e.g., *in vivo* or *in vitro* chemical and biochemical modifications that are not found in the native polypeptide. Such

30   modifications include, for example, acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid

-24-

- derivative, covalent attachment of phosphotidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cystine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation,
- 5    proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. Other modification include, *e.g.*, labeling with radionuclides, and various enzymatic modifications, as will be readily appreciated by those skilled in the art. A variety of methods for labeling polypeptides and of
- 10    substituents or labels useful for such purposes are well-known in the art, and include radioactive isotopes such as  $^{125}\text{I}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ , and  $^3\text{H}$ , ligands which bind to labeled antiligands (*e.g.*, antibodies), fluorophores, chemiluminescent agents, enzymes, and antiligands which can serve as specific binding pair members for a labeled ligand. The choice of label depends on the sensitivity required, ease of conjugation with the primer,
- 15    stability requirements, and available instrumentation. Methods for labeling polypeptides are well-known in the art. *See Ausubel (1992), supra; Ausubel (1999), supra, herein incorporated by reference.*

The term “fusion protein” refers to polypeptides of the instant invention comprising polypeptides or fragments coupled to heterologous amino acid sequences.

- 20    Fusion proteins are useful because they can be constructed to contain two or more desired functional elements from two or more different proteins. A fusion protein comprises at least 10 contiguous amino acids from a polypeptide of interest, more preferably at least 20 or 30 amino acids, even more preferably at least 40, 50 or 60 amino acids, yet more preferably at least 75, 100 or 125 amino acids. Fusion proteins can be
- 25    produced recombinantly by constructing a nucleic acid sequence which encodes the polypeptide or a fragment thereof in frame with a nucleic acid sequence encoding a different protein or peptide and then expressing the fusion protein. Alternatively, a fusion protein can be produced chemically by crosslinking the polypeptide or a fragment thereof to another protein.

- 30    The term “analog” refers to both polypeptide analogs and non-peptide analogs. The term “polypeptide analog” as used herein refers to a polypeptide of the instant invention that is comprised of a segment of at least 25 amino acids that has substantial

- identity to a portion of an amino acid sequence but which contains non-natural amino acids or non-natural inter-residue bonds. In a preferred embodiment, the analog has the same or similar biological activity as the native polypeptide. Typically, polypeptide analogs comprise a conservative amino acid substitution (or insertion or deletion) with respect to the naturally-occurring sequence. Analogs typically are at least 20 amino acids long, preferably at least 50 amino acids long or longer, and can often be as long as a full-length naturally-occurring polypeptide.

The term "non-peptide analog" refers to a compound with properties that are analogous to those of a reference polypeptide of the instant invention. A non-peptide compound may also be termed a "peptide mimetic" or a "peptidomimetic." Such compounds are often developed with the aid of computerized molecular modeling. Peptide mimetics that are structurally similar to useful peptides may be used to produce an equivalent effect. Generally, peptidomimetics are structurally similar to a paradigm polypeptide (*i.e.*, a polypeptide that has a desired biochemical property or pharmacological activity), but have one or more peptide linkages optionally replaced by a linkage selected from the group consisting of: --CH<sub>2</sub>NH--, --CH<sub>2</sub>S--, --CH<sub>2</sub>-CH<sub>2</sub>--, --CH=CH--(cis and trans), --COCH<sub>2</sub>--, --CH(OH)CH<sub>2</sub>--, and --CH<sub>2</sub>SO--, by methods well-known in the art. Systematic substitution of one or more amino acids of a consensus sequence with a D-amino acid of the same type (*e.g.*, D-lysine in place of L-lysine) may also be used to generate more stable peptides. In addition, constrained peptides comprising a consensus sequence or a substantially identical consensus sequence variation may be generated by methods known in the art (Rizo *et al.*, *Ann. Rev. Biochem.* 61:387-418 (1992), incorporated herein by reference). For example, one may add internal cysteine residues capable of forming intramolecular disulfide bridges which cyclize the peptide.

A "polypeptide mutant" or "mutein" refers to a polypeptide of the instant invention whose sequence contains substitutions, insertions or deletions of one or more amino acids compared to the amino acid sequence of a native or wild-type protein. A mutein may have one or more amino acid point substitutions, in which a single amino acid at a position has been changed to another amino acid, one or more insertions and/or deletions, in which one or more amino acids are inserted or deleted, respectively, in the sequence of the naturally-occurring protein, and/or truncations of the amino acid

- sequence at either or both the amino or carboxy termini. Further, a mutein may have the same or different biological activity as the naturally-occurring protein. For instance, a mutein may have an increased or decreased biological activity. A mutein has at least 50% sequence similarity to the wild type protein, preferred is 60% sequence similarity,
- 5 more preferred is 70% sequence similarity. Even more preferred are muteins having 80%, 85% or 90% sequence similarity to the wild type protein. In an even more preferred embodiment, a mutein exhibits 95% sequence identity, even more preferably 97%, even more preferably 98% and even more preferably 99%. Sequence similarity may be measured by any common sequence analysis algorithm, such as Gap or Bestfit.
- 10 Preferred amino acid substitutions are those which: (1) reduce susceptibility to proteolysis, (2) reduce susceptibility to oxidation, (3) alter binding affinity for forming protein complexes, (4) alter binding affinity or enzymatic activity, and (5) confer or modify other physicochemical or functional properties of such analogs. For example, single or multiple amino acid substitutions (preferably conservative amino acid
- 15 substitutions) may be made in the naturally-occurring sequence (preferably in the portion of the polypeptide outside the domain(s) forming intermolecular contacts. In a preferred embodiment, the amino acid substitutions are moderately conservative substitutions or conservative substitutions. In a more preferred embodiment, the amino acid substitutions are conservative substitutions. A conservative amino acid substitution should not
- 20 substantially change the structural characteristics of the parent sequence (e.g., a replacement amino acid should not tend to disrupt a helix that occurs in the parent sequence, or disrupt other types of secondary structure that characterizes the parent sequence). Examples of art-recognized polypeptide secondary and tertiary structures are described in Creighton (ed.), Proteins, Structures and Molecular Principles, W. H.
- 25 Freeman and Company (1984); Branden *et al.* (ed.), Introduction to Protein Structure, Garland Publishing (1991); Thornton *et al.*, *Nature* 354:105-106 (1991), each of which are incorporated herein by reference.

As used herein, the twenty conventional amino acids and their abbreviations follow conventional usage. See Golub *et al.* (eds.), Immunology - A Synthesis 2<sup>nd</sup> Ed.,

30 Sinauer Associates (1991), which is incorporated herein by reference. Stereoisomers (e.g., D-amino acids) of the twenty conventional amino acids, unnatural amino acids such as - , -disubstituted amino acids, N-alkyl amino acids, and other unconventional amino

acids may also be suitable components for polypeptides of the present invention.

Examples of unconventional amino acids include: 4-hydroxyproline,  $\gamma$ -carboxyglutamate, -N,N,N-trimethyllysine, -N-acetyllysine, O-phosphoserine, N-acetylserine,

N-formylmethionine, 3-methylhistidine, 5-hydroxylysine, s-N-methylarginine, and other

- 5 similar amino acids and imino acids (e.g., 4-hydroxyproline). In the polypeptide notation used herein, the lefthand direction is the amino terminal direction and the right hand direction is the carboxy-terminal direction, in accordance with standard usage and convention.

A protein has "homology" or is "homologous" to a protein from another organism

- 10 if the encoded amino acid sequence of the protein has a similar sequence to the encoded amino acid sequence of a protein of a different organism and has a similar biological activity or function. Alternatively, a protein may have homology or be homologous to another protein if the two proteins have similar amino acid sequences and have similar biological activities or functions. Although two proteins are said to be "homologous,"  
15 this does not imply that there is necessarily an evolutionary relationship between the proteins. Instead, the term "homologous" is defined to mean that the two proteins have similar amino acid sequences and similar biological activities or functions. In a preferred embodiment, a homologous protein is one that exhibits 50% sequence similarity to the wild type protein, preferred is 60% sequence similarity, more preferred is 70% sequence  
20 similarity. Even more preferred are homologous proteins that exhibit 80%, 85% or 90% sequence similarity to the wild type protein. In a yet more preferred embodiment, a homologous protein exhibits 95%, 97%, 98% or 99% sequence similarity.

- When "sequence similarity" is used in reference to proteins or peptides, it is recognized that residue positions that are not identical often differ by conservative amino  
25 acid substitutions. In a preferred embodiment, a polypeptide that has "sequence similarity" comprises conservative or moderately conservative amino acid substitutions. A "conservative amino acid substitution" is one in which an amino acid residue is substituted by another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). In general, a conservative amino  
30 acid substitution will not substantially change the functional properties of a protein. In cases where two or more amino acid sequences differ from each other by conservative substitutions, the percent sequence identity or degree of similarity may be adjusted

upwards to correct for the conservative nature of the substitution. Means for making this adjustment are well-known to those of skill in the art. *See, e.g., Pearson, Methods Mol. Biol.* 24: 307-31 (1994), herein incorporated by reference.

For instance, the following six groups each contain amino acids that are  
5 conservative substitutions for one another:

- 1) Serine (S), Threonine (T);
- 2) Aspartic Acid (D), Glutamic Acid (E);
- 3) Asparagine (N), Glutamine (Q);
- 4) Arginine (R), Lysine (K);
- 10 5) Isoleucine (I), Leucine (L), Methionine (M), Alanine (A), Valine (V), and
- 6) Phenylalanine (F), Tyrosine (Y), Tryptophan (W).

Alternatively, a conservative replacement is any change having a positive value in the PAM250 log-likelihood matrix disclosed in Gonnet *et al.*, *Science* 256: 1443-45 (1992), herein incorporated by reference. A "moderately conservative" replacement is  
15 any change having a nonnegative value in the PAM250 log-likelihood matrix.

Sequence similarity for polypeptides, which is also referred to as sequence identity, is typically measured using sequence analysis software. Protein analysis software matches similar sequences using measures of similarity assigned to various substitutions, deletions and other modifications, including conservative amino acid  
20 substitutions. For instance, GCG contains programs such as "Gap" and "Bestfit" which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of organisms or between a wild type protein and a mutein thereof. *See, e.g.,* GCG Version 6.1. Other programs include FASTA, discussed *supra*.

25 A preferred algorithm when comparing a sequence of the invention to a database containing a large number of sequences from different organisms is the computer program BLAST, especially blastp or tblastn. *See, e.g., Altschul *et al.*, J. Mol. Biol.* 215: 403-410 (1990); Altschul *et al.*, *Nucleic Acids Res.* 25:3389-402 (1997); herein incorporated by reference. Preferred parameters for blastp are:

- 30 Expectation value: 10 (default)  
Filter: seg (default)  
Cost to open a gap: 11 (default)

-29-

Cost to extend a gap: 1 (default)

Max. alignments: 100 (default)

Word size: 11 (default)

No. of descriptions: 100 (default)

5 Penalty Matrix: BLOSUM62

The length of polypeptide sequences compared for homology will generally be at least about 16 amino acid residues, usually at least about 20 residues, more usually at least about 24 residues, typically at least about 28 residues, and preferably more than about 35 residues. When searching a database containing sequences from a large number 10 of different organisms, it is preferable to compare amino acid sequences.

Database searching using amino acid sequences can be measured by algorithms other than blastp are known in the art. For instance, polypeptide sequences can be compared using FASTA, a program in GCG Version 6.1. FASTA (*e.g.*, FASTA2 and FASTA3) provides alignments and percent sequence identity of the regions of the best 15 overlap between the query and search sequences (Pearson (1990), *supra*; Pearson (2000), *supra*. For example, percent sequence identity between amino acid sequences can be determined using FASTA with its default or recommended parameters (a word size of 2 and the PAM250 scoring matrix), as provided in GCG Version 6.1, herein incorporated by reference.

20 An "antibody" refers to an intact immunoglobulin, or to an antigen-binding portion thereof that competes with the intact antibody for specific binding to a molecular species, *e.g.*, a polypeptide of the instant invention. Antigen-binding portions may be produced by recombinant DNA techniques or by enzymatic or chemical cleavage of intact antibodies. Antigen-binding portions include, *inter alia*, Fab, Fab', F(ab')<sub>2</sub>, Fv, 25 dAb, and complementarity determining region (CDR) fragments, single-chain antibodies (scFv), chimeric antibodies, diabodies and polypeptides that contain at least a portion of an immunoglobulin that is sufficient to confer specific antigen binding to the polypeptide. An Fab fragment is a monovalent fragment consisting of the VL, VH, CL and CH1 domains; an F(ab')<sub>2</sub> fragment is a bivalent fragment comprising two Fab 30 fragments linked by a disulfide bridge at the hinge region; an Fd fragment consists of the VH and CH1 domains; an Fv fragment consists of the VL and VH domains of a single

-30-

arm of an antibody; and a dAb fragment consists of a VH domain. *See, e.g., Ward et al., Nature* 341: 544-546 (1989).

By "bind specifically" and "specific binding" is here intended the ability of the antibody to bind to a first molecular species in preference to binding to other molecular species with which the antibody and first molecular species are admixed. An antibody is said specifically to "recognize" a first molecular species when it can bind specifically to that first molecular species.

A single-chain antibody (scFv) is an antibody in which a VL and VH region are paired to form a monovalent molecule via a synthetic linker that enables them to be made as a single protein chain. *See, e.g., Bird et al., Science* 242: 423-426 (1988); Huston et al., *Proc. Natl. Acad. Sci. USA* 85: 5879-5883 (1988). Diabodies are bivalent, bispecific antibodies in which VH and VL domains are expressed on a single polypeptide chain, but using a linker that is too short to allow for pairing between the two domains on the same chain, thereby forcing the domains to pair with complementary domains of another chain and creating two antigen binding sites. *See e.g., Holliger et al., Proc. Natl. Acad. Sci. USA* 90: 6444-6448 (1993); Poljak et al., *Structure* 2: 1121-1123 (1994). One or more CDRs may be incorporated into a molecule either covalently or noncovalently to make it an immunoadhesin. An immunoadhesin may incorporate the CDR(s) as part of a larger polypeptide chain, may covalently link the CDR(s) to another polypeptide chain, or may incorporate the CDR(s) noncovalently. The CDRs permit the immunoadhesin to specifically bind to a particular antigen of interest. A chimeric antibody is an antibody that contains one or more regions from one antibody and one or more regions from one or more other antibodies.

An antibody may have one or more binding sites. If there is more than one binding site, the binding sites may be identical to one another or may be different. For instance, a naturally-occurring immunoglobulin has two identical binding sites, a single-chain antibody or Fab fragment has one binding site, while a "bispecific" or "bifunctional" antibody has two different binding sites.

An "isolated antibody" is an antibody that (1) is not associated with naturally-associated components, including other naturally-associated antibodies, that accompany it in its native state, (2) is free of other proteins from the same species, (3) is expressed by a cell from a different species, or (4) does not occur in nature. It is known that

purified proteins, including purified antibodies, may be stabilized with non-naturally-associated components. The non-naturally-associated component may be a protein, such as albumin (*e.g.*, BSA) or a chemical such as polyethylene glycol (PEG).

A "neutralizing antibody" or "an inhibitory antibody" is an antibody that inhibits 5 the activity of a polypeptide or blocks the binding of a polypeptide to a ligand that normally binds to it. An "activating antibody" is an antibody that increases the activity of a polypeptide.

The term "epitope" includes any protein determinant capable of specifically binding to an immunoglobulin or T-cell receptor. Epitopic determinants usually consist 10 of chemically active surface groupings of molecules such as amino acids or sugar side chains and usually have specific three-dimensional structural characteristics, as well as specific charge characteristics. An antibody is said to specifically bind an antigen when the dissociation constant is less than 1  $\mu$ M, preferably less than 100 nM and most preferably less than 10 nM.

15 The term "patient" as used herein includes human and veterinary subjects.

Throughout this specification and claims, the word "comprise," or variations such as "comprises" or "comprising," will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

20 The term "ovary specific" refers to a nucleic acid molecule or polypeptide that is expressed predominantly in the ovary as compared to other tissues in the body. In a preferred embodiment, a "ovary specific" nucleic acid molecule or polypeptide is expressed at a level that is 5-fold higher than any other tissue in the body. In a more preferred embodiment, the "ovary specific" nucleic acid molecule or polypeptide is

25 expressed at a level that is 10-fold higher than any other tissue in the body, more preferably at least 15-fold, 20-fold, 25-fold, 50-fold or 100-fold higher than any other tissue in the body. Nucleic acid molecule levels may be measured by nucleic acid hybridization, such as Northern blot hybridization, or quantitative PCR. Polypeptide levels may be measured by any method known to accurately quantitate protein levels,

30 such as Western blot analysis.

Nucleic Acid Molecules, Regulatory Sequences, Vectors, Host Cells and Recombinant Methods of Making Polypeptides

*Nucleic Acid Molecules*

- 5        One aspect of the invention provides isolated nucleic acid molecules that are specific to the ovary or to ovary cells or tissue or that are derived from such nucleic acid molecules. These isolated ovary specific nucleic acids (OSNAs) may comprise a cDNA, a genomic DNA, RNA, or a fragment of one of these nucleic acids, or may be a non-naturally-occurring nucleic acid molecule. In a preferred embodiment, the nucleic acid  
10      molecule encodes a polypeptide that is specific to ovary, an ovary-specific polypeptide (OSP). In a more preferred embodiment, the nucleic acid molecule encodes a polypeptide that comprises an amino acid sequence of SEQ ID NO: 138 through 238. In another highly preferred embodiment, the nucleic acid molecule comprises a nucleic acid sequence of SEQ ID NO: 1 through 137.
- 15       AN OSNA may be derived from a human or from another animal. In a preferred embodiment, the OSNA is derived from a human or other mammal. In a more preferred embodiment, the OSNA is derived from a human or other primate. In an even more preferred embodiment, the OSNA is derived from a human.
- By “nucleic acid molecule” for purposes of the present invention, it is also meant  
20      to be inclusive of nucleic acid sequences that selectively hybridize to a nucleic acid molecule encoding an OSNA or a complement thereof. The hybridizing nucleic acid molecule may or may not encode a polypeptide or may not encode an OSP. However, in a preferred embodiment, the hybridizing nucleic acid molecule encodes an OSP. In a more preferred embodiment, the invention provides a nucleic acid molecule that  
25      selectively hybridizes to a nucleic acid molecule that encodes a polypeptide comprising an amino acid sequence of SEQ ID NO: 138 through 238. In an even more preferred embodiment, the invention provides a nucleic acid molecule that selectively hybridizes to a nucleic acid molecule comprising the nucleic acid sequence of SEQ ID NO: 1 through 137.
- 30       In a preferred embodiment, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule encoding an OSP under low stringency conditions. In a more preferred embodiment, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule encoding an OSP under moderate stringency conditions. In a more preferred

- embodiment, the nucleic acid molecule selectively hybridizes to a nucleic acid molecule encoding an OSP under high stringency conditions. In an even more preferred embodiment, the nucleic acid molecule hybridizes under low, moderate or high stringency conditions to a nucleic acid molecule encoding a polypeptide comprising an
- 5 amino acid sequence of SEQ ID NO: 138 through 238. In a yet more preferred embodiment, the nucleic acid molecule hybridizes under low, moderate or high stringency conditions to a nucleic acid molecule comprising a nucleic acid sequence selected from SEQ ID NO: 1 through 137. In a preferred embodiment of the invention, the hybridizing nucleic acid molecule may be used to express recombinantly a
- 10 polypeptide of the invention.

By "nucleic acid molecule" as used herein it is also meant to be inclusive of sequences that exhibits substantial sequence similarity to a nucleic acid encoding an OSP or a complement of the encoding nucleic acid molecule. In a preferred embodiment, the nucleic acid molecule exhibits substantial sequence similarity to a nucleic acid molecule

15 encoding human OSP. In a more preferred embodiment, the nucleic acid molecule exhibits substantial sequence similarity to a nucleic acid molecule encoding a polypeptide having an amino acid sequence of SEQ ID NO: 138 through 238. In a preferred embodiment, the similar nucleic acid molecule is one that has at least 60% sequence identity with a nucleic acid molecule encoding an OSP, such as a polypeptide

20 having an amino acid sequence of SEQ ID NO: 138 through 238, more preferably at least 70%, even more preferably at least 80% and even more preferably at least 85%. In a more preferred embodiment, the similar nucleic acid molecule is one that has at least 90% sequence identity with a nucleic acid molecule encoding an OSP, more preferably at least 95%, more preferably at least 97%, even more preferably at least 98%, and still

25 more preferably at least 99%. In another highly preferred embodiment, the nucleic acid molecule is one that has at least 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity with a nucleic acid molecule encoding an OSP.

In another preferred embodiment, the nucleic acid molecule exhibits substantial sequence similarity to an OSNA or its complement. In a more preferred embodiment, the

30 nucleic acid molecule exhibits substantial sequence similarity to a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1 through 137. In a preferred embodiment, the nucleic acid molecule is one that has at least 60% sequence identity

with an OSNA, such as one having a nucleic acid sequence of SEQ ID NO: 1 through 137, more preferably at least 70%, even more preferably at least 80% and even more preferably at least 85%. In a more preferred embodiment, the nucleic acid molecule is one that has at least 90% sequence identity with an OSNA, more preferably at least 95%,  
5 more preferably at least 97%, even more preferably at least 98%, and still more preferably at least 99%. In another highly preferred embodiment, the nucleic acid molecule is one that has at least 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity with an OSNA.

A nucleic acid molecule that exhibits substantial sequence similarity may be one  
10 that exhibits sequence identity over its entire length to an OSNA or to a nucleic acid molecule encoding an OSP, or may be one that is similar over only a part of its length. In this case, the part is at least 50 nucleotides of the OSNA or the nucleic acid molecule encoding an OSP, preferably at least 100 nucleotides, more preferably at least 150 or 200 nucleotides, even more preferably at least 250 or 300 nucleotides, still more preferably at  
15 least 400 or 500 nucleotides.

The substantially similar nucleic acid molecule may be a naturally-occurring one that is derived from another species, especially one derived from another primate, wherein the similar nucleic acid molecule encodes an amino acid sequence that exhibits significant sequence identity to that of SEQ ID NO: 138 through 238 or demonstrates  
20 significant sequence identity to the nucleotide sequence of SEQ ID NO: 1 through 137. The similar nucleic acid molecule may also be a naturally-occurring nucleic acid molecule from a human, when the OSNA is a member of a gene family. The similar nucleic acid molecule may also be a naturally-occurring nucleic acid molecule derived from a non-primate, mammalian species, including without limitation, domesticated  
25 species, *e.g.*, dog, cat, mouse, rat, rabbit, hamster, cow, horse and pig; and wild animals, *e.g.*, monkey, fox, lions, tigers, bears, giraffes, zebras, etc. The substantially similar nucleic acid molecule may also be a naturally-occurring nucleic acid molecule derived from a non-mammalian species, such as birds or reptiles. The naturally-occurring substantially similar nucleic acid molecule may be isolated directly from humans or other  
30 species. In another embodiment, the substantially similar nucleic acid molecule may be one that is experimentally produced by random mutation of a nucleic acid molecule. In another embodiment, the substantially similar nucleic acid molecule may be one that is

experimentally produced by directed mutation of an OSNA. Further, the substantially similar nucleic acid molecule may or may not be an OSNA. However, in a preferred embodiment, the substantially similar nucleic acid molecule is an OSNA.

- By "nucleic acid molecule" it is also meant to be inclusive of allelic variants of an
- 5 OSNA or a nucleic acid encoding an OSP. For instance, single nucleotide polymorphisms (SNPs) occur frequently in eukaryotic genomes. In fact, more than 1.4 million SNPs have already identified in the human genome, International Human Genome Sequencing Consortium, *Nature* 409: 860-921 (2001). Thus, the sequence determined from one individual of a species may differ from other allelic forms present
- 10 within the population. Additionally, small deletions and insertions, rather than single nucleotide polymorphisms, are not uncommon in the general population, and often do not alter the function of the protein. Further, amino acid substitutions occur frequently among natural allelic variants, and often do not substantially change protein function.

In a preferred embodiment, the nucleic acid molecule comprising an allelic

15 variant is a variant of a gene, wherein the gene is transcribed into an mRNA that encodes an OSP. In a more preferred embodiment, the gene is transcribed into an mRNA that encodes an OSP comprising an amino acid sequence of SEQ ID NO: 138 through 238. In another preferred embodiment, the allelic variant is a variant of a gene, wherein the gene is transcribed into an mRNA that is an OSNA. In a more preferred embodiment,

20 the gene is transcribed into an mRNA that comprises the nucleic acid sequence of SEQ ID NO: 1 through 137. In a preferred embodiment, the allelic variant is a naturally-occurring allelic variant in the species of interest. In a more preferred embodiment, the species of interest is human.

By "nucleic acid molecule" it is also meant to be inclusive of a part of a nucleic

25 acid sequence of the instant invention. The part may or may not encode a polypeptide, and may or may not encode a polypeptide that is an OSP. However, in a preferred embodiment, the part encodes an OSP. In one aspect, the invention comprises a part of an OSNA. In a second aspect, the invention comprises a part of a nucleic acid molecule that hybridizes or exhibits substantial sequence similarity to an OSNA. In a third aspect,

30 the invention comprises a part of a nucleic acid molecule that is an allelic variant of an OSNA. In a fourth aspect, the invention comprises a part of a nucleic acid molecule that encodes an OSP. A part comprises at least 10 nucleotides, more preferably at least 15,

17, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400 or 500 nucleotides. The maximum size of a nucleic acid part is one nucleotide shorter than the sequence of the nucleic acid molecule encoding the full-length protein.

- By "nucleic acid molecule" it is also meant to be inclusive of sequence that
- 5 encoding a fusion protein, a homologous protein, a polypeptide fragment, a mutein or a polypeptide analog, as described below.

Nucleotide sequences of the instantly-described nucleic acids were determined by sequencing a DNA molecule that had resulted, directly or indirectly, from at least one enzymatic polymerization reaction (e.g., reverse transcription and/or polymerase chain

10 reaction) using an automated sequencer (such as the MegaBACE™ 1000, Molecular Dynamics, Sunnyvale, CA, USA). Further, all amino acid sequences of the polypeptides of the present invention were predicted by translation from the nucleic acid sequences so determined, unless otherwise specified.

In a preferred embodiment of the invention, the nucleic acid molecule contains

15 modifications of the native nucleic acid molecule. These modifications include nonnative internucleoside bonds, post-synthetic modifications or altered nucleotide analogues. One having ordinary skill in the art would recognize that the type of modification that can be made will depend upon the intended use of the nucleic acid molecule. For instance, when the nucleic acid molecule is used as a hybridization probe,

20 the range of such modifications will be limited to those that permit sequence-discriminating base pairing of the resulting nucleic acid. When used to direct expression of RNA or protein *in vitro* or *in vivo*, the range of such modifications will be limited to those that permit the nucleic acid to function properly as a polymerization substrate.

When the isolated nucleic acid is used as a therapeutic agent, the modifications will be

25 limited to those that do not confer toxicity upon the isolated nucleic acid.

In a preferred embodiment, isolated nucleic acid molecules can include nucleotide analogues that incorporate labels that are directly detectable, such as radiolabels or fluorophores, or nucleotide analogues that incorporate labels that can be visualized in a subsequent reaction, such as biotin or various haptens. In a more preferred embodiment,

30 the labeled nucleic acid molecule may be used as a hybridization probe.

Common radiolabeled analogues include those labeled with  $^{33}\text{P}$ ,  $^{32}\text{P}$ , and  $^{35}\text{S}$ , such as  $^{-32}\text{P}$ -dATP,  $^{-32}\text{P}$ -dCTP,  $^{-32}\text{P}$ -dGTP,  $^{-32}\text{P}$ -dTTP,  $^{-32}\text{P}$ -3'-dATP,  $^{-32}\text{P}$ -ATP,  $^{-32}\text{P}$ -CTP,  $^{-32}\text{P}$ -GTP,  $^{-32}\text{P}$ -UTP,  $^{-35}\text{S}$ -dATP,  $\alpha$ - $^{35}\text{S}$ -GTP,  $\alpha$ - $^{33}\text{P}$ -dATP, and the like.

Commercially available fluorescent nucleotide analogues readily incorporated  
5 into the nucleic acids of the present invention include Cy3-dCTP, Cy3-dUTP, Cy5-  
dCTP, Cy3-dUTP (Amersham Pharmacia Biotech, Piscataway, New Jersey, USA),  
fluorescein-12-dUTP, tetramethylrhodamine-6-dUTP, Texas Red®-5-dUTP, Cascade  
Blue®-7-dUTP, BODIPY® FL-14-dUTP, BODIPY® TMR-14-dUTP, BODIPY®  
TR-14-dUTP, Rhodamine Green™-5-dUTP, Oregon Green® 488-5-dUTP, Texas  
10 Red®-12-dUTP, BODIPY® 630/650-14-dUTP, BODIPY® 650/665-14-dUTP, Alexa  
Fluor® 488-5-dUTP, Alexa Fluor® 532-5-dUTP, Alexa Fluor® 568-5-dUTP, Alexa  
Fluor® 594-5-dUTP, Alexa Fluor® 546-14-dUTP, fluorescein-12-UTP,  
tetramethylrhodamine-6-UTP, Texas Red®-5-UTP, Cascade Blue®-7-UTP, BODIPY®  
FL-14-UTP, BODIPY® TMR-14-UTP, BODIPY® TR-14-UTP, Rhodamine  
15 Green™-5-UTP, Alexa Fluor® 488-5-UTP, Alexa Fluor® 546-14-UTP (Molecular  
Probes, Inc. Eugene, OR, USA). One may also custom synthesize nucleotides having  
other fluorophores. See Henegariu *et al.*, *Nature Biotechnol.* 18: 345-348 (2000), the  
disclosure of which is incorporated herein by reference in its entirety.

Haptens that are commonly conjugated to nucleotides for subsequent labeling  
20 include biotin (biotin-11-dUTP, Molecular Probes, Inc., Eugene, OR, USA;  
biotin-21-UTP, biotin-21-dUTP, Clontech Laboratories, Inc., Palo Alto, CA, USA),  
digoxigenin (DIG-11-dUTP, alkali labile, DIG-11-UTP, Roche Diagnostics Corp.,  
Indianapolis, IN, USA), and dinitrophenyl (dinitrophenyl-11-dUTP, Molecular Probes,  
Inc., Eugene, OR, USA).

25 Nucleic acid molecules can be labeled by incorporation of labeled nucleotide  
analogues into the nucleic acid. Such analogues can be incorporated by enzymatic  
polymerization, such as by nick translation, random priming, polymerase chain reaction  
(PCR), terminal transferase tailing, and end-filling of overhangs, for DNA molecules,  
and *in vitro* transcription driven, *e.g.*, from phage promoters, such as T7, T3, and SP6, for  
30 RNA molecules. Commercial kits are readily available for each such labeling approach.  
Analogues can also be incorporated during automated solid phase chemical synthesis.  
Labels can also be incorporated after nucleic acid synthesis, with the 5' phosphate and 3'

hydroxyl providing convenient sites for post-synthetic covalent attachment of detectable labels.

Other post-synthetic approaches also permit internal labeling of nucleic acids.

For example, fluorophores can be attached using a cisplatin reagent that reacts with the

- 5 N7 of guanine residues (and, to a lesser extent, adenine bases) in DNA, RNA, and PNA to provide a stable coordination complex between the nucleic acid and fluorophore label (Universal Linkage System) (available from Molecular Probes, Inc., Eugene, OR, USA and Amersham Pharmacia Biotech, Piscataway, NJ, USA); *see Alers et al., Genes, Chromosomes & Cancer 25:* 301- 305 (1999); *Jelsma et al., J. NIH Res.* 5: 82 (1994);
- 10 Van Belkum *et al., BioTechniques* 16: 148-153 (1994), incorporated herein by reference. As another example, nucleic acids can be labeled using a disulfide-containing linker (FastTag™ Reagent, Vector Laboratories, Inc., Burlingame, CA, USA) that is photo- or thermally-coupled to the target nucleic acid using aryl azide chemistry; after reduction, a free thiol is available for coupling to a hapten, fluorophore, sugar, affinity ligand, or
- 15 other marker.

One or more independent or interacting labels can be incorporated into the nucleic acid molecules of the present invention. For example, both a fluorophore and a moiety that in proximity thereto acts to quench fluorescence can be included to report specific hybridization through release of fluorescence quenching or to report

- 20 exonucleotidic excision. *See, e.g., Tyagi et al., Nature Biotechnol.* 14: 303-308 (1996); *Tyagi et al., Nature Biotechnol.* 16: 49-53 (1998); *Sokol et al., Proc. Natl. Acad. Sci. USA* 95: 11538-11543 (1998); *Kostrikis et al., Science* 279: 1228-1229 (1998); *Marras et al., Genet. Anal.* 14: 151-156 (1999); U. S. Patent 5,846,726; 5,925,517; 5,925,517; 5,723,591 and 5,538,848; *Holland et al., Proc. Natl. Acad. Sci. USA* 88: 7276-7280
- 25 (1991); *Heid et al., Genome Res.* 6(10): 986-94 (1996); *Kuimelis et al., Nucleic Acids Symp. Ser.* (37): 255-6 (1997); the disclosures of which are incorporated herein by reference in their entireties.

Nucleic acid molecules of the invention may be modified by altering one or more native phosphodiester internucleoside bonds to more nuclease-resistant, internucleoside

- 30 bonds. *See Hartmann et al. (eds.), Manual of Antisense Methodology: Perspectives in Antisense Science*, Kluwer Law International (1999); *Stein et al. (eds.), Applied Antisense Oligonucleotide Technology*, Wiley-Liss (1998); *Chadwick et al. (eds.),*

Oligonucleotides as Therapeutic Agents - Symposium No. 209, John Wiley & Son Ltd (1997); the disclosures of which are incorporated herein by reference in their entireties. Such altered internucleoside bonds are often desired for antisense techniques or for targeted gene correction. See Gamper *et al.*, *Nucl. Acids Res.* 28(21): 4332-4339 (2000),  
5 the disclosure of which is incorporated herein by reference in its entirety.

Modified oligonucleotide backbones include, without limitation, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including  
10 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'. Representative United States patents that teach the preparation of the above  
15 phosphorus-containing linkages include, but are not limited to, U. S. Patents 3,687,808; 4,469,863; 4,476,301; 5,023,243; 5,177,196; 5,188,897; 5,264,423; 5,276,019; 5,278,302; 5,286,717; 5,321,131; 5,399,676; 5,405,939; 5,453,496; 5,455,233; 5,466,677; 5,476,925; 5,519,126; 5,536,821; 5,541,306; 5,550,111; 5,563,253; 5,571,799; 5,587,361; and 5,625,050, the disclosures of which are incorporated herein by  
20 reference in their entireties. In a preferred embodiment, the modified internucleoside linkages may be used for antisense techniques.

Other modified oligonucleotide backbones do not include a phosphorus atom, but have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or  
25 more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and  
30 methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH<sub>2</sub> component parts. Representative U.S. patents that teach the preparation of the above backbones include, but are not limited to, U.S.

-40-

Patent 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437 and 5,677,439; the disclosures of which are incorporated herein by reference in their entireties.

In other preferred oligonucleotide mimetics, both the sugar and the internucleoside linkage are replaced with novel groups, such as peptide nucleic acids (PNA). In PNA compounds, the phosphodiester backbone of the nucleic acid is replaced with an amide-containing backbone, in particular by repeating N-(2-aminoethyl) glycine units linked by amide bonds. Nucleobases are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone, typically by methylene carbonyl linkages. PNA can be synthesized using a modified peptide synthesis protocol. PNA oligomers can be synthesized by both Fmoc and tBoc methods. Representative U.S. patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Patent 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Automated PNA synthesis is readily achievable on commercial synthesizers (*see, e.g.*, "PNA User's Guide," Rev. 2, February 1998, Perseptive Biosystems Part No. 60138, Applied Biosystems, Inc., Foster City, CA).

PNA molecules are advantageous for a number of reasons. First, because the PNA backbone is uncharged, PNA/DNA and PNA/RNA duplexes have a higher thermal stability than is found in DNA/DNA and DNA/RNA duplexes. The Tm of a PNA/DNA or PNA/RNA duplex is generally 1°C higher per base pair than the Tm of the corresponding DNA/DNA or DNA/RNA duplex (in 100 mM NaCl). Second, PNA molecules can also form stable PNA/DNA complexes at low ionic strength, under conditions in which DNA/DNA duplex formation does not occur. Third, PNA also demonstrates greater specificity in binding to complementary DNA because a PNA/DNA mismatch is more destabilizing than DNA/DNA mismatch. A single mismatch in mixed a PNA/DNA 15-mer lowers the Tm by 8–20°C (15°C on average). In the corresponding DNA/DNA duplexes, a single mismatch lowers the Tm by 4–16°C (11°C on average). Because PNA probes can be significantly shorter than DNA probes, their specificity is greater. Fourth, PNA oligomers are resistant to degradation by enzymes, and the lifetime of these compounds is extended both *in vivo* and *in vitro* because nucleases and proteases

do not recognize the PNA polyamide backbone with nucleobase sidechains. See, e.g., Ray *et al.*, *FASEB J.* 14(9): 1041-60 (2000); Nielsen *et al.*, *Pharmacol Toxicol.* 86(1): 3-7 (2000); Larsen *et al.*, *Biochim Biophys Acta.* 1489(1): 159-66 (1999); Nielsen, *Curr. Opin. Struct. Biol.* 9(3): 353-7 (1999), and Nielsen, *Curr. Opin. Biotechnol.* 10(1): 71-5 5 (1999), the disclosures of which are incorporated herein by reference in their entireties.

Nucleic acid molecules may be modified compared to their native structure throughout the length of the nucleic acid molecule or can be localized to discrete portions thereof. As an example of the latter, chimeric nucleic acids can be synthesized that have discrete DNA and RNA domains and that can be used for targeted gene repair and 10 modified PCR reactions, as further described in U.S. Patents 5,760,012 and 5,731,181, Misra *et al.*, *Biochem.* 37: 1917-1925 (1998); and Finn *et al.*, *Nucl. Acids Res.* 24: 3357-3363 (1996), the disclosures of which are incorporated herein by reference in their entireties.

Unless otherwise specified, nucleic acids of the present invention can include any 15 topological conformation appropriate to the desired use; the term thus explicitly comprehends, among others, single-stranded, double-stranded, triplexed, quadruplexed, partially double-stranded, partially-triplexed, partially-quadruplexed, branched, hairpinned, circular, and padlocked conformations. Padlock conformations and their utilities are further described in Banér *et al.*, *Curr. Opin. Biotechnol.* 12: 11-15 (2001); 20 Escude *et al.*, *Proc. Natl. Acad. Sci. USA* 14: 96(19):10603-7 (1999); Nilsson *et al.*, *Science* 265(5181): 2085-8 (1994), the disclosures of which are incorporated herein by reference in their entireties. Triplex and quadruplex conformations, and their utilities, are reviewed in Praseuth *et al.*, *Biochim. Biophys. Acta.* 1489(1): 181-206 (1999); Fox, *Curr. Med. Chem.* 7(1): 17-37 (2000); Kochetkova *et al.*, *Methods Mol. Biol.* 130: 189-201 25 (2000); Chan *et al.*, *J. Mol. Med.* 75(4): 267-82 (1997), the disclosures of which are incorporated herein by reference in their entireties.

#### *Methods for Using Nucleic Acid Molecules as Probes and Primers*

The isolated nucleic acid molecules of the present invention can be used as 30 hybridization probes to detect, characterize, and quantify hybridizing nucleic acids in, and isolate hybridizing nucleic acids from, both genomic and transcript-derived nucleic acid samples. When free in solution, such probes are typically, but not invariably,

detectably labeled; bound to a substrate, as in a microarray, such probes are typically, but not invariably unlabeled.

- In one embodiment, the isolated nucleic acids of the present invention can be used as probes to detect and characterize gross alterations in the gene of an OSNA, such
- 5 as deletions, insertions, translocations, and duplications of the OSNA genomic locus through fluorescence *in situ* hybridization (FISH) to chromosome spreads. *See, e.g., Andreeff et al. (eds.), Introduction to Fluorescence In Situ Hybridization: Principles and Clinical Applications, John Wiley & Sons (1999), the disclosure of which is incorporated herein by reference in its entirety.* The isolated nucleic acids of the present invention can
- 10 be used as probes to assess smaller genomic alterations using, *e.g.*, Southern blot detection of restriction fragment length polymorphisms. The isolated nucleic acid molecules of the present invention can be used as probes to isolate genomic clones that include the nucleic acid molecules of the present invention, which thereafter can be restriction mapped and sequenced to identify deletions, insertions, translocations, and
- 15 substitutions (single nucleotide polymorphisms, SNPs) at the sequence level.

- In another embodiment, the isolated nucleic acid molecules of the present invention can be used as probes to detect, characterize, and quantify OSNA in, and isolate OSNA from, transcript-derived nucleic acid samples. In one aspect, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to
- 20 detect, characterize by length, and quantify mRNA by Northern blot of total or poly-A<sup>+</sup>- selected RNA samples. In another aspect, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to detect, characterize by location, and quantify mRNA by *in situ* hybridization to tissue sections. *See, e.g., Schwarchzacher et al., In Situ Hybridization, Springer-Verlag New York (2000), the disclosure of which*
- 25 is incorporated herein by reference in its entirety. In another preferred embodiment, the isolated nucleic acid molecules of the present invention can be used as hybridization probes to measure the representation of clones in a cDNA library or to isolate hybridizing nucleic acid molecules acids from cDNA libraries, permitting sequence level characterization of mRNAs that hybridize to OSNAs, including, without limitations,
- 30 identification of deletions, insertions, substitutions, truncations, alternatively spliced forms and single nucleotide polymorphisms. In yet another preferred embodiment, the nucleic acid molecules of the instant invention may be used in microarrays.

All of the aforementioned probe techniques are well within the skill in the art, and are described at greater length in standard texts such as Sambrook (2001), *supra*; Ausubel (1999), *supra*; and Walker *et al.* (eds.), The Nucleic Acids Protocols Handbook, Humana Press (2000), the disclosures of which are incorporated herein by reference in 5 their entirety.

- Thus, in one embodiment, a nucleic acid molecule of the invention may be used as a probe or primer to identify or amplify a second nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of the invention. In a preferred embodiment, the probe or primer is derived from a nucleic acid molecule encoding an OSP. In a more 10 preferred embodiment, the probe or primer is derived from a nucleic acid molecule encoding a polypeptide having an amino acid sequence of SEQ ID NO: 138 through 238. In another preferred embodiment, the probe or primer is derived from an OSNA. In a more preferred embodiment, the probe or primer is derived from a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1 through 137.
- 15 In general, a probe or primer is at least 10 nucleotides in length, more preferably at least 12, more preferably at least 14 and even more preferably at least 16 or 17 nucleotides in length. In an even more preferred embodiment, the probe or primer is at least 18 nucleotides in length, even more preferably at least 20 nucleotides and even more preferably at least 22 nucleotides in length. Primers and probes may also be longer 20 in length. For instance, a probe or primer may be 25 nucleotides in length, or may be 30, 40 or 50 nucleotides in length. Methods of performing nucleic acid hybridization using oligonucleotide probes are well-known in the art. See, e.g., Sambrook *et al.*, 1989, *supra*, Chapter 11 and pp. 11.31-11.32 and 11.40-11.44, which describes radiolabeling of short probes, and pp. 11.45-11.53, which describe hybridization conditions for oligonucleotide 25 probes, including specific conditions for probe hybridization (pp. 11.50-11.51).

Methods of performing primer-directed amplification are also well-known in the art. Methods for performing the polymerase chain reaction (PCR) are compiled, *inter alia*, in McPherson, PCR Basics: From Background to Bench, Springer Verlag (2000); Innis *et al.* (eds.), PCR Applications: Protocols for Functional Genomics, Academic 30 Press (1999); Gelfand *et al.* (eds.), PCR Strategies, Academic Press (1998); Newton *et al.*, PCR, Springer-Verlag New York (1997); Burke (ed.), PCR: Essential Techniques, John Wiley & Son Ltd (1996); White (ed.), PCR Cloning Protocols: From Molecular

Cloning to Genetic Engineering, Vol. 67, Humana Press (1996); McPherson *et al.* (eds.), PCR 2: A Practical Approach, Oxford University Press, Inc. (1995); the disclosures of which are incorporated herein by reference in their entireties. Methods for performing RT-PCR are collected, *e.g.*, in Siebert *et al.* (eds.), Gene Cloning and Analysis by

- 5    RT-PCR, Eaton Publishing Company/Bio Techniques Books Division, 1998; Siebert (ed.), PCR Technique:RT-PCR, Eaton Publishing Company/ BioTechniques Books (1995); the disclosure of which is incorporated herein by reference in its entirety.

PCR and hybridization methods may be used to identify and/or isolate allelic variants, homologous nucleic acid molecules and fragments of the nucleic acid molecules 10 of the invention. PCR and hybridization methods may also be used to identify, amplify and/or isolate nucleic acid molecules that encode homologous proteins, analogs, fusion protein or muteins of the invention. The nucleic acid primers of the present invention can be used to prime amplification of nucleic acid molecules of the invention, using transcript-derived or genomic DNA as template.

- 15       The nucleic acid primers of the present invention can also be used, for example, to prime single base extension (SBE) for SNP detection (*See, e.g.*, U.S. Patent 6,004,744, the disclosure of which is incorporated herein by reference in its entirety).

Isothermal amplification approaches, such as rolling circle amplification, are also now well-described. *See, e.g.*, Schweitzer *et al.*, *Curr. Opin. Biotechnol.* 12(1): 21-7 20 (2001); U.S. Patents 5,854,033 and 5,714,320; and international patent publications WO 97/19193 and WO 00/15779, the disclosures of which are incorporated herein by reference in their entireties. Rolling circle amplification can be combined with other techniques to facilitate SNP detection. *See, e.g.*, Lizardi *et al.*, *Nature Genet.* 19(3): 225-32 (1998).

25       Nucleic acid molecules of the present invention may be bound to a substrate either covalently or noncovalently. The substrate can be porous or solid, planar or non-planar, unitary or distributed. The bound nucleic acid molecules may be used as hybridization probes, and may be labeled or unlabeled. In a preferred embodiment, the bound nucleic acid molecules are unlabeled.

30       In one embodiment, the nucleic acid molecule of the present invention is bound to a porous substrate, *e.g.*, a membrane, typically comprising nitrocellulose, nylon, or positively-charged derivatized nylon. The nucleic acid molecule of the present invention

-45-

can be used to detect a hybridizing nucleic acid molecule that is present within a labeled nucleic acid sample, e.g., a sample of transcript-derived nucleic acids. In another embodiment, the nucleic acid molecule is bound to a solid substrate, including, without limitation, glass, amorphous silicon, crystalline silicon or plastics. Examples of plastics 5 include, without limitation, polymethylacrylic, polyethylene, polypropylene, polyacrylate, polymethylmethacrylate, polyvinylchloride, polytetrafluoroethylene, polystyrene, polycarbonate, polyacetal, polysulfone, celluloseacetate, cellulosenitrate, nitrocellulose, or mixtures thereof. The solid substrate may be any shape, including rectangular, disk-like and spherical. In a preferred embodiment, the solid substrate is a 10 microscope slide or slide-shaped substrate.

The nucleic acid molecule of the present invention can be attached covalently to a surface of the support substrate or applied to a derivatized surface in a chaotropic agent that facilitates denaturation and adherence by presumed noncovalent interactions, or some combination thereof. The nucleic acid molecule of the present invention can be 15 bound to a substrate to which a plurality of other nucleic acids are concurrently bound, hybridization to each of the plurality of bound nucleic acids being separately detectable. At low density, e.g. on a porous membrane, these substrate-bound collections are typically denominated macroarrays; at higher density, typically on a solid support, such as glass, these substrate bound collections of plural nucleic acids are colloquially termed 20 microarrays. As used herein, the term microarray includes arrays of all densities. It is, therefore, another aspect of the invention to provide microarrays that include the nucleic acids of the present invention.

#### *Expression Vectors, Host Cells and Recombinant Methods of Producing Polypeptides*

Another aspect of the present invention relates to vectors that comprise one or 25 more of the isolated nucleic acid molecules of the present invention, and host cells in which such vectors have been introduced.

The vectors can be used, *inter alia*, for propagating the nucleic acids of the present invention in host cells (cloning vectors), for shuttling the nucleic acids of the present invention between host cells derived from disparate organisms (shuttle vectors), 30 for inserting the nucleic acids of the present invention into host cell chromosomes (insertion vectors), for expressing sense or antisense RNA transcripts of the nucleic acids of the present invention *in vitro* or within a host cell, and for expressing polypeptides

-46-

encoded by the nucleic acids of the present invention, alone or as fusions to heterologous polypeptides (expression vectors). Vectors of the present invention will often be suitable for several such uses.

- Vectors are by now well-known in the art, and are described, *inter alia*, in Jones 5 *et al.* (eds.), Vectors: Cloning Applications: Essential Techniques (Essential Techniques Series), John Wiley & Son Ltd. (1998); Jones *et al.* (eds.), Vectors: Expression Systems: Essential Techniques (Essential Techniques Series), John Wiley & Son Ltd. (1998); Gacesa *et al.*, Vectors: Essential Data, John Wiley & Sons Ltd. (1995); Cid-Arregui (eds.), Viral Vectors: Basic Science and Gene Therapy, Eaton Publishing Co. (2000); 10 Sambrook (2001), *supra*; Ausubel (1999), *supra*; the disclosures of which are incorporated herein by reference in their entireties. Furthermore, an enormous variety of vectors are available commercially. Use of existing vectors and modifications thereof being well within the skill in the art, only basic features need be described here.

- Nucleic acid sequences may be expressed by operatively linking them to an 15 expression control sequence in an appropriate expression vector and employing that expression vector to transform an appropriate unicellular host. Expression control sequences are sequences which control the transcription, post-transcriptional events and translation of nucleic acid sequences. Such operative linking of a nucleic sequence of this invention to an expression control sequence, of course, includes, if not already part 20 of the nucleic acid sequence, the provision of a translation initiation codon, ATG or GTG, in the correct reading frame upstream of the nucleic acid sequence.

- A wide variety of host/expression vector combinations may be employed in expressing the nucleic acid sequences of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, non-chromosomal and synthetic 25 nucleic acid sequences.

- In one embodiment, prokaryotic cells may be used with an appropriate vector. Prokaryotic host cells are often used for cloning and expression. In a preferred embodiment, prokaryotic host cells include *E. coli*, *Pseudomonas*, *Bacillus* and *Streptomyces*. In a preferred embodiment, bacterial host cells are used to express the 30 nucleic acid molecules of the instant invention. Useful expression vectors for bacterial hosts include bacterial plasmids, such as those from *E. coli*, *Bacillus* or *Streptomyces*, including pBluescript, pGEX-2T, pUC vectors, col E1, pCR1, pBR322, pMB9 and their

- derivatives, wider host range plasmids, such as RP4, phage DNAs, e.g., the numerous derivatives of phage lambda, e.g., NM989, λGT10 and λGT11, and other phages, e.g., M13 and filamentous single-stranded phage DNA. Where *E. coli* is used as host, selectable markers are, analogously, chosen for selectivity in gram negative bacteria: e.g.,
- 5 typical markers confer resistance to antibiotics, such as ampicillin, tetracycline, chloramphenicol, kanamycin, streptomycin and zeocin; auxotrophic markers can also be used.

In other embodiments, eukaryotic host cells, such as yeast, insect, mammalian or plant cells, may be used. Yeast cells, typically *S. cerevisiae*, are useful for eukaryotic

10 genetic studies, due to the ease of targeting genetic changes by homologous recombination and the ability to easily complement genetic defects using recombinantly expressed proteins. Yeast cells are useful for identifying interacting protein components, e.g. through use of a two-hybrid system. In a preferred embodiment, yeast cells are useful for protein expression. Vectors of the present invention for use in yeast will

15 typically, but not invariably, contain an origin of replication suitable for use in yeast and a selectable marker that is functional in yeast. Yeast vectors include Yeast Integrating plasmids (e.g., YIp5) and Yeast Replicating plasmids (the YRp and YEpl series plasmids), Yeast Centromere plasmids (the YCp series plasmids), Yeast Artificial Chromosomes (YACs) which are based on yeast linear plasmids, denoted YLp, pGPD-2,

20 2μ plasmids and derivatives thereof, and improved shuttle vectors such as those described in Gietz *et al.*, *Gene*, 74: 527-34 (1988) (YIplac, YEplac and YCplac). Selectable markers in yeast vectors include a variety of auxotrophic markers, the most common of which are (in *Saccharomyces cerevisiae*) URA3, HIS3, LEU2, TRP1 and LYS2, which complement specific auxotrophic mutations, such as ura3-52, his3-D1,

25 leu2-D1, trp1-D1 and lys2-201.

Insect cells are often chosen for high efficiency protein expression. Where the host cells are from *Spodoptera frugiperda*, e.g., Sf9 and Sf21 cell lines, and expresSF™ cells (Protein Sciences Corp., Meriden, CT, USA)), the vector replicative strategy is typically based upon the baculovirus life cycle. Typically, baculovirus transfer vectors

30 are used to replace the wild-type AcMNPV polyhedrin gene with a heterologous gene of interest. Sequences that flank the polyhedrin gene in the wild-type genome are positioned 5' and 3' of the expression cassette on the transfer vectors. Following co-

transfection with AcMNPV DNA, a homologous recombination event occurs between these sequences resulting in a recombinant virus carrying the gene of interest and the polyhedrin or p10 promoter. Selection can be based upon visual screening for lacZ fusion activity.

- 5        In another embodiment, the host cells may be mammalian cells, which are particularly useful for expression of proteins intended as pharmaceutical agents, and for screening of potential agonists and antagonists of a protein or a physiological pathway. Mammalian vectors intended for autonomous extrachromosomal replication will typically include a viral origin, such as the SV40 origin (for replication in cell lines
- 10      expressing the large T-antigen, such as COS1 and COS7 cells), the papillomavirus origin, or the EBV origin for long term episomal replication (for use, e.g., in 293-EBNA cells, which constitutively express the EBV EBNA-1 gene product and adenovirus E1A). Vectors intended for integration, and thus replication as part of the mammalian chromosome, can, but need not, include an origin of replication functional in mammalian
- 15      cells, such as the SV40 origin. Vectors based upon viruses, such as adenovirus, adeno-associated virus, vaccinia virus, and various mammalian retroviruses, will typically replicate according to the viral replicative strategy. Selectable markers for use in mammalian cells include resistance to neomycin (G418), blasticidin, hygromycin and to zeocin, and selection based upon the purine salvage pathway using HAT medium.
- 20      Expression in mammalian cells can be achieved using a variety of plasmids, including pSV2, pBC12BI, and p91023, as well as lytic virus vectors (e.g., vaccinia virus, adeno virus, and baculovirus), episomal virus vectors (e.g., bovine papillomavirus), and retroviral vectors (e.g., murine retroviruses). Useful vectors for insect cells include baculoviral vectors and pVL 941.
- 25      Plant cells can also be used for expression, with the vector replicon typically derived from a plant virus (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) and selectable markers chosen for suitability in plants.
- 30      It is known that codon usage of different host cells may be different. For example, a plant cell and a human cell may exhibit a difference in codon preference for encoding a particular amino acid. As a result, human mRNA may not be efficiently translated in a plant, bacteria or insect host cell. Therefore, another embodiment of this invention is directed to codon optimization. The codons of the nucleic acid molecules of

the invention may be modified to resemble, as much as possible, genes naturally contained within the host cell without altering the amino acid sequence encoded by the nucleic acid molecule.

- Any of a wide variety of expression control sequences may be used in these vectors to express the DNA sequences of this invention. Such useful expression control sequences include the expression control sequences associated with structural genes of the foregoing expression vectors. Expression control sequences that control transcription include, *e.g.*, promoters, enhancers and transcription termination sites. Expression control sequences in eukaryotic cells that control post-transcriptional events include splice donor and acceptor sites and sequences that modify the half-life of the transcribed RNA, *e.g.*, sequences that direct poly(A) addition or binding sites for RNA-binding proteins. Expression control sequences that control translation include ribosome binding sites, sequences which direct targeted expression of the polypeptide to or within particular cellular compartments, and sequences in the 5' and 3' untranslated regions that modify the rate or efficiency of translation.

Examples of useful expression control sequences for a prokaryote, *e.g.*, *E. coli*, will include a promoter, often a phage promoter, such as phage lambda pL promoter, the trc promoter, a hybrid derived from the trp and lac promoters, the bacteriophage T7 promoter (in *E. coli* cells engineered to express the T7 polymerase), the TAC or TRC system, the major operator and promoter regions of phage lambda, the control regions of fd coat protein, or the araBAD operon. Prokaryotic expression vectors may further include transcription terminators, such as the aspA terminator, and elements that facilitate translation, such as a consensus ribosome binding site and translation termination codon, Schomer *et al.*, *Proc. Natl. Acad. Sci. USA* 83: 8506-8510 (1986).

Expression control sequences for yeast cells, typically *S. cerevisiae*, will include a yeast promoter, such as the CYC1 promoter, the GAL1 promoter, the GAL10 promoter, ADH1 promoter, the promoters of the yeast  $\alpha$ -mating system, or the GPD promoter, and will typically have elements that facilitate transcription termination, such as the transcription termination signals from the CYC1 or ADH1 gene.

Expression vectors useful for expressing proteins in mammalian cells will include a promoter active in mammalian cells. These promoters include those derived from mammalian viruses, such as the enhancer-promoter sequences from the immediate early

-50-

- gene of the human cytomegalovirus (CMV), the enhancer-promoter sequences from the Rous sarcoma virus long terminal repeat (RSV LTR), the enhancer-promoter from SV40 or the early and late promoters of adenovirus. Other expression control sequences include the promoter for 3-phosphoglycerate kinase or other glycolytic enzymes, the
- 5 promoters of acid phosphatase. Other expression control sequences include those from the gene comprising the OSNA of interest. Often, expression is enhanced by incorporation of polyadenylation sites, such as the late SV40 polyadenylation site and the polyadenylation signal and transcription termination sequences from the bovine growth hormone (BGH) gene, and ribosome binding sites. Furthermore, vectors can include
- 10 introns, such as intron II of rabbit β-globin gene and the SV40 splice elements.

Preferred nucleic acid vectors also include a selectable or amplifiable marker gene and means for amplifying the copy number of the gene of interest. Such marker genes are well-known in the art. Nucleic acid vectors may also comprise stabilizing sequences (e.g., ori- or ARS-like sequences and telomere-like sequences), or may

- 15 alternatively be designed to favor directed or non-directed integration into the host cell genome. In a preferred embodiment, nucleic acid sequences of this invention are inserted in frame into an expression vector that allows high level expression of an RNA which encodes a protein comprising the encoded nucleic acid sequence of interest. Nucleic acid cloning and sequencing methods are well-known to those of skill in the art and are
- 20 described in an assortment of laboratory manuals, including Sambrook (1989), *supra*, Sambrook (2000), *supra*; and Ausubel (1992), *supra*, Ausubel (1999), *supra*. Product information from manufacturers of biological, chemical and immunological reagents also provide useful information.

- Expression vectors may be either constitutive or inducible. Inducible vectors
- 25 include either naturally inducible promoters, such as the trc promoter, which is regulated by the lac operon, and the pL promoter, which is regulated by tryptophan, the MMTV-LTR promoter, which is inducible by dexamethasone, or can contain synthetic promoters and/or additional elements that confer inducible control on adjacent promoters. Examples of inducible synthetic promoters are the hybrid Plac/ara-1 promoter and the
- 30 PLtetO-1 promoter. The PLtetO-1 promoter takes advantage of the high expression levels from the PL promoter of phage lambda, but replaces the lambda repressor sites with two copies of operator 2 of the Tn10 tetracycline resistance operon, causing this promoter to

be tightly repressed by the Tet repressor protein and induced in response to tetracycline (Tc) and Tc derivatives such as anhydrotetracycline. Vectors may also be inducible because they contain hormone response elements, such as the glucocorticoid response element (GRE) and the estrogen response element (ERE), which can confer hormone 5 inducibility where vectors are used for expression in cells having the respective hormone receptors. To reduce background levels of expression, elements responsive to ecdysone, an insect hormone, can be used instead, with coexpression of the ecdysone receptor.

In one aspect of the invention, expression vectors can be designed to fuse the expressed polypeptide to small protein tags that facilitate purification and/or 10 visualization. Tags that facilitate purification include a polyhistidine tag that facilitates purification of the fusion protein by immobilized metal affinity chromatography, for example using NiNTA resin (Qiagen Inc., Valencia, CA, USA) or TALON™ resin (cobalt immobilized affinity chromatography medium, Clontech Labs, Palo Alto, CA, USA). The fusion protein can include a chitin-binding tag and self-excising intein, 15 permitting chitin-based purification with self-removal of the fused tag (IMPACT™ system, New England Biolabs, Inc., Beverley, MA, USA). Alternatively, the fusion protein can include a calmodulin-binding peptide tag, permitting purification by calmodulin affinity resin (Stratagene, La Jolla, CA, USA), or a specifically excisable fragment of the biotin carboxylase carrier protein, permitting purification of *in vivo* 20 biotinylated protein using an avidin resin and subsequent tag removal (Promega, Madison, WI, USA). As another useful alternative, the proteins of the present invention can be expressed as a fusion protein with glutathione-S-transferase, the affinity and specificity of binding to glutathione permitting purification using glutathione affinity 25 resins, such as Glutathione-Superflow Resin (Clontech Laboratories, Palo Alto, CA, USA), with subsequent elution with free glutathione. Other tags include, for example, the Xpress epitope, detectable by anti-Xpress antibody (Invitrogen, Carlsbad, CA, USA), a myc tag, detectable by anti-myc tag antibody, the V5 epitope, detectable by anti-V5 antibody (Invitrogen, Carlsbad, CA, USA), FLAG® epitope, detectable by anti-FLAG® antibody (Stratagene, La Jolla, CA, USA), and the HA epitope.

30 For secretion of expressed proteins, vectors can include appropriate sequences that encode secretion signals, such as leader peptides. For example, the pSecTag2 vectors (Invitrogen, Carlsbad, CA, USA) are 5.2 kb mammalian expression vectors that

carry the secretion signal from the V-J2-C region of the mouse Ig kappa-chain for efficient secretion of recombinant proteins from a variety of mammalian cell lines.

Expression vectors can also be designed to fuse proteins encoded by the heterologous nucleic acid insert to polypeptides that are larger than purification and/or 5 identification tags. Useful fusion proteins include those that permit display of the encoded protein on the surface of a phage or cell, fusion to intrinsically fluorescent proteins, such as those that have a green fluorescent protein (GFP)-like chromophore, fusions to the IgG Fc region, and fusion proteins for use in two hybrid systems.

Vectors for phage display fuse the encoded polypeptide to, e.g., the gene III 10 protein (pIII) or gene VIII protein (pVIII) for display on the surface of filamentous phage, such as M13. See Barbas *et al.*, Phage Display: A Laboratory Manual, Cold Spring Harbor Laboratory Press (2001); Kay *et al.* (eds.), Phage Display of Peptides and Proteins: A Laboratory Manual, Academic Press, Inc., (1996); Abelson *et al.* (eds.), Combinatorial Chemistry (Methods in Enzymology, Vol. 267) Academic Press (1996). 15 Vectors for yeast display, e.g. the pYD1 yeast display vector (Invitrogen, Carlsbad, CA, USA), use the -agglutinin yeast adhesion receptor to display recombinant protein on the surface of *S. cerevisiae*. Vectors for mammalian display, e.g., the pDisplay™ vector (Invitrogen, Carlsbad, CA, USA), target recombinant proteins using an N-terminal cell surface targeting signal and a C-terminal transmembrane anchoring domain of platelet 20 derived growth factor receptor.

A wide variety of vectors now exist that fuse proteins encoded by heterologous nucleic acids to the chromophore of the substrate-independent, intrinsically fluorescent green fluorescent protein from *Aequorea victoria* ("GFP") and its variants. The GFP-like chromophore can be selected from GFP-like chromophores found in naturally occurring 25 proteins, such as *A. victoria* GFP (GenBank accession number AAA27721), *Renilla reniformis* GFP, FP583 (GenBank accession no. AF168419) (DsRed), FP593 (AF272711), FP483 (AF168420), FP484 (AF168424), FP595 (AF246709), FP486 (AF168421), FP538 (AF168423), and FP506 (AF168422), and need include only so much of the native protein as is needed to retain the chromophore's intrinsic 30 fluorescence. Methods for determining the minimal domain required for fluorescence are known in the art. See Li *et al.*, *J. Biol. Chem.* 272: 28545-28549 (1997). Alternatively, the GFP-like chromophore can be selected from GFP-like chromophores modified from

- those found in nature. The methods for engineering such modified GFP-like chromophores and testing them for fluorescence activity, both alone and as part of protein fusions, are well-known in the art. See Heim *et al.*, *Curr. Biol.* 6: 178-182 (1996) and Palm *et al.*, *Methods Enzymol.* 302: 378-394 (1999), incorporated herein by reference in its entirety. A variety of such modified chromophores are now commercially available and can readily be used in the fusion proteins of the present invention. These include EGFP ("enhanced GFP"), EBFP ("enhanced blue fluorescent protein"), BFP2, EYFP ("enhanced yellow fluorescent protein"), ECFP ("enhanced cyan fluorescent protein") or Citrine. EGFP (*see, e.g.*, Cormack *et al.*, *Gene* 173: 33-38 (1996); United States Patent Nos. 6,090,919 and 5,804,387) is found on a variety of vectors, both plasmid and viral, which are available commercially (Clontech Labs, Palo Alto, CA, USA); EBFP is optimized for expression in mammalian cells whereas BFP2, which retains the original jellyfish codons, can be expressed in bacteria (*see, e.g.*, Heim *et al.*, *Curr. Biol.* 6: 178-182 (1996) and Cormack *et al.*, *Gene* 173: 33-38 (1996)).
- Vectors containing these blue-shifted variants are available from Clontech Labs (Palo Alto, CA, USA). Vectors containing EYFP, ECFP (*see, e.g.*, Heim *et al.*, *Curr. Biol.* 6: 178-182 (1996); Miyawaki *et al.*, *Nature* 388: 882-887 (1997)) and Citrine (*see, e.g.*, Heikal *et al.*, *Proc. Natl. Acad. Sci. USA* 97: 11996-12001 (2000)) are also available from Clontech Labs. The GFP-like chromophore can also be drawn from other modified GFPs, including those described in U.S. Patents 6,124,128; 6,096,865; 6,090,919; 6,066,476; 6,054,321; 6,027,881; 5,968,750; 5,874,304; 5,804,387; 5,777,079; 5,741,668; and 5,625,048, the disclosures of which are incorporated herein by reference in their entireties. *See also* Conn (ed.), Green Fluorescent Protein (Methods in Enzymology, Vol. 302), Academic Press, Inc. (1999). The GFP-like chromophore of each of these GFP variants can usefully be included in the fusion proteins of the present invention.

Fusions to the IgG Fc region increase serum half life of protein pharmaceutical products through interaction with the FcRn receptor (also denominated the FcRp receptor and the Brambell receptor, FcRb), further described in International Patent Application Nos. WO 97/43316, WO 97/34631, WO 96/32478, WO 96/18412.

For long-term, high-yield recombinant production of the proteins, protein fusions, and protein fragments of the present invention, stable expression is preferred. Stable

- expression is readily achieved by integration into the host cell genome of vectors having selectable markers, followed by selection of these integrants. Vectors such as pUB6/V5-His A, B, and C (Invitrogen, Carlsbad, CA, USA) are designed for high-level stable expression of heterologous proteins in a wide range of mammalian tissue types and 5 cell lines. pUB6/V5-His uses the promoter/enhancer sequence from the human ubiquitin C gene to drive expression of recombinant proteins: expression levels in 293, CHO, and NIH3T3 cells are comparable to levels from the CMV and human EF-1a promoters. The bsd gene permits rapid selection of stably transfected mammalian cells with the potent antibiotic blasticidin.
- 10 Replication incompetent retroviral vectors, typically derived from Moloney murine leukemia virus, also are useful for creating stable transfectants having integrated provirus. The highly efficient transduction machinery of retroviruses, coupled with the availability of a variety of packaging cell lines such as RetroPack™ PT 67, EcoPack2™-293, Amphotropic-293, and GP2-293 cell lines (all available from Clontech Laboratories, 15 Palo Alto, CA, USA), allow a wide host range to be infected with high efficiency; varying the multiplicity of infection readily adjusts the copy number of the integrated provirus.

Of course, not all vectors and expression control sequences will function equally well to express the nucleic acid sequences of this invention. Neither will all hosts 20 function equally well with the same expression system. However, one of skill in the art may make a selection among these vectors, expression control sequences and hosts without undue experimentation and without departing from the scope of this invention. For example, in selecting a vector, the host must be considered because the vector must be replicated in it. The vector's copy number, the ability to control that copy number, the 25 ability to control integration, if any, and the expression of any other proteins encoded by the vector, such as antibiotic or other selection markers, should also be considered. The present invention further includes host cells comprising the vectors of the present invention, either present episomally within the cell or integrated, in whole or in part, into the host cell chromosome. Among other considerations, some of which are described 30 above, a host cell strain may be chosen for its ability to process the expressed protein in the desired fashion. Such post-translational modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation,

and acylation, and it is an aspect of the present invention to provide OSPs with such post-translational modifications.

- Polypeptides of the invention may be post-translationally modified. Post-translational modifications include phosphorylation of amino acid residues serine, threonine and/or tyrosine, N-linked and/or O-linked glycosylation, methylation, acetylation, prenylation, methylation, acetylation, arginylation, ubiquination and racemization. One may determine whether a polypeptide of the invention is likely to be post-translationally modified by analyzing the sequence of the polypeptide to determine if there are peptide motifs indicative of sites for post-translational modification. There are a number of computer programs that permit prediction of post-translational modifications. See, e.g., [www.expasy.org](http://www.expasy.org) (accessed August 31, 2001), which includes PSORT, for prediction of protein sorting signals and localization sites, SignalP, for prediction of signal peptide cleavage sites, MITOPROT and Predotar, for prediction of mitochondrial targeting sequences, NetOGlyc, for prediction of type O-glycosylation sites in mammalian proteins, big-PI Predictor and DGPI, for prediction of prenylation-anchor and cleavage sites, and NetPhos, for prediction of Ser, Thr and Tyr phosphorylation sites in eukaryotic proteins. Other computer programs, such as those included in GCG, also may be used to determine post-translational modification peptide motifs.
- General examples of types of post-translational modifications may be found in web sites such as the Delta Mass database <http://www.abrf.org/ABRF/Research Committees/deltamass/deltamass.html> (accessed October 19, 2001); "GlycoSuiteDB: a new curated relational database of glycoprotein glycan structures and their biological sources" Cooper et al. Nucleic Acids Res. 29; 332-335 (2001) and <http://www.glycosuite.com/> (accessed October 19, 2001); "O-GLYCBASE version 4.0: a revised database of O-glycosylated proteins" Gupta et al. Nucleic Acids Research, 27: 370-372 (1999) and <http://www.cbs.dtu.dk/databases/OGLYCBASE/> (accessed October 19, 2001); "PhosphoBase, a database of phosphorylation sites: release 2.0.", Kreegipuu et al. Nucleic Acids Res 27(1):237-239 (1999) and <http://www.cbs.dtu.dk/databases/PhosphoBase/> (accessed October 19, 2001); or <http://pir.georgetown.edu/pirwww/search/textresid.html> (accessed October 19, 2001).

Tumorigenesis is often accompanied by alterations in the post-translational modifications of proteins. Thus, in another embodiment, the invention provides polypeptides from cancerous cells or tissues that have altered post-translational modifications compared to the post-translational modifications of polypeptides from normal cells or tissues. A number of altered post-translational modifications are known.

One common alteration is a change in phosphorylation state, wherein the polypeptide from the cancerous cell or tissue is hyperphosphorylated or hypophosphorylated compared to the polypeptide from a normal tissue, or wherein the polypeptide is phosphorylated on different residues than the polypeptide from a normal cell. Another common alteration is a change in glycosylation state, wherein the polypeptide from the cancerous cell or tissue has more or less glycosylation than the polypeptide from a normal tissue, and/or wherein the polypeptide from the cancerous cell or tissue has a different type of glycosylation than the polypeptide from a noncancerous cell or tissue. Changes in glycosylation may be critical because carbohydrate-protein and carbohydrate-carbohydrate interactions are important in cancer cell progression, dissemination and invasion. See, e.g., Barchi, *Curr. Pharm. Des.* 6: 485-501 (2000), Verma, *Cancer Biochem. Biophys.* 14: 151-162 (1994) and Dennis et al., *Bioessays* 5: 412-421 (1999).

Another post-translational modification that may be altered in cancer cells is prenylation. Prenylation is the covalent attachment of a hydrophobic prenyl group (either farnesyl or geranylgeranyl) to a polypeptide. Prenylation is required for localizing a protein to a cell membrane and is often required for polypeptide function. For instance, the Ras superfamily of GTPase signaling proteins must be prenylated for function in a cell. See, e.g., Prendergast et al., *Semin. Cancer Biol.* 10: 443-452 (2000) and Khwaja et al., *Lancet* 355: 741-744 (2000).

Other post-translation modifications that may be altered in cancer cells include, without limitation, polypeptide methylation, acetylation, arginylation or racemization of amino acid residues. In these cases, the polypeptide from the cancerous cell may exhibit either increased or decreased amounts of the post-translational modification compared to the corresponding polypeptides from noncancerous cells.

Other polypeptide alterations in cancer cells include abnormal polypeptide cleavage of proteins and aberrant protein-protein interactions. Abnormal polypeptide cleavage may be cleavage of a polypeptide in a cancerous cell that does not usually occur

- in a normal cell, or a lack of cleavage in a cancerous cell, wherein the polypeptide is cleaved in a normal cell. Aberrant protein-protein interactions may be either covalent cross-linking or non-covalent binding between proteins that do not normally bind to each other. Alternatively, in a cancerous cell, a protein may fail to bind to another protein to
- 5 which it is bound in a noncancerous cell. Alterations in cleavage or in protein-protein interactions may be due to over- or underproduction of a polypeptide in a cancerous cell compared to that in a normal cell, or may be due to alterations in post-translational modifications (see above) of one or more proteins in the cancerous cell. See, e.g., Henschen-Edman, *Ann. N.Y. Acad. Sci.* 936: 580-593 (2001).
- 10 Alterations in polypeptide post-translational modifications, as well as changes in polypeptide cleavage and protein-protein interactions, may be determined by any method known in the art. For instance, alterations in phosphorylation may be determined by using anti-phosphoserine, anti-phosphothreonine or anti-phosphotyrosine antibodies or by amino acid analysis. Glycosylation alterations may be determined using antibodies
- 15 specific for different sugar residues, by carbohydrate sequencing, or by alterations in the size of the glycoprotein, which can be determined by, e.g., SDS polyacrylamide gel electrophoresis (PAGE). Other alterations of post-translational modifications, such as prenylation, racemization, methylation, acetylation and arginylation, may be determined by chemical analysis, protein sequencing, amino acid analysis, or by using antibodies
- 20 specific for the particular post-translational modifications. Changes in protein-protein interactions and in polypeptide cleavage may be analyzed by any method known in the art including, without limitation, non-denaturing PAGE (for non-covalent protein-protein interactions), SDS PAGE (for covalent protein-protein interactions and protein cleavage), chemical cleavage, protein sequencing or immunoassays.
- 25 In another embodiment, the invention provides polypeptides that have been post-translationally modified. In one embodiment, polypeptides may be modified enzymatically or chemically, by addition or removal of a post-translational modification. For example, a polypeptide may be glycosylated or deglycosylated enzymatically. Similarly, polypeptides may be phosphorylated using a purified kinase, such as a MAP
- 30 kinase (e.g., p38, ERK, or JNK) or a tyrosine kinase (e.g., Src or erbB2). A polypeptide may also be modified through synthetic chemistry. Alternatively, one may isolate the polypeptide of interest from a cell or tissue that expresses the polypeptide with the

- desired post-translational modification. In another embodiment, a nucleic acid molecule encoding the polypeptide of interest is introduced into a host cell that is capable of post-translationally modifying the encoded polypeptide in the desired fashion. If the polypeptide does not contain a motif for a desired post-translational modification, one
- 5 may alter the post-translational modification by mutating the nucleic acid sequence of a nucleic acid molecule encoding the polypeptide so that it contains a site for the desired post-translational modification. Amino acid sequences that may be post-translationally modified are known in the art. See, e.g., the programs described above on the website [www.expasy.org](http://www.expasy.org). The nucleic acid molecule is then be introduced into a host cell that is
- 10 capable of post-translationally modifying the encoded polypeptide. Similarly, one may delete sites that are post-translationally modified by either mutating the nucleic acid sequence so that the encoded polypeptide does not contain the post-translational modification motif, or by introducing the native nucleic acid molecule into a host cell that is not capable of post-translationally modifying the encoded polypeptide.
- 15 In selecting an expression control sequence, a variety of factors should also be considered. These include, for example, the relative strength of the sequence, its controllability, and its compatibility with the nucleic acid sequence of this invention, particularly with regard to potential secondary structures. Unicellular hosts should be selected by consideration of their compatibility with the chosen vector, the toxicity of the
- 20 product coded for by the nucleic acid sequences of this invention, their secretion characteristics, their ability to fold the polypeptide correctly, their fermentation or culture requirements, and the ease of purification from them of the products coded for by the nucleic acid sequences of this invention.
- The recombinant nucleic acid molecules and more particularly, the expression
- 25 vectors of this invention may be used to express the polypeptides of this invention as recombinant polypeptides in a heterologous host cell. The polypeptides of this invention may be full-length or less than full-length polypeptide fragments recombinantly expressed from the nucleic acid sequences according to this invention. Such polypeptides include analogs, derivatives and muteins that may or may not have
- 30 biological activity.

Vectors of the present invention will also often include elements that permit *in vitro* transcription of RNA from the inserted heterologous nucleic acid. Such vectors

typically include a phage promoter, such as that from T7, T3, or SP6, flanking the nucleic acid insert. Often two different such promoters flank the inserted nucleic acid, permitting separate *in vitro* production of both sense and antisense strands.

Transformation and other methods of introducing nucleic acids into a host cell

- 5 (e.g., conjugation, protoplast transformation or fusion, transfection, electroporation, liposome delivery, membrane fusion techniques, high velocity DNA-coated pellets, viral infection and protoplast fusion) can be accomplished by a variety of methods which are well-known in the art (See, for instance, Ausubel, *supra*, and Sambrook *et al.*, *supra*).  
Bacterial, yeast, plant or mammalian cells are transformed or transfected with an
- 10 expression vector, such as a plasmid, a cosmid, or the like, wherein the expression vector comprises the nucleic acid of interest. Alternatively, the cells may be infected by a viral expression vector comprising the nucleic acid of interest. Depending upon the host cell, vector, and method of transformation used, transient or stable expression of the polypeptide will be constitutive or inducible. One having ordinary skill in the art will be
- 15 able to decide whether to express a polypeptide transiently or stably, and whether to express the protein constitutively or inducibly.

A wide variety of unicellular host cells are useful in expressing the DNA sequences of this invention. These hosts may include well-known eukaryotic and prokaryotic hosts, such as strains of, fungi, yeast, insect cells such as *Spodoptera frugiperda* (SF9), animal cells such as CHO, as well as plant cells in tissue culture. Representative examples of appropriate host cells include, but are not limited to, bacterial cells, such as *E. coli*, *Caulobacter crescentus*, *Streptomyces* species, and *Salmonella typhimurium*; yeast cells, such as *Saccharomyces cerevisiae*, *Schizosaccharomyces pombe*, *Pichia pastoris*, *Pichia methanolica*; insect cell lines, such as those from *Spodoptera frugiperda*, e.g., Sf9 and Sf21 cell lines, and expresSFT™ cells (Protein Sciences Corp., Meriden, CT, USA), *Drosophila* S2 cells, and *Trichoplusia ni* High Five® Cells (Invitrogen, Carlsbad, CA, USA); and mammalian cells. Typical mammalian cells include BHK cells, BSC 1 cells, BSC 40 cells, BMT 10 cells, VERO cells, COS1 cells, COS7 cells, Chinese hamster ovary (CHO) cells, 3T3 cells, NIH 3T3 cells, 293 cells, HEPG2 cells, HeLa cells, L cells, MDCK cells, HEK293 cells, WI38 cells, murine ES cell lines (e.g., from strains 129/SV, C57/BL6, DBA-1, 129/SVJ), K562 cells, Jurkat cells, and BW5147 cells. Other mammalian cell lines are well-known and

-60-

readily available from the American Type Culture Collection (ATCC) (Manassas, VA, USA) and the National Institute of General Medical Sciences (NIGMS) Human Genetic Cell Repository at the Coriell Cell Repositories (Camden, NJ, USA). Cells or cell lines derived from ovary are particularly preferred because they may provide a more native  
5 post-translational processing. Particularly preferred are human ovary cells.

Particular details of the transfection, expression and purification of recombinant proteins are well documented and are understood by those of skill in the art. Further details on the various technical aspects of each of the steps used in recombinant production of foreign genes in bacterial cell expression systems can be found in a number  
10 of texts and laboratory manuals in the art. *See, e.g., Ausubel (1992), supra, Ausubel (1999), supra, Sambrook (1989), supra, and Sambrook (2001), supra, herein incorporated by reference.*

Methods for introducing the vectors and nucleic acids of the present invention into the host cells are well-known in the art; the choice of technique will depend  
15 primarily upon the specific vector to be introduced and the host cell chosen.

Nucleic acid molecules and vectors may be introduced into prokaryotes, such as *E. coli*, in a number of ways. For instance, phage lambda vectors will typically be packaged using a packaging extract (*e.g., Gigapack® packaging extract, Stratagene, La Jolla, CA, USA*), and the packaged virus used to infect *E. coli*.

20 Plasmid vectors will typically be introduced into chemically competent or electrocompetent bacterial cells. *E. coli* cells can be rendered chemically competent by treatment, *e.g.*, with CaCl<sub>2</sub>, or a solution of Mg<sup>2+</sup>, Mn<sup>2+</sup>, Ca<sup>2+</sup>, Rb<sup>+</sup> or K<sup>+</sup>, dimethyl sulfoxide, dithiothreitol, and hexamine cobalt (III), Hanahan, *J. Mol. Biol.* 166(4):557-80 (1983), and vectors introduced by heat shock. A wide variety of chemically competent  
25 strains are also available commercially (*e.g., Epicurian Coli® XL10-Gold® Ultracompetent Cells (Stratagene, La Jolla, CA, USA); DH5 competent cells (Clontech Laboratories, Palo Alto, CA, USA); and TOP10 Chemically Competent E. coli Kit (Invitrogen, Carlsbad, CA, USA)*). Bacterial cells can be rendered electrocompetent, that is, competent to take up exogenous DNA by electroporation, by various pre-pulse  
30 treatments; vectors are introduced by electroporation followed by subsequent outgrowth in selected media. An extensive series of protocols is provided online in Electroprotocols

(BioRad, Richmond, CA, USA) ([http://www.biorad.com/LifeScience/pdf/  
New\\_Gene\\_Pulser.pdf](http://www.biorad.com/LifeScience/pdf/New_Gene_Pulser.pdf)).

Vectors can be introduced into yeast cells by spheroplasting, treatment with lithium salts, electroporation, or protoplast fusion. Spheroplasts are prepared by the 5 action of hydrolytic enzymes such as snail-gut extract, usually denoted Glusulase, or Zymolyase, an enzyme from *Arthrobacter luteus*, to remove portions of the cell wall in the presence of osmotic stabilizers, typically 1 M sorbitol. DNA is added to the spheroplasts, and the mixture is co-precipitated with a solution of polyethylene glycol (PEG) and Ca<sup>2+</sup>. Subsequently, the cells are resuspended in a solution of sorbitol, mixed 10 with molten agar and then layered on the surface of a selective plate containing sorbitol.

For lithium-mediated transformation, yeast cells are treated with lithium acetate, which apparently permeabilizes the cell wall, DNA is added and the cells are co-precipitated with PEG. The cells are exposed to a brief heat shock, washed free of PEG and lithium acetate, and subsequently spread on plates containing ordinary selective 15 medium. Increased frequencies of transformation are obtained by using specially-prepared single-stranded carrier DNA and certain organic solvents. Schiestl *et al.*, *Curr. Genet.* 16(5-6): 339-46 (1989).

For electroporation, freshly-grown yeast cultures are typically washed, suspended in an osmotic protectant, such as sorbitol, mixed with DNA, and the cell suspension 20 pulsed in an electroporation device. Subsequently, the cells are spread on the surface of plates containing selective media. Becker *et al.*, *Methods Enzymol.* 194: 182-187 (1991). The efficiency of transformation by electroporation can be increased over 100-fold by using PEG, single-stranded carrier DNA and cells that are in late log-phase of growth. Larger constructs, such as YACs, can be introduced by protoplast fusion.

25 Mammalian and insect cells can be directly infected by packaged viral vectors, or transfected by chemical or electrical means. For chemical transfection, DNA can be coprecipitated with CaPO<sub>4</sub> or introduced using liposomal and nonliposomal lipid-based agents. Commercial kits are available for CaPO<sub>4</sub> transfection (CalPhos™ Mammalian Transfection Kit, Clontech Laboratories, Palo Alto, CA, USA), and lipid-mediated 30 transfection can be practiced using commercial reagents, such as LIPOFECTAMINE™ 2000, LIPOFECTAMINE™ Reagent, CELLFECTIN® Reagent, and LIPOFECTIN® Reagent (Invitrogen, Carlsbad, CA, USA), DOTAP Liposomal Transfection Reagent,

-62-

FuGENE 6, X-tremeGENE Q2, DOSPER, (Roche Molecular Biochemicals, Indianapolis, IN USA), Effectene™, PolyFect®, Superfect® (Qiagen, Inc., Valencia, CA, USA).

Protocols for electroporating mammalian cells can be found online in Electroprotocols (Bio-Rad, Richmond, CA, USA) (<http://www.bio-rad.com/LifeScience/pdf/>)

- 5 New\_Gene\_Pulser.pdf); Norton *et al.* (eds.), Gene Transfer Methods: Introducing DNA  
into Living Cells and Organisms, BioTechniques Books, Eaton Publishing Co. (2000);  
incorporated herein by reference in its entirety. Other transfection techniques include  
transfection by particle bombardment and microinjection. See, e.g., Cheng *et al.*, *Proc.  
Natl. Acad. Sci. USA* 90(10): 4455-9 (1993); Yang *et al.*, *Proc. Natl. Acad. Sci. USA*  
10 87(24): 9568-72 (1990).

Production of the recombinantly produced proteins of the present invention can  
optionally be followed by purification.

Purification of recombinantly expressed proteins is now well known by those skilled in  
the art. See, e.g., Thorner *et al.* (eds.), Applications of Chimeric Genes and Hybrid

- 15 Proteins, Part A: Gene Expression and Protein Purification (Methods in Enzymology,  
Vol. 326), Academic Press (2000); Harbin (ed.), Cloning, Gene Expression and Protein  
Purification : Experimental Procedures and Process Rationale, Oxford Univ. Press  
(2001); Marshak *et al.*, Strategies for Protein Purification and Characterization: A  
Laboratory Course Manual, Cold Spring Harbor Laboratory Press (1996); and Roe (ed.),  
20 Protein Purification Applications, Oxford University Press (2001); the disclosures of  
which are incorporated herein by reference in their entireties, and thus need not be  
detailed here.

Briefly, however, if purification tags have been fused through use of an  
expression vector that appends such tags, purification can be effected, at least in part, by  
25 means appropriate to the tag, such as use of immobilized metal affinity chromatography  
for polyhistidine tags. Other techniques common in the art include ammonium sulfate  
fractionation, immunoprecipitation, fast protein liquid chromatography (FPLC), high  
performance liquid chromatography (HPLC), and preparative gel electrophoresis.

#### Polypeptides

- 30 Another object of the invention is to provide polypeptides encoded by the nucleic  
acid molecules of the instant invention. In a preferred embodiment, the polypeptide is an  
ovary specific polypeptide (OSP). In an even more preferred embodiment, the

polypeptide is derived from a polypeptide comprising the amino acid sequence of SEQ ID NO: 138 through 238. A polypeptide as defined herein may be produced recombinantly, as discussed *supra*, may be isolated from a cell that naturally expresses the protein, or may be chemically synthesized following the teachings of the specification 5 and using methods well-known to those having ordinary skill in the art.

In another aspect, the polypeptide may comprise a fragment of a polypeptide, wherein the fragment is as defined herein. In a preferred embodiment, the polypeptide fragment is a fragment of an OSP. In a more preferred embodiment, the fragment is derived from a polypeptide comprising the amino acid sequence of SEQ ID NO: 138 10 through 238. A polypeptide that comprises only a fragment of an entire OSP may or may not be a polypeptide that is also an OSP. For instance, a full-length polypeptide may be ovary-specific, while a fragment thereof may be found in other tissues as well as in ovary. A polypeptide that is not an OSP, whether it is a fragment, analog, mutein, homologous protein or derivative, is nevertheless useful, especially for immunizing 15 animals to prepare anti-OSP antibodies. However, in a preferred embodiment, the part or fragment is an OSP. Methods of determining whether a polypeptide is an OSP are described *infra*.

Fragments of at least 6 contiguous amino acids are useful in mapping B cell and T cell epitopes of the reference protein. See, e.g., Geysen *et al.*, *Proc. Natl. Acad. Sci. USA* 20 81: 3998-4002 (1984) and U.S. Patents 4,708,871 and 5,595,915, the disclosures of which are incorporated herein by reference in their entireties. Because the fragment need not itself be immunogenic, part of an immunodominant epitope, nor even recognized by native antibody, to be useful in such epitope mapping, all fragments of at least 6 amino acids of the proteins of the present invention have utility in such a study.

25 Fragments of at least 8 contiguous amino acids, often at least 15 contiguous amino acids, are useful as immunogens for raising antibodies that recognize the proteins of the present invention. See, e.g., Lerner, *Nature* 299: 592-596 (1982); Shinnick *et al.*, *Annu. Rev. Microbiol.* 37: 425-46 (1983); Sutcliffe *et al.*, *Science* 219: 660-6 (1983), the disclosures of which are incorporated herein by reference in their entireties. As further 30 described in the above-cited references, virtually all 8-mers, conjugated to a carrier, such as a protein, prove immunogenic, meaning that they are capable of eliciting antibody for

-64-

the conjugated peptide; accordingly, all fragments of at least 8 amino acids of the proteins of the present invention have utility as immunogens.

Fragments of at least 8, 9, 10 or 12 contiguous amino acids are also useful as competitive inhibitors of binding of the entire protein, or a portion thereof, to antibodies 5 (as in epitope mapping), and to natural binding partners, such as subunits in a multimeric complex or to receptors or ligands of the subject protein; this competitive inhibition permits identification and separation of molecules that bind specifically to the protein of interest, U.S. Patents 5,539,084 and 5,783,674, incorporated herein by reference in their entireties.

10 The protein, or protein fragment, of the present invention is thus at least 6 amino acids in length, typically at least 8, 9, 10 or 12 amino acids in length, and often at least 15 amino acids in length. Often, the protein of the present invention, or fragment thereof, is at least 20 amino acids in length, even 25 amino acids, 30 amino acids, 35 amino acids, or 50 amino acids or more in length. Of course, larger fragments having at least 75 15 amino acids, 100 amino acids, or even 150 amino acids are also useful, and at times preferred.

One having ordinary skill in the art can produce fragments of a polypeptide by truncating the nucleic acid molecule, *e.g.*, an OSNA, encoding the polypeptide and then expressing it recombinantly. Alternatively, one can produce a fragment by chemically 20 synthesizing a portion of the full-length polypeptide. One may also produce a fragment by enzymatically cleaving either a recombinant polypeptide or an isolated naturally- occurring polypeptide. Methods of producing polypeptide fragments are well-known in the art. *See, e.g.*, Sambrook (1989), *supra*; Sambrook (2001), *supra*; Ausubel (1992), *supra*; and Ausubel (1999), *supra*. In one embodiment, a polypeptide comprising only a 25 fragment of polypeptide of the invention, preferably an OSP, may be produced by chemical or enzymatic cleavage of a polypeptide. In a preferred embodiment, a polypeptide fragment is produced by expressing a nucleic acid molecule encoding a fragment of the polypeptide, preferably an OSP, in a host cell.

By "polypeptides" as used herein it is also meant to be inclusive of mutants, 30 fusion proteins, homologous proteins and allelic variants of the polypeptides specifically exemplified.

A mutant protein, or mutein, may have the same or different properties compared to a naturally-occurring polypeptide and comprises at least one amino acid insertion, duplication, deletion, rearrangement or substitution compared to the amino acid sequence of a native protein. Small deletions and insertions can often be found that do not alter the function of the protein. In one embodiment, the mutein may or may not be ovary-specific. In a preferred embodiment, the mutein is ovary-specific. In a preferred embodiment, the mutein is a polypeptide that comprises at least one amino acid insertion, duplication, deletion, rearrangement or substitution compared to the amino acid sequence of SEQ ID NO: 138 through 238. In a more preferred embodiment, the mutein is one that exhibits at least 50% sequence identity, more preferably at least 60% sequence identity, even more preferably at least 70%, yet more preferably at least 80% sequence identity to an OSP comprising an amino acid sequence of SEQ ID NO: 138 through 238. In yet a more preferred embodiment, the mutein exhibits at least 85%, more preferably 90%, even more preferably 95% or 96%, and yet more preferably at least 97%, 98%, 99% or 99.5% sequence identity to an OSP comprising an amino acid sequence of SEQ ID NO: 138 through 238.

A mutein may be produced by isolation from a naturally-occurring mutant cell, tissue or organism. A mutein may be produced by isolation from a cell, tissue or organism that has been experimentally mutagenized. Alternatively, a mutein may be produced by chemical manipulation of a polypeptide, such as by altering the amino acid residue to another amino acid residue using synthetic or semi-synthetic chemical techniques. In a preferred embodiment, a mutein may be produced from a host cell comprising an altered nucleic acid molecule compared to the naturally-occurring nucleic acid molecule. For instance, one may produce a mutein of a polypeptide by introducing one or more mutations into a nucleic acid sequence of the invention and then expressing it recombinantly. These mutations may be targeted, in which particular encoded amino acids are altered, or may be untargeted, in which random encoded amino acids within the polypeptide are altered. Muteins with random amino acid alterations can be screened for a particular biological activity or property, particularly whether the polypeptide is ovary-specific, as described below. Multiple random mutations can be introduced into the gene by methods well-known to the art, e.g., by error-prone PCR, shuffling, oligonucleotide-directed mutagenesis, assembly PCR, sexual PCR mutagenesis, *in vivo*

-66-

mutagenesis, cassette mutagenesis, recursive ensemble mutagenesis, exponential ensemble mutagenesis and site-specific mutagenesis. Methods of producing muteins with targeted or random amino acid alterations are well-known in the art. See, e.g., Sambrook (1989), *supra*; Sambrook (2001), *supra*; Ausubel (1992), *supra*; and Ausubel 5 (1999), U.S. Patent 5,223,408, and the references discussed *supra*, each herein incorporated by reference.

By "polypeptide" as used herein it is also meant to be inclusive of polypeptides homologous to those polypeptides exemplified herein. In a preferred embodiment, the polypeptide is homologous to an OSP. In an even more preferred embodiment, the 10 polypeptide is homologous to an OSP selected from the group having an amino acid sequence of SEQ ID NO: 138 through 238. In a preferred embodiment, the homologous polypeptide is one that exhibits significant sequence identity to an OSP. In a more preferred embodiment, the polypeptide is one that exhibits significant sequence identity to an comprising an amino acid sequence of SEQ ID NO: 138 through 238. In an even 15 more preferred embodiment, the homologous polypeptide is one that exhibits at least 50% sequence identity, more preferably at least 60% sequence identity, even more preferably at least 70%, yet more preferably at least 80% sequence identity to an OSP comprising an amino acid sequence of SEQ ID NO: 138 through 238. In a yet more preferred embodiment, the homologous polypeptide is one that exhibits at least 85%, 20 more preferably 90%, even more preferably 95% or 96%, and yet more preferably at least 97% or 98% sequence identity to an OSP comprising an amino acid sequence of SEQ ID NO: 138 through 238. In another preferred embodiment, the homologous polypeptide is one that exhibits at least 99%, more preferably 99.5%, even more preferably 99.6%, 99.7%, 99.8% or 99.9% sequence identity to an OSP comprising an 25 amino acid sequence of SEQ ID NO: 138 through 238. In a preferred embodiment, the amino acid substitutions are conservative amino acid substitutions as discussed above.

In another embodiment, the homologous polypeptide is one that is encoded by a nucleic acid molecule that selectively hybridizes to an OSNA. In a preferred embodiment, the homologous polypeptide is encoded by a nucleic acid molecule that 30 hybridizes to an OSNA under low stringency, moderate stringency or high stringency conditions, as defined herein. In a more preferred embodiment, the OSNA is selected from the group consisting of SEQ ID NO: 1 through 137. In another preferred

embodiment, the homologous polypeptide is encoded by a nucleic acid molecule that hybridizes to a nucleic acid molecule that encodes an OSP under low stringency, moderate stringency or high stringency conditions, as defined herein. In a more preferred embodiment, the OSP is selected from the group consisting of SEQ ID NO: 138 through 5 238.

The homologous polypeptide may be a naturally-occurring one that is derived from another species, especially one derived from another primate, such as chimpanzee, gorilla, rhesus macaque, baboon or gorilla, wherein the homologous polypeptide comprises an amino acid sequence that exhibits significant sequence identity to that of 10 SEQ ID NO: 138 through 238. The homologous polypeptide may also be a naturally-occurring polypeptide from a human, when the OSP is a member of a family of polypeptides. The homologous polypeptide may also be a naturally-occurring polypeptide derived from a non-primate, mammalian species, including without limitation, domesticated species, e.g., dog, cat, mouse, rat, rabbit, guinea pig, hamster, 15 cow, horse, goat or pig. The homologous polypeptide may also be a naturally-occurring polypeptide derived from a non-mammalian species, such as birds or reptiles. The naturally-occurring homologous protein may be isolated directly from humans or other species. Alternatively, the nucleic acid molecule encoding the naturally-occurring homologous polypeptide may be isolated and used to express the homologous 20 polypeptide recombinantly. In another embodiment, the homologous polypeptide may be one that is experimentally produced by random mutation of a nucleic acid molecule and subsequent expression of the nucleic acid molecule. In another embodiment, the homologous polypeptide may be one that is experimentally produced by directed mutation of one or more codons to alter the encoded amino acid of an OSP. Further, the 25 homologous protein may or may not encode polypeptide that is an OSP. However, in a preferred embodiment, the homologous polypeptide encodes a polypeptide that is an OSP.

Relatedness of proteins can also be characterized using a second functional test, the ability of a first protein competitively to inhibit the binding of a second protein to an 30 antibody. It is, therefore, another aspect of the present invention to provide isolated proteins not only identical in sequence to those described with particularity herein, but also to provide isolated proteins ("cross-reactive proteins") that competitively inhibit the

binding of antibodies to all or to a portion of various of the isolated polypeptides of the present invention. Such competitive inhibition can readily be determined using immunoassays well-known in the art.

As discussed above, single nucleotide polymorphisms (SNPs) occur frequently in 5 eukaryotic genomes, and the sequence determined from one individual of a species may differ from other allelic forms present within the population. Thus, by "polypeptide" as used herein it is also meant to be inclusive of polypeptides encoded by an allelic variant of a nucleic acid molecule encoding an OSP. In a preferred embodiment, the polypeptide is encoded by an allelic variant of a gene that encodes a polypeptide having the amino 10 acid sequence selected from the group consisting of SEQ ID NO: 138 through 238. In a yet more preferred embodiment, the polypeptide is encoded by an allelic variant of a gene that has the nucleic acid sequence selected from the group consisting of SEQ ID NO: 1 through 137.

In another embodiment, the invention provides polypeptides which comprise 15 derivatives of a polypeptide encoded by a nucleic acid molecule according to the instant invention. In a preferred embodiment, the polypeptide is an OSP. In a preferred embodiment, the polypeptide has an amino acid sequence selected from the group consisting of SEQ ID NO: 138 through 238, or is a mutein, allelic variant, homologous protein or fragment thereof. In a preferred embodiment, the derivative has been 20 acetylated, carboxylated, phosphorylated, glycosylated or ubiquitinated. In another preferred embodiment, the derivative has been labeled with, e.g., radioactive isotopes such as <sup>125</sup>I, <sup>32</sup>P, <sup>35</sup>S, and <sup>3</sup>H. In another preferred embodiment, the derivative has been labeled with fluorophores, chemiluminescent agents, enzymes, and antiligands that can serve as specific binding pair members for a labeled ligand.

25 Polypeptide modifications are well-known to those of skill and have been described in great detail in the scientific literature. Several particularly common modifications, glycosylation, lipid attachment, sulfation, gamma-carboxylation of glutamic acid residues, hydroxylation and ADP-ribosylation, for instance, are described in most basic texts, such as, for instance Creighton, Protein Structure and Molecular Properties, 2nd ed., W. H. Freeman and Company (1993). Many detailed reviews are available on this subject, such as, for example, those provided by Wold, in Johnson (ed.), Posttranslational Covalent Modification of Proteins, pgs. 1-12, Academic Press (1983);

Seifert *et al.*, *Meth. Enzymol.* 182: 626-646 (1990) and Rattan *et al.*, *Ann. N.Y. Acad. Sci.* 663: 48-62 (1992).

It will be appreciated, as is well-known and as noted above, that polypeptides are not always entirely linear. For instance, polypeptides may be branched as a result of ubiquitination, and they may be circular, with or without branching, generally as a result of posttranslation events, including natural processing event and events brought about by human manipulation which do not occur naturally. Circular, branched and branched circular polypeptides may be synthesized by non-translation natural process and by entirely synthetic methods, as well. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. In fact, blockage of the amino or carboxyl group in a polypeptide, or both, by a covalent modification, is common in naturally occurring and synthetic polypeptides and such modifications may be present in polypeptides of the present invention, as well. For instance, the amino terminal residue of polypeptides made in *E. coli*, prior to proteolytic processing, almost invariably will be N-formylmethionine.

Useful post-synthetic (and post-translational) modifications include conjugation to detectable labels, such as fluorophores. A wide variety of amine-reactive and thiol-reactive fluorophore derivatives have been synthesized that react under nondenaturing conditions with N-terminal amino groups and epsilon amino groups of lysine residues, on the one hand, and with free thiol groups of cysteine residues, on the other.

Kits are available commercially that permit conjugation of proteins to a variety of amine-reactive or thiol-reactive fluorophores: Molecular Probes, Inc. (Eugene, OR, USA), e.g., offers kits for conjugating proteins to Alexa Fluor 350, Alexa Fluor 430, Fluorescein-EX, Alexa Fluor 488, Oregon Green 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, and Texas Red-X.

A wide variety of other amine-reactive and thiol-reactive fluorophores are available commercially (Molecular Probes, Inc., Eugene, OR, USA), including Alexa Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 647 (monoclonal antibody labeling kits available from Molecular Probes, Inc., Eugene, OR, USA), BODIPY dyes, such as BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591,

-70-

BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, OR, USA).

- 5       The polypeptides of the present invention can also be conjugated to fluorophores, other proteins, and other macromolecules, using bifunctional linking reagents. Common homobifunctional reagents include, e.g., APG, AEDP, BASED, BMB, BMDB, BMH, BMOE, BM[PEO]3, BM[PEO]4, BS3, BSOCOES, DF DN, DMA, DMP, DMS, DPD PB, DSG, DSP (Lomant's Reagent), DSS, DST, DTBP, DTME, DTSSP, EGS,
- 10      HBVS, Sulfo-BSOCOES, Sulfo-DST, Sulfo-EGS (all available from Pierce, Rockford, IL, USA); common heterobifunctional cross-linkers include ABH, AMAS, ANB-NOS, APDP, ASBA, BMPA, BMPH, BMPS, EDC, EMCA, EMCH, EMCS, KMUA, KMUH, GMBS, LC-SMCC, LC-SPDP, MBS, M2C2H, MPBH, MSA, NHS-ASA, PDPH, PMPI, SADP, SAED, SAND, SANPAH, SASD, SATP, SBAP, SFAD, SIA, SIAB, SMCC,
- 15      SMPB, SMPH, SMPT, SPDP, Sulfo-EMCS, Sulfo-GMBS, Sulfo-HSAB, Sulfo-KMUS, Sulfo-LC-SPDP, Sulfo-MBS, Sulfo-NHS-LC-ASA, Sulfo-SADP, Sulfo-SANPAH, Sulfo-SIAB, Sulfo-SMCC, Sulfo-SMPB, Sulfo-LC-SMPT, SVSB, TFCS (all available Pierce, Rockford, IL, USA).

The polypeptides, fragments, and fusion proteins of the present invention can be  
20 conjugated, using such cross-linking reagents, to fluorophores that are not amine- or thiol-reactive. Other labels that usefully can be conjugated to the polypeptides, fragments, and fusion proteins of the present invention include radioactive labels, echosonographic contrast reagents, and MRI contrast agents.

The polypeptides, fragments, and fusion proteins of the present invention can also  
25 usefully be conjugated using cross-linking agents to carrier proteins, such as KLH, bovine thyroglobulin, and even bovine serum albumin (BSA), to increase immunogenicity for raising anti-OSP antibodies.

The polypeptides, fragments, and fusion proteins of the present invention can also usefully be conjugated to polyethylene glycol (PEG); PEGylation increases the serum  
30 half-life of proteins administered intravenously for replacement therapy. Delgado *et al.*, *Crit. Rev. Ther. Drug Carrier Syst.* 9(3-4): 249-304 (1992); Scott *et al.*, *Curr. Pharm. Des.* 4(6): 423-38 (1998); De Santis *et al.*, *Curr. Opin. Biotechnol.* 10(4): 324-30 (1999),

incorporated herein by reference in their entireties. PEG monomers can be attached to the protein directly or through a linker, with PEGylation using PEG monomers activated with tresyl chloride (2,2,2-trifluoroethanesulphonyl chloride) permitting direct attachment under mild conditions.

- 5        In yet another embodiment, the invention provides analogs of a polypeptide encoded by a nucleic acid molecule according to the instant invention. In a preferred embodiment, the polypeptide is an OSP. In a more preferred embodiment, the analog is derived from a polypeptide having part or all of the amino acid sequence of SEQ ID NO: 138 through 238. In a preferred embodiment, the analog is one that comprises one or  
10 more substitutions of non-natural amino acids or non-native inter-residue bonds compared to the naturally-occurring polypeptide. In general, the non-peptide analog is structurally similar to an OSP, but one or more peptide linkages is replaced by a linkage selected from the group consisting of --CH<sub>2</sub>NH--, --CH<sub>2</sub>S--, --CH<sub>2</sub>-CH<sub>2</sub>--,  
--CH=CH--(cis and trans), --COCH<sub>2</sub>--, --CH(OH)CH<sub>2</sub>-- and --CH<sub>2</sub>SO--. In another  
15 embodiment, the non-peptide analog comprises substitution of one or more amino acids of an OSP with a D-amino acid of the same type or other non-natural amino acid in order to generate more stable peptides. D-amino acids can readily be incorporated during chemical peptide synthesis: peptides assembled from D-amino acids are more resistant to proteolytic attack; incorporation of D-amino acids can also be used to confer specific  
20 three-dimensional conformations on the peptide. Other amino acid analogues commonly added during chemical synthesis include ornithine, norleucine, phosphorylated amino acids (typically phosphoserine, phosphothreonine, phosphotyrosine), L-malonyltyrosine, a non-hydrolyzable analog of phosphotyrosine (*see, e.g., Kole et al., Biochem. Biophys. Res. Com. 209: 817-821 (1995)*), and various halogenated phenylalanine derivatives.  
25        Non-natural amino acids can be incorporated during solid phase chemical synthesis or by recombinant techniques, although the former is typically more common. Solid phase chemical synthesis of peptides is well established in the art. Procedures are described, *inter alia*, in Chan *et al.* (eds.), Fmoc Solid Phase Peptide Synthesis: A Practical Approach (Practical Approach Series), Oxford Univ. Press (March 2000);  
30 Jones, Amino Acid and Peptide Synthesis (Oxford Chemistry Primers, No 7), Oxford Univ. Press (1992); and Bodanszky, Principles of Peptide Synthesis (Springer

Laboratory), Springer Verlag (1993); the disclosures of which are incorporated herein by reference in their entireties.

- Amino acid analogues having detectable labels are also usefully incorporated during synthesis to provide derivatives and analogs. Biotin, for example can be added
- 5 using biotinoyl-(9-fluorenylmethoxycarbonyl)-L-lysine (FMOC biocytin) (Molecular Probes, Eugene, OR, USA). Biotin can also be added enzymatically by incorporation into a fusion protein of a *E. coli* BirA substrate peptide. The FMOC and *t*BOC derivatives of dabcyl-L-lysine (Molecular Probes, Inc., Eugene, OR, USA) can be used to incorporate the dabcyl chromophore at selected sites in the peptide sequence during
- 10 synthesis. The aminonaphthalene derivative EDANS, the most common fluorophore for pairing with the dabcyl quencher in fluorescence resonance energy transfer (FRET) systems, can be introduced during automated synthesis of peptides by using EDANS-FMOC-L-glutamic acid or the corresponding *t*BOC derivative (both from Molecular Probes, Inc., Eugene, OR, USA). Tetramethylrhodamine fluorophores can be
- 15 incorporated during automated FMOC synthesis of peptides using (FMOC)-TMR-L-lysine (Molecular Probes, Inc. Eugene, OR, USA).

Other useful amino acid analogues that can be incorporated during chemical synthesis include aspartic acid, glutamic acid, lysine, and tyrosine analogues having allyl side-chain protection (Applied Biosystems, Inc., Foster City, CA, USA); the allyl side chain permits synthesis of cyclic, branched-chain, sulfonated, glycosylated, and phosphorylated peptides.

A large number of other FMOC-protected non-natural amino acid analogues capable of incorporation during chemical synthesis are available commercially, including, e.g., Fmoc-2-aminobicyclo[2.2.1]heptane-2-carboxylic acid, Fmoc-3-endo-  
25 aminobicyclo[2.2.1]heptane-2-endo-carboxylic acid, Fmoc-3-exo-aminobicyclo[2.2.1]heptane-2-exo-carboxylic acid, Fmoc-3-endo-amino-bicyclo[2.2.1]hept-5-ene-2-exo-carboxylic acid, Fmoc-cis-2-amino-1-cyclohexanecarboxylic acid, Fmoc-trans-2-amino-1-cyclohexanecarboxylic acid, Fmoc-1-amino-1-cyclopentanecarboxylic  
30 acid, Fmoc-cis-2-amino-1-cyclopentanecarboxylic acid, Fmoc-1-amino-1-cyclopropanecarboxylic acid, Fmoc-D-2-amino-4-(ethylthio)butyric acid, Fmoc-L-2-amino-4-(ethylthio)butyric acid, Fmoc-L-buthionine, Fmoc-S-methyl-L-Cysteine, Fmoc-

-73-

- 2-aminobenzoic acid (anthranillic acid), Fmoc-3-aminobenzoic acid, Fmoc-4-aminobenzoic acid, Fmoc-2-aminobenzophenone-2'-carboxylic acid, Fmoc-N-(4-aminobenzoyl)- $\beta$ -alanine, Fmoc-2-amino-4,5-dimethoxybenzoic acid, Fmoc-4-aminohippuric acid, Fmoc-2-amino-3-hydroxybenzoic acid, Fmoc-2-amino-5-hydroxybenzoic acid, Fmoc-3-amino-4-hydroxybenzoic acid, Fmoc-4-amino-3-hydroxybenzoic acid, Fmoc-4-amino-2-hydroxybenzoic acid, Fmoc-5-amino-2-hydroxybenzoic acid, Fmoc-2-amino-3-methoxybenzoic acid, Fmoc-4-amino-3-methoxybenzoic acid, Fmoc-2-amino-3-methylbenzoic acid, Fmoc-2-amino-5-methylbenzoic acid, Fmoc-2-amino-6-methylbenzoic acid, Fmoc-3-amino-2-methylbenzoic acid, Fmoc-3-amino-4-methylbenzoic acid, Fmoc-4-amino-3-methylbenzoic acid, Fmoc-3-amino-2-naphtoic acid, Fmoc-D,L-3-amino-3-phenylpropionic acid, Fmoc-L-Methyldopa, Fmoc-2-amino-4,6-dimethyl-3-pyridinecarboxylic acid, Fmoc-D,L-amino-2-thiophenacetic acid, Fmoc-4-(carboxymethyl)piperazine, Fmoc-4-carboxypiperazine, Fmoc-4-(carboxymethyl)homopiperazine, Fmoc-4-phenyl-4-piperidinecarboxylic acid, Fmoc-L-1,2,3,4-tetrahydronorharman-3-carboxylic acid, Fmoc-L-thiazolidine-4-carboxylic acid, all available from The Peptide Laboratory (Richmond, CA, USA).

Non-natural residues can also be added biosynthetically by engineering a suppressor tRNA, typically one that recognizes the UAG stop codon, by chemical aminoacylation with the desired unnatural amino acid. Conventional site-directed mutagenesis is used to introduce the chosen stop codon UAG at the site of interest in the protein gene. When the acylated suppressor tRNA and the mutant gene are combined in an *in vitro* transcription/translation system, the unnatural amino acid is incorporated in response to the UAG codon to give a protein containing that amino acid at the specified position. Liu *et al.*, *Proc. Natl Acad. Sci. USA* 96(9): 4780-5 (1999); Wang *et al.*, *Science* 292(5516): 498-500 (2001).

#### Fusion Proteins

The present invention further provides fusions of each of the polypeptides and fragments of the present invention to heterologous polypeptides. In a preferred embodiment, the polypeptide is an OSP. In a more preferred embodiment, the polypeptide that is fused to the heterologous polypeptide comprises part or all of the amino acid sequence of SEQ ID NO: 138 through 238, or is a mutein, homologous

polypeptide, analog or derivative thereof. In an even more preferred embodiment, the nucleic acid molecule encoding the fusion protein comprises all or part of the nucleic acid sequence of SEQ ID NO: 1 through 137, or comprises all or part of a nucleic acid sequence that selectively hybridizes or is homologous to a nucleic acid molecule

5 comprising a nucleic acid sequence of SEQ ID NO: 1 through 137.

The fusion proteins of the present invention will include at least one fragment of the protein of the present invention, which fragment is at least 6, typically at least 8, often at least 15, and usefully at least 16, 17, 18, 19, or 20 amino acids long. The fragment of the protein of the present to be included in the fusion can usefully be at least 25 amino

10 acids long, at least 50 amino acids long, and can be at least 75, 100, or even 150 amino acids long. Fusions that include the entirety of the proteins of the present invention have particular utility.

The heterologous polypeptide included within the fusion protein of the present invention is at least 6 amino acids in length, often at least 8 amino acids in length, and

15 usefully at least 15, 20, and 25 amino acids in length. Fusions that include larger polypeptides, such as the IgG Fc region, and even entire proteins (such as GFP chromophore-containing proteins) are particular useful.

As described above in the description of vectors and expression vectors of the present invention, which discussion is incorporated here by reference in its entirety,

20 heterologous polypeptides to be included in the fusion proteins of the present invention can usefully include those designed to facilitate purification and/or visualization of recombinantly-expressed proteins. *See, e.g., Ausubel, Chapter 16, (1992), supra.* Although purification tags can also be incorporated into fusions that are chemically synthesized, chemical synthesis typically provides sufficient purity that further

25 purification by HPLC suffices; however, visualization tags as above described retain their utility even when the protein is produced by chemical synthesis, and when so included render the fusion proteins of the present invention useful as directly detectable markers of the presence of a polypeptide of the invention.

As also discussed above, heterologous polypeptides to be included in the fusion

30 proteins of the present invention can usefully include those that facilitate secretion of recombinantly expressed proteins — into the periplasmic space or extracellular milieu for prokaryotic hosts, into the culture medium for eukaryotic cells — through incorporation

- of secretion signals and/or leader sequences. For example, a His<sup>6</sup> tagged protein can be purified on a Ni affinity column and a GST fusion protein can be purified on a glutathione affinity column. Similarly, a fusion protein comprising the Fc domain of IgG can be purified on a Protein A or Protein G column and a fusion protein comprising an epitope tag such as myc can be purified using an immunoaffinity column containing an anti-c-myc antibody. It is preferable that the epitope tag be separated from the protein encoded by the essential gene by an enzymatic cleavage site that can be cleaved after purification. See also the discussion of nucleic acid molecules encoding fusion proteins that may be expressed on the surface of a cell.
- 10 Other useful protein fusions of the present invention include those that permit use of the protein of the present invention as bait in a yeast two-hybrid system. See Bartel *et al.* (eds.), The Yeast Two-Hybrid System, Oxford University Press (1997); Zhu *et al.*, Yeast Hybrid Technologies, Eaton Publishing (2000); Fields *et al.*, *Trends Genet.* 10(8): 286-92 (1994); Mendelsohn *et al.*, *Curr. Opin. Biotechnol.* 5(5): 482-6 (1994); Luban *et al.*, *Curr. Opin. Biotechnol.* 6(1): 59-64 (1995); Allen *et al.*, *Trends Biochem. Sci.* 20(12): 511-6 (1995); Drees, *Curr. Opin. Chem. Biol.* 3(1): 64-70 (1999); Topcu *et al.*, *Pharm. Res.* 17(9): 1049-55 (2000); Fashena *et al.*, *Gene* 250(1-2): 1-14 (2000); ; Colas *et al.*, (1996) Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2. *Nature* 380, 548-550; Norman, T. *et al.*, (1999) Genetic selection of peptide inhibitors of biological pathways. *Science* 285, 591-595, Fabbrizio *et al.*, (1999) Inhibition of mammalian cell proliferation by genetically selected peptide aptamers that functionally antagonize E2F activity. *Oncogene* 18, 4357-4363; Xu *et al.*, (1997) Cells that register logical relationships among proteins. *Proc Natl Acad Sci U S A.* 94, 12473-12478; Yang, *et al.*, (1995) Protein-peptide interactions analyzed with the yeast two-hybrid system. *Nuc. Acids Res.* 23, 1152-1156; Kolonin *et al.*, (1998) Targeting cyclin-dependent kinases in Drosophila with peptide aptamers. *Proc Natl Acad Sci U S A* 95, 14266-14271; Cohen *et al.*, (1998) An artificial cell-cycle inhibitor isolated from a combinatorial library. *Proc Natl Acad Sci U S A* 95, 14272-14277; Uetz, P.; Giot, L.; al. e.; Fields, S.; Rothberg, J. M. (2000) A comprehensive analysis of protein-protein interactions in *Saccharomyces cerevisiae*. *Nature* 403, 623-627; Ito, *et al.*, (2001) A comprehensive two-hybrid analysis to explore the yeast protein interactome. *Proc Natl Acad Sci U S A* 98, 4569-4574, the disclosures of which are incorporated herein by

-76-

reference in their entireties. Typically, such fusion is to either *E. coli* LexA or yeast GAL4 DNA binding domains. Related bait plasmids are available that express the bait fused to a nuclear localization signal.

Other useful fusion proteins include those that permit display of the encoded 5 protein on the surface of a phage or cell, fusions to intrinsically fluorescent proteins, such as green fluorescent protein (GFP), and fusions to the IgG Fc region, as described above, which discussion is incorporated here by reference in its entirety.

The polypeptides and fragments of the present invention can also usefully be fused to protein toxins, such as *Pseudomonas* exotoxin A, *diphtheria* toxin, *shiga* toxin 10 10 *A*, *anthrax* toxin lethal factor, ricin, in order to effect ablation of cells that bind or take up the proteins of the present invention.

Fusion partners include, *inter alia*, *myc*, hemagglutinin (HA), GST, 15 immunoglobulins,  $\beta$ -galactosidase, biotin trpE, protein A,  $\beta$ -lactamase, -amylase, maltose binding protein, alcohol dehydrogenase, polyhistidine (for example, six histidine at the amino and/or carboxyl terminus of the polypeptide), lacZ, green fluorescent protein (GFP), yeast \_ mating factor, GAL4 transcription activation or DNA binding domain, luciferase, and serum proteins such as ovalbumin, albumin and the constant domain of IgG. See, e.g., Ausubel (1992), *supra* and Ausubel (1999), *supra*. Fusion proteins may also contain sites for specific enzymatic cleavage, such as a site that is recognized by 20 enzymes such as Factor XIII, trypsin, pepsin, or any other enzyme known in the art. Fusion proteins will typically be made by either recombinant nucleic acid methods, as described above, chemically synthesized using techniques well-known in the art (e.g., a Merrifield synthesis), or produced by chemical cross-linking.

Another advantage of fusion proteins is that the epitope tag can be used to bind 25 the fusion protein to a plate or column through an affinity linkage for screening binding proteins or other molecules that bind to the OSP.

As further described below, the isolated polypeptides, muteins, fusion proteins, homologous proteins or allelic variants of the present invention can readily be used as specific immunogens to raise antibodies that specifically recognize OSPs, their allelic 30 variants and homologues. The antibodies, in turn, can be used, *inter alia*, specifically to assay for the polypeptides of the present invention, particularly OSPs, e.g. by ELISA for detection of protein fluid samples, such as serum, by immunohistochemistry or laser

scanning cytometry, for detection of protein in tissue samples, or by flow cytometry, for detection of intracellular protein in cell suspensions, for specific antibody-mediated isolation and/or purification of OSPs, as for example by immunoprecipitation, and for use as specific agonists or antagonists of OSPs.

- 5 One may determine whether polypeptides including muteins, fusion proteins, homologous proteins or allelic variants are functional by methods known in the art. For instance, residues that are tolerant of change while retaining function can be identified by altering the protein at known residues using methods known in the art, such as alanine scanning mutagenesis, Cunningham *et al.*, *Science* 244(4908): 1081-5 (1989); transposon  
10 linker scanning mutagenesis, Chen *et al.*, *Gene* 263(1-2): 39-48 (2001); combinations of homolog- and alanine-scanning mutagenesis, Jin *et al.*, *J. Mol. Biol.* 226(3): 851-65 (1992); combinatorial alanine scanning, Weiss *et al.*, *Proc. Natl. Acad. Sci USA* 97(16): 8950-4 (2000), followed by functional assay. Transposon linker scanning kits are available commercially (New England Biolabs, Beverly, MA, USA, catalog. no. E7-  
15 102S; EZ::TNT™ In-Frame Linker Insertion Kit, catalogue no. EZI04KN, Epicentre Technologies Corporation, Madison, WI, USA).

- Purification of the polypeptides including fragments, homologous polypeptides, muteins, analogs, derivatives and fusion proteins is well-known and within the skill of one having ordinary skill in the art. *See, e.g.*, Scopes, Protein Purification, 2d ed. (1987).  
20 Purification of recombinantly expressed polypeptides is described above. Purification of chemically-synthesized peptides can readily be effected, *e.g.*, by HPLC.

- Accordingly, it is an aspect of the present invention to provide the isolated proteins of the present invention in pure or substantially pure form in the presence of absence of a stabilizing agent. Stabilizing agents include both proteinaceous or non-  
25 proteinaceous material and are well-known in the art. Stabilizing agents, such as albumin and polyethylene glycol (PEG) are known and are commercially available.

- Although high levels of purity are preferred when the isolated proteins of the present invention are used as therapeutic agents, such as in vaccines and as replacement therapy, the isolated proteins of the present invention are also useful at lower purity. For  
30 example, partially purified proteins of the present invention can be used as immunogens to raise antibodies in laboratory animals.

In preferred embodiments, the purified and substantially purified proteins of the present invention are in compositions that lack detectable ampholytes, acrylamide monomers, bis-acrylamide monomers, and polyacrylamide.

The polypeptides, fragments, analogs, derivatives and fusions of the present invention can usefully be attached to a substrate. The substrate can be porous or solid, planar or non-planar; the bond can be covalent or noncovalent.

For example, the polypeptides, fragments, analogs, derivatives and fusions of the present invention can usefully be bound to a porous substrate, commonly a membrane, typically comprising nitrocellulose, polyvinylidene fluoride (PVDF), or cationically derivatized, hydrophilic PVDF; so bound, the proteins, fragments, and fusions of the present invention can be used to detect and quantify antibodies, *e.g.* in serum, that bind specifically to the immobilized protein of the present invention.

As another example, the polypeptides, fragments, analogs, derivatives and fusions of the present invention can usefully be bound to a substantially nonporous substrate, such as plastic, to detect and quantify antibodies, *e.g.* in serum, that bind specifically to the immobilized protein of the present invention. Such plastics include polymethylacrylic, polyethylene, polypropylene, polyacrylate, polymethylmethacrylate, polyvinylchloride, polytetrafluoroethylene, polystyrene, polycarbonate, polyacetal, polysulfone, celluloseacetate, cellulosenitrate, nitrocellulose, or mixtures thereof; when the assay is performed in a standard microtiter dish, the plastic is typically polystyrene.

The polypeptides, fragments, analogs, derivatives and fusions of the present invention can also be attached to a substrate suitable for use as a surface enhanced laser desorption ionization source; so attached, the protein, fragment, or fusion of the present invention is useful for binding and then detecting secondary proteins that bind with sufficient affinity or avidity to the surface-bound protein to indicate biologic interaction there between. The proteins, fragments, and fusions of the present invention can also be attached to a substrate suitable for use in surface plasmon resonance detection; so attached, the protein, fragment, or fusion of the present invention is useful for binding and then detecting secondary proteins that bind with sufficient affinity or avidity to the surface-bound protein to indicate biological interaction there between.

Antibodies

- In another aspect, the invention provides antibodies, including fragments and derivatives thereof, that bind specifically to polypeptides encoded by the nucleic acid molecules of the invention, as well as antibodies that bind to fragments, muteins, derivatives and analogs of the polypeptides. In a preferred embodiment, the antibodies are specific for a polypeptide that is an OSP, or a fragment, mutein, derivative, analog or fusion protein thereof. In a more preferred embodiment, the antibodies are specific for a polypeptide that comprises SEQ ID NO: 138 through 238, or a fragment, mutein, derivative, analog or fusion protein thereof.
- 10       The antibodies of the present invention can be specific for linear epitopes, discontinuous epitopes, or conformational epitopes of such proteins or protein fragments, either as present on the protein in its native conformation or, in some cases, as present on the proteins as denatured, as, *e.g.*, by solubilization in SDS. New epitopes may be also due to a difference in post translational modifications (PTMs) in disease versus normal tissue. For example, a particular site on an OSP may be glycosylated in cancerous cells, but not glycosylated in normal cells or visa versa. In addition, alternative splice forms of an OSP may be indicative of cancer. Differential degradation of the C or N-terminus of an OSP may also be a marker or target for anticancer therapy. For example, an OSP may be N-terminal degraded in cancer cells exposing new epitopes to which antibodies
- 15       may selectively bind for diagnostic or therapeutic uses.
- 20       As is well-known in the art, the degree to which an antibody can discriminate as among molecular species in a mixture will depend, in part, upon the conformational relatedness of the species in the mixture; typically, the antibodies of the present invention will discriminate over adventitious binding to non-OSP polypeptides by at least 2-fold,
- 25       more typically by at least 5-fold, typically by more than 10-fold, 25-fold, 50-fold, 75-fold, and often by more than 100-fold, and on occasion by more than 500-fold or 1000-fold. When used to detect the proteins or protein fragments of the present invention, the antibody of the present invention is sufficiently specific when it can be used to determine the presence of the protein of the present invention in samples derived from human
- 30       ovary.

Typically, the affinity or avidity of an antibody (or antibody multimer, as in the case of an IgM pentamer) of the present invention for a protein or protein fragment of the

-80-

present invention will be at least about  $1 \times 10^{-6}$  molar (M), typically at least about  $5 \times 10^{-7}$  M,  $1 \times 10^{-7}$  M, with affinities and avidities of at least  $1 \times 10^{-8}$  M,  $5 \times 10^{-9}$  M,  $1 \times 10^{-10}$  M and up to  $1 \times 10^{-13}$  M proving especially useful.

The antibodies of the present invention can be naturally-occurring forms, such as  
5 IgG, IgM, IgD, IgE, IgY, and IgA, from any avian, reptilian, or mammalian species.

Human antibodies can, but will infrequently, be drawn directly from human  
donors or human cells. In this case, antibodies to the proteins of the present invention  
will typically have resulted from fortuitous immunization, such as autoimmune  
immunization, with the protein or protein fragments of the present invention. Such  
10 antibodies will typically, but will not invariably, be polyclonal. In addition, individual  
polyclonal antibodies may be isolated and cloned to generate monoclonals.

Human antibodies are more frequently obtained using transgenic animals that  
express human immunoglobulin genes, which transgenic animals can be affirmatively  
immunized with the protein immunogen of the present invention. Human Ig-transgenic  
15 mice capable of producing human antibodies and methods of producing human  
antibodies therefrom upon specific immunization are described, *inter alia*, in U.S. Patents  
6,162,963; 6,150,584; 6,114,598; 6,075,181; 5,939,598; 5,877,397; 5,874,299;  
5,814,318; 5,789,650; 5,770,429; 5,661,016; 5,633,425; 5,625,126; 5,569,825;  
5,545,807; 5,545,806, and 5,591,669, the disclosures of which are incorporated herein by  
20 reference in their entireties. Such antibodies are typically monoclonal, and are typically  
produced using techniques developed for production of murine antibodies.

Human antibodies are particularly useful, and often preferred, when the  
antibodies of the present invention are to be administered to human beings as *in vivo*  
diagnostic or therapeutic agents, since recipient immune response to the administered  
25 antibody will often be substantially less than that occasioned by administration of an  
antibody derived from another species, such as mouse.

IgG, IgM, IgD, IgE, IgY, and IgA antibodies of the present invention can also be  
obtained from other species, including mammals such as rodents (typically mouse, but  
also rat, guinea pig, and hamster) lagomorphs, typically rabbits, and also larger  
30 mammals, such as sheep, goats, cows, and horses, and other egg laying birds or reptiles  
such as chickens or alligators. For example, avian antibodies may be generated using  
techniques described in WO 00/29444, published 25 May 2000, the contents of which are

-81-

hereby incorporated in their entirety. In such cases, as with the transgenic human-antibody-producing non-human mammals, fortuitous immunization is not required, and the non-human mammal is typically affirmatively immunized, according to standard immunization protocols, with the protein or protein fragment of the present invention.

5 As discussed above, virtually all fragments of 8 or more contiguous amino acids of the proteins of the present invention can be used effectively as immunogens when conjugated to a carrier, typically a protein such as bovine thyroglobulin, keyhole limpet hemocyanin, or bovine serum albumin, conveniently using a bifunctional linker such as those described elsewhere above, which discussion is incorporated by reference here.

10 Immunogenicity can also be conferred by fusion of the polypeptide and fragments of the present invention to other moieties. For example, peptides of the present invention can be produced by solid phase synthesis on a branched polylysine core matrix; these multiple antigenic peptides (MAPs) provide high purity, increased avidity, accurate chemical definition and improved safety in vaccine development. Tam *et al.*, *Proc. Natl.*

15 *Acad. Sci. USA* 85: 5409-5413 (1988); Posnett *et al.*, *J. Biol. Chem.* 263: 1719-1725 (1988).

Protocols for immunizing non-human mammals or avian species are well-established in the art. See Harlow *et al.* (eds.), Using Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory (1998); Coligan *et al.* (eds.), Current Protocols in Immunology, John Wiley & Sons, Inc. (2001); Zola, Monoclonal Antibodies: Preparation and Use of Monoclonal Antibodies and Engineered Antibody Derivatives (Basics: From Background to Bench), Springer Verlag (2000); Gross M, Speck *J.Dtsch. Tierarztl. Wochenschr.* 103: 417-422 (1996), the disclosures of which are incorporated herein by reference. Immunization protocols often include multiple immunizations, either with or without adjuvants such as Freund's complete adjuvant and Freund's incomplete adjuvant, and may include naked DNA immunization (Moss, *Semin. Immunol.* 2: 317-327 (1990)).

Antibodies from non-human mammals and avian species can be polyclonal or monoclonal, with polyclonal antibodies having certain advantages in immunohistochemical detection of the proteins of the present invention and monoclonal antibodies having advantages in identifying and distinguishing particular epitopes of the proteins of the present invention. Antibodies from avian species may have particular

advantage in detection of the proteins of the present invention, in human serum or tissues (Vikinge et al., *Biosens. Bioelectron.* 13: 1257-1262 (1998)).

Following immunization, the antibodies of the present invention can be produced using any art-accepted technique. Such techniques are well-known in the art, Coligan, 5 *supra*; Zola, *supra*; Howard et al. (eds.), Basic Methods in Antibody Production and Characterization, CRC Press (2000); Harlow, *supra*; Davis (ed.), Monoclonal Antibody Protocols, Vol. 45, Humana Press (1995); Delves (ed.), Antibody Production: Essential Techniques, John Wiley & Son Ltd (1997); Kenney, Antibody Solution: An Antibody Methods Manual, Chapman & Hall (1997), incorporated herein by reference in their 10 entireties, and thus need not be detailed here.

Briefly, however, such techniques include, *inter alia*, production of monoclonal antibodies by hybridomas and expression of antibodies or fragments or derivatives thereof from host cells engineered to express immunoglobulin genes or fragments thereof. These two methods of production are not mutually exclusive: genes encoding 15 antibodies specific for the proteins or protein fragments of the present invention can be cloned from hybridomas and thereafter expressed in other host cells. Nor need the two necessarily be performed together: e.g., genes encoding antibodies specific for the proteins and protein fragments of the present invention can be cloned directly from B cells known to be specific for the desired protein, as further described in U.S Patent 20 5,627,052, the disclosure of which is incorporated herein by reference in its entirety, or from antibody-displaying phage.

Recombinant expression in host cells is particularly useful when fragments or derivatives of the antibodies of the present invention are desired.

Host cells for recombinant production of either whole antibodies, antibody 25 fragments, or antibody derivatives can be prokaryotic or eukaryotic.

Prokaryotic hosts are particularly useful for producing phage displayed antibodies of the present invention.

The technology of phage-displayed antibodies, in which antibody variable region fragments are fused, for example, to the gene III protein (pIII) or gene VIII protein 30 (pVIII) for display on the surface of filamentous phage, such as M13, is by now well-established. See, e.g., Sidhu, *Curr. Opin. Biotechnol.* 11(6): 610-6 (2000); Griffiths et al., *Curr. Opin. Biotechnol.* 9(1): 102-8 (1998); Hoogenboom et al., *Immunotechnology*,

-83-

4(1): 1-20 (1998); Rader *et al.*, *Current Opinion in Biotechnology* 8: 503-508 (1997); Aujame *et al.*, *Human Antibodies* 8: 155-168 (1997); Hoogenboom, *Trends in Biotechnol.* 15: 62-70 (1997); de Kruif *et al.*, 17: 453-455 (1996); Barbas *et al.*, *Trends in Biotechnol.* 14: 230-234 (1996); Winter *et al.*, *Ann. Rev. Immunol.* 433-455 (1994).

5 Techniques and protocols required to generate, propagate, screen (pan), and use the antibody fragments from such libraries have recently been compiled. See, e.g., Barbas (2001), *supra*; Kay, *supra*; Abelson, *supra*, the disclosures of which are incorporated herein by reference in their entireties.

Typically, phage-displayed antibody fragments are scFv fragments or Fab fragments; when desired, full length antibodies can be produced by cloning the variable regions from the displaying phage into a complete antibody and expressing the full length antibody in a further prokaryotic or a eukaryotic host cell.

Eukaryotic cells are also useful for expression of the antibodies, antibody fragments, and antibody derivatives of the present invention.

15 For example, antibody fragments of the present invention can be produced in *Pichia pastoris* and in *Saccharomyces cerevisiae*. See, e.g., Takahashi *et al.*, *Biosci. Biotechnol. Biochem.* 64(10): 2138-44 (2000); Freyre *et al.*, *J. Biotechnol.* 76(2-3):1 57-63 (2000); Fischer *et al.*, *Biotechnol. Appl. Biochem.* 30 (Pt 2): 117-20 (1999); Pennell *et al.*, *Res. Immunol.* 149(6): 599-603 (1998); Eldin *et al.*, *J. Immunol. Methods.* 20 201(1): 67-75 (1997); Frenken *et al.*, *Res. Immunol.* 149(6): 589-99 (1998); Shusta *et al.*, *Nature Biotechnol.* 16(8): 773-7 (1998), the disclosures of which are incorporated herein by reference in their entireties.

Antibodies, including antibody fragments and derivatives, of the present invention can also be produced in insect cells. See, e.g., Li *et al.*, *Protein Expr. Purif.* 25 21(1): 121-8 (2001); Ailor *et al.*, *Biotechnol. Bioeng.* 58(2-3): 196-203 (1998); Hsu *et al.*, *Biotechnol. Prog.* 13(1): 96-104 (1997); Edelman *et al.*, *Immunology* 91(1): 13-9 (1997); and Nesbit *et al.*, *J. Immunol. Methods* 151(1-2): 201-8 (1992), the disclosures of which are incorporated herein by reference in their entireties.

Antibodies and fragments and derivatives thereof of the present invention can 30 also be produced in plant cells, particularly maize or tobacco, Giddings *et al.*, *Nature Biotechnol.* 18(11): 1151-5 (2000); Gavilondo *et al.*, *Biotechniques* 29(1): 128-38 (2000); Fischer *et al.*, *J. Biol. Regul. Homeost. Agents* 14(2): 83-92 (2000); Fischer *et al.*,

-84-

*Biotechnol. Appl. Biochem.* 30 (Pt 2): 113-6 (1999); Fischer et al., *Biol. Chem.* 380(7-8): 825-39 (1999); Russell, *Curr. Top. Microbiol. Immunol.* 240: 119-38 (1999); and Ma et al., *Plant Physiol.* 109(2): 341-6 (1995), the disclosures of which are incorporated herein by reference in their entireties.

- 5        Antibodies, including antibody fragments and derivatives, of the present invention can also be produced in transgenic, non-human, mammalian milk. See, e.g. Pollock et al., *J. Immunol. Methods.* 231: 147-57 (1999); Young et al., *Res. Immunol.* 149: 609-10 (1998); Limonta et al., *Immunotechnology* 1: 107-13 (1995), the disclosures of which are incorporated herein by reference in their entireties.
- 10      Mammalian cells useful for recombinant expression of antibodies, antibody fragments, and antibody derivatives of the present invention include CHO cells, COS cells, 293 cells, and myeloma cells.
- 15      Verma et al., *J. Immunol. Methods* 216(1-2):165-81 (1998), herein incorporated by reference, review and compare bacterial, yeast, insect and mammalian expression systems for expression of antibodies.
- 20      Antibodies of the present invention can also be prepared by cell free translation, as further described in Merk et al., *J. Biochem.* (Tokyo) 125(2): 328-33 (1999) and Ryabova et al., *Nature Biotechnol.* 15(1): 79-84 (1997), and in the milk of transgenic animals, as further described in Pollock et al., *J. Immunol. Methods* 231(1-2): 147-57 (1999), the disclosures of which are incorporated herein by reference in their entireties.
- 25      The invention further provides antibody fragments that bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention.
- 30      Among such useful fragments are Fab, Fab', Fv, F(ab)'<sub>2</sub>, and single chain Fv (scFv) fragments. Other useful fragments are described in Hudson, *Curr. Opin. Biotechnol.* 9(4): 395-402 (1998).
- 35      It is also an aspect of the present invention to provide antibody derivatives that bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated

nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention.

5 Among such useful derivatives are chimeric, primatized, and humanized antibodies; such derivatives are less immunogenic in human beings, and thus more suitable for *in vivo* administration, than are unmodified antibodies from non-human mammalian species. Another useful derivative is PEGylation to increase the serum half life of the antibodies.

10 Chimeric antibodies typically include heavy and/or light chain variable regions (including both CDR and framework residues) of immunoglobulins of one species, typically mouse, fused to constant regions of another species, typically human. *See, e.g.,* United States Patent No. 5,807,715; Morrison *et al.*, *Proc. Natl. Acad. Sci USA* 81(21): 6851-5 (1984); Sharon *et al.*, *Nature* 309(5966): 364-7 (1984); Takeda *et al.*, *Nature*

15 314(6010): 452-4 (1985), the disclosures of which are incorporated herein by reference in their entireties. Primatized and humanized antibodies typically include heavy and/or light chain CDRs from a murine antibody grafted into a non-human primate or human antibody V region framework, usually further comprising a human constant region, Riechmann *et al.*, *Nature* 332(6162): 323-7 (1988); Co *et al.*, *Nature* 351(6326): 501-2 (1991); United States Patent Nos. 6,054,297; 5,821,337; 5,770,196; 5,766,886; 5,821,123; 5,869,619; 6,180,377; 6,013,256; 5,693,761; and 6,180,370, the disclosures of which are incorporated herein by reference in their entireties.

20 Other useful antibody derivatives of the invention include heteromeric antibody complexes and antibody fusions, such as diabodies (bispecific antibodies), single-chain diabodies, and intrabodies.

25 It is contemplated that the nucleic acids encoding the antibodies of the present invention can be operably joined to other nucleic acids forming a recombinant vector for cloning or for expression of the antibodies of the invention. The present invention includes any recombinant vector containing the coding sequences, or part thereof, whether for eukaryotic transduction, transfection or gene therapy. Such vectors may be prepared using conventional molecular biology techniques, known to those with skill in the art, and would comprise DNA encoding sequences for the immunoglobulin V-regions

including framework and CDRs or parts thereof, and a suitable promoter either with or without a signal sequence for intracellular transport. Such vectors may be transduced or transfected into eukaryotic cells or used for gene therapy (Marasco et al., *Proc. Natl. Acad. Sci. (USA)* 90: 7889-7893 (1993); Duan et al., *Proc. Natl. Acad. Sci. (USA)* 91: 5 5075-5079 (1994), by conventional techniques, known to those with skill in the art.

The antibodies of the present invention, including fragments and derivatives thereof, can usefully be labeled. It is, therefore, another aspect of the present invention to provide labeled antibodies that bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention.

10 The choice of label depends, in part, upon the desired use.  
15 For example, when the antibodies of the present invention are used for immunohistochemical staining of tissue samples, the label is preferably an enzyme that catalyzes production and local deposition of a detectable product.

Enzymes typically conjugated to antibodies to permit their immunohistochemical visualization are well-known, and include alkaline phosphatase, β-galactosidase, glucose 20 oxidase, horseradish peroxidase (HRP), and urease. Typical substrates for production and deposition of visually detectable products include o-nitrophenyl-beta-D-galactopyranoside (ONPG); o-phenylenediamine dihydrochloride (OPD); p-nitrophenyl phosphate (PNPP); p-nitrophenyl-beta-D-galactopyranoside (PNPG); 3',3'-diaminobenzidine (DAB); 3-amino-9-ethylcarbazole (AEC); 4-chloro-1-naphthol (CN); 25 5-bromo-4-chloro-3-indolyl-phosphate (BCIP); ABTS®; BluoGal; iodonitrotetrazolium (INT); nitroblue tetrazolium chloride (NBT); phenazine methosulfate (PMS); phenolphthalein monophosphate (PMP); tetramethyl benzidine (TMB); tetranitroblue tetrazolium (TNBT); X-Gal; X-Gluc; and X-Glucoside.

Other substrates can be used to produce products for local deposition that are 30 luminescent. For example, in the presence of hydrogen peroxide ( $H_2O_2$ ), horseradish peroxidase (HRP) can catalyze the oxidation of cyclic diacylhydrazides, such as luminol. Immediately following the oxidation, the luminol is in an excited state (intermediate

reaction product), which decays to the ground state by emitting light. Strong enhancement of the light emission is produced by enhancers, such as phenolic compounds. Advantages include high sensitivity, high resolution, and rapid detection without radioactivity and requiring only small amounts of antibody. *See, e.g., Thorpe et al., Methods Enzymol.* 133: 331-53 (1986); Kricka et al., *J. Immunoassay* 17(1): 67-83 (1996); and Lundqvist et al., *J. Biolumin. Chemilumin.* 10(6): 353-9 (1995), the disclosures of which are incorporated herein by reference in their entireties. Kits for such enhanced chemiluminescent detection (ECL) are available commercially.

The antibodies can also be labeled using colloidal gold.

10 As another example, when the antibodies of the present invention are used, *e.g.*, for flow cytometric detection, for scanning laser cytometric detection, or for fluorescent immunoassay, they can usefully be labeled with fluorophores.

There are a wide variety of fluorophore labels that can usefully be attached to the antibodies of the present invention.

15 For flow cytometric applications, both for extracellular detection and for intracellular detection, common useful fluorophores can be fluorescein isothiocyanate (FITC), allophycocyanin (APC), R-phycoerythrin (PE), peridinin chlorophyll protein (PerCP), Texas Red, Cy3, Cy5, fluorescence resonance energy tandem fluorophores such as PerCP-Cy5.5, PE-Cy5, PE-Cy5.5, PE-Cy7, PE-Texas Red, and APC-Cy7.

20 Other fluorophores include, *inter alia*, Alexa Fluor® 350, Alexa Fluor® 488, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 647 (monoclonal antibody labeling kits available from Molecular Probes, Inc., Eugene, OR, USA), BODIPY dyes, such as BODIPY 493/503, BODIPY FL, BODIPY R6G, BODIPY 530/550, BODIPY TMR, BODIPY 558/568, BODIPY 558/568,

25 BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY TR, BODIPY 630/650, BODIPY 650/665, Cascade Blue, Cascade Yellow, Dansyl, lissamine rhodamine B, Marina Blue, Oregon Green 488, Oregon Green 514, Pacific Blue, rhodamine 6G, rhodamine green, rhodamine red, tetramethylrhodamine, Texas Red (available from Molecular Probes, Inc., Eugene, OR, USA), and Cy2, Cy3, Cy3.5, Cy5,

30 Cy5.5, Cy7, all of which are also useful for fluorescently labeling the antibodies of the present invention.

For secondary detection using labeled avidin, streptavidin, captavidin or neutravidin, the antibodies of the present invention can usefully be labeled with biotin.

When the antibodies of the present invention are used, e.g., for Western blotting applications, they can usefully be labeled with radioisotopes, such as  $^{33}\text{P}$ ,  $^{32}\text{P}$ ,  $^{35}\text{S}$ ,  $^3\text{H}$ , 5 and  $^{125}\text{I}$ .

As another example, when the antibodies of the present invention are used for radioimmunotherapy, the label can usefully be  $^{228}\text{Th}$ ,  $^{227}\text{Ac}$ ,  $^{225}\text{Ac}$ ,  $^{223}\text{Ra}$ ,  $^{213}\text{Bi}$ ,  $^{212}\text{Pb}$ ,  $^{212}\text{Bi}$ ,  $^{211}\text{At}$ ,  $^{203}\text{Pb}$ ,  $^{194}\text{Os}$ ,  $^{188}\text{Re}$ ,  $^{186}\text{Re}$ ,  $^{153}\text{Sm}$ ,  $^{149}\text{Tb}$ ,  $^{131}\text{I}$ ,  $^{125}\text{I}$ ,  $^{111}\text{In}$ ,  $^{105}\text{Rh}$ ,  $^{99m}\text{Tc}$ ,  $^{97}\text{Ru}$ ,  $^{90}\text{Y}$ ,  $^{90}\text{Sr}$ ,  $^{88}\text{Y}$ ,  $^{72}\text{Se}$ ,  $^{67}\text{Cu}$ , or  $^{47}\text{Sc}$ .

10 As another example, when the antibodies of the present invention are to be used for *in vivo* diagnostic use, they can be rendered detectable by conjugation to MRI contrast agents, such as gadolinium diethylenetriaminepentaacetic acid (DTPA), Lauffer *et al.*, *Radiology* 207(2): 529-38 (1998), or by radioisotopic labeling.

15 As would be understood, use of the labels described above is not restricted to the application for which they are mentioned.

The antibodies of the present invention, including fragments and derivatives thereof, can also be conjugated to toxins, in order to target the toxin's ablative action to cells that display and/or express the proteins of the present invention. Commonly, the antibody in such immunotoxins is conjugated to *Pseudomonas* exotoxin A, *diphtheria* 20 toxin, *shiga* toxin A, *anthrax* toxin lethal factor, or ricin. See Hall (ed.), Immunotoxin Methods and Protocols (Methods in Molecular Biology, vol. 166), Humana Press (2000); and Frankel *et al.* (eds.), Clinical Applications of Immunotoxins, Springer-Verlag (1998), the disclosures of which are incorporated herein by reference in their entireties.

25 The antibodies of the present invention can usefully be attached to a substrate, and it is, therefore, another aspect of the invention to provide antibodies that bind specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more 30 of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, attached to a substrate.

Substrates can be porous or nonporous, planar or nonplanar.

-89-

For example, the antibodies of the present invention can usefully be conjugated to filtration media, such as NHS-activated Sepharose or CNBr-activated Sepharose for purposes of immunoaffinity chromatography.

For example, the antibodies of the present invention can usefully be attached to 5 paramagnetic microspheres, typically by biotin-streptavidin interaction, which microspheres can then be used for isolation of cells that express or display the proteins of the present invention. As another example, the antibodies of the present invention can usefully be attached to the surface of a microtiter plate for ELISA.

As noted above, the antibodies of the present invention can be produced in 10 prokaryotic and eukaryotic cells. It is, therefore, another aspect of the present invention to provide cells that express the antibodies of the present invention, including hybridoma cells, B cells, plasma cells, and host cells recombinantly modified to express the antibodies of the present invention.

In yet a further aspect, the present invention provides aptamers evolved to bind 15 specifically to one or more of the proteins and protein fragments of the present invention, to one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present invention, or the binding of which can be competitively inhibited by one or more of the proteins and protein fragments of the present invention or one or more of the proteins and protein fragments encoded by the isolated nucleic acids of the present 20 invention.

In sum, one of skill in the art, provided with the teachings of this invention, has available a variety of methods which may be used to alter the biological properties of the antibodies of this invention including methods which would increase or decrease the stability or half-life, immunogenicity, toxicity, affinity or yield of a given antibody 25 molecule, or to alter it in any other way that may render it more suitable for a particular application.

#### Transgenic Animals and Cells

In another aspect, the invention provides transgenic cells and non-human 30 organisms comprising nucleic acid molecules of the invention. In a preferred embodiment, the transgenic cells and non-human organisms comprise a nucleic acid molecule encoding an OSP. In a preferred embodiment, the OSP comprises an amino

-90-

- acid sequence selected from SEQ ID NO: 138 through 238, or a fragment, mutein, homologous protein or allelic variant thereof. In another preferred embodiment, the transgenic cells and non-human organism comprise an OSNA of the invention, preferably an OSNA comprising a nucleotide sequence selected from the group 5 consisting of SEQ ID NO: 1 through 137, or a part, substantially similar nucleic acid molecule, allelic variant or hybridizing nucleic acid molecule thereof.

In another embodiment, the transgenic cells and non-human organisms have a targeted disruption or replacement of the endogenous orthologue of the human OSG. The transgenic cells can be embryonic stem cells or somatic cells. The transgenic non-10 human organisms can be chimeric, nonchimeric heterozygotes, and nonchimeric homozygotes. Methods of producing transgenic animals are well-known in the art. *See, e.g., Hogan et al., Manipulating the Mouse Embryo: A Laboratory Manual*, 2d ed., Cold Spring Harbor Press (1999); Jackson et al., *Mouse Genetics and Transgenics: A Practical Approach*, Oxford University Press (2000); and Pinkert, *Transgenic Animal Technology: A Laboratory Handbook*, Academic Press (1999).

Any technique known in the art may be used to introduce a nucleic acid molecule of the invention into an animal to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection. (*see, e.g., Paterson et al., Appl. Microbiol. Biotechnol. 40: 691-698 (1994); Carver et al., Biotechnology 11: 20 1263-1270 (1993); Wright et al., Biotechnology 9: 830-834 (1991); and U.S. Patent 4,873,191 (1989) retrovirus-mediated gene transfer into germ lines, blastocysts or embryos (see, e.g., Van der Putten et al., Proc. Natl. Acad. Sci., USA 82: 6148-6152 (1985)); gene targeting in embryonic stem cells (see, e.g., Thompson et al., Cell 56: 313-321 (1989)); electroporation of cells or embryos (see, e.g., Lo, 1983, Mol. Cell. Biol. 25: 3: 1803-1814 (1983)); introduction using a gene gun (see, e.g., Ulmer et al., Science 259: 1745-49 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (see, e.g., Lavitrano et al., Cell 57: 717-723 (1989)).*

Other techniques include, for example, nuclear transfer into enucleated oocytes of 30 nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (*see, e.g., Campell et al., Nature 380: 64-66 (1996); Wilmut et al., Nature 385: 810-813 (1997)).* The present invention provides for transgenic animals that carry the transgene (*i.e., a*

-91-

nucleic acid molecule of the invention) in all their cells, as well as animals which carry the transgene in some, but not all their cells, i. e., mosaic animals or chimeric animals.

The transgene may be integrated as a single transgene or as multiple copies, such as in concatamers, e. g., head-to-head tandems or head-to-tail tandems. The transgene

5 may also be selectively introduced into and activated in a particular cell type by following, e.g., the teaching of Lasko *et al. et al.*, *Proc. Natl. Acad. Sci. USA* 89: 6232-6236 (1992). The regulatory sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

10 Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using  
15 techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse transcriptase-PCR (RT-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

20 Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce ovaries of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels  
25 because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is  
30 appropriate for an experimental model of interest.

Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of

the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

Methods for creating a transgenic animal with a disruption of a targeted gene are also well-known in the art. In general, a vector is designed to comprise some nucleotide sequences homologous to the endogenous targeted gene. The vector is introduced into a cell so that it may integrate, via homologous recombination with chromosomal sequences, into the endogenous gene, thereby disrupting the function of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type. *See, e.g., Gu et al., Science 265: 103-106 (1994).* The regulatory sequences required for such a cell-type specific inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. *See, e.g., Smithies et al., Nature 317: 230-234 (1985); Thomas et al., Cell 51: 503-512 (1987); Thompson et al., Cell 5: 313-321 (1989).*

In one embodiment, a mutant, non-functional nucleic acid molecule of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous nucleic acid sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfet cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene. *See, e.g., Thomas, supra and Thompson, supra.* However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (*e.g.*, knockouts) are administered to a patient *in vivo*. Such cells may be obtained from an animal or patient or an MHC

-93-

- compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (*e.g.*, lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt
- 5 the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, *e.g.*, by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc.
- 10 The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, *e.g.*, in the circulation, or intraperitoneally.
- 15 Alternatively, the cells can be incorporated into a matrix and implanted in the body, *e.g.*, genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. *See, e.g.*, U.S. Patents 5,399,349 and 5,460,959, each of which is incorporated by reference herein in its entirety.
- 20 When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well-known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the
- 25 introduced cells to be recognized by the host immune system.
- Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such
- 30 conditions and/or disorders.

Computer Readable Means

A further aspect of the invention relates to a computer readable means for storing the nucleic acid and amino acid sequences of the instant invention. In a preferred embodiment, the invention provides a computer readable means for storing SEQ ID NO: 5 1 through 137 and SEQ ID NO: 138 through 238 as described herein, as the complete set of sequences or in any combination. The records of the computer readable means can be accessed for reading and display and for interface with a computer system for the application of programs allowing for the location of data upon a query for data meeting certain criteria, the comparison of sequences, the alignment or ordering of sequences 10 meeting a set of criteria, and the like.

The nucleic acid and amino acid sequences of the invention are particularly useful as components in databases useful for search analyses as well as in sequence analysis algorithms. As used herein, the terms "nucleic acid sequences of the invention" and "amino acid sequences of the invention" mean any detectable chemical or physical 15 characteristic of a polynucleotide or polypeptide of the invention that is or may be reduced to or stored in a computer readable form. These include, without limitation, chromatographic scan data or peak data, photographic data or scan data therefrom, and mass spectrographic data.

This invention provides computer readable media having stored thereon 20 sequences of the invention. A computer readable medium may comprise one or more of the following: a nucleic acid sequence comprising a sequence of a nucleic acid sequence of the invention; an amino acid sequence comprising an amino acid sequence of the invention; a set of nucleic acid sequences wherein at least one of said sequences comprises the sequence of a nucleic acid sequence of the invention; a set of amino acid 25 sequences wherein at least one of said sequences comprises the sequence of an amino acid sequence of the invention; a data set representing a nucleic acid sequence comprising the sequence of one or more nucleic acid sequences of the invention; a data set representing a nucleic acid sequence encoding an amino acid sequence comprising the sequence of an amino acid sequence of the invention; a set of nucleic acid sequences 30 wherein at least one of said sequences comprises the sequence of a nucleic acid sequence of the invention; a set of amino acid sequences wherein at least one of said sequences comprises the sequence of an amino acid sequence of the invention; a data set

-95-

representing a nucleic acid sequence comprising the sequence of a nucleic acid sequence of the invention; a data set representing a nucleic acid sequence encoding an amino acid sequence comprising the sequence of an amino acid sequence of the invention. The computer readable medium can be any composition of matter used to store information or 5 data, including, for example, commercially available floppy disks, tapes, hard drives, compact disks, and video disks.

Also provided by the invention are methods for the analysis of character sequences, particularly genetic sequences. Preferred methods of sequence analysis include, for example, methods of sequence homology analysis, such as identity and 10 similarity analysis, RNA structure analysis, sequence assembly, cladistic analysis, sequence motif analysis, open reading frame determination, nucleic acid base calling, and sequencing chromatogram peak analysis.

A computer-based method is provided for performing nucleic acid sequence identity or similarity identification. This method comprises the steps of providing a 15 nucleic acid sequence comprising the sequence of a nucleic acid of the invention in a computer readable medium; and comparing said nucleic acid sequence to at least one nucleic acid or amino acid sequence to identify sequence identity or similarity.

A computer-based method is also provided for performing amino acid homology identification, said method comprising the steps of: providing an amino acid sequence 20 comprising the sequence of an amino acid of the invention in a computer readable medium; and comparing said an amino acid sequence to at least one nucleic acid or an amino acid sequence to identify homology.

A computer-based method is still further provided for assembly of overlapping nucleic acid sequences into a single nucleic acid sequence, said method comprising the 25 steps of: providing a first nucleic acid sequence comprising the sequence of a nucleic acid of the invention in a computer readable medium; and screening for at least one overlapping region between said first nucleic acid sequence and a second nucleic acid sequence.

#### Diagnostic Methods for Ovarian Cancer

30 The present invention also relates to quantitative and qualitative diagnostic assays and methods for detecting, diagnosing, monitoring, staging and predicting cancers by

-96-

comparing expression of an OSNA or an OSP in a human patient that has or may have ovarian cancer, or who is at risk of developing ovarian cancer, with the expression of an OSNA or an OSP in a normal human control. For purposes of the present invention, "expression of an OSNA" or "OSNA expression" means the quantity of OSG mRNA that 5 can be measured by any method known in the art or the level of transcription that can be measured by any method known in the art in a cell, tissue, organ or whole patient. Similarly, the term "expression of an OSP" or "OSP expression" means the amount of OSP that can be measured by any method known in the art or the level of translation of an OSG OSNA that can be measured by any method known in the art.

- 10       The present invention provides methods for diagnosing ovarian cancer in a patient, in particular squamous cell carcinoma, by analyzing for changes in levels of OSNA or OSP in cells, tissues, organs or bodily fluids compared with levels of OSNA or OSP in cells, tissues, organs or bodily fluids of preferably the same type from a normal human control, wherein an increase, or decrease in certain cases, in levels of an OSNA or 15 OSP in the patient versus the normal human control is associated with the presence of ovarian cancer or with a predilection to the disease. In another preferred embodiment, the present invention provides methods for diagnosing ovarian cancer in a patient by analyzing changes in the structure of the mRNA of an OSG compared to the mRNA from a normal control. These changes include, without limitation, aberrant splicing, 20 alterations in polyadenylation and/or alterations in 5' nucleotide capping. In yet another preferred embodiment, the present invention provides methods for diagnosing ovarian cancer in a patient by analyzing changes in an OSP compared to an OSP from a normal control. These changes include, e.g., alterations in glycosylation and/or phosphorylation of the OSP or subcellular OSP localization.
- 25       In a preferred embodiment, the expression of an OSNA is measured by determining the amount of an mRNA that encodes an amino acid sequence selected from SEQ ID NO: 138 through 238, a homolog, an allelic variant, or a fragment thereof. In a more preferred embodiment, the OSNA expression that is measured is the level of expression of an OSNA mRNA selected from SEQ ID NO: 1 through 137, or a 30 hybridizing nucleic acid, homologous nucleic acid or allelic variant thereof, or a part of any of these nucleic acids. OSNA expression may be measured by any method known in the art, such as those described *supra*, including measuring mRNA expression by

-97-

- Northern blot, quantitative or qualitative reverse transcriptase PCR (RT-PCR), microarray, dot or slot blots or *in situ* hybridization. *See, e.g., Ausubel (1992), supra; Ausubel (1999), supra; Sambrook (1989), supra; and Sambrook (2001), supra.* OSNA transcription may be measured by any method known in the art including using a reporter gene hooked up to the promoter of an OSG of interest or doing nuclear run-off assays. Alterations in mRNA structure, *e.g.*, aberrant splicing variants, may be determined by any method known in the art, including, RT-PCR followed by sequencing or restriction analysis. As necessary, OSNA expression may be compared to a known control, such as normal ovary nucleic acid, to detect a change in expression.
- 10 In another preferred embodiment, the expression of an OSP is measured by determining the level of an OSP having an amino acid sequence selected from the group consisting of SEQ ID NO: 138 through 238, a homolog, an allelic variant, or a fragment thereof. Such levels are preferably determined in at least one of cells, tissues, organs and/or bodily fluids, including determination of normal and abnormal levels. Thus, for 15 instance, a diagnostic assay in accordance with the invention for diagnosing over- or underexpression of OSNA or OSP compared to normal control bodily fluids, cells, or tissue samples may be used to diagnose the presence of ovarian cancer. The expression level of an OSP may be determined by any method known in the art, such as those described *supra*. In a preferred embodiment, the OSP expression level may be 20 determined by radioimmunoassays, competitive-binding assays, ELISA, Western blot, FACS, immunohistochemistry, immunoprecipitation, proteomic approaches: two-dimensional gel electrophoresis (2D electrophoresis) and non-gel-based approaches such as mass spectrometry or protein interaction profiling. *See, e.g., Harlow (1999), supra; Ausubel (1992), supra; and Ausubel (1999), supra.* Alterations in the OSP 25 structure may be determined by any method known in the art, including, *e.g.*, using antibodies that specifically recognize phosphoserine, phosphothreonine or phosphotyrosine residues, two-dimensional polyacrylamide gel electrophoresis (2D PAGE) and/or chemical analysis of amino acid residues of the protein. *Id.*
- In a preferred embodiment, a radioimmunoassay (RIA) or an ELISA is used. An 30 antibody specific to an OSP is prepared if one is not already available. In a preferred embodiment, the antibody is a monoclonal antibody. The anti-OSP antibody is bound to a solid support and any free protein binding sites on the solid support are blocked with a

-98-

- protein such as bovine serum albumin. A sample of interest is incubated with the antibody on the solid support under conditions in which the OSP will bind to the anti-OSP antibody. The sample is removed, the solid support is washed to remove unbound material, and an anti-OSP antibody that is linked to a detectable reagent (a radioactive substance for RIA and an enzyme for ELISA) is added to the solid support and incubated under conditions in which binding of the OSP to the labeled antibody will occur. After binding, the unbound labeled antibody is removed by washing. For an ELISA, one or more substrates are added to produce a colored reaction product that is based upon the amount of an OSP in the sample. For an RIA, the solid support is counted for radioactive decay signals by any method known in the art. Quantitative results for both RIA and ELISA typically are obtained by reference to a standard curve.

Other methods to measure OSP levels are known in the art. For instance, a competition assay may be employed wherein an anti-OSP antibody is attached to a solid support and an allocated amount of a labeled OSP and a sample of interest are incubated with the solid support. The amount of labeled OSP detected which is attached to the solid support can be correlated to the quantity of an OSP in the sample.

Of the proteomic approaches, 2D PAGE is a well-known technique. Isolation of individual proteins from a sample such as serum is accomplished using sequential separation of proteins by isoelectric point and molecular weight. Typically, polypeptides are first separated by isoelectric point (the first dimension) and then separated by size using an electric current (the second dimension). In general, the second dimension is perpendicular to the first dimension. Because no two proteins with different sequences are identical on the basis of both size and charge, the result of 2D PAGE is a roughly square gel in which each protein occupies a unique spot. Analysis of the spots with chemical or antibody probes, or subsequent protein microsequencing can reveal the relative abundance of a given protein and the identity of the proteins in the sample.

Expression levels of an OSNA can be determined by any method known in the art, including PCR and other nucleic acid methods, such as ligase chain reaction (LCR) and nucleic acid sequence based amplification (NASBA), can be used to detect malignant cells for diagnosis and monitoring of various malignancies. For example, reverse-transcriptase PCR (RT-PCR) is a powerful technique which can be used to detect the presence of a specific mRNA population in a complex mixture of thousands of other

mRNA species. In RT-PCR, an mRNA species is first reverse transcribed to complementary DNA (cDNA) with use of the enzyme reverse transcriptase; the cDNA is then amplified as in a standard PCR reaction.

- Hybridization to specific DNA molecules (*e.g.*, oligonucleotides) arrayed on a solid support can be used to both detect the expression of and quantitate the level of expression of one or more OSNAs of interest. In this approach, all or a portion of one or more OSNAs is fixed to a substrate. A sample of interest, which may comprise RNA, *e.g.*, total RNA or polyA-selected mRNA, or a complementary DNA (cDNA) copy of the RNA is incubated with the solid support under conditions in which hybridization will occur between the DNA on the solid support and the nucleic acid molecules in the sample of interest. Hybridization between the substrate-bound DNA and the nucleic acid molecules in the sample can be detected and quantitated by several means, including, without limitation, radioactive labeling or fluorescent labeling of the nucleic acid molecule or a secondary molecule designed to detect the hybrid.
- The above tests can be carried out on samples derived from a variety of cells, bodily fluids and/or tissue extracts such as homogenates or solubilized tissue obtained from a patient. Tissue extracts are obtained routinely from tissue biopsy and autopsy material. Bodily fluids useful in the present invention include blood, urine, saliva or any other bodily secretion or derivative thereof. By blood it is meant to include whole blood, plasma, serum or any derivative of blood. In a preferred embodiment, the specimen tested for expression of OSNA or OSP includes, without limitation, ovary tissue, fluid obtained by bronchial alveolar lavage (BAL), sputum, ovary cells grown in cell culture, blood, serum, lymph node tissue and lymphatic fluid. In another preferred embodiment, especially when metastasis of a primary ovarian cancer is known or suspected, specimens include, without limitation, tissues from brain, bone, bone marrow, liver, adrenal glands and breast. In general, the tissues may be sampled by biopsy, including, without limitation, needle biopsy, *e.g.*, transthoracic needle aspiration, cervical mediastinoscopy, endoscopic lymph node biopsy, video-assisted thoracoscopy, exploratory thoracotomy, bone marrow biopsy and bone marrow aspiration. *See Scott, supra* and Franklin, pp. 529-570, in Kane, *supra*. For early and inexpensive detection, assaying for changes in OSNAs or OSPs in cells in sputum samples may be particularly useful. Methods of obtaining and analyzing sputum samples is disclosed in Franklin, *supra*.

-100-

All the methods of the present invention may optionally include determining the expression levels of one or more other cancer markers in addition to determining the expression level of an OSNA or OSP. In many cases, the use of another cancer marker will decrease the likelihood of false positives or false negatives. In one embodiment, the  
5 one or more other cancer markers include other OSNA or OSPs as disclosed herein. Other cancer markers useful in the present invention will depend on the cancer being tested and are known to those of skill in the art. In a preferred embodiment, at least one other cancer marker in addition to a particular OSNA or OSP is measured. In a more preferred embodiment, at least two other additional cancer markers are used. In an even  
10 more preferred embodiment, at least three, more preferably at least five, even more preferably at least ten additional cancer markers are used.

#### *Diagnosing*

In one aspect, the invention provides a method for determining the expression levels and/or structural alterations of one or more OSNAs and/or OSPs in a sample from  
15 a patient suspected of having ovarian cancer. In general, the method comprises the steps of obtaining the sample from the patient, determining the expression level or structural alterations of an OSNA and/or OSP and then ascertaining whether the patient has ovarian cancer from the expression level of the OSNA or OSP. In general, if high expression relative to a control of an OSNA or OSP is indicative of ovarian cancer, a diagnostic  
20 assay is considered positive if the level of expression of the OSNA or OSP is at least two times higher, and more preferably are at least five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of an OSNA or OSP is indicative of ovarian cancer, a diagnostic assay is considered positive if the level  
25 of expression of the OSNA or OSP is at least two times lower, more preferably are at least five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control. The normal human control may be from a different patient or from uninvolved tissue of the same patient.

The present invention also provides a method of determining whether ovarian  
30 cancer has metastasized in a patient. One may identify whether the ovarian cancer has metastasized by measuring the expression levels and/or structural alterations of one or more OSNAs and/or OSPs in a variety of tissues. The presence of an OSNA or OSP in a

-101-

certain tissue at levels higher than that of corresponding noncancerous tissue (e.g., the same tissue from another individual) is indicative of metastasis if high level expression of an OSNA or OSP is associated with ovarian cancer. Similarly, the presence of an OSNA or OSP in a tissue at levels lower than that of corresponding noncancerous tissue is 5 indicative of metastasis if low level expression of an OSNA or OSP is associated with ovarian cancer. Further, the presence of a structurally altered OSNA or OSP that is associated with ovarian cancer is also indicative of metastasis.

In general, if high expression relative to a control of an OSNA or OSP is indicative of metastasis, an assay for metastasis is considered positive if the level of 10 expression of the OSNA or OSP is at least two times higher, and more preferably are at least five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of an OSNA or OSP is indicative of metastasis, an assay for metastasis is considered positive if the level of expression of the OSNA or OSP is at 15 least two times lower, more preferably are at least five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control.

The OSNA or OSP of this invention may be used as element in an array or a multi-analyte test to recognize expression patterns associated with ovarian cancers or 20 other ovary related disorders. In addition, the sequences of either the nucleic acids or proteins may be used as elements in a computer program for pattern recognition of ovarian disorders.

#### *Staging*

25 The invention also provides a method of staging ovarian cancer in a human patient. The method comprises identifying a human patient having ovarian cancer and analyzing cells, tissues or bodily fluids from such human patient for expression levels and/or structural alterations of one or more OSNAs or OSPs. First, one or more tumors from a variety of patients are staged according to procedures well-known in the art, and 30 the expression level of one or more OSNAs or OSPs is determined for each stage to obtain a standard expression level for each OSNA and OSP. Then, the OSNA or OSP expression levels are determined in a biological sample from a patient whose stage of

-102-

cancer is not known. The OSNA or OSP expression levels from the patient are then compared to the standard expression level. By comparing the expression level of the OSNAs and OSPs from the patient to the standard expression levels, one may determine the stage of the tumor. The same procedure may be followed using structural alterations 5 of an OSNA or OSP to determine the stage of an ovarian cancer.

*Monitoring*

Further provided is a method of monitoring ovarian cancer in a human patient. One may monitor a human patient to determine whether there has been metastasis and, if there has been, when metastasis began to occur. One may also monitor a human patient 10 to determine whether a preneoplastic lesion has become cancerous. One may also monitor a human patient to determine whether a therapy, e.g., chemotherapy, radiotherapy or surgery, has decreased or eliminated the ovarian cancer. The method comprises identifying a human patient that one wants to monitor for ovarian cancer, periodically analyzing cells, tissues or bodily fluids from such human patient for 15 expression levels of one or more OSNAs or OSPs, and comparing the OSNA or OSP levels over time to those OSNA or OSP expression levels obtained previously. Patients may also be monitored by measuring one or more structural alterations in an OSNA or OSP that are associated with ovarian cancer.

If increased expression of an OSNA or OSP is associated with metastasis, 20 treatment failure, or conversion of a preneoplastic lesion to a cancerous lesion, then detecting an increase in the expression level of an OSNA or OSP indicates that the tumor is metastasizing, that treatment has failed or that the lesion is cancerous, respectively. One having ordinary skill in the art would recognize that if this were the case, then a decreased expression level would be indicative of no metastasis, effective therapy or 25 failure to progress to a neoplastic lesion. If decreased expression of an OSNA or OSP is associated with metastasis, treatment failure, or conversion of a preneoplastic lesion to a cancerous lesion, then detecting an decrease in the expression level of an OSNA or OSP indicates that the tumor is metastasizing, that treatment has failed or that the lesion is cancerous, respectively. In a preferred embodiment, the levels of OSNAs or OSPs are 30 determined from the same cell type, tissue or bodily fluid as prior patient samples. Monitoring a patient for onset of ovarian cancer metastasis is periodic and preferably is done on a quarterly basis, but may be done more or less frequently.

The methods described herein can further be utilized as prognostic assays to identify subjects having or at risk of developing a disease or disorder associated with increased or decreased expression levels of an OSNA and/or OSP. The present invention provides a method in which a test sample is obtained from a human patient and one or

5 more OSNAs and/or OSPs are detected. The presence of higher (or lower) OSNA or OSP levels as compared to normal human controls is diagnostic for the human patient being at risk for developing cancer, particularly ovarian cancer. The effectiveness of therapeutic agents to decrease (or increase) expression or activity of one or more OSNAs and/or OSPs of the invention can also be monitored by analyzing levels of expression of

10 the OSNAs and/or OSPs in a human patient in clinical trials or in *in vitro* screening assays such as in human cells. In this way, the gene expression pattern can serve as a marker, indicative of the physiological response of the human patient or cells, as the case may be, to the agent being tested.

*Detection of Genetic Lesions or Mutations*

15 The methods of the present invention can also be used to detect genetic lesions or mutations in an OSG, thereby determining if a human with the genetic lesion is susceptible to developing ovarian cancer or to determine what genetic lesions are responsible, or are partly responsible, for a person's existing ovarian cancer. Genetic lesions can be detected, for example, by ascertaining the existence of a deletion, insertion

20 and/or substitution of one or more nucleotides from the OSGs of this invention, a chromosomal rearrangement of OSG, an aberrant modification of OSG (such as of the methylation pattern of the genomic DNA), or allelic loss of an OSG. Methods to detect such lesions in the OSG of this invention are known to those having ordinary skill in the art following the teachings of the specification.

25 Methods of Detecting Noncancerous Ovarian Diseases

The invention also provides a method for determining the expression levels and/or structural alterations of one or more OSNAs and/or OSPs in a sample from a patient suspected of having or known to have a noncancerous ovarian disease. In

30 general, the method comprises the steps of obtaining a sample from the patient, determining the expression level or structural alterations of an OSNA and/or OSP, comparing the expression level or structural alteration of the OSNA or OSP to a normal

-104-

ovary control, and then ascertaining whether the patient has a noncancerous ovarian disease. In general, if high expression relative to a control of an OSNA or OSP is indicative of a particular noncancerous ovarian disease, a diagnostic assay is considered positive if the level of expression of the OSNA or OSP is at least two times higher, and 5 more preferably are at least five times higher, even more preferably at least ten times higher, than in preferably the same cells, tissues or bodily fluid of a normal human control. In contrast, if low expression relative to a control of an OSNA or OSP is indicative of a noncancerous ovarian disease, a diagnostic assay is considered positive if the level of expression of the OSNA or OSP is at least two times lower, more preferably 10 are at least five times lower, even more preferably at least ten times lower than in preferably the same cells, tissues or bodily fluid of a normal human control. The normal human control may be from a different patient or from uninvolved tissue of the same patient.

One having ordinary skill in the art may determine whether an OSNA and/or OSP 15 is associated with a particular noncancerous ovarian disease by obtaining ovary tissue from a patient having a noncancerous ovarian disease of interest and determining which OSNAs and/or OSPs are expressed in the tissue at either a higher or a lower level than in normal ovary tissue. In another embodiment, one may determine whether an OSNA or OSP exhibits structural alterations in a particular noncancerous ovarian disease state by 20 obtaining ovary tissue from a patient having a noncancerous ovarian disease of interest and determining the structural alterations in one or more OSNAs and/or OSPs relative to normal ovary tissue.

#### Methods for Identifying Ovary Tissue

25 In another aspect, the invention provides methods for identifying ovary tissue. These methods are particularly useful in, e.g., forensic science, ovary cell differentiation and development, and in tissue engineering.

In one embodiment, the invention provides a method for determining whether a 30 sample is ovary tissue or has ovary tissue-like characteristics. The method comprises the steps of providing a sample suspected of comprising ovary tissue or having ovary tissue-like characteristics, determining whether the sample expresses one or more OSNAs and/or OSPs, and, if the sample expresses one or more OSNAs and/or OSPs, concluding

-105-

that the sample comprises ovary tissue. In a preferred embodiment, the OSNA encodes a polypeptide having an amino acid sequence selected from SEQ ID NO: 138 through 238, or a homolog, allelic variant or fragment thereof. In a more preferred embodiment, the OSNA has a nucleotide sequence selected from SEQ ID NO: 1 through 137, or a

.5 hybridizing nucleic acid, an allelic variant or a part thereof. Determining whether a sample expresses an OSNA can be accomplished by any method known in the art. Preferred methods include hybridization to microarrays, Northern blot hybridization, and quantitative or qualitative RT-PCR. In another preferred embodiment, the method can be practiced by determining whether an OSP is expressed. Determining whether a

10 sample expresses an OSP can be accomplished by any method known in the art. Preferred methods include Western blot, ELISA, RIA and 2D PAGE. In one embodiment, the OSP has an amino acid sequence selected from SEQ ID NO: 138 through 238, or a homolog, allelic variant or fragment thereof. In another preferred embodiment, the expression of at least two OSNAs and/or OSPs is determined. In a

15 more preferred embodiment, the expression of at least three, more preferably four and even more preferably five OSNAs and/or OSPs are determined.

In one embodiment, the method can be used to determine whether an unknown tissue is ovary tissue. This is particularly useful in forensic science, in which small, damaged pieces of tissues that are not identifiable by microscopic or other means are recovered from a crime or accident scene. In another embodiment, the method can be used to determine whether a tissue is differentiating or developing into ovary tissue. This is important in monitoring the effects of the addition of various agents to cell or tissue culture, *e.g.*, in producing new ovary tissue by tissue engineering. These agents include, *e.g.*, growth and differentiation factors, extracellular matrix proteins and culture medium.

20 Other factors that may be measured for effects on tissue development and differentiation include gene transfer into the cells or tissues, alterations in pH, aqueous:air interface and various other culture conditions.

25

#### Methods for Producing and Modifying Ovary Tissue

30 In another aspect, the invention provides methods for producing engineered ovary tissue or cells. In one embodiment, the method comprises the steps of providing cells, introducing an OSNA or an OSG into the cells, and growing the cells under conditions in

-106-

which they exhibit one or more properties of ovary tissue cells. In a preferred embodiment, the cells are pluripotent. As is well-known in the art, normal ovary tissue comprises a large number of different cell types. Thus, in one embodiment, the engineered ovary tissue or cells comprises one of these cell types. In another 5 embodiment, the engineered ovary tissue or cells comprises more than one ovary cell type. Further, the culture conditions of the cells or tissue may require manipulation in order to achieve full differentiation and development of the ovary cell tissue. Methods for manipulating culture conditions are well-known in the art.

Nucleic acid molecules encoding one or more OSPs are introduced into cells, 10 preferably pluripotent cells. In a preferred embodiment, the nucleic acid molecules encode OSPs having amino acid sequences selected from SEQ ID NO: 138 through 238, or homologous proteins, analogs, allelic variants or fragments thereof. In a more preferred embodiment, the nucleic acid molecules have a nucleotide sequence selected from SEQ ID NO: 1 through 137, or hybridizing nucleic acids, allelic variants or parts 15 thereof. In another highly preferred embodiment, an OSG is introduced into the cells. Expression vectors and methods of introducing nucleic acid molecules into cells are well-known in the art and are described in detail, *supra*.

Artificial ovary tissue may be used to treat patients who have lost some or all of their ovary function.

20 **Pharmaceutical Compositions**

In another aspect, the invention provides pharmaceutical compositions comprising the nucleic acid molecules, polypeptides, antibodies, antibody derivatives, antibody fragments, agonists, antagonists, and inhibitors of the present invention. In a 25 preferred embodiment, the pharmaceutical composition comprises an OSNA or part thereof. In a more preferred embodiment, the OSNA has a nucleotide sequence selected from the group consisting of SEQ ID NO: 1 through 137, a nucleic acid that hybridizes thereto, an allelic variant thereof, or a nucleic acid that has substantial sequence identity thereto. In another preferred embodiment, the pharmaceutical composition comprises an 30 OSP or fragment thereof. In a more preferred embodiment, the OSP having an amino acid sequence that is selected from the group consisting of SEQ ID NO: 138 through 238, a polypeptide that is homologous thereto, a fusion protein comprising all or a portion of

the polypeptide, or an analog or derivative thereof. In another preferred embodiment, the pharmaceutical composition comprises an anti-OSP antibody, preferably an antibody that specifically binds to an OSP having an amino acid that is selected from the group consisting of SEQ ID NO: 138 through 238, or an antibody that binds to a polypeptide

- 5 that is homologous thereto, a fusion protein comprising all or a portion of the polypeptide, or an analog or derivative thereof.

Such a composition typically contains from about 0.1 to 90% by weight of a therapeutic agent of the invention formulated in and/or with a pharmaceutically acceptable carrier or excipient.

- 10 Pharmaceutical formulation is a well-established art, and is further described in Gennaro (ed.), Remington: The Science and Practice of Pharmacy, 20<sup>th</sup> ed., Lippincott, Williams & Wilkins (2000); Ansel *et al.*, Pharmaceutical Dosage Forms and Drug Delivery Systems, 7<sup>th</sup> ed., Lippincott Williams & Wilkins (1999); and Kibbe (ed.), Handbook of Pharmaceutical Excipients American Pharmaceutical Association, 3<sup>rd</sup> ed. 15 (2000), the disclosures of which are incorporated herein by reference in their entireties, and thus need not be described in detail herein.

- Briefly, formulation of the pharmaceutical compositions of the present invention will depend upon the route chosen for administration. The pharmaceutical compositions utilized in this invention can be administered by various routes including both enteral and 20 parenteral routes, including oral, intravenous, intramuscular, subcutaneous, inhalation, topical, sublingual, rectal, intra-arterial, intramedullary, intrathecal, intraventricular, transmucosal, transdermal, intranasal, intraperitoneal, intrapulmonary, and intrauterine.

Oral dosage forms can be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, and the like, for ingestion by the patient.

- 25 Solid formulations of the compositions for oral administration can contain suitable carriers or excipients, such as carbohydrate or protein fillers, such as sugars, including lactose, sucrose, mannitol, or sorbitol; starch from corn, wheat, rice, potato, or other plants; cellulose, such as methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, or microcrystalline cellulose; gums including arabic and 30 tragacanth; proteins such as gelatin and collagen; inorganics, such as kaolin, calcium carbonate, dicalcium phosphate, sodium chloride; and other agents such as acacia and alginic acid.

Agents that facilitate disintegration and/or solubilization can be added, such as the cross-linked polyvinyl pyrrolidone, agar, alginic acid, or a salt thereof, such as sodium alginate, microcrystalline cellulose, corn starch, sodium starch glycolate, and alginic acid.

- 5       Tablet binders that can be used include acacia, methylcellulose, sodium carboxymethylcellulose, polyvinylpyrrolidone (Povidone<sup>TM</sup>), hydroxypropyl methylcellulose, sucrose, starch and ethylcellulose.

Lubricants that can be used include magnesium stearates, stearic acid, silicone fluid, talc, waxes, oils, and colloidal silica.

- 10      Fillers, agents that facilitate disintegration and/or solubilization, tablet binders and lubricants, including the aforementioned, can be used singly or in combination.

Solid oral dosage forms need not be uniform throughout. For example, dragee cores can be used in conjunction with suitable coatings, such as concentrated sugar solutions, which can also contain gum arabic, talc, polyvinylpyrrolidone, carbopol gel, 15 polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.

Oral dosage forms of the present invention include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a coating, such as glycerol or sorbitol. Push-fit capsules can contain active ingredients mixed with a filler or binders, 20 such as lactose or starches, lubricants, such as talc or magnesium stearate, and, optionally, stabilizers. In soft capsules, the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid, or liquid polyethylene glycol with or without stabilizers.

Additionally, dyestuffs or pigments can be added to the tablets or dragee coatings 25 for product identification or to characterize the quantity of active compound, *i.e.*, dosage.

Liquid formulations of the pharmaceutical compositions for oral (enteral) administration are prepared in water or other aqueous vehicles and can contain various suspending agents such as methylcellulose, alginates, tragacanth, pectin, kelgin, carrageenan, acacia, polyvinylpyrrolidone, and polyvinyl alcohol. The liquid 30 formulations can also include solutions, emulsions, syrups and elixirs containing, together with the active compound(s), wetting agents, sweeteners, and coloring and flavoring agents.

The pharmaceutical compositions of the present invention can also be formulated for parenteral administration. Formulations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions.

- For intravenous injection, water soluble versions of the compounds of the present invention are formulated in, or if provided as a lyophilate, mixed with, a physiologically acceptable fluid vehicle, such as 5% dextrose ("D5"), physiologically buffered saline, 0.9% saline, Hanks' solution, or Ringer's solution. Intravenous formulations may include carriers, excipients or stabilizers including, without limitation, calcium, human serum albumin, citrate, acetate, calcium chloride, carbonate, and other salts.
- 10        Intramuscular preparations, *e.g.* a sterile formulation of a suitable soluble salt form of the compounds of the present invention, can be dissolved and administered in a pharmaceutical excipient such as Water-for-Injection, 0.9% saline, or 5% glucose solution. Alternatively, a suitable insoluble form of the compound can be prepared and administered as a suspension in an aqueous base or a pharmaceutically acceptable oil base, such as an ester of a long chain fatty acid (*e.g.*, ethyl oleate), fatty oils such as sesame oil, triglycerides, or liposomes.
- 15

Parenteral formulations of the compositions can contain various carriers such as vegetable oils, dimethylacetamide, dimethylformamide, ethyl lactate, ethyl carbonate, isopropyl myristate, ethanol, polyols (glycerol, propylene glycol, liquid polyethylene glycol, and the like).

20        Aqueous injection suspensions can also contain substances that increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Non-lipid polycationic amino polymers can also be used for delivery. Optionally, the suspension can also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.

25        Pharmaceutical compositions of the present invention can also be formulated to permit injectable, long-term, deposition. Injectable depot forms may be made by forming microencapsulated matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature 30 of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot

-110-

injectable formulations are also prepared by entrapping the drug in microemulsions that are compatible with body tissues.

The pharmaceutical compositions of the present invention can be administered topically.

- 5        For topical use the compounds of the present invention can also be prepared in suitable forms to be applied to the skin, or mucus membranes of the nose and throat, and can take the form of lotions, creams, ointments, liquid sprays or inhalants, drops, tinctures, lozenges, or throat paints. Such topical formulations further can include chemical compounds such as dimethylsulfoxide (DMSO) to facilitate surface penetration
- 10      of the active ingredient. In other transdermal formulations, typically in patch-delivered formulations, the pharmaceutically active compound is formulated with one or more skin penetrants, such as 2-N-methyl-pyrrolidone (NMP) or Azone. A topical semi-solid ointment formulation typically contains a concentration of the active ingredient from about 1 to 20%, e.g., 5 to 10%, in a carrier such as a pharmaceutical cream base.
- 15      For application to the eyes or ears, the compounds of the present invention can be presented in liquid or semi-liquid form formulated in hydrophobic or hydrophilic bases as ointments, creams, lotions, paints or powders.

- 20      For rectal administration the compounds of the present invention can be administered in the form of suppositories admixed with conventional carriers such as cocoa butter, wax or other glyceride.

- 25      Inhalation formulations can also readily be formulated. For inhalation, various powder and liquid formulations can be prepared. For aerosol preparations, a sterile formulation of the compound or salt form of the compound may be used in inhalers, such as metered dose inhalers, and nebulizers. Aerosolized forms may be especially useful for treating respiratory disorders.

Alternatively, the compounds of the present invention can be in powder form for reconstitution in the appropriate pharmaceutically acceptable carrier at the time of delivery.

- 30      The pharmaceutically active compound in the pharmaceutical compositions of the present invention can be provided as the salt of a variety of acids, including but not limited to hydrochloric, sulfuric, acetic, lactic, tartaric, malic, and succinic acid. Salts

-111-

tend to be more soluble in aqueous or other protonic solvents than are the corresponding free base forms.

After pharmaceutical compositions have been prepared, they are packaged in an appropriate container and labeled for treatment of an indicated condition.

5       The active compound will be present in an amount effective to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

A "therapeutically effective dose" refers to that amount of active ingredient, for example OSP polypeptide, fusion protein, or fragments thereof, antibodies specific for  
10 OSP, agonists, antagonists or inhibitors of OSP, which ameliorates the signs or symptoms of the disease or prevents progression thereof; as would be understood in the medical arts, cure, although desired, is not required.

The therapeutically effective dose of the pharmaceutical agents of the present invention can be estimated initially by *in vitro* tests, such as cell culture assays, followed  
15 by assay in model animals, usually mice, rats, rabbits, dogs, or pigs. The animal model can also be used to determine an initial preferred concentration range and route of administration.

For example, the ED50 (the dose therapeutically effective in 50% of the population) and LD50 (the dose lethal to 50% of the population) can be determined in  
20 one or more cell culture of animal model systems. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as LD50/ED50. Pharmaceutical compositions that exhibit large therapeutic indices are preferred.

The data obtained from cell culture assays and animal studies are used in formulating an initial dosage range for human use, and preferably provide a range of  
25 circulating concentrations that includes the ED50 with little or no toxicity. After administration, or between successive administrations, the circulating concentration of active agent varies within this range depending upon pharmacokinetic factors well-known in the art, such as the dosage form employed, sensitivity of the patient, and the route of administration.

30       The exact dosage will be determined by the practitioner, in light of factors specific to the subject requiring treatment. Factors that can be taken into account by the practitioner include the severity of the disease state, general health of the subject, age,

-112-

weight, gender of the subject, diet, time and frequency of administration, drug combination(s), reaction sensitivities, and tolerance/response to therapy. Long-acting pharmaceutical compositions can be administered every 3 to 4 days, every week, or once every two weeks depending on half-life and clearance rate of the particular formulation.

- 5       Normal dosage amounts may vary from 0.1 to 100,000 micrograms, up to a total dose of about 1 g, depending upon the route of administration. Where the therapeutic agent is a protein or antibody of the present invention, the therapeutic protein or antibody agent typically is administered at a daily dosage of 0.01 mg to 30 mg/kg of body weight of the patient (*e.g.*, 1 mg/kg to 5 mg/kg). The pharmaceutical formulation can be  
10      administered in multiple doses per day, if desired, to achieve the total desired daily dose.

Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors.

- 15      Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells, conditions, locations, etc.

Conventional methods, known to those of ordinary skill in the art of medicine, can be used to administer the pharmaceutical formulation(s) of the present invention to the patient. The pharmaceutical compositions of the present invention can be administered alone, or in combination with other therapeutic agents or interventions.

20      Therapeutic Methods

- The present invention further provides methods of treating subjects having defects in a gene of the invention, *e.g.*, in expression, activity, distribution, localization, and/or solubility, which can manifest as a disorder of ovary function. As used herein,  
25      “treating” includes all medically-acceptable types of therapeutic intervention, including palliation and prophylaxis (prevention) of disease. The term “treating” encompasses any improvement of a disease, including minor improvements. These methods are discussed below.

*Gene Therapy and Vaccines*

- 30      The isolated nucleic acids of the present invention can also be used to drive *in vivo* expression of the polypeptides of the present invention. *In vivo* expression can be driven from a vector, typically a viral vector, often a vector based upon a replication

-113-

- incompetent retrovirus, an adenovirus, or an adeno-associated virus (AAV), for purpose of gene therapy. *In vivo* expression can also be driven from signals endogenous to the nucleic acid or from a vector, often a plasmid vector, such as pVAX1 (Invitrogen, Carlsbad, CA, USA), for purpose of "naked" nucleic acid vaccination, as further described in U.S. Patents 5,589,466; 5,679,647; 5,804,566; 5,830,877; 5,843,913; 5,880,104; 5,958,891; 5,985,847; 6,017,897; 6,110,898; and 6,204,250, the disclosures of which are incorporated herein by reference in their entireties. For cancer therapy, it is preferred that the vector also be tumor-selective. *See, e.g.*, Doronin *et al.*, *J. Virol.* 75: 3314-24 (2001).
- 10 In another embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising a nucleic acid of the present invention is administered. The nucleic acid can be delivered in a vector that drives expression of an OSP, fusion protein, or fragment thereof, or without such vector. Nucleic acid compositions that can drive expression of an OSP are administered, for example, to complement a deficiency in the native OSP, or as DNA vaccines. Expression vectors derived from virus, replication deficient retroviruses, adenovirus, adeno-associated (AAV) virus, herpes virus, or vaccinia virus can be used as can plasmids. *See, e.g.*, Cid-Arregui, *supra*. In a preferred embodiment, the nucleic acid molecule encodes an OSP having the amino acid sequence of SEQ ID NO: 138 through 20 238, or a fragment, fusion protein, allelic variant or homolog thereof.

In still other therapeutic methods of the present invention, pharmaceutical compositions comprising host cells that express an OSP, fusions, or fragments thereof can be administered. In such cases, the cells are typically autologous, so as to circumvent xenogeneic or allotypic rejection, and are administered to complement defects in OSP production or activity. In a preferred embodiment, the nucleic acid molecules in the cells encode an OSP having the amino acid sequence of SEQ ID NO: 138 through 238, or a fragment, fusion protein, allelic variant or homolog thereof.

#### *Antisense Administration*

Antisense nucleic acid compositions, or vectors that drive expression of an OSG antisense nucleic acid, are administered to downregulate transcription and/or translation of an OSG in circumstances in which excessive production, or production of aberrant protein, is the pathophysiologic basis of disease.

Antisense compositions useful in therapy can have a sequence that is complementary to coding or to noncoding regions of an OSG. For example, oligonucleotides derived from the transcription initiation site, e.g., between positions -10 and +10 from the start site, are preferred.

5       Catalytic antisense compositions, such as ribozymes, that are capable of sequence-specific hybridization to OSG transcripts, are also useful in therapy. See, e.g., Phylactou, *Adv. Drug Deliv. Rev.* 44(2-3): 97-108 (2000); Phylactou *et al.*, *Hum. Mol. Genet.* 7(10): 1649-53 (1998); Rossi, *Ciba Found. Symp.* 209: 195-204 (1997); and Sigurdsson *et al.*, *Trends Biotechnol.* 13(8): 286-9 (1995), the disclosures of which are  
10 incorporated herein by reference in their entireties.

Other nucleic acids useful in the therapeutic methods of the present invention are those that are capable of triplex helix formation in or near the OSG genomic locus. Such triplexing oligonucleotides are able to inhibit transcription. See, e.g., Intody *et al.*, *Nucleic Acids Res.* 28(21): 4283-90 (2000); McGuffie *et al.*, *Cancer Res.* 60(14): 3790-9  
15 (2000), the disclosures of which are incorporated herein by reference. Pharmaceutical compositions comprising such triplex forming oligos (TFOs) are administered in circumstances in which excessive production, or production of aberrant protein, is a pathophysiologic basis of disease.

In a preferred embodiment, the antisense molecule is derived from a nucleic acid  
20 molecule encoding an OSP, preferably an OSP comprising an amino acid sequence of SEQ ID NO: 138 through 238, or a fragment, allelic variant or homolog thereof. In a more preferred embodiment, the antisense molecule is derived from a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1 through 137, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

25       *Polypeptide Administration*

In one embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising an OSP, a fusion protein, fragment, analog or derivative thereof is administered to a subject with a clinically-significant OSP defect.

30       Protein compositions are administered, for example, to complement a deficiency in native OSP. In other embodiments, protein compositions are administered as a vaccine to elicit a humoral and/or cellular immune response to OSP. The immune

response can be used to modulate activity of OSP or, depending on the immunogen, to immunize against aberrant or aberrantly expressed forms, such as mutant or inappropriately expressed isoforms. In yet other embodiments, protein fusions having a toxic moiety are administered to ablate cells that aberrantly accumulate OSP.

- 5       In a preferred embodiment, the polypeptide is an OSP comprising an amino acid sequence of SEQ ID NO: 138 through 238, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred embodiment, the polypeptide is encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1 through 137, or a part, allelic variant, substantially similar or hybridizing nucleic acid  
10 thereof.

*Antibody, Agonist and Antagonist Administration*

- In another embodiment of the therapeutic methods of the present invention, a therapeutically effective amount of a pharmaceutical composition comprising an antibody (including fragment or derivative thereof) of the present invention is  
15 administered. As is well-known, antibody compositions are administered, for example, to antagonize activity of OSP, or to target therapeutic agents to sites of OSP presence and/or accumulation. In a preferred embodiment, the antibody specifically binds to an OSP comprising an amino acid sequence of SEQ ID NO: 138 through 238, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred  
20 embodiment, the antibody specifically binds to an OSP encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1 through 137, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

- The present invention also provides methods for identifying modulators which bind to an OSP or have a modulatory effect on the expression or activity of an OSP.  
25 Modulators which decrease the expression or activity of OSP (antagonists) are believed to be useful in treating ovarian cancer. Such screening assays are known to those of skill in the art and include, without limitation, cell-based assays and cell-free assays. Small molecules predicted via computer imaging to specifically bind to regions of an OSP can also be designed, synthesized and tested for use in the imaging and treatment of ovarian  
30 cancer. Further, libraries of molecules can be screened for potential anticancer agents by assessing the ability of the molecule to bind to the OSPs identified herein. Molecules identified in the library as being capable of binding to an OSP are key candidates for

further evaluation for use in the treatment of ovarian cancer. In a preferred embodiment, these molecules will downregulate expression and/or activity of an OSP in cells.

In another embodiment of the therapeutic methods of the present invention, a pharmaceutical composition comprising a non-antibody antagonist of OSP is administered. Antagonists of OSP can be produced using methods generally known in the art. In particular, purified OSP can be used to screen libraries of pharmaceutical agents, often combinatorial libraries of small molecules, to identify those that specifically bind and antagonize at least one activity of an OSP.

In other embodiments a pharmaceutical composition comprising an agonist of an OSP is administered. Agonists can be identified using methods analogous to those used to identify antagonists.

In a preferred embodiment, the antagonist or agonist specifically binds to and antagonizes or agonizes, respectively, an OSP comprising an amino acid sequence of SEQ ID NO: 138 through 238, or a fusion protein, allelic variant, homolog, analog or derivative thereof. In a more preferred embodiment, the antagonist or agonist specifically binds to and antagonizes or agonizes, respectively, an OSP encoded by a nucleic acid molecule having a nucleotide sequence of SEQ ID NO: 1 through 137, or a part, allelic variant, substantially similar or hybridizing nucleic acid thereof.

#### *Targeting Ovary Tissue*

The invention also provides a method in which a polypeptide of the invention, or an antibody thereto, is linked to a therapeutic agent such that it can be delivered to the ovary or to specific cells in the ovary. In a preferred embodiment, an anti-OSP antibody is linked to a therapeutic agent and is administered to a patient in need of such therapeutic agent. The therapeutic agent may be a toxin, if ovary tissue needs to be selectively destroyed. This would be useful for targeting and killing ovarian cancer cells. In another embodiment, the therapeutic agent may be a growth or differentiation factor, which would be useful for promoting ovary cell function.

In another embodiment, an anti-OSP antibody may be linked to an imaging agent that can be detected using, e.g., magnetic resonance imaging, CT or PET. This would be useful for determining and monitoring ovary function, identifying ovarian cancer tumors, and identifying noncancerous ovarian diseases.

## EXAMPLES

### Example 1: Gene Expression analysis

OSGs were identified by a systematic analysis of gene expression data in the LIFESEQ® Gold database available from Incyte Genomics Inc (Palo Alto, CA) using 5 the data mining software package CLASP™ (Candidate Lead Automatic Search Program). CLASP™ is a set of algorithms that interrogate Incyte's database to identify genes that are both specific to particular tissue types as well as differentially expressed in tissues from patients with cancer. LifeSeq® Gold contains information about which genes are expressed in various tissues in the body and about the dynamics of expression 10 in both normal and diseased states. CLASP™ first sorts the LifeSeq® Gold database into defined tissue types, such as breast, ovary and prostate. CLASP™ categorizes each tissue sample by disease state. Disease states include "healthy," "cancer," "associated with cancer," "other disease" and "other." Categorizing the disease states improves our ability to identify tissue and cancer-specific molecular targets. CLASP™ then performs a 15 simultaneous parallel search for genes that are expressed both (1) selectively in the defined tissue type compared to other tissue types and (2) differentially in the "cancer" disease state compared to the other disease states affecting the same, or different, tissues. This sorting is accomplished by using mathematical and statistical filters that specify the minimum change in expression levels and the minimum frequency that the differential 20 expression pattern must be observed across the tissue samples for the gene to be considered statistically significant. The CLASP™ algorithm quantifies the relative abundance of a particular gene in each tissue type and in each disease state.

To find the OSGs of this invention, the following specific CLASP™ profiles were utilized: tissue-specific expression (CLASP 1), detectable expression only in cancer 25 tissue (CLASP 2), and differential expression in cancer tissue (CLASP 5). cDNA libraries were divided into 60 unique tissue types (early versions of LifeSeq® had 48 tissue types). Genes or ESTs were grouped into "gene bins," where each bin is a cluster of sequences grouped together where they share a common contig. The expression level for each gene bin was calculated for each tissue type. Differential expression 30 significance was calculated with rigorous statistical significant testing taking into account variations in sample size and relative gene abundance in different libraries and within

- each library (for the equations used to determine statistically significant expression see Audic and Claverie "The significance of digital gene expression profiles," Genome Res 7(10): 986-995 (1997), including Equation 1 on page 987 and Equation 2 on page 988, the contents of which are incorporated by reference). Differentially expressed tissue-specific genes were selected based on the percentage abundance level in the targeted tissue versus all the other tissues (tissue-specificity). The expression levels for each gene in libraries of normal tissues or non-tumor tissues from cancer patients were compared with the expression levels in tissue libraries associated with tumor or disease (cancer-specificity). The results were analyzed for statistical significance.
- 10        The selection of the target genes meeting the rigorous CLASP™ profile criteria were as follows:
- (a)      CLASP 1: tissue-specific expression: To qualify as a CLASP 1 candidate, a gene must exhibit statistically significant expression in the tissue of interest compared to all other tissues. Only if the gene exhibits such differential expression with a 90% of confidence level is it selected as a CLASP 1 candidate.
  - (b)      CLASP 2: detectable expression only in cancer tissue: To qualify as a CLASP 2 candidate, a gene must exhibit detectable expression in tumor tissues and undetectable expression in libraries from normal individuals and libraries from normal tissue obtained from diseased patients. In addition, such a gene must also exhibit further specificity for the tumor tissues of interest.
  - (c)      CLASP 5: differential expression in cancer tissue: To qualify as a CLASP 5 candidate, a gene must be differentially expressed in tumor libraries in the tissue of interest compared to normal libraries for all tissues. Only if the gene exhibits such differential expression with a 90% of confidence level is it selected as a CLASP 5 candidate.

The CLASP™ scores for SEQ ID NO: 1-137 are listed below:

SEQ ID NO: 1	DEX0257_1	CLASP2
SEQ ID NO: 2	DEX0257_2	CLASP2
SEQ ID NO: 3	DEX0257_3	CLASP2
SEQ ID NO: 4	DEX0257_4	CLASP5 CLASP1
SEQ ID NO: 5	DEX0257_5	CLASP5 CLASP1
SEQ ID NO: 6	DEX0257_6	CLASP2

-119-

	SEQ ID NO: 7	DEX0257_7 CLASP2
	SEQ ID NO: 8	DEX0257_8 CLASP2
	SEQ ID NO: 9	DEX0257_9 CLASP2
	SEQ ID NO: 10	DEX0257_10 CLASP2
5	SEQ ID NO: 11	DEX0257_11 CLASP2
	SEQ ID NO: 12	DEX0257_12 CLASP2
	SEQ ID NO: 13	DEX0257_13 CLASP2
	SEQ ID NO: 14	DEX0257_14 CLASP2
	SEQ ID NO: 15	DEX0257_15 CLASP2
10	SEQ ID NO: 16	DEX0257_16 CLASP2
	SEQ ID NO: 17	DEX0257_17 CLASP2
	SEQ ID NO: 18	DEX0257_18 CLASP2
	SEQ ID NO: 19	DEX0257_19 CLASP2
	SEQ ID NO: 20	DEX0257_20 CLASP2
15	SEQ ID NO: 21	DEX0257_21 CLASP2
	SEQ ID NO: 22	DEX0257_22 CLASP2
	SEQ ID NO: 23	DEX0257_23 CLASP2
	SEQ ID NO: 24	DEX0257_24 CLASP2
	SEQ ID NO: 25	DEX0257_25 CLASP2
20	SEQ ID NO: 26	DEX0257_26 CLASP2
	SEQ ID NO: 27	DEX0257_27 CLASP2
	SEQ ID NO: 28	DEX0257_28 CLASP2
	SEQ ID NO: 29	DEX0257_29 CLASP2
	SEQ ID NO: 30	DEX0257_30 CLASP2
25	SEQ ID NO: 31	DEX0257_31 CLASP2
	SEQ ID NO: 32	DEX0257_32 CLASP2
	SEQ ID NO: 33	DEX0257_33 CLASP2
.	SEQ ID NO: 34	DEX0257_34 CLASP2
	SEQ ID NO: 35	DEX0257_35 CLASP2
30	SEQ ID NO: 36	DEX0257_36 CLASP2
	SEQ ID NO: 37	DEX0257_37 CLASP2
	SEQ ID NO: 38	DEX0257_38 CLASP2
	SEQ ID NO: 39	DEX0257_39 CLASP2
	SEQ ID NO: 40	DEX0257_40 CLASP2
35	SEQ ID NO: 41	DEX0257_41 CLASP2
	SEQ ID NO: 42	DEX0257_42 CLASP2
	SEQ ID NO: 43	DEX0257_43 CLASP2
	SEQ ID NO: 44	DEX0257_44 CLASP2
	SEQ ID NO: 45	DEX0257_45 CLASP2
40	SEQ ID NO: 48	DEX0257_48 CLASP2
	SEQ ID NO: 49	DEX0257_49 CLASP2
	SEQ ID NO: 50	DEX0257_50 CLASP2
	SEQ ID NO: 51	DEX0257_51 CLASP2
	SEQ ID NO: 52	DEX0257_52 CLASP2
45	SEQ ID NO: 53	DEX0257_53 CLASP2
	SEQ ID NO: 54	DEX0257_54 CLASP2
	SEQ ID NO: 55	DEX0257_55 CLASP2
	SEQ ID NO: 56	DEX0257_56 CLASP2

-120-

	SEQ ID NO: 57	DEX0257_57 CLASP2
	SEQ ID NO: 58	DEX0257_58 CLASP2
	SEQ ID NO: 59	DEX0257_59 CLASP2
	SEQ ID NO: 60	DEX0257_60 CLASP2
5	SEQ ID NO: 61	DEX0257_61 CLASP2
	SEQ ID NO: 62	DEX0257_62 CLASP2
	SEQ ID NO: 63	DEX0257_63 CLASP2
	SEQ ID NO: 64	DEX0257_64 CLASP2
	SEQ ID NO: 65	DEX0257_65 CLASP2
10	SEQ ID NO: 66	DEX0257_66 CLASP2
	SEQ ID NO: 67	DEX0257_67 CLASP2
	SEQ ID NO: 68	DEX0257_68 CLASP2
	SEQ ID NO: 69	DEX0257_69 CLASP2 CLASP1
	SEQ ID NO: 70	DEX0257_70 CLASP2
15	SEQ ID NO: 71	DEX0257_71 CLASP2
	SEQ ID NO: 72	DEX0257_72 CLASP2
	SEQ ID NO: 73	DEX0257_73 CLASP2
	SEQ ID NO: 74	DEX0257_74 CLASP2
	SEQ ID NO: 75	DEX0257_75 CLASP2
20	SEQ ID NO: 76	DEX0257_76 CLASP2
	SEQ ID NO: 78	DEX0257_78 CLASP5 CLASP1
	SEQ ID NO: 79	DEX0257_79 CLASP2
	SEQ ID NO: 80	DEX0257_80 CLASP2
	SEQ ID NO: 81	DEX0257_81 CLASP1
25	SEQ ID NO: 82	DEX0257_82 CLASP2
	SEQ ID NO: 83	DEX0257_83 CLASP2
	SEQ ID NO: 84	DEX0257_84 CLASP2
	SEQ ID NO: 85	DEX0257_85 CLASP2
	SEQ ID NO: 86	DEX0257_86 CLASP2
30	SEQ ID NO: 87	DEX0257_87 CLASP2
	SEQ ID NO: 88	DEX0257_88 CLASP2
	SEQ ID NO: 89	DEX0257_89 CLASP5 CLASP1
	SEQ ID NO: 90	DEX0257_90 CLASP5 CLASP1
	SEQ ID NO: 91	DEX0257_91 CLASP5 CLASP1
35	SEQ ID NO: 92	DEX0257_92 CLASP1
	SEQ ID NO: 93	DEX0257_93 CLASP2
	SEQ ID NO: 94	DEX0257_94 CLASP2
	SEQ ID NO: 95	DEX0257_95 CLASP2
	SEQ ID NO: 96	DEX0257_96 CLASP2
40	SEQ ID NO: 97	DEX0257_97 CLASP2
	SEQ ID NO: 98	DEX0257_98 CLASP2
	SEQ ID NO: 99	DEX0257_99 CLASP2
	SEQ ID NO: 100	DEX0257_100 CLASP2
	SEQ ID NO: 101	DEX0257_101 CLASP2
45	SEQ ID NO: 102	DEX0257_102 CLASP2
	SEQ ID NO: 103	DEX0257_103 CLASP2
	SEQ ID NO: 104	DEX0257_104 CLASP2
	SEQ ID NO: 105	DEX0257_105 CLASP2

-121-

	SEQ ID NO: 106	DEX0257_106	CLASP2
	SEQ ID NO: 107	DEX0257_107	CLASP2
	SEQ ID NO: 108	DEX0257_108	CLASP2
	SEQ ID NO: 109	DEX0257_109	CLASP2
5	SEQ ID NO: 110	DEX0257_110	CLASP2
	SEQ ID NO: 111	DEX0257_111	CLASP2
	SEQ ID NO: 112	DEX0257_112	CLASP5 CLASP1
	SEQ ID NO: 113	DEX0257_113	CLASP5 CLASP1
	SEQ ID NO: 114	DEX0257_114	CLASP5 CLASP1
10	SEQ ID NO: 115	DEX0257_115	CLASP5 CLASP1
	SEQ ID NO: 117	DEX0257_117	CLASP2
	SEQ ID NO: 118	DEX0257_118	CLASP2
	SEQ ID NO: 119	DEX0257_119	CLASP2
	SEQ ID NO: 120	DEX0257_120	CLASP2
15	SEQ ID NO: 121	DEX0257_121	CLASP2
	SEQ ID NO: 122	DEX0257_122	CLASP2 CLASP1
	SEQ ID NO: 123	DEX0257_123	CLASP2 CLASP1
	SEQ ID NO: 124	DEX0257_124	CLASP2
	SEQ ID NO: 125	DEX0257_125	CLASP1
20	SEQ ID NO: 126	DEX0257_126	CLASP1
	SEQ ID NO: 127	DEX0257_127	CLASP2
	SEQ ID NO: 128	DEX0257_128	CLASP2
	SEQ ID NO: 129	DEX0257_129	CLASP1
	SEQ ID NO: 130	DEX0257_130	CLASP1
25	SEQ ID NO: 131	DEX0257_131	CLASP1
	SEQ ID NO: 132	DEX0257_132	CLASP2
	SEQ ID NO: 133	DEX0257_133	CLASP2
	SEQ ID NO: 134	DEX0257_134	CLASP2
	SEQ ID NO: 135	DEX0257_135	CLASP2
30	SEQ ID NO: 136	DEX0257_136	CLASP2
	SEQ ID NO: 137	DEX0257_137	CLASP2

#### CLASP Expression percentage levels for DEX0257 genes

	SEQ ID NO: 1	OVR .0051					
	SEQ ID NO: 2	OVR .0064					
	SEQ ID NO: 3	OVR .0064					
	SEQ ID NO: 4	OVR .0032	BRN .0003	UTR .0004	KID .0006	STO .0021	
	SEQ ID NO: 5	OVR .0032	BRN .0003	UTR .0004	KID .0006	STO .0021	
35	SEQ ID NO: 6	OVR .0023					
	SEQ ID NO: 7	OVR .0023					
	SEQ ID NO: 8	OVR .0023					
	SEQ ID NO: 9	OVR .0023					
	SEQ ID NO: 10	OVR .0023					
40	SEQ ID NO: 11	OVR .0023					
	SEQ ID NO: 12	OVR .0023					
	SEQ ID NO: 13	OVR .0023					
	SEQ ID NO: 14	OVR .0023					
45							

-122-

	SEQ ID NO: 15	OVR .0023
	SEQ ID NO: 16	OVR .0023
	SEQ ID NO: 17	OVR .0023
	SEQ ID NO: 18	OVR .0023
5	SEQ ID NO: 19	OVR .0063
	SEQ ID NO: 20	OVR .0063
	SEQ ID NO: 21	OVR .0063
	SEQ ID NO: 22	OVR .0063
	SEQ ID NO: 23	OVR .0056
10	SEQ ID NO: 24	OVR .0056
	SEQ ID NO: 25	OVR .0056
	SEQ ID NO: 26	OVR .0056
	SEQ ID NO: 27	OVR .0059
	SEQ ID NO: 28	OVR .0059
15	SEQ ID NO: 29	OVR .0059
	SEQ ID NO: 30	OVR .0059
	SEQ ID NO: 31	OVR .0059
	SEQ ID NO: 32	OVR .0059
	SEQ ID NO: 33	OVR .0051
20	SEQ ID NO: 34	OVR .0051
	SEQ ID NO: 35	OVR .0051
	SEQ ID NO: 36	OVR .0051
	SEQ ID NO: 37	OVR .0051
	SEQ ID NO: 38	OVR .0051
25	SEQ ID NO: 39	OVR .0051
	SEQ ID NO: 40	OVR .0051
	SEQ ID NO: 41	OVR .0051
	SEQ ID NO: 42	OVR .0051
	SEQ ID NO: 43	OVR .0051
30	SEQ ID NO: 44	OVR .0051
	SEQ ID NO: 45	OVR .0051
	SEQ ID NO: 48	OVR .0051
	SEQ ID NO: 49	OVR .0051
	SEQ ID NO: 50	OVR .0051
35	SEQ ID NO: 51	OVR .0051
	SEQ ID NO: 52	OVR .0051
	SEQ ID NO: 53	OVR .0051
	SEQ ID NO: 54	OVR .0062
	SEQ ID NO: 55	OVR .0062
40	SEQ ID NO: 56	OVR .0062
	SEQ ID NO: 57	OVR .0062
	SEQ ID NO: 58	OVR .0062
	SEQ ID NO: 59	OVR .0062
	SEQ ID NO: 60	OVR .0062
45	SEQ ID NO: 61	OVR .0062
	SEQ ID NO: 62	OVR .0062
	SEQ ID NO: 63	OVR .0062
	SEQ ID NO: 64	OVR .0062

-123-

	SEQ ID NO: 65	OVR .0062				
	SEQ ID NO: 66	OVR .0062				
	SEQ ID NO: 67	OVR .0062	BRN .0004			
	SEQ ID NO: 68	OVR .0062	BRN .0004			
5	SEQ ID NO: 69	OVR .0088				
	SEQ ID NO: 70	OVR .0062				
	SEQ ID NO: 71	OVR .0062				
	SEQ ID NO: 72	OVR .0062				
	SEQ ID NO: 73	OVR .0062				
10	SEQ ID NO: 74	OVR .0062				
	SEQ ID NO: 75	OVR .0062				
	SEQ ID NO: 76	OVR .0062				
	SEQ ID NO: 78	OVR .0032	CON .0007	PRO .0007	CRD .002	CRD .0023
	SEQ ID NO: 79	OVR .0059				
15	SEQ ID NO: 80	OVR .0131				
	SEQ ID NO: 81	OVR .0032	FTS .0001	BRN .0003	KID .0006	NRV .0009
	SEQ ID NO: 82	OVR .0042	PRO .0019	THR .0127		
	SEQ ID NO: 83	OVR .0042	PRO .0019	THR .0127		
	SEQ ID NO: 84	OVR .0023				
20	SEQ ID NO: 85	OVR .0023				
	SEQ ID NO: 86	OVR .0062				
	SEQ ID NO: 87	OVR .0062				
	SEQ ID NO: 88	OVR .0051	CON .0007			
	SEQ ID NO: 89	OVR .0043				
25	SEQ ID NO: 90	OVR .0043				
	SEQ ID NO: 91	OVR .0032	FTS .0003	INL .0004	INS .001	
	SEQ ID NO: 92	OVR .0032	INL .0012	KID .0013	TNS .0017	CRD .002
	SEQ ID NO: 93	OVR .0062				
	SEQ ID NO: 94	OVR .0052				
30	SEQ ID NO: 95	OVR .0064	STO .0185			
	SEQ ID NO: 96	OVR .0064	STO .0185			
	SEQ ID NO: 97	OVR .0097				
	SEQ ID NO: 98	OVR .0097				
	SEQ ID NO: 99	OVR .0052				
35	SEQ ID NO: 100	OVR .0064				
	SEQ ID NO: 101	OVR .0058	MAM .002			
	SEQ ID NO: 102	OVR .0058	MAM .002			
	SEQ ID NO: 103	OVR .0043				
	SEQ ID NO: 104	OVR .0043				
40	SEQ ID NO: 105	OVR .0023				
	SEQ ID NO: 106	OVR .0052				
	SEQ ID NO: 107	OVR .0052				
	SEQ ID NO: 108	OVR .0062				
	SEQ ID NO: 109	OVR .0064				
45	SEQ ID NO: 110	OVR .0051	CON .0007	UTR .005		
	SEQ ID NO: 111	OVR .0051	CON .0007	UTR .005		
	SEQ ID NO: 112	OVR .0064	FTS .0003	LNG .0004	LNG .0006	BLO .0006
	SEQ ID NO: 113	OVR .0064	FTS .0003	LNG .0004	LNG .0006	BLO .0006

-124-

SEQ ID NO: 114	OVR .0064	FTS .0003	LNG .0004	LNG .0006	BLO .0006
SEQ ID NO: 115	OVR .0064	FTS .0003	LNG .0004	LNG .0006	BLO .0006
SEQ ID NO: 117	OVR .0064				
SEQ ID NO: 118	OVR .0023				
5 SEQ ID NO: 119	OVR .0023				
SEQ ID NO: 120	OVR .0064				
SEQ ID NO: 121	OVR .0064				
SEQ ID NO: 122	OVR .0034				
SEQ ID NO: 123	OVR .0034				
10 SEQ ID NO: 124	OVR .0023				
SEQ ID NO: 125	OVR .0021	MSL .002			
SEQ ID NO: 126	OVR .0021	MSL .002			
SEQ ID NO: 127	OVR .0093				
SEQ ID NO: 128	OVR .0093				
15 SEQ ID NO: 129	OVR .0063	FTS .0003	LNG .0004	INL .0004	CON .0007
SEQ ID NO: 130	OVR .0063	FTS .0003	LNG .0004	INL .0004	CON .0007
SEQ ID NO: 131	OVR .0063	FTS .0003	LNG .0004	INL .0004	CON .0007
SEQ ID NO: 132	OVR .0052				
SEQ ID NO: 133	OVR .0052				
20 SEQ ID NO: 134	OVR .0063				
SEQ ID NO: 135	OVR .0063				
SEQ ID NO: 136	OVR .0063				
SEQ ID NO: 137	OVR .0063				
25 Abbreviation for tissues:					
	BLO Blood; BRN Brain; CON Connective Tissue; CRD Heart; FTS Fetus; INL Intestine, Large; INS Intestine, Small; KID Kidney; LIV Liver; LNG Lung; MAM Breast; MSL Muscles; NRV Nervous Tissue; OVR Ovary; PRO Prostate; STO Stomach; THR Thyroid Gland; TNS Tonsil / Adenoids; UTR Uterus				
30					

#### Example 2: Relative Quantitation of Gene Expression

Real-Time quantitative PCR with fluorescent Taqman probes is a quantitation detection system utilizing the 5'- 3' nuclease activity of Taq DNA polymerase. The method uses an internal fluorescent oligonucleotide probe (Taqman) labeled with a 5' reporter dye and a downstream, 3' quencher dye. During PCR, the 5'-3' nuclease activity of Taq DNA polymerase releases the reporter, whose fluorescence can then be detected by the laser detector of the Model 7700 Sequence Detection System (PE Applied Biosystems, Foster City, CA, USA). Amplification of an endogenous control is used to standardize the amount of sample RNA added to the reaction and normalize for Reverse Transcriptase (RT) efficiency. Either cyclophilin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), ATPase, or 18S ribosomal RNA (rRNA) is used as this endogenous control. To calculate relative quantitation between all the samples studied,

-125-

the target RNA levels for one sample were used as the basis for comparative results (calibrator). Quantitation relative to the "calibrator" can be obtained using the standard curve method or the comparative method (User Bulletin #2: ABI PRISM 7700 Sequence Detection System).

- 5       The tissue distribution and the level of the target gene are evaluated for every sample in normal and cancer tissues. Total RNA is extracted from normal tissues, cancer tissues, and from cancers and the corresponding matched adjacent tissues. Subsequently, first strand cDNA is prepared with reverse transcriptase and the polymerase chain reaction is done using primers and Taqman probes specific to each target gene. The  
10      results are analyzed using the ABI PRISM 7700 Sequence Detector. The absolute numbers are relative levels of expression of the target gene in a particular tissue compared to the calibrator tissue.

One of ordinary skill can design appropriate primers. The relative levels of expression of the OSNA versus normal tissues and other cancer tissues can then be  
15      determined. All the values are compared to normal thymus (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

The relative levels of expression of the OSNA in pairs of matching samples and 1 cancer and 1 normal/normal adjacent of tissue may also be determined. All the values  
20      are compared to normal thymus (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

In the analysis of matching samples, the OSNAs that show a high degree of tissue specificity for the tissue of interest. These results confirm the tissue specificity results  
25      obtained with normal pooled samples.

Further, the level of mRNA expression in cancer samples and the isogenic normal adjacent tissue from the same individual are compared. This comparison provides an indication of specificity for the cancer stage (e.g. higher levels of mRNA expression in the cancer sample compared to the normal adjacent).

30       Altogether, the high level of tissue specificity, plus the mRNA overexpression in matching samples tested are indicative of SEQ ID NO: 1 through 137 being a diagnostic marker for cancer.

-126-

**Sequence****Dex0097\_24 (ovr125-sqovr007)****Sequence ID No.****DEX0257\_33 (SEQ ID No. 33)**

Semi-quantitative PCR was done using the following primers:

5

Primer	DexSeqID	From	To	Primer Length
sqovr007F	DEX0257_33	15	37	23
sqovr007R	DEX0257_33	233	213	21

Data from the semiQ-PCR experiment showed that sqovr007 was overexpressed in 3 of 6 (50%) ovarian cancer matching samples. Sqovr007 was advanced to quantitative PCR and named ovr125.

10

Quantitative PCR was done using the following primers:

Primer	DexSeqID	From	To	Primer Length
ovr125F	DEX0257_33		17	38
ovr125R	DEX0257_33		120	98
ovr125probe	DEX0257_33		47	76

15 Table 1. The absolute numbers are relative levels of expression of ovr125 in 24 normal samples from 24 different tissues. All the values are compared to normal brain (calibrator). These RNA samples are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

Tissue	Normal
Adrenal Gland	0.00
Bladder	0.00
Brain	1.00
Cervix	0.00
Colon	0.15
Endometrium	0.00
Esophagus	0.00
Heart	0.00
Kidney	0.61
Liver	0.00
Lung	0.00
Mammary	0.68
Muscle	0.08
Ovary	7.73
Pancreas	2.59
Prostate	0.00
Rectum	0.00
Small Intestine	0.00
Spleen	12.47
Stomach	0.00

-127-

Testis	0.00
Thymus	9.09
Trachea	1.74
Uterus	0.00

The relative levels of expression in the table above show that ovr125 mRNA expression is detected in the pool of normal spleen, thymus followed by ovary. Fourteen normal samples do not show expression of ovr125.

- 5       The absolute numbers in the table were obtained analyzing pools of samples of a particular tissue from different individuals. They cannot be compared to the absolute numbers originated from RNA obtained from tissue samples of a single individual in the table below.

- 10      The relative levels of expression of ovr125 in 48 pairs of matching samples were analyzed. All the values are compared to normal brain (calibrator). A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. In addition, 9 unmatched cancer samples (from ovary) and 7 unmatched normal samples (from ovary) were also tested.

15

Sample ID	Tissue	Cancer	Normal Adjacent Tissue	Normal
OvrA084	ovary 1	72.00	59.30	
OvrG021	ovary 2	36.76	91.46	
Ovr371O	ovary 3	48.17		
Ovr638A	ovary 4	157.59		
Ovr63A	ovary 5	163.14		
Ovr773O	ovary 6	11.71		
Ovr988Z	ovary 7	38.19		
Ovr1005O	ovary 8	54.19		
Ovr1028	ovary 9	168.31		
Ovr1040O	ovary 10	38.72		
Ovr105O	ovary 11	56.69		
OvrC087	ovary 12			8.40
OvrC109	ovary 13			14.88
Ovr18GA	ovary 14			203.66
Ovr206I	ovary 15			341.32
Ovr20GA	ovary 16			58.49
Ovr247A	ovary 17			85.63
Ovr25GA	ovary 18			496.28
Bld46XK	bladder 1	0.00	0.00	
BldTR14	bladder 2	82.14	79.89	
Liv15XA	liver 1	2.35	0.00	
Utr135XO	uterus 1	115.36	121.94	
Tst647T	testis 1	16.56	128.89	

-128-

ClnDC63	Colon 1	82.14	27.57	
Thr590D	thymus 1	25.11	7.52	
LngSQ80	lung 1	66.72	11.27	
Endo12XA	endometrium 1	71.01	0.00	
Mam986	mammary gland 1	0.00	0.00	

0.00= Negative

The table above represents 40 samples in 10 different tissues. The two tables above represent a combined total of 64 samples in 24 human tissue types.

Comparisons of the level of mRNA expression in ovarian cancer samples with  
 5 normal ovarian tissue are shown. The analysis of two ovarian matching samples showed no difference (ovary 1) or downregulation (ovary 2) when cancer was compared with normal adjacent tissue. For the unmatched ovarian samples, the median of the normal ovarian samples (85.63) was compared with the cancer samples. Three out of nine ovarian cancer samples (ovary 4, 5, and 9: 33%) showed expression over 1.5 times the  
 10 value of the median for normal ovary.

Sequence	Sequence ID #
Dex0097_29 (sqovr008)	DEX0257_39 (SEQ ID NO:39)

Semi-quantitative PCR was done using the following primers:

Primer	DexSeqID	From	To	Primer Length
sqovr008F	DEX0257_39	62	83	22
sqovr008R	DEX0257_39	195	174	22

15 **Table 1.** The relative levels of expression of sqovr008 in 12 normal samples from 12 different tissues were analyzed. These RNA samples are from single individual or are commercially available pools, originated by pooling samples of a particular tissue from different individuals. Using Polymerase Chain Reaction (PCR) technology expression levels were analyzed from four 10x serial cDNA dilutions in duplicate. Relative  
 20 expression levels of 0, 1, 10, 100 and 1000 are used to evaluate gene expression. A positive reaction in the most dilute sample indicates the highest relative expression value.

TISSUE	NORMAL
Breast	0
Colon	0
Endometrium	0
Kidney	0
Liver	0
Lung	0
Ovary	0
Prostate	0

-129-

Small Intestine	0
Stomach	0
Testis	0
Uterus	0

Relative levels of expression in the table above show no sqovr008 expression in any of the normal tissues analyzed.

The relative levels of expression of sqovr008 in 12 cancer samples from 12 different tissues were analyzed. Using Polymerase Chain Reaction (PCR) technology expression levels were analyzed from four 10x serial cDNA dilutions in duplicate. Relative expression levels of 0, 1, 10, 100 and 1000 are used to evaluate gene expression. A positive reaction in the most dilute sample indicates the highest relative expression value.

10

TISSUE	CANCER
Bladder	0
Breast	0
Colon	0
Kidney	0
Liver	0
Lung	1
Ovary	0
Pancreas	0
Prostate	0
Stomach	0
Testes	1
Uterus	0

Relative levels of expression in the table above show that sqovr008 is expressed only in lung and testes carcinomas.

The relative levels of expression of sqovr008 in 6 ovarian cancer matching samples. A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual.

Using Polymerase Chain Reaction (PCR) technology expression levels were analyzed from four 10x serial cDNA dilutions in duplicate. Relative expression levels of 0, 1, 10, 100 and 1000 are used to evaluate gene expression. A positive reaction in the most dilute sample indicates the highest relative expression value.

-130-

SAMPLE ID	TISSUE	CANCER	NORMAL ADJACENT TISSUE
VNM-00116D04/N05	ovary 1	1.00	0
VNM-00291D01/N04	ovary 2	0	0
S99-5693A/B	ovary 3	1	0
9708G021SP1/N1	ovary 4	0	0
9704A081F/2D	ovary 5	0	0
9803G010SP1/N1	ovary 6	0	1

Relative levels of expression in Table 2 shows that sqovr008 is upregulated in 2 out of 6 (33%) of the matching samples analyzed.

Experiments are underway to design and test primers and probe for quantitative PCR.

Sequence  
Dex0097\_74 (sqovr013)  
Sequence ID #  
DEX0257\_103 (SEQ ID NO: 103)  
DEXO257\_104 (SEQ ID NO: 104)

Semi-quantitative PCR was done using the following primers:

Primer	DexSeqID	From	To	Primer Length
sqovr013F	DEX0257_104	1538	1514	25
sqovr013F	DEX0257_103	17	41	25
sqovr013R	DEX0257_103	163	139	25
sqovr013R	DEX0257_104	1392	1416	25

15 The relative levels of expression of sqovr013 in 12 normal samples from 12 different tissues were analyzed. These RNA samples are from single individual or are commercially available pools, originated by pooling samples of a particular tissue from different individuals.

Using Polymerase Chain Reaction (PCR) technology expression levels were analyzed from four 10x serial cDNA dilutions in duplicate. Relative expression levels of 0, 1, 10, 100 and 1000 are used to evaluate gene expression. A positive reaction in the most dilute sample indicates the highest relative expression value.

<b>TISSUE</b>	<b>NORMAL</b>
Breast	10
Colon	10
Endometrium	10
Kidney	100
Liver	10
Lung	0
Ovary	100

-131-

Prostate	10
Small Intestine	100
Stomach	100
Testis	10
Uterus	0

Relative levels of expression in Table 1 show sqovr013 expression in most of the normal tissues analyzed, including ovary among the tissues with highest expression.

The relative levels of expression of sqovr013 in 12 cancer samples from 12 different tissues were analyzed. Using Polymerase Chain Reaction (PCR) technology expression levels were analyzed from four 10x serial cDNA dilutions in duplicate. Relative expression levels of 0, 1, 10, 100 and 1000 are used to evaluate gene expression. A positive reaction in the most dilute sample indicates the highest relative expression value.

10

TISSUE	CANCER
Bladder	1000
Breast	1
Colon	10
Kidney	10
Liver	10
Lung	10
Ovary	10
Pancreas	100
Prostate	100
Stomach	1
Testes	1
Uterus	10

Relative levels of expression in the table above show that sqovr013 is expressed in all carcinomas tested with highest expression in bladder carcinoma.

The relative levels of expression of sqovr013 in 6 ovarian cancer matching samples were analyzed. A matching pair is formed by mRNA from the cancer sample for a particular tissue and mRNA from the normal adjacent sample for that same tissue from the same individual. Using Polymerase Chain Reaction (PCR) technology expression levels were analyzed from four 10x serial cDNA dilutions in duplicate. Relative expression levels of 0, 1, 10, 100 and 1000 are used to evaluate gene expression. 20 A positive reaction in the most dilute sample indicates the highest relative expression value.

SAMPLE ID	TISSUE	CANCER	NORMAL ADJACENT TISSUE
VNM-00116D04/N05	ovary 1	100	1
VNM-00291D01/N04	ovary 2	100	1
S99-5693A/B	ovary 3	100	10
9708G021SP1/N1	ovary 4	1	10
9704A081F/2D	ovary 5	10	10
9803G010SP1/N1	ovary 6	1	1

Relative levels of expression in Table 2 shows that sqovr013 is upregulated in 3 out of 6 (50%) of the matching samples analyzed.

- 5 Experiments are underway to design and test primers and probe for quantitative PCR.

### Example 3: Protein Expression

The OSNA is amplified by polymerase chain reaction (PCR) and the amplified DNA fragment encoding the OSNA is subcloned in pET-21d for expression in *E. coli*. In 10 addition to the OSNA coding sequence, codons for two amino acids, Met-Ala, flanking the NH<sub>2</sub>-terminus of the coding sequence of OSNA, and six histidines, flanking the COOH-terminus of the coding sequence of OSNA, are incorporated to serve as initiating Met/restriction site and purification tag, respectively.

An over-expressed protein band of the appropriate molecular weight may be 15 observed on a Coomassie blue stained polyacrylamide gel. This protein band is confirmed by Western blot analysis using monoclonal antibody against 6X Histidine tag.

Large-scale purification of OSP was achieved using cell paste generated from 6-liter bacterial cultures, and purified using immobilized metal affinity chromatography (IMAC). Soluble fractions that had been separated from total cell lysate were incubated 20 with a nickle chelating resin. The column was packed and washed with five column volumes of wash buffer. OSP was eluted stepwise with various concentration imidazole buffers.

### Example 4: Protein Fusions

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using 25 primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector. For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI

-133-

cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 2, is ligated into this BamHI site. Note that the polynucleotide is cloned without 5 a stop codon, otherwise a fusion protein will not be produced. If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. *See, e. g., WO 96/34891.*

10 **Example 5: Production of an Antibody from a Polypeptide**

In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine 15 serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100, µg/ml of streptomycin. The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP20), available from 20 the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands *et al., Gastroenterology 80: 225-232 (1981).*

The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

25 Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The 30 splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such

-134-

antibodies comprise anti-idiotypic antibodies to the protein specific antibody and can be used to immunize an animal to induce formation of further protein-specific antibodies. Using the Jameson-Wolf methods the following epitopes were predicted. (Jameson and Wolf, CABIOS, 4(1), 181-186, 1988, the contents of which are incorporated by reference).

5	DEX0257_140	Antigenicity Index(Jameson-Wolf)
	positions	AI   avg length
	19-29	1.09   11
	414-425	1.01   12
10	DEX0257_149	Antigenicity Index(Jameson-Wolf)
	positions	AI   avg length
	33-45	1.18   13
	17-26	1.00   10
15	DEX0257_155	Antigenicity Index(Jameson-Wolf)
	positions	AI   avg length
	20-35	1.05   16
	DEX0257_157	Antigenicity Index(Jameson-Wolf)
	positions	AI   avg length
	60-70	1.29   11
20	14-57	1.11   44
	DEX0257_160	Antigenicity Index(Jameson-Wolf)
	positions	AI   avg length
	26-36	1.31   11
25	DEX0257_161	Antigenicity Index(Jameson-Wolf)
	positions	AI   avg length
	17-50	1.12   34
	DEX0257_163	Antigenicity Index(Jameson-Wolf)
	positions	AI   avg length
	4-17	1.14   14
30	DEX0257_166	Antigenicity Index(Jameson-Wolf)
	positions	AI   avg length
	9-18	1.05   10
	DEX0257_167	Antigenicity Index(Jameson-Wolf)
	positions	AI   avg length
35	37-53	1.01   17
	DEX0257_172	Antigenicity Index(Jameson-Wolf)
	positions	AI   avg length
	40-52	1.03   13
40	DEX0257_180	Antigenicity Index(Jameson-Wolf)
	positions	AI   avg length
	42-58	1.42   17
	18-38	1.10   21
	DEX0257_200	Antigenicity Index(Jameson-Wolf)
	positions	AI   avg length
45	47-63	1.09   17
	DEX0257_201	Antigenicity Index(Jameson-Wolf)

-135-

	positions	AI	avg length
	103-113	1.18	11
	67-87	1.11	21
5	DEX0257_207	Antigenicity Index(Jameson-Wolf)	
	positions	AI	avg length
	29-38	1.08	10
	DEX0257_209	Antigenicity Index(Jameson-Wolf)	
	positions	AI	avg length
10	13-24	1.11	12
	DEX0257_212	Antigenicity Index(Jameson-Wolf)	
	positions	AI	avg length
	264-279	1.35	16
	151-171	1.19	21
	361-374	1.08	14
15	333-344	1.02	12
	DEX0257_218	Antigenicity Index(Jameson-Wolf)	
	positions	AI	avg length
	7-37	1.16	31
20	DEX0257_220	Antigenicity Index(Jameson-Wolf)	
	positions	AI	avg length
	2-14	1.22	13
	33-44	1.21	12
	DEX0257_221	Antigenicity Index(Jameson-Wolf)	
	positions	AI	avg length
25	89-104	1.16	16
	19-58	1.14	40
	136-165	1.12	30
	115-130	1.11	16
	359-370	1.08	12
30	DEX0257_225	Antigenicity Index(Jameson-Wolf)	
	positions	AI	avg length
	25-34	1.19	10
	DEX0257_231	Antigenicity Index(Jameson-Wolf)	
	positions	AI	avg length
35	448-476	1.20	29
	246-277	1.19	32
	868-888	1.19	21
	532-631	1.17	100
	45-54	1.10	10
40	817-833	1.09	17
	314-382	1.08	69
	784-811	1.06	28
	387-423	1.04	37
	425-440	1.04	16
45	225-240	1.03	16
	638-675	1.01	38
	838-865	1.01	28
	DEX0257_233	Antigenicity Index(Jameson-Wolf)	



	positions	AI	avg length
	348-385	1.14	38
	48-74	1.12	27
	230-252	1.06	23
5	322-342	1.01	21
	DEX0257_235	Antigenicity Index(Jameson-Wolf)	
	positions	AI	avg length
	7-16	1.28	.10

10 Examples of post-translational modifications (PTMs) of the BSPs of this invention are listed below. In addition, antibodies that specifically bind such post-translational modifications may be useful as a diagnostic or as therapeutic. Using the ProSite database (Bairoch et al., Nucleic Acids Res. 25(1):217-221 (1997), the contents of which are incorporated by reference), the following PTMs were predicted for the LSPs 15 of the invention ([http://npsa-pbil.ibcp.fr/cgi-bin/npsa\\_automat.pl?page=npsa\\_prosite.html](http://npsa-pbil.ibcp.fr/cgi-bin/npsa_automat.pl?page=npsa_prosite.html) most recently accessed October 23, 2001). For full definitions of the PTMs see <http://www.expasy.org/cgi-bin/prosite-list.pl> most recently accessed October 23, 2001.

20	DEX0257_140      Amidation 202-205; Asn_Glycosylation 185-188; Camp_Phospho_Site 405-408; Ck2_Phospho_Site 75-78;159-162;223-226;267-270;291-294;414-417; Myristyl 9-14;91-96;155-160;262-267;268-273;340-345;389-394;435-440; Pkc_Phospho_Site 159-161;191-193;254-256;392-394;393-395;
25	DEX0257_142      Ck2_Phospho_Site 18-21; Pkc_Phospho_Site 37-39; Tyr_Phospho_Site 4-11; Ck2_Phospho_Site 21-24;
30	DEX0257_144      Myristyl 18-23;23-28;44-49;47-52;73-78;92-97; Prokar_Lipoprotein 39-49; DEX0257_148      Myristyl 19-24;84-89; Prokar_Lipoprotein 61-71; DEX0257_149      Amidation 59-62; Ck2_Phospho_Site 23-26; Myristyl 13-18;41-46; DEX0257_150      Ck2_Phospho_Site 4-7; Pkc_Phospho_Site 19-21; DEX0257_154      Ck2_Phospho_Site 16-19; DEX0257_156      Ck2_Phospho_Site 16-19; DEX0257_157      Amidation 19-22; Ck2_Phospho_Site 47-50; Myristyl 14-19;15-20; Pkc_Phospho_Site 5-7;55-57;
35	DEX0257_158      Myristyl 59-64; Pkc_Phospho_Site 26-28; DEX0257_159      Ck2_Phospho_Site 15-18; Pkc_Phospho_Site 3-5; DEX0257_160      Myristyl 30-35; DEX0257_161      Camp_Phospho_Site 24-27; Pkc_Phospho_Site 31-33;
40	DEX0257_162      Myristyl 2-7; Pkc_Phospho_Site 3-5; DEX0257_163      Pkc_Phospho_Site 14-16; DEX0257_164      Pkc_Phospho_Site 57-59; DEX0257_165      Asn_Glycosylation 44-47; Ck2_Phospho_Site 37-40;51-54; Pkc_Phospho_Site 50-52;

-137-

DEX0257\_167 Ck2\_Phospho\_Site 71-74;96-99; Myristyl 66-71;67-72;68-73;  
Pkc\_Phospho\_Site 71-73;96-98;  
Ck2\_Phospho\_Site 38-41;  
Ck2\_Phospho\_Site 25-28; Myristyl 18-23;  
Myristyl 37-42; Pkc\_Phospho\_Site 38-40; Tyr\_Phospho\_Site 13-  
19;  
Ck2\_Phospho\_Site 12-15; Pkc\_Phospho\_Site 2-4;49-51;  
Asn\_Glycosylation 7-10; Ck2\_Phospho\_Site 9-12; Myristyl 5-10;  
Camp\_Phospho\_Site 53-56; Ck2\_Phospho\_Site 39-42;41-44;  
Myristyl 12-17;15-20;16-21;20-25;22-27;59-64;  
Camp\_Phospho\_Site 11-14; Pkc\_Phospho\_Site 14-16;  
Pkc\_Phospho\_Site 25-27;  
Myristyl 5-10;  
Myristyl 4-9;  
DEX0257\_183 Ck2\_Phospho\_Site 7-10; Pkc\_Phospho\_Site 19-21;  
Amidation 21-24; Camp\_Phospho\_Site 23-26; Ck2\_Phospho\_Site  
12-15; Myristyl 41-46;44-49;  
Ck2\_Phospho\_Site 11-14;  
Ck2\_Phospho\_Site 46-49; Myristyl 97-102;  
Myristyl 15-20;  
Myristyl 29-34; Pkc\_Phospho\_Site 35-37;  
Pkc\_Phospho\_Site 27-29; Rgd 30-32;  
Asn\_Glycosylation 19-22; Ck2\_Phospho\_Site 21-24;  
Pkc\_Phospho\_Site 26-28;  
DEX0257\_193 Camp\_Phospho\_Site 117-120; Ck2\_Phospho\_Site 78-81; Myristyl  
17-22;98-103; Pkc\_Phospho\_Site 22-24;109-111;115-117;116-  
118;120-122;  
Asn\_Glycosylation 14-17; Pkc\_Phospho\_Site 13-15;  
Asn\_Glycosylation 17-20;  
Myristyl 2-7;6-11;  
Asn\_Glycosylation 25-28; Ck2\_Phospho\_Site 37-40;  
Camp\_Phospho\_Site 49-52; Ck2\_Phospho\_Site 32-35;  
Pkc\_Phospho\_Site 22-24;  
DEX0257\_201 Asn\_Glycosylation 11-14;108-111;127-130; Ck2\_Phospho\_Site  
28-31; Myristyl 78-83; Pkc\_Phospho\_Site 13-15;74-76;82-84;  
Asn\_Glycosylation 55-58; Pkc\_Phospho\_Site 39-41;  
Ck2\_Phospho\_Site 28-31; Myristyl 21-26; Pkc\_Phospho\_Site 28-  
30;  
DEX0257\_205 Asn\_Glycosylation 30-33; Myristyl 31-36;100-105;103-108;  
Pkc\_Phospho\_Site 23-25;  
Asn\_Glycosylation 9-12; Pkc\_Phospho\_Site 4-6;  
Asn\_Glycosylation 9-12;24-27;64-67; Ck2\_Phospho\_Site 49-52;  
Myristyl 41-46;  
DEX0257\_210 Ck2\_Phospho\_Site 21-24;  
Pkc\_Phospho\_Site 16-18;  
Asn\_Glycosylation 43-46;69-72;93-96;303-306;368-371;462-465;  
Camp\_Phospho\_Site 360-363; Ck2\_Phospho\_Site 272-275;284-  
287;288-291;466-469; Myristyl 76-81; Pkc\_Phospho\_Site 45-

-138-

47;64-66;96-98;163-165;206-208;236-238;293-295;294-296;339-  
341;359-361;363-365;370-372; Tyr\_Phospho\_Site 164-171;165-  
171;  
5 DEX0257\_213 Camp\_Phospho\_Site 22-25;29-32; Pkc\_Phospho\_Site 32-34;  
DEX0257\_214 Asn\_Glycosylation 36-39;  
DEX0257\_216 Ck2\_Phospho\_Site 26-29;  
DEX0257\_217 Ck2\_Phospho\_Site 19-22;  
DEX0257\_218 Amidation 43-46;50-53; Camp\_Phospho\_Site 11-14; Myristyl 9-  
14; Pkc\_Phospho\_Site 10-12;50-52;  
10 DEX0257\_220 Myristyl 44-49;60-65; Pkc\_Phospho\_Site 34-36;73-75;  
DEX0257\_221 Asn\_Glycosylation 105-108;201-204; Camp\_Phospho\_Site 73-76;  
Ck2\_Phospho\_Site 4-7;23-26;44-47;107-110;359-362;372-375;  
Fork\_Head\_1 54-67; Fork\_Head\_2 98-104; Myristyl 37-42;38-  
43;39-44;40-45;125-130;165-170;168-173;170-175;171-176;175-  
180;177-182;237-242;269-274;278-283;342-347;368-373;  
15 DEX0257\_223 Pkc\_Phospho\_Site 20-22;23-25;101-103; Prokar\_Lipoprotein 166-  
176;  
DEX0257\_224 Asn\_Glycosylation 21-24;  
DEX0257\_225 Myristyl 26-31;  
20 DEX0257\_225 Asn\_Glycosylation 28-31;46-49; Myristyl 2-7;  
DEX0257\_227 Myristyl 18-23;46-51; Pkc\_Phospho\_Site 11-13;  
DEX0257\_228 Asn\_Glycosylation 14-17; Myristyl 11-16; Pkc\_Phospho\_Site 16-  
18;27-29;80-82;  
DEX0257\_229 Asn\_Glycosylation 70-73;87-90; Camp\_Phospho\_Site 19-22;  
25 DEX0257\_230 Ck2\_Phospho\_Site 22-25;72-75;79-82; Myristyl 3-8;7-12;10-15;  
Pkc\_Phospho\_Site 53-55;79-81;  
DEX0257\_230 Asn\_Glycosylation 23-26; Camp\_Phospho\_Site 62-65;  
Pkc\_Phospho\_Site 27-29;61-63;  
30 DEX0257\_231 Amidation 709-712; Asn\_Glycosylation 193-196;213-216;220-  
223;781-784;908-911; Camp\_Phospho\_Site 112-115;361-364;  
Ck2\_Phospho\_Site 4-7;13-16;97-100;162-165;363-366;503-  
506;633-636; Cytochrome\_C 772-777; Myristyl 52-57;304-  
309;429-434;734-739; Pkc\_Phospho\_Site 4-6;23-25;45-47;46-  
48;97-99;172-174;176-178;215-217;293-295;360-362;367-  
369;405-407;416-418;433-435;507-509;554-556;563-565;584-  
586;612-614;629-631;696-698;797-799;881-883;892-894;  
Zinc\_Finger\_C2h2 240-260;268-288;296-316;324-344;352-  
372;380-400;408-428;436-456;464-484;520-540;548-568;576-  
596;604-624;632-652;660-680;688-708;716-736;744-764;800-  
820;828-848;884-904;  
40 DEX0257\_232 Ck2\_Phospho\_Site 93-96;101-104; Myristyl 27-32;115-120;118-  
123;122-127;125-130;133-138;146-151;152-157;156-161;170-  
175;175-180;270-275;274-279;276-281;317-322;  
Pkc\_Phospho\_Site 28-30;194-196;  
45 DEX0257\_233 Amidation 27-30; Asn\_Glycosylation 250-253;450-453;  
Bpti\_Kunitz 345-363; Ck2\_Phospho\_Site 51-54;152-155;415-  
418;452-455; Myristyl 14-19;58-63;97-102;213-218;224-229;235-  
240;240-245;340-345;348-353;349-354;352-357;372-377;478-  
800;

-139-

- 483; Pkc\_Phospho\_Site 104-106;218-220;409-411;481-483;  
Tyr\_Phospho\_Site 208-215;  
DEX0257\_234 Ck2\_Phospho\_Site 66-69; Myristyl 79-84;83-88;  
Pkc\_Phospho\_Site 56-58;  
5 DEX0257\_235 Pkc\_Phospho\_Site 13-15;  
DEX0257\_236 Ck2\_Phospho\_Site 3-6;  
DEX0257\_237 Pkc\_Phospho\_Site 19-21;  
DEX0257\_238 Asn\_Glycosylation 79-82; Camp\_Phospho\_Site 40-43;  
Ck2\_Phospho\_Site 45-48;

10

**Example 6: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide**

RNA is isolated from individual patients or from a family of individuals that have a phenotype of interest. cDNA is then generated from these RNA samples using 15 protocols known in the art. *See, Sambrook (2001), supra.* The cDNA is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO: 1 through 137. Suggested PCR conditions consist of 35 cycles at 95°C for 30 seconds; 60-120 seconds at 52-58°C; and 60-120 seconds at 70°C, using buffer solutions described in Sidransky *et al.*, *Science* 252(5006): 706-9 (1991). *See also* Sidransky *et al.*, 20 *Science* 278(5340): 1054-9 (1997).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiT<sup>TM</sup> Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations are then 25 cloned and sequenced to validate the results of the direct sequencing. PCR products is cloned into T-tailed vectors as described in Holton *et al.*, *Nucleic Acids Res.*, 19: 1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements may also be determined. Genomic clones are 30 nick-translated with digoxigenin deoxyuridine 5' triphosphate (Boehringer Manheim), and FISH is performed as described in Johnson *et al.*, *Methods Cell Biol.* 35: 73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium 35 iodide, producing a combination of C-and R-bands. Aligned images for precise mapping

-140-

are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. *Id.* Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical

- 5 Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

**Example 7: Method of Detecting Abnormal Levels of a Polypeptide in a Biological**

10 **Sample**

Antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 µg/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described above. The wells

- 15 are blocked so that non-specific binding of the polypeptide to the well is reduced. The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbound polypeptide. Next, 50 µl of specific antibody-alkaline phosphatase conjugate,
- 20 at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbound conjugate. 75 µl of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution are added to each well and incubated 1 hour at room temperature.

- 25 The reaction is measured by a microtiter plate reader. A standard curve is prepared, using serial dilutions of a control sample, and polypeptide concentrations are plotted on the X-axis (log scale) and fluorescence or absorbance on the Y-axis (linear scale). The concentration of the polypeptide in the sample is calculated using the standard curve.

**Example 8: Formulating a Polypeptide**

The secreted polypeptide composition will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the secreted polypeptide alone), the site of delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of secreted polypeptide administered parenterally per dose will be in the range of about 1 ,  $\mu\text{g}/\text{kg}/\text{day}$  to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01 mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the secreted polypeptide is typically administered at a dose rate of about 1  $\mu\text{g}/\text{kg}/\text{hour}$  to about 50 mg/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Pharmaceutical compositions containing the secreted protein of the invention are administered orally, rectally, parenterally, intracistemally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

The secreted polypeptide is also suitably administered by sustained-release systems. Suitable examples of sustained-release compositions include semipermeable polymer matrices in the form of shaped articles, e. g., films, or microcapsules. Sustained-release matrices include polylactides (U. S. Pat. No.3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman, U. et al., Biopolymers 22: 547-556 (1983)), poly (2-hydroxyethyl methacrylate) (R. Langer et al., J. Biomed. Mater.

-142-

Res. 15: 167-277 (1981), and R. Langer, Chem. Tech. 12: 98-105 (1982)), ethylene vinyl acetate (R. Langer et al.) or poly-D- (-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomally entrapped polypeptides. Liposomes containing the secreted polypeptide are prepared by methods known per se: DE Epstein 5 et al., Proc. Natl. Acad. Sci. USA 82: 3688-3692 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77: 4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U. S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent 10 cholesterol, the selected proportion being adjusted for the optimal secreted polypeptide therapy.

For parenteral administration, in one embodiment, the secreted polypeptide is formulated generally by mixing it at the desired degree of purity, in a unit dosage injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable 15 carrier, I. e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation.

For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to polypeptides. Generally, the formulations are prepared by contacting the polypeptide uniformly and intimately with 20 liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as 25 liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic 30 acid; low molecular weight (less than about ten residues) polypeptides, e. g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid,

aspartic acid, or arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

5       The secreted polypeptide is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any polypeptide to be used for therapeutic administration can be sterile. Sterility  
10      is readily accomplished by filtration through sterile filtration membranes (e. g., 0.2 micron membranes). Therapeutic polypeptide compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Polyptides ordinarily will be stored in unit or multi-dose containers, for  
15      example, sealed ampules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml vials are filled with 5 ml of sterile-filtered 1 % (w/v) aqueous polypeptide solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized polypeptide using bacteriostatic Water-for-Injection.

20       The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Associated with such container (s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of  
25      manufacture, use or sale for human administration. In addition, the polypeptides of the present invention may be employed in conjunction with other therapeutic compounds.

**Example 9: Method of Treating Decreased Levels of the Polypeptide**

It will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by  
30      administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering to such an individual a

pharmaceutical composition comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

- For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 µg/kg of the polypeptide for six consecutive days. Preferably, the 5 polypeptide is in the secreted form. The exact details of the dosing scheme, based on administration and formulation, are provided above.

**Example 10: Method of Treating Increased Levels of the Polypeptide**

- Antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of decreasing levels of a 10 polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer.

- For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation of the antisense polynucleotide is provided 15 above.

**Example 11: Method of Treatment Using Gene Therapy**

- One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and 20 separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed to the bottom of the flask and fresh media (e. g., Ham's F12 media, with 10% FBS, penicillin and 25 streptomycin) is added. The flasks are then incubated at 37°C for approximately one week.

- At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge. The monolayer is trypsinized and scaled into larger flasks. pMV-7 (Kirschmeier, P. T. et al., 30 DNA, 7: 219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf

intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5'and 3'end sequences respectively as set forth in Example 1. Preferably, the 5'primer contains an EcoRI site and the 3'primer includes a HindIII site. Equal quantities of the Moloney murine sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB 101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene of interest properly inserted.

The amphotropic pA317 or GP+aml2 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector. The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media.

If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

**30 Example 12: Method of Treatment Using Gene Therapy-*In Vivo***

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the

-146-

introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide.

The polynucleotide of the present invention may be operatively linked to a promoter or any other genetic elements necessary for the expression of the polypeptide 5 by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO 90/11092, WO 98/11779; U. S. Patent 5,693,622; 5,705,151; 5,580,859; Tabata H. et al. (1997) *Cardiovasc. Res.* 35 (3): 470-479, Chao J et al. (1997) *Pharmacol. Res.* 35 (6): 517-522, Wolff J. A. (1997) *Neuromuscul. Disord.* 7 (5): 314-318, Schwartz B. et al. (1996) *Gene Ther.* 3 (5): 405-411, Tsurumi Y. et al. 10 (1996) *Circulation* 94 (12): 3281-3290 (incorporated herein by reference).

The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

15 The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P. L. et 20 al. (1995) *Ann. NY Acad. Sci.* 772: 126-139 and Abdallah B. et al. (1995) *Biol. Cell* 85 (1): 1-7) which can be prepared by methods well known to those skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the 25 art can be used for driving the expression of DNA. Unlike other gene therapies techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

30 The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach,

- intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue
- 5   ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are
- 10   differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or

15   RNA will be in the range of from about 0.05 µg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be

20   determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the

25   nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard

30   recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute,

5 approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

After an appropriate incubation time (e. g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual

10 quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice.

15 The results of the above experimentation in mice can be used to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

#### **Example 13: Transgenic Animals**

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea

20 pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, e. g., baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (i. e.,

25 polynucleotides of the invention) into animals to produce the founder lines of transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40: 691-698 (1994); Carver et al., Biotechnology (NY) 11: 1263-1270 (1993); Wright et al., Biotechnology (NY) 9: 830-834 (1991); and Hoppe et al., U. S. Patent 4,873,191 (1989)); retrovirus mediated gene

30 transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci., USA 82: 6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56: 313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell.

-149-

Biol. 3: 1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, e. g., Ulmer et al., Science 259: 1745 (1993); introducing nucleic acid constructs into embryonic pluripotent stem cells and transferring the stem cells back into the blastocyst; and sperm mediated gene transfer (Lavitrano et al., Cell 57: 717-723  
5 (1989); etc. For a review of such techniques, see Gordon, "Transgenic Animals," Intl.  
Rev. Cytol. 115: 171-229 (1989), which is incorporated by reference herein in its  
entirety.

Any technique known in the art may be used to produce transgenic clones  
containing polynucleotides of the invention, for example, nuclear transfer into enucleated  
10 oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence  
(Campell et al., Nature 380: 64-66 (1996); Wilmut et al., Nature 385: 810813 (1997)).

The present invention provides for transgenic animals that carry the transgene in  
all their cells, as well as animals which carry the transgene in some, but not all their cells,  
I. e., mosaic animals or chimeric. The transgene may be integrated as a single transgene  
15 or as multiple copies such as in concatamers, e. g., head-to-head tandems or head-to-tail  
tandems. The transgene may also be selectively introduced into and activated in a  
particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al.,  
Proc. Natl. Acad. Sci. USA 89: 6232-6236 (1992)). The regulatory sequences required  
for such a cell-type specific activation will depend upon the particular cell type of  
20 interest, and will be apparent to those of skill in the art. When it is desired that the  
polynucleotide transgene be integrated into the chromosomal site of the endogenous  
gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors  
containing some nucleotide sequences homologous to the endogenous gene are designed  
for the purpose of integrating, via homologous recombination with chromosomal  
25 sequences, into and disrupting the function of the nucleotide sequence of the endogenous  
gene. The transgene may also be selectively introduced into a particular cell type, thus  
inactivating the endogenous gene in only that cell type, by following, for example, the  
teaching of Gu et al. (Gu et al., Science 265: 103-106 (1994)). The regulatory sequences  
required for such a cell-type specific inactivation will depend upon the particular cell  
30 type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant  
gene may be assayed utilizing standard techniques. Initial screening may be

-150-

accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples 5 obtained from the animal, in situ hybridization analysis, and reverse transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or 10 crossbred to produce colonies of the particular animal. Examples of such breeding strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous 15 transgenic animals to produce animals homozygous for a given integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

20 Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

25 **Example 14: Knock-Out Animals**

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (E. g., see Smithies et al., Nature 317: 230-234 (1985); Thomas & Capecchi, Cell 51: 503512 30 (1987); Thompson et al., Cell 5: 313-321 (1989); each of which is incorporated by reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions

-151-

- of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via
- 5 targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be used to generate animal offspring with an inactive targeted gene (e. g., see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the
- 10 recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically engineered not to express the polypeptides of the invention (e. g., knockouts) are administered to a

15 patient *in vivo*. Such cells may be obtained from the patient (I. e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e. g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or

20 alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e. g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc.

- 25 The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e. g., in the circulation, or intraperitoneally.
- 30 Alternatively, the cells can be incorporated into a matrix and implanted in the body, e. g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or

-152-

vascular graft. (See, for example, Anderson et al. U. S. Patent 5,399,349; and Mulligan & Wilson, U. S. Patent 5,460,959 each of which is incorporated by reference herein in its entirety).

When the cells to be administered are non-autologous or non-MHC compatible  
5 cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

10 Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying conditions and/or disorders associated with aberrant expression, and in screening for compounds effective in ameliorating such conditions and/or disorders.

15 All patents, patent publications, and other published references mentioned herein are hereby incorporated by reference in their entireties as if each had been individually and specifically incorporated by reference herein. While preferred illustrative embodiments of the present invention are described, one skilled in the art will appreciate that the present invention can be practiced by other than the described embodiments,  
20 which are presented for purposes of illustration only and not by way of limitation. The present invention is limited only by the claims that follow.

## CLAIMS

We claim:

1. An isolated nucleic acid molecule comprising
  - (a) a nucleic acid molecule comprising a nucleic acid sequence that encodes 5 an amino acid sequence of SEQ ID NO: 138 through 238;
  - (b) a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1 through 137;
  - (c) a nucleic acid molecule that selectively hybridizes to the nucleic acid molecule of (a) or (b); or
  - 10 (d) a nucleic acid molecule having at least 60% sequence identity to the nucleic acid molecule of (a) or (b).
2. The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is a cDNA.
- 15 3. The nucleic acid molecule according to claim 1, wherein the nucleic acid molecule is genomic DNA.
4. The nucleic acid molecule according to claim 1, wherein the nucleic acid 20 molecule is a mammalian nucleic acid molecule.
5. The nucleic acid molecule according to claim 4, wherein the nucleic acid molecule is a human nucleic acid molecule.
- 25 6. A method for determining the presence of an ovary specific nucleic acid (OSNA) in a sample, comprising the steps of:
  - (a) contacting the sample with the nucleic acid molecule according to claim 1 under conditions in which the nucleic acid molecule will selectively hybridize to an ovary specific nucleic acid; and
  - 30 (b) detecting hybridization of the nucleic acid molecule to an OSNA in the sample, wherein the detection of the hybridization indicates the presence of an OSNA in the sample.

7. A vector comprising the nucleic acid molecule of claim 1.

8. A host cell comprising the vector according to claim 7.

5

9. A method for producing a polypeptide encoded by the nucleic acid molecule according to claim 1, comprising the steps of (a) providing a host cell comprising the nucleic acid molecule operably linked to one or more expression control sequences, and (b) incubating the host cell under conditions in which the polypeptide is produced.

10

10. A polypeptide encoded by the nucleic acid molecule according to claim 1.

11. An isolated polypeptide selected from the group consisting of:

(a) a polypeptide comprising an amino acid sequence with at least 60% sequence identity to of SEQ ID NO: 138 through 238; or  
(b) a polypeptide comprising an amino acid sequence encoded by a nucleic acid molecule comprising a nucleic acid sequence of SEQ ID NO: 1 through 137.

12. An antibody or fragment thereof that specifically binds to the polypeptide according to claim 11.

20  
13. A method for determining the presence of an ovary specific protein in a sample, comprising the steps of:  
(a) contacting the sample with the antibody according to claim 12 under conditions in which the antibody will selectively bind to the ovary specific protein; and  
(b) detecting binding of the antibody to an ovary specific protein in the sample, wherein the detection of binding indicates the presence of an ovary specific protein in the sample.

30  
14. A method for diagnosing and monitoring the presence and metastases of ovarian cancer in a patient, comprising the steps of:

-155-

- (a) determining an amount of the nucleic acid molecule of claim 1 or a polypeptide of claim 6 in a sample of a patient; and
- (b) comparing the amount of the determined nucleic acid molecule or the polypeptide in the sample of the patient to the amount of the ovary specific marker in a normal control; wherein a difference in the amount of the nucleic acid molecule or the polypeptide in the sample compared to the amount of the nucleic acid molecule or the polypeptide in the normal control is associated with the presence of ovarian cancer.

15. A kit for detecting a risk of cancer or presence of cancer in a patient, said kit comprising a means for determining the presence the nucleic acid molecule of claim 1 or a polypeptide of claim 6 in a sample of a patient.

16. A method of treating a patient with ovarian cancer, comprising the step of administering a composition according to claim 12 to a patient in need thereof, wherein said administration induces an immune response against the ovarian cancer cell expressing the nucleic acid molecule or polypeptide.

17. A vaccine comprising the polypeptide or the nucleic acid encoding the polypeptide of claim 11.

1

## SEQUENCE LISTING

<110> Sun, Yongming  
Recipon, Herve  
Salceda, Susana  
Liu, Chenghua  
diaDexus, Inc.

<120> Compositions and Methods Relating to Ovary Specific Genes and Proteins

<130> DEX-0258

<140>  
<141>

<150> 60/246,640  
<151> 2000-11-08

<160> 238

<170> PatentIn Ver. 2.1

<210> 1  
<211> 151  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (77)..(78)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (82)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (129)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (143)  
<223> a, c, g or t

<400> 1  
atcccáctca atcatgggtt attatgtttc tgatgtgctg ttagatttgg ttttctagta 60  
tttgctgag gattttnngc anttaatgtt ccactagagg taattgcctt ggttgtggcc 120  
ttgtctggng ttgggatcag ganttatgct g 151

<210> 2  
<211> 59  
<212> DNA  
<213> Homo sapiens

<400> 2  
cgataaatgt agatatgaaa gcagactaca gtataaaaca ctgctcagaa acatttgc 59

<210> 3  
 <211> 2330  
 <212> DNA  
 <213> Homo sapiens

<400> 3  
 taaaacacctt gccccagggtg gtacaaacac caactcgccc accacgaggc taagcccca 60  
 aaggcgggga ccaagagcag agccatggta ccggaaagg ttcaacaaaa ataaggtaaa 120  
 aaaatgtgtg tgcgtgtgaa aaaatttggc cggtaacggg ggctaaaatg caatggtgca 180  
 acctcagctg atggccaagt cggtaccta ggtaacacg aatctaccgc gctaaggc 240  
 cgaagtagct ggtataacag ggcacatgc acgatgccc gccaattgtg catgcttagt 300  
 acagactggg tttcaccatg ttgtcagcc cctcgaactc ctgacccatg gtgatccgt 360  
 gcctcgccat cccaaagtgc tggataacag gcctgagcca ctgcgcaccc gtcgcaaaat 420  
 gtttctgago agtgttttat actgtatct gctttcatat ctacatttat cgtattata 480  
 tattttatcta ctgagacagg gtctcactt gtttcccagg ctggagtatg gtggcacaat 540  
 ctggccttac tgcaacccctt acctcccaagg ctcacagcaat cctccacccat cagccccc 600  
 agtagctggg actagagatg tatgcacatc cacctggctt tgcgtgtgt tgcgtgtgt 660  
 tgcgtgtgt tgcgtgtgt tgcgtgtgt tgcgtgtgt tgcgtgtgt 720  
 tgcgtgtgt tgcgtgtgt tgcgtgtgt tgcgtgtgt tgcgtgtgt 780  
 gcataaagtca ctgcacccatgg ccatggcatg attttttat ctctccctgg gctgaactcc 840  
 ctacatggc ttacacccatgg cctggaaagac ccaagatccc ctcacaata ctacttctat 900  
 acccaggggcc aggtgtatg tttttttttt tcaggactgtg gctttattat gcatctccca 960  
 gcaaggcacc tggggcttct gatactggcc gggagatgg ggggaaatgg gctgttctg 1020  
 acttccatcaca caaggagtgg ctaatcttct gtccttttc taaccaaaggc catctctgg 1080  
 coaccaagag caagtggca gaggtccctc atcctggcag gagagcagat ctgcagca 1140  
 tggaaagaaca gaaataggca aatgagaact caggctgtg cacagaaacc tccctccctt 1200  
 agtccatccct tcaactgaaga tggatgttt attttttat taatttaatta attttttttt 1260  
 tgcgtgtgt tgcgtgtgt tgcgtgtgt tgcgtgtgt tgcgtgtgt 1320  
 ggctcaactgc aacctctgcc tccctgggttca aagtgtttcc cctgcctcag cctctgtgt 1380  
 agctgggatt acaggagcc tgcacccatgc cccggctaaatt tttttttttt ttaatagaga 1440  
 cagggtttca ccatattatgc cagatctcgat tccctgacc ttgtatccg cctgcgtcgg 1500  
 cctcccaaag tgcgtggatt acaggcatgc gcaactgtgc ccaggccatg gtttactatt 1560  
 atgtgtctgg atacattggc aaacaagatc gctgttactc tttttttttt tttttttttt 1620  
 tttgagacgg agtctcgaaat tgcgtgtgt gctggaaaggc tggagcgcag tggcgcgc 1680  
 tcaactcgga gatcactgca acctctgcct cccggctca agcgattctc ctgcctcagc 1740  
 ctccctgagta gctggacta cagggtgcacg ccaccacgcc tggctcattt ttgtactttt 1800  
 agtagagacg gcttttccat atgtgtgtca ggtgttctc tatctctgtc ctcgtgtatc 1860  
 caccggccctc agcctcccaag agtctggaaat ttacagggtt gatttgcgtt gcccggctat 1920  
 cctagctgtt actctttacc agatccatgtt tagggccctt gggactggatg ccaaggcatg 1980  
 aatggttctc ctgggtccact ttctggcctc tttctctgg tgcgtgtgtca aaccccgat 2040  
 ccctattatc ccctctatca gaaaaatgg aacgtgtatc actgcacccacc tggcacacaa 2100  
 gggaggagga aatcgacact tctgaagatc tatggttctg caccacccatc cacagcctgc 2160  
 accactaccc tgggtcagcc agcataggat tcccttagctg cttctctt gtcggcagg 2220  
 tctgtttcca gaaaggagag gactgagacc cagcagttat cttccaggt tctgggttta 2280  
 taacacagct tgcgtgtgtt cttttttttt tttttttttt tttttttttt 2330

<210> 4  
 <211> 266  
 <212> DNA  
 <213> Homo sapiens

<400> 4  
 cagagtgaga ctttgcgttca aaaacaaaaa taccttagaaa atcaatctac tctgtttttt 60  
 aatgtgaaat gtttttatgtt tagctatctt tcttagtttcc tttttttttt gaaatgtatc 120  
 acacaacccatc taggtttat ctctggggcc tggaaacag aaccttaatg ttacaggatc 180  
 aaaagcaaac agatgtatc gttttttttt ttctgtgtgtt gaaatgtatc cttttttttt 240  
 atcttatgtt aatgtatc aaaaat 266

<210> 5  
<211> 1483  
<212> DNA  
<213> Homo sapiens

<400> 5  
atgagtagtt ttcctagctg atttttttt tttaataga ttttgaagtc agatggataa 60  
aaatgccatg tggacaagtg cttactttgg cattatgaaa attttataat ttaacccaaa 120  
caaaagtcaa ataataattt ttgagtttca tgcccttga ggtgccttt taaaaataat 180  
caaaatgttggggagacc ccatccaatt taatcggtt ttatattaatt atactactat 240  
aatttgttta ttgcagggtt tgactgttct cagggAACgc tgaaggttca taacagtagt 300  
gatttgtaat tgtgaggcgtt gagtggtggaa ttgaattact tcattaaaga gtaaccagtt 360  
actgagaatc catgtttcat tgagactgggtt gttttctac tttatcctt tttttttttt 420  
tttgagacgg agtcttgcgtc tccagcctgg caatcagagt gagacctgtt ctcaaaaaca 480  
aaaataccta gaaaatcaat ctactctgtc tttaatgtt aaatgttctt atgatagcta 540  
tctttcttag ttctgaagca ctaaacacaa cctgttaggtc ttatctctgg 600  
ggctgggaa acagaacccat aatgttacag gtacaaaagc aaacagagtg attagttccc 660  
cattttctgg tagtgaacaa ctgacattttt tcaatctt tgtaaaatgtt gaataaaaat 720  
aatttttagaa aagttatcta tttttatgtt ctgttaacaca aatagttaaag aaaatgaata 780  
cttgttatgtt aatgaagct tcacagcagg acctccggca taactttgtat catgttgtat 840  
ctcttaagca ttttatatacg gaattctggt gtggctaccc aaagcagaag ggaaggcaat 900  
caactaaaaaa tccctttcta ttgagtttattt ttcatcatgtt aaattacttc aggctttct 960  
tggtagggct tcttgaatgc acatgttca ttatctgtat accaaagggtt agctttttttt 1020  
tttaatccat gtgattttt tgagttgaaa gctataaggt tttaatatta aaaattttctt 1080  
tctaaatggc aaattttgtgtt gacagcatttt aagacactca gtttctattt aaaaagcaata 1140  
agaaaaacaag ttatgttccac gggttatgtt ataataaggtt ccctggact ttataaaact 1200  
gtcatctatc atactgttcat gaaatctggt cctagttttt aacagatctt ctgaccagtg 1260  
ggtaactccggacttcaacg tgccccgtt cccaaacactt cgtccctgtctt cggttacact 1320  
tgaagcttat ggtctttcca atgcgacagc ggggttggca acggcatata ttccggggct 1380  
gaggggccctt gccccaaagag ggggacgcgc cccctgcgca cttttccgg tggggcacccc 1440  
tttggggcat acaactcccc gagggttta taagtataact ata 1483

<210> 6  
<211> 345  
<212> DNA  
<213> Homo sapiens

<400> 6  
tatctttcca tgctgtctgg cttggtcag tgcattccca gcccacatcttta actcattttt 60  
ctctccttga acctgagaga agatgttgc gtcctagttcc ttttcttccc aggaggcatt 120  
tctgcccctt gcaaattcat ggatgctaaa caaaatgtgg agaaaacata ttgcctgtct 180  
ctatctggca gcttccaaga ttcaatgata tattggaaa ggagtaactc acttccctt 240  
ccagcaacat gtaagcccta gactcctgc aggccaaaaa tatcccgat taaacaaatt 300  
atgttagcaga aagtcttga attaataaac caaatttgaa taatt 345

<210> 7  
<211> 491  
<212> DNA  
<213> Homo sapiens

<400> 7  
acaaccatac cagaagggtt tccaccattt gcctactctt ataatcagaa ccaatgtct 60  
tcacctacaa tccggacact ggtatagcac ttgtcagggg tccagactctt cccttttta 120  
tagtaggtttt ccttgcgtc ctttattatc ttccatgtt gtctggcctt ggtcagtgtc 180  
atcccaagcc atcttaactc attttcttctt ctttgcactt gagagaagat gtgcgttcc 240  
tagtctttt cctcccaagga ggcatttctg cccttgcctt attcatggat gctaaacaaa 300  
atgtggagaa aacatattgc cctgtctat ctggcagctt ccaagattca atgatatattt 360  
ggaaaggag taactcactt ccccttccag caacatgtaa gcccttagact cctggcaggc 420

caaaaatatac cccgattaaa caaattatgt agcagaaagt ctttgaatta ataaaccaa 480  
tttgaataat t 491

<210> 8  
<211> 91  
<212> DNA  
<213> Homo sapiens

<400> 8  
cccacgcgtc cgaaaagatag gccaagctgg taccaaggcat ggatggattt gtcaaagatc 60  
aggccacctc atctcttcca ttggccacca g 91

<210> 9  
<211> 890  
<212> DNA  
<213> Homo sapiens

<400> 9  
cgtaatttgg agttctcctt cgaatttgac caactcaggt agagtaatc aaatctgatg 60  
gaagaaaaacc aaaataacaa aacaaatatg attactgagg acttttaatg gtaaggagaa 120  
gttaagacca gttacttgtc aatcttaact ttttagtact aaggggaatt ttcagacaa 180  
aactctaatt gagctactta cctaggaatg aggctcacgc tgaacactgc tgtctaccat 240  
ctatgaagca ggaaaaaaact caaactcaact ttctctgtg gaaggagca gaaactccag 300  
aaaggacttg ctggccctcc atcatcatgg aaacaggaaa actaatctc cttgttggaa 360  
gtgagtaaaa ctccaaaaaa ggaggagttg tacagcaaaa tgaaccttag acctcaacca 420  
aatttggggg gagaatgtat tctctgaagg gaccccacg acctcagcaa attgtattat 480  
tggttggc aataaagata ggccaagctg gtaccaagca tggatggatt tgtcaaagat 540  
caggccaccc catctcttcc attggccacc agttttaaa ccaaagagta tctgagacag 600  
gtctcaatca attcagaatg ttatttgcc aaggtaaag acatgcctgg aagaaaataa 660  
catggaccca caggaacagt ctgtggctcg agtctttctc caaagataaa ttcaaggct 720  
tcaatattta aaggaaaaat gtaggctgga ggggagaggg gtagagtata gtaatcccc 780  
tggtaaga gaaaaggagc gggtagggg atagtcaatt atgttattcat ctcatgctca 840  
ataaaattggc actttacata agaaaaaaaaaaaaaaaaaa aaatgcggcc 890

<210> 10  
<211> 386  
<212> DNA  
<213> Homo sapiens

<400> 10  
gactgaaatt agaaatgaaa aaaaaggta ttcattgatt gaattagcag tgcgtggcac 60  
acagtaatgt aatatataaa gtaagttggg cttggatgcc atctaaaagg gcttagttat 120  
tgaagcagtt ttatcttgc agtataacta aagaataggc atgcgtgtcc aggcttagtt 180  
cagttaaatt taggataaag gcacagtaat aaagataacta tcttagact tgaaaattat 240  
aaatccttag ttgttattcc ttatcgttt ataaagttaa caatgaatgt acagactaca 300  
agctatcaaa tgtactgttag atgaaaagggg caataaacac tagtcagagt tagaggtaga 360  
atgatataat ggaaaggtagc gaattt 386

<210> 11  
<211> 458  
<212> DNA  
<213> Homo sapiens

<400> 11  
gaaaaaaaaagggt ttatctca caattgagtg ttccgttgta gaatgtctct tatatatctt 60  
tagagtta ctatgtcttgc ttcaagttagc acagggccg ggaaatacaa ttgttggaa 120  
gaggctaato tttaaaggca gtcattgatt gtatTTAAA ttacaattta caacccatg 180

gtaatgaaca cataggctaa acaaataataa actcaattaa aataacatgc aatgatactt 240  
tacaaaaatg ctgctgagaa gaacatcgag tttacatcat gctgaatatc taaaaatagc 300  
tagatgacta tttaaccttc tatttatatg tatagatata gcgttataat tttccacta 360  
gaatttaatt ttatattata gacccttca gtgccttag tgaccctatg agtgtcttt 420  
taagattgcc tttggaccct ggtgtcggtt tgggactg 458

<210> 12  
<211> 490  
<212> DNA  
<213> Homo sapiens

<400> 12  
aaaaaaaaagggt ttatatctca caattgagtg ttccgttgta gaatgtctct tatatatctt 60  
tagagtgtta ctatgtcttg ttcaagtgc acaggggccg ggaaatacaa tttgaaggga 120  
gaggcataatc tttaaggca gtcattgatt gtatTTaaa ttacaattta caaccccatt 180  
gtaatgaaca cataggctaa acaaataataa actcaattaa aataacatgc aatgatactt 240  
tacaaaaatg ctgctgagaa gaacatcgag tttacatcat gctgaatatc taaaaatagc 300  
tagatgacta tttaaccttc tatttatatg tatagatata gcgttataat tttccacta 360  
gaatttaatt ttatattata gacccttca gtgccttag tgaccctatg agtgtcttt 420  
taagattgcc tttggaccct ggtgtcggtt tgggactggc actaagtgc atcctaaaat 480  
tttccataaa 490

<210> 13  
<211> 64  
<212> DNA  
<213> Homo sapiens

<400> 13  
agaaatgtaa atgctatatt agaaaatatt tactaagtcc aagagaaaagc aataatagag 60  
gcac 64

<210> 14  
<211> 921  
<212> DNA  
<213> Homo sapiens

<400> 14  
accacttttg ttccggctat tgtctctgat gactttctat tgctccctat ttaccctctg 60  
ctgtcttnag aaaaggaact agagaagtac agggtcgatt gtagggctgt gtctagggca 120  
tattccctgg aaataaaaata ggttcttgg gctgtactga gagcagcttt cgaccatgct 180  
aaattccat tagtagttt tttaaatga accaatttgc tattaatatg tattctttgg 240  
tggaaactgtc caaatatttt gaccatctt tattttatata ttattattga tatagctgg 300  
ttcaggagtg ccaactttat cattttagt gtgtctctt tctttttgg ccctcttata 360  
ttgtttctc ttggacttag taaatatttt ctaatatagc atttacattt ctttgatgt 420  
tttttccac atatattttt acttgtatcc ttgttagttc ctcttaggaac ttacaatgt 480  
ctattttat tattttttt tttaagaga gagtctcaact ctgtcaacttgg ggttagatg 540  
cagtgggtgtg accatggctc accagaccat caacatcccg ggttcaagca atttctcctgt 600  
gtagttggga ctacagggtgc gtgccacaat gcctgggtga tttttgtgtt ttttagtaga 660  
gacagggttg caccatgtt gccaggctgg tctcgggctc ctgggttcaa gtgtatgtc 720  
tgccttggcc tctccaagtg ctgggattat aggtttgagc cactgcaccc agcaaaaaac 780  
caactttta aagcagaact tctgaagaaa gataaataatg tattaatgtt gactatgt 840  
cagatgccat gctgtgtatt acatgcttct gttcatttca tactccctag taataactgtat 900  
aatgtttttg gatagtcatg g 921

<210> 15  
<211> 270  
<212> DNA

<213> Homo sapiens

<400> 15

tgaacatcg tttcttagg tgacttcctc cacatagttt tttgtgaatt gtaatattgt 60  
gtggcaatat tatccaaaaa gtatggttt ttattgtatt ttgcaatccc taggacatata 120  
taaatagctc aagtgtggg atgttcttct taaaattcga tctcatagtc taaaatggtg 180  
acttgcacat gagttgcct cattaagtcc tggacgaatg gcaaatgcta taatttcctg 240  
tctcacttct ggatatcaca gtgtcatctt 270

<210> 16

<211> 651

<212> DNA

<213> Homo sapiens

<400> 16

cgtggagct tccgaggggaa aacggctggg tatcttataa gtcctgaggg ctttcactcc 60  
cccaaccatcg tcttttgcac attttttattt ttccttttag agacaggatg tctctatgct 120  
gccttaggctg gagtatagtg gtgggatcat agctcaactgc aagctcgacg tcctggattc 180  
aagtgaacctt actgccttga cttcccaaat agctgggact acaggcgtgc accaccatgc 240  
tcggctaatt tttacaatgtt ttagtcagat ggggtcttgc tctgttgctc aggcttgc 300  
caaactccctg gcctcagatg atccctctgc ttttgggtcc caaagtgcgtg ggattgcaga 360  
tgtggctcac cacgccccgc ctgaacatcg tttttcttagt gtgacttcct ccacatagtt 420  
atttgcataat tggatattgtt tggcataata ttatccaaaa agtattttgtt tttattgtat 480  
tttgcataatcc cttagacata taaaatagct caagtgtgg gatgttctc taaaatcg 540  
atctcatatgtt ctaaaatggt gacttgcaca tgagttgcc tcattaagtc ctggacgaat 600  
ggcaaatgct ataatttcctt gtctcaacttc tggatatcac agtgcatactt 651

<210> 17

<211> 702

<212> DNA

<213> Homo sapiens

<400> 17

gaaaaatacg ccaggctgtg tgctgaaggc atcccatctc ttcctcgcc cctctcggt 60  
ggatcggggtt ggggcagcgg gtggatgagt gtgtctgtcc tgccagttca gcctccaact 120  
ggctgtgtgtt ggggcaggag cccacctggc ttcctcgcc agctgcattgg cctgccttgc 180  
ctcacccgtg acaacagaga ctttgggtctt ccacatcgcc acgcattgtt cttgtttctt 240  
attcgggtcca gaactcggtt gggaaagaagg gtgatgttat ttgggtcccc tcaagacatt 300  
gacaacagat agtttttaat atcacatttt aaagccgcac acttttcctc ctccactttt 360  
gtatccctt gatttttaaa cagaatgtcg gctctggagg cagaaagctt gggcttggat 420  
ctggccctgtt ccacgcagta gctatgtggc cagggaaatc atagctcccg gatctcccgat 480  
ccctacagta aagtacagat aaaaatactt ttcattgtat tgtttggaaat cgaatgagat 540  
agttaatgaa tgagtaagtg ctctgcacac tccagagcgg ggtgcgcgtt ctgatctgtt 600  
tcatagaatc tgacacgtac ctttccccac cccagcgctc ctgaattggg atgcatactga 660  
cagcaagtgtt ggcacatccggg ctgcagttgc cggtgtctgc tc 702

<210> 18

<211> 1760

<212> DNA

<213> Homo sapiens

<400> 18

gtccacccgtg aggatggtca caccccatag ctttggat gctgtggctg tagcaggccc 60  
agtggctccg ctgagcctcc ctagcaccag tgcccagtgaa agtgtggggg gctggacata 120  
ggtggccctca gttccctggaa ctcccccaaa gctctggttt ccccccgtct cccaggcttc 180  
agggtggacga gtttagtgacc acccccactc cagacccctcc tcccccgtcc acccccacag 240  
ttataaaaaac cttcattctc atatggaaacc ccctttccctg aaatccgttag agtgactgac 300  
tgctttcttg agtgaatctg gactggccca catgatgatc gctgtacaga gcaatgtgac 360

tcctctgtct	cagcctccct	gagttcacag	caggctctgg	gcatcatctc	cgtgtcatcc	420
taaggccacg	ggcggggttc	ccaccaaaca	ggagagcagc	tctcccaga	tgaaggcttc	480
tgatagccct	agaaccaaga	gaaaccgtgt	ggggttgggt	gggtgttta	ctgtgcactc	540
ctgatgttcc	ctcccagtga	aggacacccca	cctgggacac	tgtggccctt	ggccctccct	600
ccccccctcc	ggtggcagag	agaacttctt	ggtgggtgac	agcccatggt	ccacccttgc	660
cagggtggatt	caggcaaaat	acgccaggct	gtgtgtgaa	ggcatcccat	ctcttcctcg	720
tccccctctcg	gctggatcgg	ggtggggcag	cgggtgtga	gtgtgtctgt	cctgcccatt	780
cagcctccaa	ctggctctgt	gtggggcagg	agcccacctg	gtctctctgc	agagctgcat	840
ggcctgcctt	gcctcaccccg	tgacaacaga	gactttggtt	ctccatctgc	agacgcattt	900
gtcttggttt	ttattcggtc	cagaactcgg	gtgggaagaa	gggtgtatgt	atttgggtcc	960
cctcaagacc	ttgacaacag	atagttttta	atatcacatt	ttaaagccgc	caacttctc	1020
tcctccactt	tggtatttcc	ctgattttta	aacagaatgt	cggctctgga	ggcagaaaagc	1080
ttgggcttgg	atctggggcc	tgccacgcag	tagctatgt	gccaaggaaat	acatagcttc	1140
cggatctccg	atccccatcag	taaagtacag	ataaaaaatac	ttttcattga	tgtgttgaa	1200
atcgaatgag	atagttaatg	aatgatgtaa	tgctctgaa	actccagagc	gggggtgcgc	1260
ttctgatctg	tttcatagaa	tctgacacgt	accctttccc	acccccagct	ctctgaattt	1320
ggatgcattt	gacagcaagt	gtggcatccg	ggctgcagtt	gcccgtgtt	gctcacatgt	1380
gaattaaaaa	aacaatctca	gcatatgaaa	tctctaattcg	cgtatgaact	tggtggttat	1440
tcctgggtcc	gtgtggataa	ctgcagccctc	aacaccccaag	tccacaaaacc	acgtacggac	1500
caactgagga	aggagttaggg	gttcttggtt	ttgcagaaaa	ccctccctca	acttgctcta	1560
gaagataccca	gcattcatac	ttggagtggg	catcagcagc	ttggaagaca	cagcagtgaaa	1620
ccccctttag	caggagtgcc	ccatctcatg	ggctcccgac	gacgaccccg	aggggtgtat	1680
ctgcgttaggg	gctcacggac	attggcactc	taagtcagag	atgctcagg	gaagggggct	1740
ctgatgggttga	ggacattcag					1760

<210> 19  
<211> 284  
<212> DNA  
<213> *Homo sapiens*

```
<400> 19
gatattttcc ttcaagagacc ctttacattt gagagatcct ttagactttt gtaaaactta 60
ataattttaa ttaataacta gcgtaattt aatttttcct ctgtcaagg ccacgttcta 120
agtgccttcc tcacagcaat qctgtgaagt acttattcctc ctgtttcttc tgaggaaaca 180
aggctgacag gcctgagatc acagagccag taaaatggtag agtcaggaat tgaacctgag 240
aattctgact ccagactttc ctgtttttagc caccqtqcaq tact 284
```

<210> 20  
<211> 1150  
<212> DNA  
<213> *Homo sapiens*

```
<400> 20
gatattttcc ttcaagagacc ct当地tacattt gagagatctt ttagactttt gtaaaaactta 60
ataattttaa ttaataacta gc当地taattt aattcttcctt ct当地caagg ccacgttcta 120
agtgccctcc tc当地agcaat gctgtgaagt actt当地tctt ctt当地ttctt tgaggaaaca 180
aggctgacag gc当地tgagatc acagaggccag taaatggtag agtc当地aggaat tgaaccttag 240
aattcttagac tccagacttt cctgtttag ccaccgtca gt当地tccttta ttggctcgt 300
taccctgaga tactcagttc attttagttc ct当地taaagtt tt当地tttattaa aaaggtaactg 360
taaatgcatt gt当地tccagag cattatagca tactttaaa aatttattcactt ttcttaaagaa 420
ttctactcat cccaccctca tctt当地tggaaa attaacttactt taccttacatg actt当地aaatc 480
atctgaagac tt当地tataaag tt当地gtgagtt tcatgttca aaccctgtta tctactactg 540
gagcaattaa aatttaccat acaacaggta acaggttaa gt当地actttgc tt当地ggttta 600
actaaggcaca gg当地tttaaagt tt当地ttaaggctt ggtataggttt ggagcaagct ct当地tagtggg 660
aatggatttt aaaccctaaagt agtaaagtggaa aaccatgc当地tggcaggctt gtc当地gtgtga 720
gactgtgctg tatgtgtctt gacttggggc gc当地gtacaga gaacagagct ggatgacttat 780
ggccaatttg gagaaagagc tccaggagat ggaggcacgg tacgagaagg agtttggaga 840
tggatcgatg gaaaatgaaa tggaaagaaca tgaactcaaa gatgaggagg atggttaatat 900
tatttttattt tt当地tttatctt ttttgggggg ttaagtqaaatctt ct当地qaaatctt cttgtctt 960
```

ttgacatctc ccaatttta aatgtggcaa ataattaaaa ataatgttgt atgggc当地 1020  
 ggtagtcggc tgagctagtc taattcaagt aatttgatta acaaattctt ttctgaccat 1080  
 gtcctaaaca gtgtgtactt ctagctgcat aatatgacaa atggacatgt ttaccagtgt 1140  
 gactattttt 1150

<210> 21  
 <211> 226  
 <212> DNA  
 <213> Homo sapiens

<400> 21  
 aaaaataaaaa aaattcaatg aatccctgtaa atcccttcat tataaaataa atttggattt 60  
 gatataacaat tatggcctct gagtagcctt tgaatcatct ttagattcta aacttaattc 120  
 tgaaaatatg ttttaccata gtataaaaata gtttttatgt ttatattaga aaaatgatgt 180  
 taaaatttat ttctaaagaat tactttaggc caggtgcaat ggttca 226

<210> 22  
 <211> 270  
 <212> DNA  
 <213> Homo sapiens

<400> 22  
 gcgtggcttc gattccggcg cctgcgtgtc accagcccg ggtggccgtg gaagctggac 60  
 ccgagccgca ggccccccag gctgggcctg ggaggaaagc ggtttgaaaa agatcggAAC 120  
 tgaggaactc tcttagagcg gggactccc tgctcctaca gccttaacca atgcccagecg 180  
 cttggaaagt ggaggactcg gggatcggg aegctttcag gcctggggaa atggaagggt 240  
 cggggaccta ggtgaaaggt tatttgccag 270

<210> 23  
 <211> 245  
 <212> DNA  
 <213> Homo sapiens

<400> 23  
 ggcacttggia ttgtctccat tctctgcacc caagctgtca gggccctcac cagaatgttt 60  
 acctaacacc ttctctctag tctggagtct ttgttagatgg aaaacttgat gtataaccct 120  
 ttgacttgat ttccaagaag caacagagtta aaaactgtta tttcttaggtg agtggcttca 180  
 tgcaggtgtg gtcaggtatt ttccctgaca gaggctgtg ttctgttga ttgcttttc 240  
 tttttt 245

<210> 24  
 <211> 460  
 <212> DNA  
 <213> Homo sapiens

<400> 24  
 atttttgggt taaaatccca tacattctag tattttttag acttttcaact gcaaatttta 60  
 acatgc当地 aatgtccctt ggtttccata agcataaataa gtataaatgc caacaataag 120  
 aatgtcttct aagcagctaa atcttgc当地 tttagttgga attgagacca gctatttggg 180  
 taagcgaatt agagtcttag tattgttaatg gggatgtttt atgtggcaca gggttgccaa 240  
 ctgcctgagg ctattcgtga gtcagaacga ctttgc当地 gtgtggggcc aagccagccc 300  
 tggttggcag cctggc当地 cc当地 aatccattaca aacagtctcc cgccattccc 360  
 gcaccatggg acttttagtgt tttgtgtac aacagtataa cctgtgtta gcccatttac 420  
 aactgactgc tatgctaaac caaaattata ataataatgc 460

<210> 25

<211> 257  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (93)..(192)  
<223> a, c, g or t

<400> 25  
gtataatcgat actaatcgta aaaacaaaaaa aaatctacta agtacttacc atttgttaga 60  
caactgggttgcg agaggtttat atgcattgtc tgnnnnnnnn nnnnnnnnnn nnnnnnnnnn 120  
nnnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 180  
nnnnnnnnnnn nnaacctcag aggccaagct cttaggcact gtgatatact actggcttg 240  
ctcagtaat ggacctt 257

<210> 26  
<211> 221  
<212> DNA  
<213> Homo sapiens

<400> 26  
ctcgagaccc cacccttcc tggattcatc agtgggctcg gaagagcgtg ggaaaggcgc 60  
taccttgggt ccacaccacc tgagtcagct ggggtactc ccagctctcc ggggtggaa 120  
actggtgccct ctggcaatgg cctgctgagt atttaacccc agggcagca gattccttg 180  
gggtgtttttt ctacaattt aacaggaagg tttttgcag g 221

<210> 27  
<211> 347  
<212> DNA  
<213> Homo sapiens

<400> 27  
tgcttgctcg gctctggctg gggttcgta gggctgggt tcttgaaggg ccctgtctaa 60  
gaagggagta ggaatccagt tatatgagtt caegctcatc agaacacctgg catatggat 120  
tgagagatat gtccagtgtat gcccgttgg aagctgctca tgaacagggc ttggtccttg 180  
acacttggtg ggcaagtaat ttacagggga aatgacaatg ttaatcctgg cccctgggt 240  
gctggcagtg tggtaagga gacccaacac acacagggat ggacccaac acaagctaag 300  
gaagggttcca cccccagcccc tgatgtctgc tggaaacaaag agaaaatg 347

<210> 28  
<211> 338  
<212> DNA  
<213> Homo sapiens

<400> 28  
tttttaaatgtgaactata acacttagga tattgcattgg atcataaaaa aagataaaatc 60  
atctcttaa aattctgtgt tattttaaaaa aacaaataat agatacagat gtctgagat 120  
tttaagacat tttggggatt ctatgtat ttagtgcatt taaccacaaa gacaaaggaa 180  
ggggtctgtc ctttttaaat acatgtatct cactgttagag ttcagccat gagttcacaa 240  
gtatcttaat attgtacnaa aacctttct ttttcattct agctcttaa cccctaagca 300  
aaacaaatgtaa aaaaaatgtatctaaact taatgttt 338

<210> 29  
<211> 622  
<212> DNA  
<213> Homo sapiens

<400> 29  
gcctgaagct gctctctagg aaaatgtggc attctctgct tgggggaggc tgggggtgggg 60  
gtaagagaga gggaaagatgc cctcagctcc caccaaggag cataaaataaa aagagaattt 120  
accccccagc acccttcata agcccaccag agttgccacc aaacagtgtt aaaaacgtgt 180  
gttttacta ttctgtgaa aataatggat gttctgtgga gattttttaga gcacacacac 240  
atatgatttca taaatcaaata tcagttgaa ctgttcccat cagaaagacc catcaagccc 300  
ataaaaagaga tcccttcata caaatatctc tttgtatcccc aattttccacc cattctacat 360  
gcattttcaaa acccatttcc tgatttcaact gtcatttagt agaaaagcagg gggctatttag 420  
cctggattgt aaggcatcca ttctccctt ttttgtttca tttagccatgtt aggaagatata 480  
ttttctttta tggttgatgg catctgtttt taaaaatggta taaactcttc aaaacatagt 540  
ttctgattct ggtagactt agatgagcag ctgtaaaata ataataatag tttgaggggt 600  
tgagaagagc tttcttttatt tt 622

<210> 30  
<211> 518  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (260)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (262)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (333)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (337)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (343)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (354)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (371)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (376)  
<223> a, c, g or t

<220>

<221> unsure  
<222> (380)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (470)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (304)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (310)  
<223> a, c, g or t

<400> 30  
cagatccccca aattcctctc caggatggtt gcacgtggcc cctcaggaac cggggaaagtg 60  
cacgtgtggg tggagaggtg tgagggaaaag agccagcttc cggacacggg tgcagggtct 120  
ccagcagctg agctcccgga gtgtcaagtt gccggaggtt ctgtgcctga gcaagcagag 180  
aaggaaactt aagoctotaa tgaaaaggcc tcctgttctc ttgcaggaga agccccccaga 240  
ggtaatggg gcagtggccn antggcctgt ggtgacccc aggagggggg ggggcccagg 300  
ccanctgggn cctcagaata ttgttcctgt gtnttcnttc gangcgggtc tggmctgtct 360  
ccgcagcctg ntgggntcan gactgaacag tctcctctca gcctcatggg cggttgtctc 420  
tggcacagg ctactcttaa cctcgcctcc ttaaccccac acagggcagn ctctgtcgc 480  
tacaaatatt tctggggaca cggctctaaa aatgacc 518

<210> 31  
<211> 556  
<212> DNA  
<213> Homo sapiens

<400> 31  
cagatccccca aattcctctc caggatggtt gcacgtggcc cctcaggaac cggggaaagtg 60  
cacgtgtggg tggagaggtg tgagggaaaag agccagcttc cggacacggg tgcagggtct 120  
ccagcagctg agctcccgga gtgtcaagtt gccggaggtt tctgtgcctg agcaagcaga 180  
gaaggaaact taagcctcta atgaaaaggc tcctgttctt cttgcaggag aagccccccag 240  
aggtaatgg ggcagtggcc tagtggcctg tggtacccc aaggaggggg aggggcccagg 300  
gcacatctggg tcctcagaat attgttcctg tgcgtttttt cgacgcgggt ctggccctgc 360  
tccgcagcct ggtgggctca ggactgaaca gtctcctctc agcctcatgg gcgggtgtct 420  
ctgggcacag gctacttta acctccctc cttaaacccca cacagggcac gcctctgc 480  
tgctacaaat atttctgggg acacggctct aaaaatgacc ctgccttcca ttcactggac 540  
agtgaacaca agaatg 556

<210> 32  
<211> 330  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (151)..(176)  
<223> a, c, g or t

<220>  
<221> unsure

12

<222> (247)..(273)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (311)  
<223> a, c, g or t

<400> 32  
tctgtgcttt gtgttaacttt ttgtctaaatt cctgtctttg tcttcggaa acagtcttct 60  
actttttaca ggtatcttcct atcttttggaa ttttatatta gttttatataaaaatataata 120  
tagttttata ttatatacgcc cactgacatg nnnnnnnnnnnnnnnnnnnnnnnntgac 180  
ttggccagag ctttcagttt ctatctctg gtaagaggta atgtgtctct ccctaggca 240  
aggctgmnnaa nnnnnnnnnnnnnnnnnnnnnnnnnnnnnn nnngatgtgt gagagaagca gggagagtaa 300  
gaatcaagac naaaactgcac tctttatac 330

<210> 33  
<211> 431  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (420)  
<223> a, c, g or t

<400> 33  
aagacagcta agtaagtgggt ggttaggaaga aagactggac aagggtttga tggactggct 60  
atgaaagatg aggaagagag aagtcccagt tgggttaagag gaagttttta aggaccacca 120  
agaaaaatgggt gacactctta ttagataacc tagaaattag acaaggatga gatgttatct 180  
ggatattcaa atgaaaatac cctcttattca gctatagtcg ggctactggg gttttaagg 240  
agaatttcag atttgggaa ctcaagagagt cctttgcatt tcaaagaagt gataattgag 300  
aagctgtgtg acaactaagg ttgtactaga agaagcttag acgtgagagc aggaagaatt 360  
catggacacgt gctaagtttag gacatatacg ttacacagat gacaccagtc tggatgtgn 420  
agccccagaca c 431

<210> 34  
<211> 275  
<212> DNA  
<213> Homo sapiens

<400> 34  
atttgattaa ttttgctttt gtagtttgcataaaaccac agtcactgtt tcattacaat 60  
taaagataat tgggtacgct actcctgagg gaaaccagca ttcaaaatgc atccccctcca 120  
tagttttat tatttgcgtt agaatgtctc attaataatt tcagagcatt ttggatttca 180  
aaatatttgc cttagacctt cttgcctcct cttctcttgt agagccatat gggcccttg 240  
tactcagaaa attgaaaatg agccaggttg cagtgc 275

<210> 35  
<211> 497  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (486)  
<223> a, c, g or t

&lt;400&gt; 35

agtgatttca ttatctccaa ttgttatggc ttgatagaaa tagattccat tatgttagcac 60  
 cttaaatcca gataaaacat aaggaaattc tattccatgt ttgttatgatc aatgttaata 120  
 atctaagaaa atctaaaaag aagctacttc ctctattaca gtatgaaata aatatgtga 180  
 atgatttggtt ttgggggggtg gaatggaaag gtataagact gaggagggtg cctgtggaa 240  
 cagtgtatgg aatcccttct taagggttgg gttttacata cgtctttaa aatagatgat 300  
 attcattaata aattatctgt gggcatcatg aaaaaagtgt ataacgtaca actttatgag 360  
 ctgcacagtt ggtgaaaact tttctgttta aaattttatt tgccctccc caaaagaaat 420  
 gtttattttat gagtatttagg atagttccag cagtaatgcc tc当地aaagaaac caggaggtat 480  
 agtgtngtct aaaatgt 497

&lt;210&gt; 36

&lt;211&gt; 1796

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 36

tgcacatctagt ccaccacactg tttttgtaaa gttatcagaa cacagtcatg cccattcatt 60  
 tacaatttgcgtt gtagggcttc tttccctgc acagcagagt tgagtgttgc aacagaaacc 120  
 tatggcctgc agagtttaaa atatctaccc tttggcctt tataaaaaaa gtttactgtat 180  
 tcctggtgag tatattaaaaa agttaggaaa acctaaatct tccagagtgg agaatttagaa 240  
 agtaagacgt gttgtatata agacagacatg tttgtgttg cgtttattttaa aatataatatt 300  
 attctgaaat aatgttgcg acatatgtt caggtctttaa aaatttggtca atatataatgt 360  
 ttaatcaaaa aatggcaaat tgtaaaatgt agacagaatg tgattgttgc ttttgcatt 420  
 acaccaacag aaaagggtgc taggaaacct gtaggaccaac atactaagtg tggctcttt 480  
 gatggtggtt tcatggattt ttaaaaaatct tcttggttt ctgttagattc tgactttctt 540  
 gtaatgagta tgaataagta tttttttttt gggaaatgtg aaaataactt tatctcccc 600  
 gatttctcat aattgaaaaat gtttgcattt atggccttgg gacagatctt tccattgaga 660  
 agggcggaag ggaaaccctg gggattcagc tgggttctg ttgcatttctt ggtacacac 720  
 agttgtgaaa agccagtgtt ggcattccc caggacatc tgggttagag gaggtcagga 780  
 ttaactact tgagggtccg gggacacat gttggccacag tccttcctga ctcactgttt 840  
 tccttcac agtccccgtc ttcttcac tttttttttt gtttgcacat agatgcctga ccagaggaga 900  
 gatttagttt tgcgttccagg attatctgtt atgttgcagt tctgaaattc ccataacgtt 960  
 taggctagaa cacaagtgtat ttcatatctt ccaatgttgc tggcttgata gaaatagatt 1020  
 ccattatgtt gcacccctttaa tccagataaa acataaggaa tttctattcc atgtttgcatt 1080  
 gatcaatgtt aataatctaa gaaaatctaa aaagaagctt cttcccttat tacagtatgt 1140  
 aataaaatatg ctgaatgtt tttttttttt ggtggatgg aaaggatataa gactgaggag 1200  
 ggtgcctgtg ggaacagtgtt taggaatccct ttcttaaggg tgggtttttt catacgtctt 1260  
 ttaaaaataga tttttttttt aataaattat ctgtggccat catgaaaaaaaaa gtttgcatt 1320  
 tacaacttta tgagcttgc agttttttttt tttttttttt tttttttttt tttttttttt 1380  
 tcctccaaaag aaatgtttt tttttttttt tttttttttt tttttttttt tttttttttt 1440  
 gaaccaggag gtatagtgtt gtctaaaatg tggactcagg agccagactg cttggctgtg 1500  
 caactagcct tttttttttt tagatatgtt gcaagttat taacttctca gtgttctt 1560  
 ctgttagaatg gggataatcc taatatacat cttttttttt tttttttttt tttttttttt 1620  
 aattttttttt aggactttaga atgatatgtt gcaaaaaaaa gtgttctttaa aagtaaaaccc 1680  
 tttttttttt tttttttttt aaatacaata atctgaaacc attagtaatt taaacatttg 1740  
 tttttttttt ggtttttttt gttttttttt gttttttttt gttttttttt gttttttttt 1796

&lt;210&gt; 37

&lt;211&gt; 83

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 37

gttgggatct gaaagaggaa tctgtggata ctgaggaaag gtagccagaa aggttcaaag 60  
 taacgccaag aaaaaatggt gtc 83

&lt;210&gt; 38

<211> 773  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (295)..(592)  
<223> a, c, g or t

<400> 38  
ggacaacaac caagggattt ggcccaagaa gaagaaatat aggcaagagg aaaaaaaaaa 60  
aaaaagagaga gagttataga atagagtaac agatttggaa atgcataat agttgaaacc 120  
tggagagcag ataaaattac ccaagttagag aatgttagagt aaaaagaaaag gaaaggatg 180  
gacagaaccc tgacaaaaca ccaggattac agttggatc tgaaagagga atctgtggat 240  
actgaggaaa ggtagccaga aagttcaaa gtaacgcca gaaaaaatgg tgcnnnnnnn 300  
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 360  
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 420  
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 480  
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 540  
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nntggtgtca 600  
taaaaccaag gagccacata aagtttaag aaggaaaaaa tgtccaaacc a tgcataatgc 660  
ttccaaaagg ttaataaga tcagaagtgg aaattattat ttgaacttaa caacatagaa 720  
tccttaagga cagttgtgga atttcactgg aatgcgagtg acaattgaca ttt 773

<210> 39  
<211> 326  
<212> DNA  
<213> Homo sapiens

<400> 39  
gaagtgaatt tacagaatct gagcatggat tagttgtata acaggggtgg tgggtcttga 60  
gggcaggtag caaagcaaag aacgacttga aggtttgaaa ttgaaattct gaatggacct 120  
ggatagcatt taatgtgata ggagaaacta tgaatgaaat atgaatatct ttgttctaca 180  
gggagtttag tggggggat gaagatagtt aattttgaat atcataaacc tgaaggactt 240  
cttaattatt cagaaaaatg tgcaaataat gcttaattga ttttgatattt aatgagtt 300  
aaggcacgt ggataaacaac acctca 326

<210> 40  
<211> 393  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (227)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (240)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (244)  
<223> a, c, g or t

<220>  
<221> unsure

<222> (317)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (330)  
<223> a. c. g

<400> 40

```

cactagctca tttttttttt cccacaacca ggttagatcgatgttatgt tatccacact 60
ttacaagaag gaaacagaag tcttagggaaat taggttaattt acattacccca caatccgtgg 120
gcaggacccg gatttgaattt ggcaatgtgg ctccagtgcctt tggtgtctcc acattgggag 180
atggtcccat caggaggatcg tctcttgacca tctccaacaa gccatcnctt tgccatgttn 240
ctancattcc aggttagccctg agtgcccccc antgaccaag gaaaagctta cccttagagg 300
gtctttactc ccaatgncccc ccacccctctt atcctctact ttttgggttt taaaatttcag 360
ctgacctgtt aqttgcnaact qgggaaaggctc tqa 393

```

<210> 41  
<211> 477  
<212> DNA  
<213> *Homo sapiens*

£400> 41

cactagctca tggtagtcctc cccacaacca ggtgagacag gtgcatttgt tatccacact 60  
ttacaagaag gaaacagaag tctagggaag tagttaatta acattaccca caatccgtgg 120  
gcaggacgg gatttgaatt ggcaatgtgg ctccagtgc tggtgtctcc acattggag 180  
atggtcccat caggaggctcg tctcttgaca tctccaaaca gccatccctt tgccatgtta 240  
ctaccatccc aggtagcctg agtgcccccc agtgaccaag gaaaagctta cccttagagg 300  
gtctttactc ccaatgcccc ccaccttccc atcctctacc tttttgttgt taaaaatcca 360  
gctgacctgt tagtgccac ctggaaaggct ctgaccactt cattctttat gcctctca 420  
cctcaqaqaq ctgcacggqc atctctaata cttcatattt ctc当地 aqgt agttctc 477

<210> 42  
<211> 515  
<212> DNA  
<213> *Homo sapiens*

<220>  
<221> unsure  
<222> (326) .. (386)  
<223> 3 - S - S or t

1400-12

<210> 43  
<211> 530  
<212> DNA  
<213> *Homo sapiens*

<220>  
<221> unsure  
<222> (326)..(386)  
<223> a, c, g or t

<400> 43  
aattcatctc ttagctata tagtctttc actcaggagc ccttaattc aagttgtctt 60  
ttaatttatt cagtaaattc ttatagtctt ttcatattc gtcctgcattg tttcttcattg 120  
aattcctgtt ttcttaata ttatgcataa cacggattt ttaattgca tattgtcatt 180  
atagaaacag ctgttaattt ctaacattt atttggagc tgacatctt aaatattcat 240  
ttcttagttc aaataatttca caactgattc atataggttc tatattatct ataaataatg 300  
ctaattctca tcgcagcaa attannnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 360  
nnnnnnnnnnn nnnnnnnnnn nnnnnnaata gccagtagcc ttgttgtgt ctgatctaa 420  
tgagaacatc tctgtttatt ttaccactaa gtatgaattt gctagtggtt gtgtttattt 480  
ctactttac actgagtgtt ttaaaacaaa atcacttgag ctgctccaaa 530

<210> 44  
<211> 446  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (425)  
<223> a, c, g or t

<400> 44  
gtgggtggaa ggcaagagaa ttctgtgaaa tggactcagt gttccctgtt aaataggagg 60  
cagtgttga agccaagagt gagcaagag gtggagaat cagaggttt aggaagccag 120  
ctcaagaaga aagtgtgtag cagagctgat gagatgaaag tggcatgctt gctggcagt 180  
gtttagagcc catctgagaa tagttataat aaatacatgg taaaattgtat ctgcctgtt 240  
gtagcactt ctcaataaaaa ctgagcagct catgccctat ctcagagcaa gaggagagtt 300  
agattcattt agttggattt ttgcccagatg agtgtgataa aaagattgcc cagagtttag 360  
agttctgaaa aaagtgttat ggagtgggtt acatgagtct aaagttgaa aaggatggaa 420  
atgangaaaa gaaactagct gataga 446

<210> 45  
<211> 906  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (707)..(812)  
<223> a, c, g or t

<400> 45  
cagctcttct gtgtcaaaaa caaacacctt cttccagcg ctgtctctgg ccggctgcc 60  
cgcctctgc caggcgttt tcagaggaca agacctaattt agtggctgc tgccagctg 120  
gtcttcacag ttcatcagta ggattccaga caggcatcg gtcaggac acgcagaga 180  
cagctgcctt ctccctttc cccggggcac ctgagacctt acgcacccga gggggccgtt 240  
gcatgggtgt ctcccaagtga gctgtaaatg cacggccaga agtacaccccg ccaccagctg 300  
cagcagcaca gttcgtcca ggcgcaccacg agaggctggg gctctctggg agtggaggag 360  
cagggtggaa tgaggctgga cttgcacgca gagctctggg ctccattaag ccccccccc 420  
gtcttagctg tgcgtctgg gacgcacgt ttcctctgag ctgtctctt cctggcagaa 480  
gggggggtcat aacagcacca acatgcggga ttgcggtagt gtctaaacag tcaggcacag 540  
gaagctgcac agagaagatg catggcaac acgcacccat gagaatccat gcagccccct 600  
aagaggggca gagagctcc aagcaaaatg cattctatct caacactcac tcccctgaag 660  
actattctgtt cttggaaat aggataccca atattgaatg tttgtgnnnn nnnnnnnnnn 720

nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 780  
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn ntacccacc acaggattac aaggagaaaa 840  
agagggaaagg gatctccccg ccctctct ttctccccct ctcccaacca gggcagaaga 900  
agaaaa 906

<210> 46  
<211> 289  
<212> DNA  
<213> *Homo sapiens*

<400> 46  
aaacacagtc ctccatgag ttctgcaa ac cttgggttgg aaaagaggct ctagtttgc 60  
ttaggctacc tggactgagc aatataaggc atgggagagg tggttatct gtttaaggtg 120  
ccatgtctt g ttatactca ctgatgagaaa gaaaaaaaaact taaatgaaga cttcagactg 180  
aattttttt ccttgtatta aaaacttaga gtgagagtta agcttagatt tagttttct 240  
aaaacctaa aaactagaaa ccatttatta aagctagatt tttttttc 289

<210> 47  
<211> 299  
<212> DNA  
<213> *Homo sapiens*

```
<400> 47
gggctgagct aaacacagtc cttccatgag ttctgcaaac ctgggttgg aaaagaggct 60
ctagttgcc ttaggctacc tggactgagc aataaaaggc atgggagagg tggtttatct 120
gtttaagtg ccatgtcttgc tttatactca ctgatgagaa gaaaaaaaaact taaatgaaga 180
cttcagactg aatttttttt ctttgtatta aaaacttaga gtgagaggtt agcttagatt 240
tagttttctt aaaaacctttaa aaactagaaaa ccattttataa aagcttagatt ttttttttc 299
```

<210> 48  
<211> 197  
<212> DNA  
<213> *Homo sapiens*

<210> 49  
<211> 453  
<212> DNA  
<213> Homo sapiens

```
<400> 49
ttacaggcgt gagcaccgtg cccagcctca agtatactct tacaacacaa ttaaaattcaa 60
tcctcagtaa tccccaaaatt tcattacccc tggaaaaatg tcctggatta gcagtcctcct 120
acttttaagtg ttttatgaaa gaatacagtt tatTTTtagta taaataaatat agccagactc 180
tatgaaaacaa aagggtgaat aatatttacc tatagctccc atttagaaatg accaaaagttt 240
tgaagcacat tcattggcta ctgtcatatt tattaggatt tatgttttat cagattataaa 300
gcactcttta gtggaaaatg ttttttccct ctttgcgtcg aaaattgtcc aacactcccg 360
gtccagtc当地 gactgtggca aaaaactccct caatTTGAAT ggctttcatt tgggtccatt 420
tatTTGGTTA caGAGAAGTT ttqataaaaat acc 453
```

<210> 50

<211> 1012  
<212> DNA  
<213> Homo sapiens

<400> 50  
gtaacattct atttataatt atgccttgtt tttattaatt ctcctatgga tggatattta 60  
ggttatatcc attttttgc tagtctttgt atgctccctt gaattttattt gtacatattt 120  
tcttgggtat ttgagagatt ttctgggta tacatatcta agatctgatg gatgctggga 180  
tatgtgcttt gtcactgag gttctcactc ccctggaagt gtgtgagatc agaatgcccc 240  
tgccttagcc cttaattata ttatgtatca gcatgattga tttgtataag actaataagg 300  
gtaaaatagct gagtgatgc cttaattact gtaattttac tttgtgttc gtcgtttgt 360  
ttaattgggg acccatctt ttccagattt gtaattttgc taaagatctt ctgtttctc 420  
agagtttaatt atcccttaag gaattccatg tggttatttt tctctgttcc aaagttacga 480  
ttctgtgtca aagtctataat tatgaaatca tcagttgtt catactttaa atctatgctt 540  
ctcccttgc gttgacagtc cccaaaggcag gcatccatga agtcaaagg actgaccaaa 600  
gtgtatctg cccttttac tgggtggca tttgtgttac tacactgcaa aagcagtgg 660  
ggataaaactg acagcacctt gcaaaggcagc aagggtgggtt caccaatttg tcattattta 720  
tgtaaaattt aatgggttca ttgttatttt taaatgaata aacatttaaa caatttctta 780  
gtttgattt ctaatagat aactatagat cagtagatgc caactatagt gtcttcctt 840  
aagagcgtga aggggcctga gactggaaag ctggagaagc accgccttta agcacatgg 900  
agacgtatga atagacaat actttattct tggtgaacat ggtcattggg aaggaaaact 960  
gaggtatgtc attctattac aagatgaatc aggctgatct gcaagttgtta ta 1012

<210> 51  
<211> 268  
<212> DNA  
<213> Homo sapiens

<400> 51  
gtggaaattha atgttagaat ttgttatttt tagatgaagg gaatgtcg atgagttttg 60  
taaaggaact ggtcatcgaa aggaaggggaa aaagatgaaa ataaaaacaaa ataagaatat 120  
aaaatagcca gagagattat acgatcatgtt attaactcct cctgagaata aaatattata 180  
ttgttatgtt tgaggctcat ttgtactcgat ttcttagtta agagttggct aacaaaaagt 240  
atatcattgtt aatgaatgtt ttcaactgtt ttgttcttgt tgtaaacctt atattctccc 268

<210> 52  
<211> 581  
<212> DNA  
<213> Homo sapiens

<400> 52  
gtggaaattha atgttagaat ttgttatttt tagatgaagg gaatgtcg atgagttttg 60  
taaaggaact ggtcatcgaa aggaaggggaa aaagatgaaa ataaaaacaaa ataagaatat 120  
aaaatagcca gagagattat acgatcatgtt attaactcct cctgagaata aaatattata 180  
ttgttatgtt tgaggctcat ttgtactcgat ttcttagtta agagttggct aacaaaaagt 240  
atatcattgtt aatgaatgtt ttcaactgtt ttgttcttgt tgtaaacctt atattctccc 300  
caggctgtgt aatccacttt ttgtactctt tgctggatgc actagatgtt acacaaaagg 360  
aattttgtgg cactaactca gtttcgcaca tttttggctt tgaaatgtgg acagaaattha 420  
ttgaaactaa tatctaaatg tagtattctt ataaacttctt tcttagccatg ttaattttgtt 480  
tctctattaa gacggacaat caaagaggaa ataaaacagaaa catattctc ctaatgaattt 540  
caggctgggg cttaaaaggctt aatatttata gatttcttctt t 581

<210> 53  
<211> 597  
<212> DNA  
<213> Homo sapiens

<400> 53

actgcacatctg ctgcctttac acggggactgc aaacctgttt tttcaacact tctgttttat 60  
 gggtgtgcac acccataaaat ctcctgtggc tgggttaagg gaacatacaa gcagctttc 120  
 agcattaaga atgtgatggg agagatttagt gtagatgttga actgccatca tcaatcaaga 180  
 ccaaggagaa ggctgcttc caggatgtac acatggccctc tgtttgcgt tgctgtttg 240  
 cttctttaa gaggtgaacc aatatatgtt tgcgttgcact tactgtcact tgcaagtc 300  
 cagaaccctg taatatacat gaacaagttt ctggaaagttt agagagatga gaagttcacc 360  
 aagtccacaa cctgactgtt accatgagga attcctttac cggagaacat gctgtcacaa 420  
 taggttaaat atatgttata caggccaaa gaatattcat gttcaatctt agttaaaaat 480  
 aaatattttat agtttagttaa attaggtata gcttttattt cccacattat aattacctgt 540  
 atttttata cttcatgtaa catcacccaa aatttttagta ttagataaat caaaaaaa 597

<210> 54  
<211> 304  
<212> DNA  
<213> Homo sapiens

<400> 54  
gctcgagatc cctcttgca tccaaagaga acacccaaact ggtgttagct atattttaa 60  
ataggacaaa aagtccctgc cagactgtgg agtctctcca cctggagaaa gcattcaatc 120  
tctgttatgt tcatgcctt cagtaccatt ctttcgtat ttttcagtt gacatgacct 180  
ttaagggttcc tccaaactaa ggttctaatt tttttttta acttgcagtc ttactcccaa 240  
caagaaaattt gatatatattag agctaacagt tctaagaagt ttaagaaat agtatgcaat 300  
ccca 304

<210> 55  
<211> 2631  
<212> DNA  
<213> Homo sapiens

<400> 55  
caggtacaca gtgcacaaat tagatattca ttctaaaact tctaatttac agataagacc 60  
gagaagggc tagtaagtca ggtatcttaa ataatggatt cgttgaaact ggctcttcag 120  
aagaggtgat tgcagaagt caaagctggc tctgaggtta aatctttatg agaaaggaaat 180  
acctttactt tgaggttata aatggcttag ctctgggata tggaaactttt taagtatctt 240  
taagcaatca gtgttcaaat caaagagtga gatgcgtat ctgacccgtt aaaatcacaa 300  
aatcaggctg ggcatttagat aatgccttc agtttaatca ctcgcgtcct ggattctgga 360  
aaatgttgct atataaaaca cataatgtat gaatagaagt atatgttaac tgacagactt 420  
ttgttataca gtgtgataaa gtgaatagaa cattagaata ctaaccgcattt gattttgact 480  
ttggtctcag ttgtcagtt ggggccttag tttcttaca ttaaaggaga agactaaact 540  
aagtttattc ttcaaaaga cccttacta ggtgtccctt tctacattt caaaatattt 600  
gacttgtcca tgaccaaaaca ggtggaaatg aaggccattt ttttgcattt ttttctcttt 660  
taagaatttc cagaatattatg ttcttgcgtt ataaagaattt acatattttgt agagttctaa 720  
gcgttcttaa aattcatttt gcccactcc ttcccttcctt aaaggagaca acagaagctg 780  
cagaatagtc ctctctgtt ttattacata gcaagcgtct cctgtcttta aatattttgaa 840  
ctaaacacat ttacatttt aatgaattttt atttacagtg tgatgtccat tattgggatt 900  
gcatactatt tctttaaaact tctttagaact gttagctcta atatatcaaa tttcttgcgtt 960  
ggagtaagac tgcaagttaa aaaaaaaaaat tagaaccttta gtttggaggg accttaaagg 1020  
tcatgtcaac tgaaaaaaaataa cggaaaggaaat ggtactgaaa ggcataaca taacagagat 1080  
tgaatgctt ctccagggtgg agagactcca cagtcgtggca gggactttt gtccttattt 1140  
aaaatatacgtaa taacaccagt ttgggttttctt tttggatgtt caagagggat ctgtcggttt 1200  
aatgtcttctt ctgcgcggcc cctcaccgcac gccccctcac acctgtgagg ctctttgac 1260  
gttgcgcgtt cacaaccgc cggccgttccaa gtcgcgcgc agccagctt 1320  
caggggagtt gtgcgcgcgtt gctacagccctt gttgtatccca tttcccttcgt ctctgtccg 1380  
ggcttagggag tggctctgc aggacttcca aggctttttt tctcgggtac tgggtttcgc 1440  
atggctcgat tggatgtttt tcttccaggc aatctcggtt agcgcttcag cttagacact 1500  
tcttgcgtt tctgtcgtt tgggtcggtt gtagtcttctt gtttgcgc tttctccacg 1560  
cccttccacg tttcccttta gcccgggg atcgctttt ctgaacgaaa agttctcaga 1620  
gcccggctga acctcccgaa aaatgtctt ctcttccgtt tgccgcggat ggggggtgggg 1680  
gtggggccaga aactgaacgc cggccgtcagg agagctgagg ggacccgacg gcccgtggcgg 1740

aggcgggaga ggtacggtcc tcggagtgaaa gctgggggtg gggaaaccga cgaggggcag 1800  
 ccccccactg tcttgggtgc agagggact ttatttcagc tgaaaccgcg cggcgaggcc 1860  
 caagtgtctc tggagagatt cggggttcag gaggtggcgg gtgcacccaa gggtgctggg 1920  
 aggaagctcc aggttccccat tcttccccag ggatcggcgt tgccctctgt cgcgggggta 1980  
 gtcttagggca acggaagatg gcggcggcgg ccgggcacgg ggttccggc tccgctcggg 2040  
 cagagcccac ccgctgacca actccgcgc ccccgccggg cggtgctgtc tcccccgcagg 2100  
 agtcggagag gatggcaggc gcccggaggcc agcaccaccc tccgggcgc gctggaggag 2160  
 cggccgcggc agccggcgcg cgggtcacct ccggcgtcgtc ctggcggggg ccggggagagg 2220  
 attcgtctga cagcgaagcg gagaagagg gaccccaaaaa actgtatccgc aaagtgtcta 2280  
 cctcggggca gatccggacc aagggttca tcatgttggc caggctggc acttctgagc 2340  
 tcaagtgtatc cgccccaccc tgcgtcccaa agtgcgggaa ttacaggtgt gagccaccgc 2400  
 gcccgccgaa aaacaataca attgtgaagc agttctacac catgttcgtt gcaagcgttat 2460  
 tcataggagc caaaaagtgg aagaaccca actgttcaact gatggatgaa tggataaaca 2520  
 aaatgtggca cacacatata ataatggac attattcagc cttgaactgg agggaaattc 2580  
 tgacaggtca ctgtgaggtg aaaggtcgc tttcaggtg tcagggaaatc t 2631

<210> 56  
<211> 401  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (279)  
<223> a, c, g or t

<400> 56  
ccttaaaaaaa atttacagaa cacaaggaa aacataaaaca caaagacatg gaaaattttt 60  
tcaactcctt aatggattc tgtatcaaa aagcaggcca gattctaattt aaaaatcagg 120  
aaattttat cacaatcaga atgtacttgc acatttcgt tgccttaactt ccaatgagat 180  
aacaaaggcctt ccaaggctac agctgaaactt ctgaaaggcc ctgtgtttt tactttacat 240  
ttagcgtcta atatttccta ggacagtatg tcccaaagna ggctgtacat agaatctcct 300  
ggagagctttt ttaaatgtcta atgccaataaa ccatatctcc ataaaatttta ccctagaattt 360  
tccctggat ggggtgcctg gccatccagt atttttaat t 401

<210> 57  
<211> 859  
<212> DNA  
<213> Homo sapiens

<400> 57  
gcacgaggtt gctttgcatt atctaaccctt tttatttttaa atctgccagg aaatcctcta 60  
actttccctt ctttttgttt cagtaagtat caggcagctt caccataacctt gagtcctttt 120  
gtcttgaagc tgccacagaa aaatcttaca gcaatcattt ctgatttagaa actgtttcag 180  
acaatcagca tgggtgttat ttaccaaattt ccccccagag tccttaggcctt cttctccaga 240  
aatatctgtat gatgaagtgc ggggaggggca acgggtctac aaaacacggc acagaggtaa 300  
agagaaggca ctactttctt gccatctttt taaatgattt ctttgttcaa acataaataaa 360  
tcttaagtcc aacacccaaat acctgttactt cctacatcaa tctcattttt ggttttaagac 420  
acagtacttag aattttccattt tttaaaatc ccttggccctt taaaaaaaaattt tacagaacac 480  
aaaggaaaaat ataaaacccaa agacatggaa aattttgtca actcccttaat ggaattctgt 540  
gatcaaaaatc caggccagat tctaatttcaaa atcaggtaaa ttttaatcac aatcagaagt 600  
acttgttacaa ttctcgttgc ccttaacttca atgagataac aaagccttcca aggctacaggc 660  
tggaaactctg aaaggccctg tgctttctac ttacatttaa gctgtcaata tttccttagga 720  
cagtagttcc caaagttaggc tgtacatttgc aatctcctgg agagctttt aaatgtcaat 780  
gccaataacc atatctccat aaaatttacc cttagaatttcc cctggatgg ggtgcctggc 840  
catccagttat ttttaatg t 859

<210> 58

<211> 343  
<212> DNA  
<213> Homo sapiens

<400> 58  
gctcgagtgt aaacattcac ttagtctttt tcctttattt aagccacaat ttaaaaaaaaa 60  
aaaatactat aaatttcagt ttaaattttag aagccagata ctttcaaa tgtatcctt 120  
atgtggtaaa atagagaata acattgttt tagttaagta aaactaaagt actgtttcta 180  
actaggtaat ctggccttcc aaacacagga gtttgaacag agagttctaa aaatttagagt 240  
gtctgttctc tgcagaacc ttctggaaag agtgtgtcaa atgagcacta ctcaggagaa 300  
atttctaagg ttttaactta gtttatactt taaaactgaga ttt 343

<210> 59  
<211> 635  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (33)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (111)  
<223> a, c, g or t

<400> 59  
tcctaatgtt atttaaaaata ccggggatga agngcattca gtatctgcct ggtcaccaaa 60  
gtccaatgcg acatcccccc tctatagaga tgtattctag caaaagactt nttcatccac 120  
catctggccc cagactaaga acacatctca ctgaatgaca cataacccag tggatgcac 180  
caaatttgct taaccatgag cacatcatct tctcataaca aaagctgaat atgaccctaa 240  
tttatatttc tgtaaactct gtttggaaa ttattaaaaac aactgtcttc tggtagtct 300  
gtaaacattc actgatottt ttccctttat tgaagccaca attaaaaaaa aaaaaatact 360  
ataaatttca gtttaatttga agaagccaga tatcttcaaa aatgtatctt ttatgtggta 420  
aaatagagaa taacattgtt tttagttaag taaaactaaa gtactgtttc taacttaggt 480  
atctggcctt ccaaacacag gagtttgaac agagagttct aaaaattttaga gtgtctgttc 540  
tctgtcagaa ccttctggaa agagtgtgtc aatgagcact tactcaggag aaatttctaa 600  
ggttttaact tagtttatac ttttaactga gattt 635

<210> 60  
<211> 474  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (335)  
<223> a, c, g or t

<400> 60  
gggaggcag aactattttc attttatgtc ttatgaaact acagtgcata gtgacgaaagt 60  
gatttgccta aagtccaaaa gcaaaaacta ctggaaaccat gtcccaagct aaagacttct 120  
cccaattata gcgtttttc ctcccatagc ctgttttcat taccttcctg tttatccatt 180  
ggctttcatg agacatgttt gctgccagtt gtgaataggt tagttccca gaggacccat 240  
gagtaccaca caaaactgcta gctgaatctt gtgagaattt taggaggtag ggctataaccg 300  
gccctgaaga aatttcttga tgactgctca gtggntttat ggaatgtgc agatattct 360  
ctggatactt taggttact ccctttaag agcatgatat tgacaattct ttttactgt 420  
ggaacagtga catctgaaca cggtgcctga ctttgcaag gtttgcaga atgc 474

<210> 61  
<211> 526  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (415)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (417)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (475)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (482)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (521)  
<223> a, c, g or t

<400> 61  
attttaaaat ataattaaat attttattcc tttattatag gaagagcttt tacgagttct 60  
actgaacaac aacaaaaaaat ccagtagaaa tggtggacaa aagatgttatatacaaaaac 120  
tagaaatgca agtaaacata aaaaagctcaa acttacttaa aaacttaaaa tggaaatattc 180  
gtttaaataaaa ctattactga gggcctataa aattttgggt taaaatgaaa tggttaatact 240  
taataaaatgt tagggcacaa tgatgctatc tttcttacat ctttctttt agaagtaact 300  
tatttcaatgt tttcttgaaa gcaatttgat aatttttata ttactacaaa aatatggtag 360  
ctaccctttg gctcaacaat ttttttagga accacaaaaaa tgcaactcaa gatgmanata 420  
aaagactgaa agcaattctt catagcctt gtttatatgaa gggaaactgaa aacngccta 480  
antatttaac aataggtaaa atgatttagaa atgtggtaaa ntcaga 526

<210> 62  
<211> 164  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (143)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (148)  
<223> a, c, g or t

<400> 62  
gacatcctat aaaaaaaaaa atcgatttgt gctttattta cataaaaata aaactataact 60

tttgataacg tcctggcac ttccctctgc ttactccccca tcaataaaa aatgccta 120  
ttaaattaaa agaaccggc cantgcantg ttcatgccta taat 164

<210> 63  
<211> 257  
<212> DNA  
<213> Homo sapiens

<400> 63  
agcatgggtt aagctaagg gacttgatc aagttgccaa aacctgtttc aggtttgtt 60  
aagtccaccag aacgcgttga tttagacatc ctataaaaaa aaaaaatcgta ttgtgtttt 120  
atttacataa aaataaaaact atactttga taacgtcctg ggcacttccc tctgcttact 180  
ccccctcaat taaaaaatgc ctaattaaa ttaaaaagaac ccggccaggt gcagtgtttc 240  
atgcctataa tccccagc 257

<210> 64  
<211> 572  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (179) .. (265)  
<223> a, c, g or t

<400> 64  
cacactttct cagctgtct tggtttgca aaggaagata ctgacatgtt cagattaaga 60  
aatcgtaaag cttctgaact actaaggaag ggaaaagagg gcccaggc ccacatgtgt 120  
gccagggtct gatctgaggg tttttgtga ctcatctat ttaatggtca cactgttcnn 180  
nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 240  
nnnnnnnnnn nnnnnnnnnn nnnnnntctg gtgttcaggc ctcatgcctt ctgttcttaa 300  
ctccatatatcc tgtgtccctg gaaaggaag gggccatagt ctggagtgtt ttccaggaga 360  
aaagagccag agtaatcttct gctttcatt tcttaacaag aatagaagac agaataaaagg 420  
gcacaggat aaaggattgt taaccagact ggcaaatcag tagactaatt aaaaatcaa 480  
caccttaaaa cactgtcgct gggtaattt taaaccaaca atgaaacgtt aaatttgc 540  
agccatgagt ttgaatgatt aactgagtga gt 572

<210> 65  
<211> 277  
<212> DNA  
<213> Homo sapiens

<400> 65  
gctggctttc ggtatttac agtgcctggg aatgttctag gctctggttc aagcctgttag 60  
ggaaaaaacct gcagctggct gagccacaga ggtcaggcgt gtctgtgatt ttcagtcagg 120  
acacagaaag caagcaggag gaactggagg accctgcggc tgcctgttaac aagaaataaa 180  
aatggcacag atattactaa ttaagcacta atcccagagg cggcgagctt gtggccttcc 240  
tgttctcctc taaaagcaa gcaaggccg ggtgtgg 277

<210> 66  
<211> 452  
<212> DNA  
<213> Homo sapiens

<400> 66  
cccaggggat gatcccaaag cattttccca ggggtccttc gttgcagggt gggcttcagt 60  
gtccttgcaa tgggcatcag agaaaaggcg tttctacag ccaggtgtt ctcggcaag 120

ggggtcaggg tatggagttt atgtgagggt ttaaggattt tggctcaggg cctgggctgg 180  
 cttdcggtat ttatcagtgc ctggaaatgt tctaggctct ggtcaagcc ttagggaaa 240  
 aacctgcagc tggctgagcc acagaggtca gggcagtctg tgatttcag tcaggacaca 300  
 gaaagcaagc aggaggaact ggaggaccct gcccgtgcgt gtaacaagaa ataaaaatgg 360  
 cacagatatt actaattaag cactaatccc agaggcggcg agcttgtggc cttcctgttc 420  
 tcctcttaaa agcaagcaag gcccgggtgt gg 452

<210> 67  
<211> 283  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (274)  
<223> a, c, g or t

<400> 67  
ggaataattc agcactttaa tgtgttattt aattctcaca gaagccccat tttacataaa 60  
aatgaaattt aatggattat gagaatattt attattgatt ggtaagtgtt aacattattt 120  
tttcaagaac agcaaccta aatactcata cagttagctc taacaatgtt tacaagtctt 180  
aaaactattt ctgcaaattt ttgttattaca taaatgttat tgactcctca accatggttt 240  
ttttaagttaa tatttgttaa ttataaagta agaaaataca agccggcat gatggcacat 283

<210> 68  
<211> 432  
<212> DNA  
<213> Homo sapiens

<400> 68  
ggaataattc agcactttaa tgtgttattt aattctcaca gaagccccat tttacataaa 60  
aatgaaattt aatggattat gagaatattt attattgatt ggtaagtgtt aacattattt 120  
tttcaagaac agcaaccta aatactcata cagttagctc taacaatgtt tacaagtctt 180  
aaaactattt ctgcaaattt ttgttattaca taaatgttat tgactcctca accatggttt 240  
ttttaagttaa tatttgttaa ttataaagta agaaaataca agccggcat gatggcacat 300  
gcctgtagtc ccatctactg gggaggctga gtcaggagga ttgtttagc ctggagttt 360  
agctacagt gagctatgtt cacattattt cacgttagcc tggtaaacac aatgagaccc 420  
tgtctcttta ac 432

<210> 69  
<211> 516  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (425)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (475)  
<223> a, c, g or t

<400> 69  
cttttctta attaaaaatc ttaaagcctt ttcccttggc tgcctctga agacagtgtg 60  
aatcttcttc aggcctgttt ttccttaattt tatacattat tgctctaact tattttctta 120  
cttattattt tattttctat ttaataaaaat acaaactaca ttgctgaat tttgttgtat 180

25

ctgcaaaaca atatggatac aaatacggat ttttagcta ttttcatgg 240  
 cattataactt cttaagctt ctgttttatt cagttgtgt agaggtgaat gccctactga 300  
 agaatctgtt ttccaaagat tatccaagaat aatattttt gagagaattc tagtggattt 360  
 aattgatgaa gacatggtaa gagaaaactgt tgaaagatac ttgaaagaaa gtcattaagt 420  
 gaganaaaaa tggagaacta aaatgtggag actcacgaag agcagagtga gcttnaagaa 480  
 taaagactgg aaacctgtgt ccttaatgca ttact 516

<210> 70  
 <211> 52  
 <212> DNA  
 <213> Homo sapiens

<400> 70  
 cattgggtta atatacctga gcacagttt aacacccccc tcctttctta tt 52

<210> 71  
 <211> 422  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> (311)  
 <223> a, c, g or t

<220>  
 <221> unsure  
 <222> (386)  
 <223> a, c, g or t

<400> 71  
 gggaaagata cttggcaca tttatagacc catgataagg agctataaaa ataatgaggt 60  
 taagatgtc acaacttattt atgcaaaatac cagagaatag ttagcttga acagaaggc 120  
 acccatctct tctctaataat tggaaacagg tggaaaaacc acctgggctc tcagacagat 180  
 gtctttgttt taaaatattt cagaaaatga ggttagggagg gactgaccaa gggcagcgag 240  
 ttttatgaat gctgttcctg gtctcagcag cgctttcctc ttccctcaact gacaactgca 300  
 gggcccaagt ngggaggaag aacagtgtgt gcctgctggg ctcagcatct gctccagtga 360  
 gcaacacggg ggtgactggg ggtctnctga atgttaaata taaagaagt tcctttccc 420  
 tc 422

<210> 72  
 <211> 521  
 <212> DNA  
 <213> Homo sapiens

<400> 72  
 gggaaagata cttggcaca tttatagacc catgataagg agctataaaa ataatgaggt 60  
 taagatgtc acaacttattt atgcaaaatac cagagaatag ttagcttga acagaaggc 120  
 acccatctct tctctaataat tggaaacagg tggaaaaacc acctgggctc tcagacagat 180  
 gtctttgttt taaaatattt cagaaaatga ggttagggagg gactgaccaa gggcagcgag 240  
 ttttatgaat gctgttcctg gtctcagcag cgctttcctc ttccctcaact gacaactgca 300  
 gggcccaagt ngggaggaag aacagtgtgt gcctgctggg ctcagcatct gctccagtga 360  
 gcaacacggg ggtgactggg ggtctgctga atgttaaata taaagaagt tcctttccc 420  
 tccttagagaa gctcatagcc aaactgaaaa gcgaggaga gataaaatga ataacctgat 480  
 tggagaact gtctgcaatg atccctcagt gcaaccccat g 521

<210> 73

<211> 140  
<212> DNA  
<213> Homo sapiens

<400> 73  
ggatatttgg ttactttgca gcctagaaat tatttcagag aatcctaatt gctgacattg 60  
catatttggtt cagtttggag tctgggttgtt agattatcaa agaaaagtcc tgctgatatg 120  
taagcatcaa atagaaaacctt 140

<210> 74  
<211> 101  
<212> DNA  
<213> Homo sapiens

<400> 74  
aagcttattaa aggctgtccg ttaaggatct ggcttcaaac tgccttcca ccttcattct 60  
actatttcct ctattaaaat atgctttgt ttttaagcaa attgttaatt tttttttttt 101  
actatttcct ctattaaaat atgctttgt ttttaagcaa a

<210> 75  
<211> 422  
<212> DNA  
<213> Homo sapiens

<400> 75  
aagcttattaa aggctgtccg ttaaggatct ggcttcaaac tgccttcca ccttcattct 60  
actatttcct ctattaaaat atgctttgt ttttaagcaa attgttaatt tttttttttt 120  
tttaagatgg agtctcgctc ttgttaccca agctggagtg cagtggcccg atctcagctc 180  
actgcaacct ctgcctctcg ggttcaagca cttctcctgc ctcagccctcc cgagtagcta 240  
ggactaagtc atgtgcacact atgcccagct aatttttaaa atttttttgtt agagatgggg 300  
tctcaactgtg ttacccaggc tggctcgca gtcttggcct gaagtgttcc tctcacctt 360  
gccccccaaa gtgctggcat tataggcatg agccatggtg cctgtcccta ttcttaattt 420  
ca 422

<210> 76  
<211> 253  
<212> DNA  
<213> Homo sapiens

<400> 76  
cacacctcat ctccctgaca ggaagacatc tttttcctg tggagcctgt ggaattttatc 60  
actttctatt tctcttgggt gggaaaatct tctcggcatc tagctaggca tggacagata 120  
ctgttgggtg atgatgccac tgaagagccg tccttagtgt cacgtggtgc tggctcgagg 180  
tcacggtcca ttgggttcca ttggcttctc aaggccaata cccagtcggc gggctaattt 240  
ctactactga gag 253

<210> 77  
<211> 493  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (199)  
<223> a, c, g or t

<220>  
<221> unsure

<222> (202)  
 <223> a, c, g or t

<220>  
 <221> unsure  
 <222> (208)  
 <223> a, c, g or t

<220>  
 <221> unsure  
 <222> (211)  
 <223> a, c, g or t

<400> 77  
 tcctgctgtt cagggAACAT tctgcggcAG ttAAACAGCA gcctccccca ttaAGTCCTG 60  
 gcaacacagg aaaggtagat gctttcagt aacctttccc tgttaggactc ttcagagcc 120  
 aagaacataa ggtgtgaccc atctggacta aaaaaaataa agcagaatttgc tatcaattgc 180  
 tactcctttt tattccanc tngtttnct nattttttt tttaattccc atcttgtaag 240  
 agaattccccca gggagccccc ttgagagaaa gttcattgga ttatTTTTT taatttttat 300  
 gccatTTTCTT gtAAAAGCAA actgtctag ttggatGCC ggtatacata aatgtattga 360  
 taatatccag tctcttgggg aactcttagga gtatTTGCTT aagacacatc ttgggttcc 420  
 ctacactct ttctaagatt tacaggagaa ggagagtctt actgtctttt ctatgtttat 480  
 gaaagtgata acc 493

<210> 78  
 <211> 652  
 <212> DNA  
 <213> Homo sapiens

<400> 78  
 tcctgctgtt cagggAACAT tctgcggcAG ttAAACAGCA gcctccccca ttaAGTCCTG 60  
 gcaacacagg aaaggtagat gctttcagt aacctttccc tgttaggactc ttcagagcc 120  
 aagaacataa ggtgtgaccc atctggacta aaaaaaataa agcagaatttgc tatcaattgc 180  
 tactcctttt tattccanc ttgTTTCTTtTtTTTTTTT aattccatc ttgtaagaga 240  
 attcccaggg agcTTTTTg agagaaagtt cattggattt atTTTTTaa ttTTTatGCC 300  
 atttcttgta aaagcaaact gctctagttt gatGCCAGGT atacataaat gtattgataa 360  
 tatccagtct ctggggAACAC tctaggagta ttgcttaag acacatctt gggtccccCTT 420  
 acactcttC taagattttac aggagaagga gagtcttact gtctttctA gtcttatgaa 480  
 agtgataacc gactggggcgc agtggctcac gcctgtgatc ccagtacttt gggaggtcta 540  
 ggtggtaggc tagcttgagg cttaggatTTT aagaccagcc tggaaACAT agactccccCTT 600  
 tccatTTTaa aaaaaaaaaa aaaaactcga gactagttt ctctctctcc 652

<210> 79  
 <211> 591  
 <212> DNA  
 <213> Homo sapiens

<400> 79  
 tgcATgtgGA agagatATCC caggaatCTG atcttgagaa cttgaACATA atgttaatgt 60  
 acgtgtata ggcttatAGG ctccatGAAG caACCTTCTG tttagatCAAG gcaaaaaaaa 120  
 aggtctacca ttccctactc cattccatG cccgtaaaaAG ttTGTttGC cactttgaaa 180  
 tctgcaatGA atcttagAGCA gttagcatAA tactttccta acactggatG gataCTATTc 240  
 acagcatCCC ccctcctcat cgTCACCGGC atcactttcc tcattaccAC catccccatc 300  
 actagcatct gtagcacACT tagtctacAA agagCTTCA ttCACCTGAC ctTCTTgaa 360  
 caagataatt atcaactttt ggtgtggac CGAGTGTtTG gacacttcat ctTGCAGTGA 420  
 ttTTGTGGGG GtAAATAGAG cAGCATTtTtG tgcacaACTC ccaACAAcAC agtGTTGCT 480  
 acataaggAG tgcttgataa atgtggattt gattaatGta aataaggAAA ctaaAGCTTA 540  
 ggagaAGTTC tgTTGTTTC tcagtatcAG gaagaaAGGA attgcAGACA C 591

<210> 80  
<211> 160  
<212> DNA  
<213> Homo sapiens

<400> 80  
ggggcagaat atctgaagag atcatggctt gaaaaacttac taaatttgat gaaaaatgtt 60  
gatcttcaca ttcaagacgt tcagtgaact ccataataggaa gaaattcaag agatccacaa 120  
ttagacatat gctactcaaa ctgtcaagag acagagacaa 160

<210> 81  
<211> 731  
<212> DNA  
<213> Homo sapiens

<400> 81  
gcagacagcc cggcgaacctg cgcaatgcgc tttcttctgc ctgcagcaga gaaaaggaaa 60  
gaaaactccg caggggctcc gttggctct ccacgagtga caaccatgtt ttcccattgtat 120  
agacagacccg gagccctgtc ccttgcgtat ccgcggagggt ctgcagagag catcctcata 180  
catttggcca cccctgcaca ggaagagccc gggccatccc ctttccggga cgtggatcct 240  
ctaagaggtg aattttcttc ggtggattcc gatttgcctt gtctgaccag cctaggcaat 300  
ccagcaatcg cggtggtaa ccaagttgcc gtttggcac acatggcttc acggccggctc 360  
cgccctcacca gcaagcggca ttccccagagg agaaaaatgag acactgagtg ggactcagg 420  
attgctccag gccacacagt cagcaggagg caaagccccag attcaatgc agattactca 480  
gctccacaat ccacatctc acaggaggct gcactcttgc cccaaaggcgtc agacaggagc 540  
aaagagaaag aaggcaacca gctggctact ttcttccctt cttggatgcc tccaacagg 600  
tgagaaggac taaacaaatg accaagtgtc atcccattttt ggacatactt aaaacacccc 660  
atgaaatttt tattctgact ttcttctgcc tttgtggcat ttatgtttaa ataaaaagaga 720  
attcaactcg t 731

<210> 82  
<211> 666  
<212> DNA  
<213> Homo sapiens

<400> 82  
cagtgttagca ctgttaattttt tttcattttct tgactaatta ttcaagccct tgataaacaa 60  
tggttatggg atgacttacg tgttagcttc aagttctaaa taatgttaag tttagcagat 120  
aaggcagttt atcacagtgt ccgttcactc agacagcata agtatgttt gataaaataa 180  
tcttaataac aagaacttta gtaaaagaaat aagccacttc attaacattt gaaaatagtt 240  
ttaagatata aagtatgaaa ggaattttac agtgtataca ttttctgact ttccaatttt 300  
caattataaa tttttatgtt caatcttatt ttgaaaacccc cggagtttc aaatattctg 360  
catttatgtt gaccattttt ccaagatgtat aaaacatgca ttattttctg ccattttata 420  
atttttacag gggggaaacag cgaagccaga tgatttttata gttattgcgg gtgaaaatac 480  
agagatccctt tgaaacattt gtctcttca gaattctcat caaaccatat gttctaaaca 540  
cagcacttaa cagtcatggg gagtatgtgg gaataacaga gactcgcttc cttggccaaa 600  
accacacata gacccacaca cttgaaaaat aaggaaataa gatcatctga gtatggagat 660  
tcctca 666

<210> 83  
<211> 673  
<212> DNA  
<213> Homo sapiens

<400> 83  
cagtgttagca ctgttaattttt tttcattttct tgactaatta ttcaagccct tgataaacaa 60  
tggttatggg atgacttacg tgttagcttc aagttctaaa taatgttaag tttagcagat 120

aaggcagttt atcacagtgt ccgttcactc agacagcata agtatgtgtt gataaaataa 180  
 tcctaaatac aagaactta gtaaagaaaat aagccacttc attaacattt taaaatagtt 240  
 ttaagatata aagtatgaaa ggaattttac agtgtataca ttttctgact ttccaatttag 300  
 caattataaa tttttatgttga caatcttatt ttgaaaaccc cggagtttc aaatattctg 360  
 catttatgtt gaccattta ccaagatgt aaaacatgca ttattttctc cattttataa 420  
 tttttacagg gggAACAGCG aagccagatg atttattatgt tattgccgt gaaaatacag 480  
 agatccttg aaacatttg ctctcctaga attctcatca aaccatatgc ttctaaca 540  
 gcaacttaaca gtcatgggg gtagtgggataa acagaga ctcgcttccc tgccaaaacc 600  
 acacatagac ccacacactt gaaaaataaag gaaataagat catctgagta tggagattcc 660  
 tcaaaaatta aaa 673

<210> 84  
<211> 488  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (392) .. (435)  
<223> a, c, g or t

<400> 84  
cctgtgaaaa tgtataatgt gtaggttatac ctaaaggcat gagccaccgt gcccgccaa 60  
gaaaaggaca tccttttcta atttaaacag aagcagcgaa gtcctagtgg tagccctgat 120  
tagcaatatg gaaaatttcc aagtacatta ttgcttgcgt cataccctac agaaggaaag 180  
aagaatgaga gaggcatata ttagagatgt gtaactgcct attgttaag gatagaataa 240  
taaatactca tccttagtat ttactaaaga tgaagggtc caggacttaa gtggcggcag 300  
tctgtgttaa tggtaaggcg gcacatcgcc tcgtcagtca gatggcctct ctcttctct 360  
aactggtcac cttatgcac ctgttgcac cnnnnnnnnn nnnnnnnnnn nnnnnnnnnnn 420  
nnnnnnnnnn nnnnnntgttag ggtggcaagg ttatacatat tataaggta tgcatttgc 480  
tgtaatct 488

<210> 85  
<211> 368  
<212> DNA  
<213> Homo sapiens

<400> 85  
ctttatatgg ttctgattta tgagaaaaca cataccaaat ttgtatgacc attattaact 60  
attattgtct atgctgcctt ttcatcctt agaaacaacc taaaaatctt ggactgtatt 120  
ttttaaatg ctaaagttagg attcagaaaa cagatttttgc tcatattgtc ttgaaaacct 180  
cattataaaat cattagctt ttgcctact tactttcagg ttgcctaa agagcacaag 240  
agataatata tatgaaaatgt atttataactt ttgttaagag ttgtgtcag tgcataatga 300  
tattacagcc tttgcctga ctcagcttgg caatctagtc tgtaacttc actctaagta 360  
ataatatt 368

<210> 86  
<211> 133  
<212> DNA  
<213> Homo sapiens

<400> 86  
gttacagcat tattaaacag tgaaatgttg ttctttatataaattgtgt ctgcctgtct 60  
ctatagtgca tatacataga ctttgcacc acagaatttt tgctattcga aacttttattt 120  
gaaaagttt ctt 133

<210> 87

<211> 626  
 <212> DNA  
 <213> Homo sapiens

<400> 87  
 gaccgctcta attaaatatt ttaaggttac agcattattt aacagtaaaa tgggtttctt 60  
 tatattaaat tgtgtcttcc tgtctctata gtgcataatac atagaccttg tgaccacaga 120  
 attttgcata ttcgaaaactt ttattgaaaa gttttcttag cctaggcaac acagcgagac 180  
 ctatgtctcta caaaaagatt tagccggca tgggtgtcata tgcctgtacg ttcagcttct 240  
 tgggaggctg aggcaggagg gtcacttgag cccgggagtt tgaggcacag tgagctgtaa 300  
 tcataccatt gcatggtgca ctccctctgg gtacctgtat agaccgtgtc tctaaaataa 360  
 gaaaataaaaa taaagggtgt gggatttgtt ttttcagtag gcaggcggtt cacggaatat 420  
 gggacatcag tgtgcaatct aagtttctag gttttcttt ttaggtttc taaaaaaaaag 480  
 atgttccctc aagtaactct taatagaact aatagtactc tcaattgttt ttttcttaca 540  
 gggctatata ttacgtgcct aacagtagct ctgggatttt atcgctgtg gatctaataa 600  
 agtgtctatt taaagtgtaa taaaaaa . 626

<210> 88  
 <211> 380  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> (372)  
 <223> a, c, g or t

<400> 88  
 tgtggccaca tcagtaagtc ctgtccgata ggatataatgc aaaagtgtca actatccact 60  
 tcctatgtatc tccttaaaaag atagtgtatg cctttgcctt tccttcttcat cctctctcta 120  
 gttgctgcct aaatatgggc atggggccg gagctccac tgcctggAAC cctgaggaca 180  
 agggctgcatt cctacttaggg aggcagagct atgagctaga cgcaatgtgg cccctggggg 240  
 ctctttgcag aacagccact atcccagccc ttctagatgg ggaaagcgag gccctgagaa 300  
 gtatgagaa tcagtgccaa agtcagatgt accacttcag tcacacactc acatttttt 360  
 gctttgttcc tntttttttt 380

<210> 89  
 <211> 493  
 <212> DNA  
 <213> Homo sapiens

<400> 89  
 ttctggacct ccatgttaaa ttcttggttt gaggcaggga aagataaaaa cttacttgca 60  
 gtgttagttatgttagagaga gaaaacagtg gctgttagtta ggaacaagtg aatgttaaca 120  
 agtttgcattc tcagggccat tggtaaaaca acttcttaac tggccagggt ccagcacgtt 180  
 aatcattaac ctatggctga gcatctgtg cctgtatgtat ccagaatttag tttatcatta 240  
 cctctaacga ccatctttt tgggtccgaa gagcctctat gcagttctt atcaccggca 300  
 tggctaatct tcatttacgg ggagcagtgt gctgtatgtt ctttagtttccagatgtaa 360  
 aattttatgg tcagttatgt aatttttaat tataactgtt taaaaagaag acgtatgtacta 420  
 tgaacacgacatctcgta gcaatctttt gacagtactt cgaagtgacc cactttccca 480  
 tttaactctt ggg . 493

<210> 90  
 <211> 1119  
 <212> DNA  
 <213> Homo sapiens

<400> 90

ttctggacct ccatgttaaa ttcttggtt gaggcaggga aagataaaaa cttacttgca 60  
 gttagttag ttagagaga gaaaacagtg gctgttagta ggaacaagtg aatgttaaca 120  
 agtttgcctc tcaggggcat tggttaaaca acttcttaac tggccagggt ccagcacgtt 180  
 aatcatttaac ctatggctga gcacatcgctg cctgtatgtat ccagaattag ttatcatta 240  
 cctctaaca ga ccatcttta tggttccgaa gagcctctat gcagtcctt atcaccgcca 300  
 tgcctaatac tcatttaccg ggagcagtgt gctgtatgtt cttagttaga ccagagtaag 360  
 aagtttatgg tcagttgatg aattttaaata tataactgtt taaaagaag acgtgacta 420  
 tgaacagcag ctcactcgta gcaatcttg gacagtactt cgaagtgacc cacttcccc 480  
 tttacttctt gggaaaggctg ggttgcctg ttttcgactt tggaggtccg tgggcttagat 540  
 tcagagtgcc ctggcaggct ggcttgggt tgaggctgt gctgcagcct ccgcaacacc 600  
 ctatctcgc acctggaaac tggcccttgg taccggattt tttctctt gtgtgtgtgt 660  
 gtaaatcatt ttcatttttt ctaatgatca aagtatacat taaaataaaat gaaagcaata 720  
 caagtccatg ttagtggtag aaaatctgaa caataactaaa aatgtacaga aatggctttt 780  
 aaagatttaat ttcaaccta taaactaagc tactttcat tttagtgtct tttttaaaac 840  
 agcttttaaa aacattttaa aggctcattt atgttcaaga atgagggat gtttggctac 900  
 aaggccttca gtatgactt atccatagc tggaggtttt ataattcaatt atattaaagc 960  
 tttctaaac ctccagaagg gtttgcctgg gtcttattta ctataacagg caagttaaag 1020  
 aaacttgagt ttaatttata ttcaatttttca cttttttag acaacaagtg caatttgggc 1080  
 ttatattatg gaaggagaga gtttgccttc tccccggaa 1119

<210> 91  
 <211> 455  
 <212> DNA  
 <213> Homo sapiens

<400> 91  
 gcaactccagc ctgggcgtcg ataaatggca ataaggagg cgtgcctgcc gcaagggttt 60  
 ttagtggaaagct ataagaacac actccctaca aatttatacc gacacaccac agacttagag 120  
 gaaaagggttt cccaggccct tcccaaggcc ctgaaggtaa ctttctaaagc caaacagacg 180  
 ggacatgtgg atggaaaggc cacttctcaa agaaaagtctg aagcaagctc agggaaacttc 240  
 tggagcttcc tggagctgca cgaaaagctg tggatatgtg gcccctatgac gtgggtctct 300  
 gaacttgcattt agacttgcac tatggcacaa aaattgcaga tggaaaagag gaaaccacag 360  
 ctttcacgct aatgaacagt gtttcttaca aagagttacc tggcttctag atctgtgatc 420  
 atgaatttcca gtaaaggcaa aaaaaaaaaa aaggg 455

<210> 92  
 <211> 891  
 <212> DNA  
 <213> Homo sapiens

<400> 92  
 gaagtcttattt atagcaattt gtttgcctta aatatgtat ttatattat ggccttatac 60  
 catccttattt ttgcaactaa cttttcattt aatattatat gcaagacattt totattcctg 120  
 taagtatagc tctgcctgca cagaattgtt ggattaatgt ttagatgtttt aatgtcagt 180  
 ggtatgtgcga gaatttgcctt catcaattca ccctccataa aaggacccat ttctccaaac 240  
 ccttgcacac agtaagtggt atcaatatcg atagggtt tttttttttt ttaaccagtc 300  
 tctgtatttgc aagtacccctt ttttcaatttgc aatttcccttgc attacgtaca aatcaaaaca 360  
 ttccatgtt tattggccat tttagatctt ctaccgtaca ttgccttataa gtgttatgtt 420  
 ggccttagttt tccctgtgggt tttttatctt ttaggattgc tccccctaaac aaaaaacaaaa 480  
 aggcaattttt tcccaatgtatc aacaaatattt cttttctcca ccagttaaa atgtcagctt 540  
 tcaactcatac acatgtcaag ttgtctattt ctgtcctgtg gatccaggtt tgggttctac 600  
 caaccacactt cctcacgttgc tcatttgggtg ctggcatgt tggtttgcctt ttcattggca 660  
 agttccctttt cctttctccc ccttcttgcgt gtcttataact tgggttgcctt ctgttccagc 720  
 tgaatcaaga attatgtttt taaatcccg taaaattgtt gttttttttt gactaggattt 780  
 gcatattttt acacattaaat ttgagaataa tagacctttt tataattaaat ataatgtttc 840  
 tgatttagtgc tatgatagc ctcattttat taaagtctttt tataatttttgc g 891

<210> 93

<211> 278  
<212> DNA  
<213> Homo sapiens

<400> 93  
aatatccaaa tccatgttga accagtattt ttgaagattt accttcagga taaactaata 60  
gcacaatctt catgcccttt cattcataac taactgaaaa ggttacttt tgtaccagga 120  
acccaacgaa gaaaacttgt atcttgcag gggtggtaac ctggctgcca ttgactgaga 180  
ccaaaatatac ccaacagttt gtcctcagct gctaagctgc tgtggtaga atcaaacgta 240  
gagtttctgg cctggcgcc tggctcatgc ctgtaatc 278

<210> 94  
<211> 274  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (95)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (194)  
<223> a, c, g or t

<400> 94  
gattaccaga ttttattttt aaaattttag caatatcggtt cttaatatta gccaatacac 60  
tgcctatggc tgcagcacca ttttccctg cacancccct gtagagacct gcctgggtct 120  
cagaagaaga aagatngaat ttgtgttcc caggaaatgc tgcacattgt ccatttacca 180  
gcatcttata gaanatataaa atatgaatct acaaattctc ttggatttaa taatgttaact 240  
tatattttatc ataagggtggc tattccagat catg 274

<210> 95  
<211> 130  
<212> DNA  
<213> Homo sapiens

<400> 95  
cagataccac tctagggtgat gactgccagt ctgtgcttac agcccaaacc tcctcctgagc 60  
accaacccat atgcccacgg tgcagagaca gcacaaccca gtgtcaagga gcctggcttt 120  
taagagtcat 130

<210> 96  
<211> 1100  
<212> DNA  
<213> Homo sapiens

<400> 96  
gtggccactg cccttggaat gaataataat cacactgaca tacaactaag aagttatgg 60  
atacattagg aatgctgagg gcacatggaa aacagtgacc cattctacct agtgggggttt 120  
taaaatactt attttaatg tttaatgct taggaaagaa agcaggaga taaaacatga 180  
aagatgaaca ggaaatggta ggagatttt atgaaggtag aagagacagg gctttggaa 240  
tgatataccc caggttaact cccagattc tggcttaggc aactgagtgg caccactgtc 300  
agagctaga aatacaggct tgaaaggaga gatgctaagt gtagctttgt tgctctttg 360  
ataaaatatgc gacctgcaacg tggagctatc caggaataac aagtcaaaag accaagtcc 420  
tcttggagat ttccctcttag ccatatatgg tttccctttt tttttttttt 480  
ttgagacaaa gtctctctgt cgccccaggct ggagtgtatgc aatggcacaa tcacagotca 540

cgggagctc gacttcctgg gctcagggtga tcctcctacc tcagcctcct gaatagctgg 600  
 gacaggtgcg caccaccaca tctagctact ttttgtattt ttttagagg tggggctcg 660  
 ctatgtgcc caggcagctc ttcaactcct gaggctcagg tgatctgccc gcctcggcct 720  
 cccaaagtac tgggatcacca ggcacaagcc actgctcctg gccatatatg gtgttattta 780  
 atcctcaca caaccctatt attatgcctc cctttaacag ctgagggaaac tgaggcacag 840  
 agaaaattaca taacctgccc aagattacat gactcttaaa agccaggctc cttgacactg 900  
 gtttgcgtg tctctgcacc gtggcatat gggttggtgc tcaggagagg ttgggctgt 960  
 aagcacagac tggcagtcac cacttagt ggtatctgaa gcctcaagag gagacaagat 1020  
 cacatggAAC gccacggaca gaaccatgtg gaggcaccatt ctcatctagg taggagtccg 1080  
 caaaaaggt taaaaagaaa 1100

<210> 97  
 <211> 591  
 <212> DNA  
 <213> Homo sapiens

<400> 97  
 cgatgtttt gatatgtttt ctagttataa attaaataac tatagtttac cagtttttgt 60  
 ttgttatgtc actctttcc ctcatcatat gatattttaa aaatctagtt cagttttct 120  
 gatatatgtat ccaaataatgtat ttaatattat taatgtgtt gaaataaac acataatacac 180  
 cttagcacac agtatacaca ctaaaagtat taatattgtt agtgtgtata tttctataaaa 240  
 cactaataat atagaataat acacactaat aatattaata ttatattttt atttttgcct 300  
 cttcattttt tggtgatcat caactcatcc tttagttactt ccaccatcat cacaatctt 360  
 ttaatattac taaaccctta ctttccttgg ttataaatta aaattaaaca caacttttgt 420  
 ctctagagat gcagatatac tctgtgaagc tgctttgtat gcagtgttgc tgaatttcct 480  
 ctgttgggtt caggtttggg taaatttctt tcagttttt tactctagtt cctactacca 540  
 atttataatgtt agcttaggac ttggacacca gaatctaagt ctatgagaaa t 591

<210> 98  
 <211> 1550  
 <212> DNA  
 <213> Homo sapiens

<400> 98  
 gatcttacat ggcttatttg taacctgcag tattgaccat tgcccocttat aatttataagg 60  
 taaaattctgt tgatcagcat ttttaacagc tcaatcgatg ttttgcataat gtttgcgtat 120  
 tataaaattaa ataactatta gttatccagt ttttagtttgc tatgotactc tcttcctca 180  
 tcataatgata ttttaaaaat ctagttcagt gtttgcataat tatgatccaa atagtttataa 240  
 tatttataat gtgttgaat aaacacacta atacacctta gcacacagta tacacactaa 300  
 aagtattaaat attgttcagt gtgtatattt ctataaacaac tcaataatata agaaatatac 360  
 acactaataa tattatattt attttattat ttttgcctt tcattttttt tgatcatca 420  
 actcatacctt agttaccc accatcatca caaatctttt aatattacta aacccttacc 480  
 ttccttgcgtt ataaatataa attaaacaca actttgtctc tagagatgca gatatagtct 540  
 tgtgaagctg ctttgatggc catgtgattt tgaacattttc tctgttttttgc tcaaggtttgg 600  
 gtaaaatttctt ttcaagtttt ttactctgtat tcctactacc aatttataatgt tagcttagga 660  
 cttggacacc agaatctaaat ttctatagag aatggactg agtctgtctt gttcacagct 720  
 agatcttgcgtt cacccttgcgtt gatgcaatgtt agttggactt cagtagatgtt 780  
 ttgttgaatg aaaaatgtcc aaatcaaaga aaccacagtc tgatccccat atattcttat 840  
 atacaaaattt gtacattata cttaatatac agaagtgtat attaaaccta aatgttctaa 900  
 tactatttt acatctacaa cataaaaaaaat aataatgttag gctcaaatat cagataaaatc 960  
 taggttgcataat ttgtggctc atcattttact taaagtgtt tcttggcat attagtaggc 1020  
 attctaaatgtt tcagttccctt ctcttgcataat attactacat ggaatttgcata 1080  
 tgggagatta atacaaaataa agctcatgtt actgtggctg tctaaatttt tagctgtcat 1140  
 tattctaaaca gtttactacta tccttattctc aactgtttt aatagatatac ttgttgcgtt 1200  
 ttaactttat gtccattttt ctgttactc ttatgagcca cagagtctgg aatccagcct 1260  
 tgggtctctc agaactattt atttctatgtt ttcttgcgtt aacaattttc tgcttttagaa 1320  
 aatctgcattc agtcttcttc ttacagatt ttcccttctt attgtaaaga tctttatcc 1380  
 atggaaatataa ttacaaatataa atgatataatg gactggctc gatgtaaataa ttccagcagct 1440  
 gaactaaggc tgcattttat agcaccacata taatgttgcattt caggtacac acaatgggtt 1500

ctttgctct gctgcagatg atagctctt acctttcggt gttttccat 1550

<210> 99  
<211> 535  
<212> DNA  
<213> Homo sapiens

<400> 99  
tatccaaat atcatctcac tttatatttt attcatgtaa actaagttc taaaagtggaa 60  
attttagaat ttcccttcgt cttctgaaaa cacttcgtg gctttcatt ggcccaaact 120  
tttgggggt agtattcaaa agttcatga tttggccctc atttgccctt ctgatgtcat 180  
catatgtcac tctctcccat atacttaat gcaagtttg tgatctctga gtacatgtca 240  
aacttctact ttaactccac ttgtcattt tggttatgaag actggaagcc ttccctttcc 300  
ccaggcttgg gtgaagccaa gtgtttaca tacctggaat gtcttgcata cagtaatttt 360  
cagtttagttt gtaattgtct atttaattaa cttagcccc tcactagatg tgagtacttt 420  
gaaggcagta atttttttt aacaatgggt gcttaacatt caataatgc ttgttagattg 480  
tggtagttt atatattttt gcagttttt aatgtttat tttgaaactg gagat 535

<210> 100  
<211> 493  
<212> DNA  
<213> Homo sapiens

<400> 100  
acatcccttt gctacacttt tcatgctcat gtttacttg gtgtgtgatt tcctttctgc 60  
ttcttacta aaccgtggac ttcttgaggg cagaggctag atcttgtca tccttggagc 120  
catagtcctcc attagtttga tgaatgatc cgtgaatgaa tgcttgaatg aatggagttgg 180  
aatgaaccct gtctccccag ttctatgtcc accttttattt cattctgtga ctttgggtag 240  
gacatttaac catgttaat aagaatcatc acaactgttt gccttctca catactggtt 300  
tcaaaatcaa taaagtattt aaggcaatgc ttaaaaacc atacagcaact gtacaaatat 360  
gctatcccat ggttaagtag aatttagtgg gaaaattgtt accataaca ttgtattgca 420  
atgattttat ctaatagaaa attaatctt cctggcaca gtggcattca cacctgtaaa 480  
tcccagcact tcg 493

<210> 101  
<211> 843  
<212> DNA  
<213> Homo sapiens

<400> 101  
ggccgaaata caatttaatt aaaatactta ttttcttattt agaaagctgc ctctcaatgg 60  
cacctactgc tacatttaca tagtaaccca aaattgcagt tgcttagcag ggagagaatc 120  
acagtgtgg atattattta tacttttct tccaaaacga tttgaggaag tactgtgctg 180  
gccattgttt acatcatattt aggagatctg gatgtcactt tctttccca tattctcgat 240  
ttcctcactt tttaaaatgtt catgtgtttt tgtaagttttt cttaaattctt ttggaaatgt 300  
gatgacgggtg aaaaatccctt gaaggcttctt atacacctgt tggcatggaa tattttgca 360  
cccgtttctt ccctacaaac agaagagaca actaaatacg gtttgcata catctgcaag 420  
agccctggcca ttctgtttaaaaatgtg gcccgggtt acggtaacc acctgaagac 480  
ctatggccctt tccttcacac tccctacttc tgcatttctt ccctcctgaa cgtctatcaa 540  
gtggaccata tgaaattggcc agtattcaac tgttttttat cttaaagggt gacaattcta 600  
tatcattcaa cttaaattaa tgcctcaaga acataacctt tgtttcttattt attggtgacct 660  
tacttttaac catccttagag ctcttaacc tggttcacact ggatttcaag gatcttaagt 720  
tggtagtttatacatc ttttttttttcaaaaaatag taataaataa cctcaagccaa 840  
tta 843

<210> 102

<211> 1101  
<212> DNA  
<213> Homo sapiens

<400> 102  
gcacgagggt ctcggctcac tgcaacctcc gcctccggc ttcaagtat tctcctgcct 60  
cagcctcccc agtagctggg atcacgtac gcccggcagc atgcctggct aagtttgtt 120  
tttttagtaa agacagggtt tcaccatgtt ggccaggctg gtcttgaact gctgaccttg 180  
tgatccgccc gcctctgcct cctaaaagtgc tgggattaca ggcatgagcc cggccgaaat 240  
acaatattaat taaaatactt atttcttat tagaaagctg cctctaattt gCACCTACTG 300  
ctacatttac atagtaaccc aaaattgcag ttgcttagca gggagagaat cacagtgtcg 360  
gatattattt atacttttc ttccaaaacg atttgaggaa gtactgtctt ggcattgtt 420  
tacatcatat taggagatct ggatgtcact ttctttccc atatctcga ttccctcact 480  
ttttaaatg tcatgtgtt ttgttaagtt tcttaaatcc tttggaaatg tgatgacgg 540  
gaaaaatccc tgaaggcttc tatacacctg ttggcatgga atatttgc acccgtttct 600  
tccctacaaa cagaagagac aactaaatac ggtttgcattt acatctgca gaggcttagcc 660  
attcagtatt aaaaagtat ggcctgggtt gacggtagcca cacctgaaga cctatgcctt 720  
ttcccttcaca ctccctactt ctgcatttctt tccctcctg acgtctatca atggaccat 780  
atggaaattgc cagtattcaa ctgtttttt tcttaaaaagg tgacaattctt atatcattca 840  
acctaaatattt atgtctcaag aacataaacct ttgtttctat tatttgtacc ttactttttaa 900  
ccatccttaga gctcttttac ctgttcacac tggatttcaa ggatcttaag ttgttctact 960  
acataatcac tatcacactt cagaaacattt ttagtttaca taaaatacac ttaacccctt 1020  
catatttcat ctcttcctttt ctccaaaata gtaataaata acctcaagcc aaaaaaaaaaa 1080  
aaaaaaaaaaa aaatatgcgg c 1101

<210> 103  
<211> 176  
<212> DNA  
<213> Homo sapiens

<400> 103  
ggtaacaga gtgagactcc gtctcaagag aaaaggaatt ttcttattttt aaaaataata 60  
ttctgttgta tatactacc acattgtctt catttactca ttagatgtt aactgtttat 120  
tctgttattttt ggctattgtt aaaaagtgtt caaacagaat tgcaaatgtt tcttca 176

<210> 104  
<211> 1689  
<212> DNA  
<213> Homo sapiens

<400> 104  
ccgctcattt tttttttttt tttttttttt tttttttttt aaacaaacaa aatttattaa 60  
actttcaaaa tacaaaaca tcataaaaaa gtcatagcat ttctatacat tagtaactat 120  
ctcaaaaatga aattcaaaa aattccatct acctaactat agtttgaagt aaatttaacc 180  
aaaaaggtaa aacacccatc attctactctt aaagaacattt atacaatattt agtaacacat 240  
aaatggataa atattactca ttcatgaactt ggcatttttta atagttaaatt atttgttattt 300  
cacaatgtt tctgcagata taatgcaccc tctatcaaaa taccagtgtac atacttcata 360  
gacatttttta aaaaagcatat cttaaaatttca tatgttacca caaaacaccc taaatagcc 420  
aagcaatcaa gacaaaagaa ggtatccccc tgactttgaa atacactaca aactgtgg 480  
aaccaaaaca gtatgtact tgaataaaaa cagatata ggcataatggg gcagaagaaa 540  
aagagagcag aatataatca gtgttatttac agttaacttga ttttaataac aggtgactttt 600  
ttttttttaa gggaaataac agtatcttca ataaatgtt ttttagaaaaac ttatgttcca 660  
catgcagaga aaaaaaaatgtt agacccctcat ctcacccat atgtaaaaat aactcaaaa 720  
taaatttagcc acttaaatgtt aaggccatca actctttaac tactactacc aaaaaataga 780  
gtgaaagccc cataacattt gtcggcag caagttttt gatttaaccc taaaatccca 840  
ggacacaaaaa ggaagaacaa gtcagtcaga tcaatttcaaaa taaaatgtt gctgcacaga 900  
atctgtatca tgaacagaat gtgacaaacta aaaaaaggaa gaaaatattt gcaaaattata 960  
catgtgacaa ggggttataa taaaaatata atacaaaact caaatgacaa tacaacaaaa 1020  
ataagtaact attaaaaata agtagctgaa ataagtattt ttcaagaaaa tacatacata 1080

atggccaaact gatataattta aaaatgctca atgtcaatta tcacaaaaag gcaaggccaa 1140  
 aaagaaaaaaa caaaaactagg agatatcaac tcattcctgt tagaatgact ctattaaaa 1200  
 agaaaaagcg ttggtaaaga tgtgaagaaa agggaaaggct tgcacactgt tggtttggaa 1260  
 tgtaaatgaa gacagccatt ataaaaaca aaatagagat ttctaaaaaa acttaaacta 1320  
 ccatgtcata acagcaattt cactactgga tatatatcca aaacaaataa aatcagaatg 1380  
 aagaaacatt tgcaattctg tttatagcac ttttcacaat agccaaaata cagaataaac 1440  
 agtttaacat ctaatgagta aatgaagaca atgtggtaga tatacacaac agaatattat 1500  
 ttttaaaaata agaaaattcc tttctcttg agacggagtc tcactctgtt acccaggctg 1560  
 gatgcagtgg cacaactcga gttcactgca acctctgcat ccctggctca agggattctc 1620  
 atgcctcagc ctctggagta gctgggatta cagggatgca ctaccatgcc catgcccagc 1680  
 tgagatttt 1689

<210> 105  
<211> 768  
<212> DNA  
<213> Homo sapiens

<400> 105  
aaaaaattaa aagcttctag agacttctgg tttctacttc cacacataag gaacttggaa 60  
atggccacte catcctatca acaagtaaaa agctaaatgg actaaaaat caacaactct 120  
tataagacgg aaagtcaactg agtcatgatgc tgcctcccaa cttggagaat acagggagtc 180  
acatctctcc agagtggaga ttcatgagaa gaaacacccaa tgagaaaaag aaatggagta 240  
tggaaacctga actctaatttgc atgaatttct ggagaataag tgaggacaag actgagaatt 300  
aaacattccaa gaaaaactaa ctctataaggg gaaacttcata atatttgag attcacccctc 360  
acaaatttga ccatttcca cagcaaatat cagagaaaaa ttaacttgcatttcaggag 420  
agaaaaggaa aaagaaacctt ctttgcataa taccacagag ctcttattctt cttatcaagg 480  
ccgtccctca gaagaaacga attaaccaaa actatcatca gggcttaatt gacctgggaa 540  
agagaaatgc ttgtctctg ctccactagt tttctacctg tgagaaggca aatacacaac 600  
tcagccccac tctagtcattt ttgtcctacc aaagcgggag aacaaaacag aacaacactt 660  
gtttaagttga caatccagac gcataactc actaaaaagc tgagatgtaa tcattaaact 720  
aaaatcccttc ccctgcact acaccatatt actaaaggcc tattttaga 768

<210> 106  
<211> 612  
<212> DNA  
<213> Homo sapiens

<400> 106  
ggaaatttca gacaacctag cctagactaa atggtggca gcacctggca gacaagaact 60  
caagaacctt ttctcagggtg gctctgcttt gctgcaggta atggagaagc actggagatt 120  
tgtaaaggccac ggagtcaaattt ggtggactgg gattttcagg agatcatttta gagagcaaga 180  
tcttacccaa tccttttagtc atggtctatt tcgttgcact catatggttt ttactgcggaa 240  
ggtaagaaac taatgactgc agcaggaaaa agaattggat gtgtcatgaa ttatggccct 300  
gcttatactt ctacttcaac cgtaatcatt tggtaaaca aaaagttctg catttgaatt 360  
gtcacaattt gttgtgtgtt ataaacatct cataatttcat ccaggctcag ccaacacttg 420  
cctttatcaa tgctcataat caagaaataa atctcataact aacccaaaat tatttcattt 480  
aagagaatat aaacagaatg ctgtttca aacttactaa ttaacacctc tatttcattt 540  
tatcaactaa cattttgtt tcgtttaaaa ataaaataaaa ctttatgaca tgctataataat 600  
ttatTTaaaa aa 612

<210> 107  
<211> 628  
<212> DNA  
<213> Homo sapiens

<400> 107  
aaatttatttg caaacacttt ttagctgaac cctctcattt cacagtggag ccttttaatg 60  
tttccttgc agaactcaag aacctttct caggtggctc tgcttgctg caggtaatgg 120

agaagcactg gagatttcta agccacggag tcaaattgggt gactgggatt ttcaggagat 180  
 catttagaga gcaagatctt accaaatcctt ttagtcatgg tctatttcgt tgcaactcata 240  
 tggtgttac tgcaaggtg aagaactaat gactgcagca ggaaaaaagaa ttggatgtgt 300  
 catgaattat ggccctgcctt atacttctac ttcaaccgtt atcatttttt taaacaaaaaa 360  
 gttctgcatt tgaatttgcata caattgtgtg tggatgtataa acatctcata tttcatccag 420  
 gctcagccaa cacttgcctt tattaatgtc cataatcaag aaataaaatct cactaacc 480  
 aaaaattatc cttcataaga gaatataaac agaagtctgg ttcataaaact tactaattaa 540  
 cacctctatt ctcatgtatc aactaacatt ttgtttcgat cttaaaataa ataaaaactttt 600  
 atgacatgtc aataatttat ttaaaaaaa 628

<210> 108  
 <211> 103  
 <212> DNA  
 <213> Homo sapiens

<400> 108  
 cttagaccacg ttgtggaaat gtctcacaac attgatctac taggcaagga ttttgaggt 60  
 cagaccgcaa aaaccacagg gcaacccaaag gccaaagtta gac 103

<210> 109  
 <211> 348  
 <212> DNA  
 <213> Homo sapiens

<400> 109  
 gtaatccctt gtaatccccc gtctccagac ggcagtggcc agagtggacg tggggcctg 60  
 agctgtggcc tgggctgtgt ctggaggctg ggattttggcc tccggctctg tcccgcccc 120  
 gatgctggtc ctttccactc tggtcagggtc agtgaataga gcacccagga aatgggtgct 180  
 gcggtcatag ttgtggctgt gtgtttaat aacactgtcg tggtactgtt atgagagagt 240  
 gtggtgagag catctgtccc agcotagcag gccacagact ttctagaggg gcagtagagg 300  
 tagaaacaac tcaggattct gagagtccctc aagtccatcc tggccctg 348

<210> 110  
 <211> 616  
 <212> DNA  
 <213> Homo sapiens

<400> 110  
 cgaggctggc ggtgcgcgtgc ttccctcagag ccgttccctc agagccggct gccccggcc 60  
 cgggcgggaa ccacggagcc cagtgcacca gctctctgg tgctaccggcg ggacacagag 120  
 gaaacaggaa cagctggttt ctgtggcag gccccgggct ggaactagag ccagggtgcg 180  
 gccggcgggg gacaggaaaa gagatcacag cgaagaccca gaagaaacaa aaggcaagcg 240  
 aatattttt tatccaactg cctactggac accaaccacg tggacaagtc ctgggtgcct 300  
 caaactcaac atgttcaaag ctgaatacat cacctgctct cccaaatatg ctccctctcct 360  
 gctgttccca aaatcagaaa atggcttcac gatcagctca gtcatctcaa gagcaaatgc 420  
 tgagagtac ccttgaatcc ttctgtgcc tccacattca aaccatcacc atatccttga 480  
 ttctctact gtatattttt catatgtgtc cacttcttcc catctgcact ctcatttagtg 540  
 aaggccacca acatctctca tctgaatgcc tgcaataacct cctcacaggt caccaggcat 600  
 ctatgttgc ccctgt 616

<210> 111  
 <211> 1049  
 <212> DNA  
 <213> Homo sapiens

<400> 111  
 atgagctccc gagcttgggt tcctgaagtg gattatgctg gaggaacaca ggtagaagca 60

gaagtaacaa aggagagaag gagactgccc tactgcccta taccaggaag gaataaagcc 120  
 aaaaaaacag aattctccaa gtgtcaagca aaaacacata ctttgcacac gtttctcgag 180  
 gtccagcccc aaagcctcg cccctggcg tccctgcttc ggccccaga ggggggcagg 240  
 cctcgctcct ccctccgcca gcctgcccc ggaggcctcg acccgccgag gtgaccgc 300  
 ccagggtcgc cggcgcgagg acgaggctgg cggtgcgtc cttcctcaga gccgcttcct 360  
 cagagccggc tgccggccggc cccggcggga accacggagc ccagtgcacc agcctcctcg 420  
 gtgctaccgc gggacacaga gaaacagga acagctggtt tctgtggca ggccccggc 480  
 tggaaactaga gccagggtgc ggccggcggg ggacaggaa agagatcaca gcaagaccc 540  
 agaagaaaaca aaaggcaagc gaatatttt atatccaact gcctactgga caccaccc 600  
 gtggacaagt cctgggtgcc tcaaactcaa catgttcaaa gctgaataca tcacctgctc 660  
 tcccaaatat gtcctctcc tgctgttccc aaaatcagaa aatggcttca cgatcagctc 720  
 agtcatctca agagcaaatg ctgagagtca cccttgaatc cttctgtgc ctccacattc 780  
 aaaccatcac catacccttg atttctctac tgtatatttt tcataatgtgt coacttcttt 840  
 ccatctgcac ttcatttagt gaaggccacc aacatcttc atctgaatgc ctgcaatacc 900  
 tcctcacagg tcaccaggca tctagtttg cccctgtctt gccctccct catctagagt 960  
 gaaggcagta ggaacctcc aaaatgaaaa tctgattaag tcacttctt gottaaaact 1020  
 ttttatggt ttcacagccc atgaaaata 1049

<210> 112  
<211> 388  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (324) .. (364)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (364)  
<223> a, c, g or t

<400> 112  
 gtgaccttgc actccccctgg cctgaagctg cctctctcg cgctttctac tgggctcg 60  
 tctttccgga gccccagcgt ctccctgcccc aattcaccgc ggaaaggccc cggggccggag 120  
 gtgcgaccgg gggcgcccg cgcacaccc ttggccttct ctcacaggc ggtgcgtcg 180  
 ctctcccggt tccccggccg actgcccgtc agtccatggc tagacgcgc ggacaggact 240  
 gatggccggg cccggctggc cgagaaaggg acggaccaat acgtgtgtt cctccgtat 300  
 cagtcccggtc gcttccggca cctncggccc cccggccgtc gctaatgttt ttttggaaag 360  
 atcngtggaa ttttaagag agtattta 388

<210> 113  
<211> 756  
<212> DNA  
<213> Homo sapiens

<400> 113  
 gccccccggc caccggccgc tggcccccacgg caccacgggg ccggccgcgc gccggccgggc 60  
 cagctcagcc ctggccagccc agccacccgc gcccggccgg cggccggcgct gcattcgcgc 120  
 ctcgatctct gagagcccac cgcacggccgg tgcagacggc tgccggatg caggacgcgc 180  
 cgcacggccgc cccggctggc gcccggccgc cccggccgg cctggacccca caccctctgg 240  
 gccccccctc tggagccagg gcccgggtc cctctgtgt ttttcgttt cctaagctcc 300  
 tgcgtcttctt ctttgtcccc tcagttatg tccctctgtc ctcacccccc tgacctctgt 360  
 gaccttgcac tccccctggcc tgaagctgcc tctctgcgcg ctttctactg ggctcgctc 420  
 ttccggagc cccagcgctc cctggccaaa ttccggccgg aaaggccgg gggccggagg 480  
 gcgaccgggc gtcggcagcg cagacccctt ggccttcct cacaggccgg tgccgtcgct 540  
 ctcccggttc cccggccggac tgccgtgcag tccatggcta gacgcgcgg acaggactga 600  
 tggccggacc gcgctgccc agaaaggac ggaccaatac gtgtttcc tccgctatca 660

<210> 114  
<211> 918  
<212> DNA  
<213> *Homo sapiens*

<220>  
<221> unsure  
<222> (314)..(342)  
<223> a, c, g or t

```

<400> 114
cgccggcggac aggactgatg gcgggaccgc gctgcccgag aaaggacgg accaatacgt 60
gtgtttgctc cgcaaccct cttgaagct ttcagaagcc gcttgcgcg gggcccacta 120
ggcgccccggg gggttggac ccagcgggag cggggcgcg ctggctccac ggccctgtact 180
cggttacac cgccggcgaa cgccggaggg a g g c t g c g t t c c t c g t a t 240
gcctcgggca cctccgggca cccggcgctg gctaatgttt tggttgcggaa atcggtgaa 300
cttttaaga gagnnnnnnn nnnnnnnnnn nnnnnnnnnn nnttcaccgg gcaaccgggg 360
aagtattgtg gccttggagt ttgctaaatc caaatatgaa aatcaaaaagc ttttagtattc 420
ctcatcttc ctcttggaaag atttgcgtt gagttttgt tgccccttca aaaagctgtg 480
ttcagagttt ggagaatata tccaataaaaa gatggtttcg tctaccaatt ggggaagttt 540
caccccttc c t a t c t g a a g a a a a a a t c a a a a a t g t c c c c g g a t c 600
agtccctggag gcaggggagat cactgcctgc ctggcccacg ctgctggac ggctcgccct 660
ccctgcttt tgttttcaa acctccgtt tctccaccc tggaaaggag aaatgtgaaa 720
cccgccagcg gccgacctag ggggtctgt ggccggagc cgcccccggcc cgaaaaccat 780
agacctggtt gtactgttagc ttgttggttt ggggacccaa ttttctagag agaacttagag 840
cacttttgtt gtgtttttt gttttgtttt tgtttttgc cttgtcgatt cccgaataaa 900
ttttgtgttc cttttttt 918

```

```
<210> 115  
<211> 2753  
<212> DNA  
<213> Homo sapiens
```

```

<400> 115
tggggcggact ccccatggcc agagggctgag ctcccactcccc gcccggccgt cccttagggga 60
aggggaagga gaggggagag cagcgacagg cctccagcaa gcaaagcgcg ggccgcattcc 120
gcagtctcca gaagtttgag acttggccgt aagcgactc gtgcgccttca actctttgcc 180
gcgcgcagcgct ctggagcgga gaggcagaggg ggcggccgt cgccgcgcgg gctttgtcat 240
gatggccagtc taccggcagc ccgaggacgc ggcggggggcc ctgtctggccc cagagaccgg 300
tcgcacagtc aaggagccag aaggggccgc gccgagccca ggcggggggcc gtgggggtgg 360
cgccgggaca gccccggaga agccggaccg ggcgcagaag ccccccgtact cgtacgtggc 420
gctcatcgcc atggcgatcc gcgagagcgcc ggagaagagg ctcacgtgt cccggcatcta 480
ccagtagatc atcgcgaagt tcccggttcta cgagaagaat aagaagggtt ggcaaaatag 540
catccgcacae aacctcagcc tcaacgagtg ctgcattcaag gtgcgcgcgg agggcggcgg 600
cgagcgcaag ggcaactact ggacgctggc cccggctgtc gaagacatgt tcgagaagg 660
caactacccgg cgccggccggc gcatgaagag gcccctccgg cccggcgcccg cgcacttccca 720
gccccggcaagg gggcttctcg gggccggagg cggccgcaggc ggggtcgccgg tgggggggcgc 780
cgggggccgac ggctactggc accttggcgc ccccaagtac ctgcagttctg gtttcttccaa 840
caactctgtgg ccgcgtaccgc acccttcctc acccatggcc tatgccttct gccagatggc 900
ggcagccgcga gggctgtcag cagctggcc tgccagccgc ggcccccggta gcccctggcgc 960
ggccgctgtg gtcaagggc tggcggggcc gggccgttccg tacggggccgt acacacgcgt 1020
gcagagcatg ggcgttccccc cccggctgt gaaactctgtc aatggcctgg gaggccggcc 1080
ggccgcaccc cccgcctccgc cccacccccc cccgcattccg caacgcacacc atctgcaccc 1140
ggccgcgcga ccgcgcgttccgc cccacccccc ccacggggcc gccgcgcgcg cgccggggcca 1200
gctcagccct gccagcccaag ccacccggcc gccccccggcg cccgcgccttca ccagtgcgc 1260
ggccctgtcag ttcgttttgtc cccggcagcc cgagctgtcc atgatgcatt gctttaactg 1320

```

ggaccacgac agcaagacccg gcgcgctgca ttgcgcgcgc gatctctgag agcccaccgc 1380  
 atgcgggtgc atgacggatg cgaggatgca gggacgcgcg acgcggcccc cggtcgcagc 1440  
 cgaacgacgcc gcccgcagcc tgacctcaca ccctctgggc cgcgcctctgg agccagcgcc 1500  
 cagggtccct ctgtgcttt tgcgttccct aagctctgt cgctctctt tgtccctca 1560  
 gtttatgtcc tcctgtgctc acctccctga cctctgtgac cttgcactcc cctggcctga 1620  
 agctgcctct ctgcgcgcct tctactgggc tgcgtctttt ccggagcccc agcgtctctt 1680  
 gcccaaattc accgcggaaa gggccgggg cggaggtgog accggggcgcc ggcagcgcc 1740  
 acctcttggc ttctctcac aggtcggtgc gtcgcctc cgcgttcccc gcccgactgc 1800  
 cgtgcagtcc atggcttagac gcgcgcggaca ggactgtatgg cgggacccgcg ctgcccggaga 1860  
 aaggggacgga ccaatacgt tggttgctcc gcaacccttc ttgaagctgt tcagaagccg 1920  
 ctgcgcgcgg ggcccactag gcggggcggg gtgtgggacc cagcgggagc cggggcagcc 1980  
 tggctccacg gcctgtactc ggtttacacc gcggggcggg gggaggag gtcgcgtttc 2040  
 ctccgcatac agtccccgtcg ctgcggcac ctccggggcc cggcgctgg ctaatgtttt 2100  
 gtttggaaaga tcgggtggaaac ttttttaagag agtatttaaaa aaaaaaaaaa 2160  
 ttacccgggc aaccggggaa gtattgtggc ttggagttt gctaaatcca aatatgaaaa 2220  
 tcaaaaagctt tagtatttctt catttctt tctggaaat ttgcgtttaga gttttgttg 2280  
 ggccttc当地 aagctgtgtt cagagttagg agaatataatc caataaaaaga tggtttcgcc 2340  
 taccatattgg ggaagttca ccctctccct atctgaagaaa aaaaatcataa aacaaatgtc 2400  
 cccggatctt tcgatgcag tcctggagggc agggagatca ctgcctgcct ggcacacgc 2460  
 gctgggacgg ctcgtcccttc ctgcgttttgc ttttcaaac ctgcgtcttc tcccaccttgc 2520  
 ggaaggagaaa atgtgaaacc cggcagcgcc cgaccttaggc ggtcttgtgg cccggagccg 2580  
 gcccgccccc aaaaccatag acctgggtgt actgtatgtt gttgtttggg ggaccaaattt 2640  
 ttcttagagag aactagagca ctgggtgtt gttttttgtt tttgtttttgtt tttttgttgc 2700  
 tgtcgattcc cgaataaattt ttgtgttccct ttttttaaaa aaaaaaaaaa agg 2753

<210> 116  
<211> 81  
<212> DNA  
<213> Homo sapiens

<400> 116  
gttgcataat ttttctcttc ctgtttgtac ttgcgtcatg gtgcctttta tttttatata 60  
attaattaat ttattgtcta a 81

<210> 117  
<211> 558  
<212> DNA  
<213> Homo sapiens

<400> 117  
gaaagtaagt taagaagagg aaatcaaagt gagctgtcta atcttaagt aggcattaca 60  
ataacaatttgc attagtctg ccaattcttt tacaaattttt gttatctaca ctttattttct 120  
gtgtgtataatgttgc atggatcac aggctgttt tactgtgtt atgcagtagc ttgaattgtg 180  
ctataaaatgc catattttgc ctgtatatac aactataagc attctctata atcaagcaat 240  
tatgcctcta aagcacatataa aatttttttttca ttagctctgg aatattttgtg 300  
gaatttttaca tggaaatcttta tctttggaaag gtagatttttgc aatatttttagt aggattttttt 360  
gtccccatctt ccattcagct gacatggtga cttttgtcac aagtctaaa aatttagaata 420  
atcagaggc aagggggaca tcaactgcag atgttgaggaa agcctagtgc aattttagaat 480  
aaattttactt atttaaaactt cacatttgc tcaagagagca attatataattt ggttaggaatg 540  
actcatctat gggctaaa 558

<210> 118  
<211> 693  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure

<222> (209)  
 <223> a, c, g or t

<220>  
 <221> unsure  
 <222> (444)  
 <223> a, c, g or t

<400> 118  
 gtcacacaca ctcttctgac actgacgacc tggagtgtca cagaccctga aggtgaagg 60  
 ctctgtccca caagactctg ccctacttc tgatgacagc cgtacatggg taccaggca 120  
 acccacactc actcctgaca actgcagatt tggggaaactt tacatcccct cagattcact 180  
 agaacacactc ccagggctca ggaaagtgn ttagtacaaa tcacgtttat tatgaaggaa 240  
 acccatgaac agctcagtga agagagtggg gaggtgggca tgatctctga gcaccgtggg 300  
 ggctccccag cctggggct ccccaaccct gatgcccaa agttttatc taggcctcat 360  
 tacacaggtt tgattgatta agtcatttgtt catttgtat tgaacacaaa ctcacatctct 420  
 ggcacctccc aggagtgggg ggcgttgggg gggctggaaag ttccctctta attacatgg 480  
 tggttctctt ggcaacaagg tccacccta aagctacctt ggggtcccccc aagagtcacc 540  
 tcatttaggtt aaacaaatgt ggtaaaaag agttgttatg aaatcagaca cccctatcag 600  
 gaaattccaa agatthaagg agttctgtcc ctggaacagg ggacaaagac cagatgtatt 660  
 ttttattata ccacaatata aatctcttaa ttt 693

<210> 119  
 <211> 838  
 <212> DNA  
 <213> Homo sapiens

<400> 119  
 tcacacacac tcttctgata ctgacgaccc ggagtgtcac agaccctgaa ggtgaagg 60  
 tctgtcccac aagactctgc ccctacttct gatgacagcc ggtacatggg taccaggca 120  
 acccacactc actcctgaca actgcagatt tggggaaactt tacatcccct cagattcact 180  
 agaacacactc ccagggctca ggaaagtgtt ttagtacaaa tcacgtttat tatgaaggaa 240  
 acccatgaac agctcagtga agagagtggg ggaggtgggca acctgatctc tgagcaccgt 300  
 gggggctccc cagcctgggg gctcccaac cctgatgccc aaaagttttt atctaggcct 360  
 cattacacag gtatgatgtt ttaagtctt ggtcatttgtt gattgaacac aaactcaatc 420  
 tctggccctt cccaggagtggggcggtga gggggctgggg aagttctct ctaattacat 480  
 ggttggttcc tctggcaaca agctccacc ctaaagctac cttgggtcc cccaagagtc 540  
 acctcattag ggtaaacaaa tgtggtggaa aagagttttt atgaaatcag acacccctat 600  
 caggaaattt caaagattt aggagttctg tccctggaa acgggacaaa gaccagatgt 660  
 attttttattt ataccacaga agagtaataa gacgaacata tataccacg atccaaatattt 720  
 agaaacataa cataaaggtt tcttttaagc ctcttggtt ctttggaa tatatttctt 780  
 ctgcttccca gaggaaacca ttatctgtt gtttgttata tctgttaccc tggcttgc 838

<210> 120  
 <211> 551  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> (494)  
 <223> a, c, g or t

<400> 120  
 gtaacttcct taacatcaca ttgcttggag atatcagttt ggctgttcat ttctaatata 60  
 gattgttcc aaatgttca aattaaaatc tgatactta aattctgtac atagatcact 120  
 ttgggagttc tgaaatattt atgaataactt gcacccctt ccagaatcta aacttcatac 180  
 atctagtttt gttcttgtaa attgttttga ggaagtgggt gtcagtgtca caaaccagct 240  
 gttggctccaa acagacacca ggatttaggc ccattacaga gagaccaccc tgaaaatattt 300

ctacagttga gaggagctt cagtcataaa gaggaggaaa tgatacttag tttagtcac 360  
 atgtgctttg gcaagaaatt acagtcggaa ggaaggaaca gataaacatt gtgtgggtga 420  
 gccactttga agagtggta aattccctgt ggcaaaactt cctcctcccc ttttcattcc 480  
 ccattcccccc tatnttgatg ttagataggt ggcactttac tgtgtcactc cccgcctatn 540  
 ctccccacaa c 551

<210> 121  
 <211> 635  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> (540)  
 <223> a, c, g or t

<400> 121  
 gtaacttcct taacatcaca ttgttggag atatcgatgg ggctgttcat ttctaattta 60  
 gattgttcc aaatgttcag aattaaaatc tggataactt aattctgtac atagatcact 120  
 ttggagttc tggaaatattc atgaataactt gcacccccc ccagaatcta aacttcatac 180  
 atctagttt gttcttggaa attgttttga ggaagtgggt gtcagtgtca caaaccagct 240  
 gttggctccaa acagacaccca ggatggtaggc ccattacaga gagaccaccc tgaaaatatt 300  
 ctacagttga gaggagctt cagtcataaa gaggaggaaa tgatacttag tttagtcac 360  
 atgtgctttg gcaagaaatt acagtcggaa ggaaggaaca gataaacatt gtgtgggtga 420  
 ggcactttga agagtggta aattccctgt ggcaaaactt cctcctcccc ttttcattcc 480  
 ccattcccccc tatnttgatg ttagataggt ggcactttac tgtgtcactc cccgcctatn 540  
 ctccccacaa cactactgg agttaatca taagatcggt gttttttttt ttcccttaa 600  
 aagatggatc ttatccctt ttacttttat attct 635

<210> 122  
 <211> 118  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> unsure  
 <222> (99)  
 <223> a, c, g or t

<220>  
 <221> unsure  
 <222> (113)  
 <223> a, c, g or t

<400> 122  
 attcagggct cttccat taccacacta ttcaaaattt ggattctcta tggtagccaa 60  
 tgataatga gaacccaaac ataaaaaaag agaagaaana aaaaaagaaa ganaaaga 118

<210> 123  
 <211> 673  
 <212> DNA  
 <213> Homo sapiens

<400> 123  
 tttttttttt ttgagacaga gtctcgctt gtcggccagg ctggagtgca gtgggtcaat 60  
 ctcagctcac tgcaaacctc cgcctccgg gttcatgccca ttttcctgcc tcagcctccc 120  
 aagtagctga gactacgggc acacggccaca acggccgggt aattttttgt attttagta 180  
 gagacagggt ttcaccgtgt tagccaggat ggtctcgatc tcctgaccc tcgtatcgcc 240

43

tgccctcgct	tccccaaagtg	ctggggattac	aggcgtgagc	caccgagccc	agcctaaaaaa	300
ctatttttat	atattctctt	tacatctcca	taatctctgt	aggacgttagg	cattattctt	360
tttttctaga	taattgccat	aataaaattca	tggaaatcagt	gttaggaaaga	caaaaaaaaaa	420
aaaaaaaaat	tcagatgaga	aaactaaggg	acttgctcaa	agctgcacaa	ctagtaggaa	480
cagaataaacc	caattcttac	agtgtcttca	ttcaggggctc	cttcacatttt	accacactat	540
tcaaaaatttg	gattctctat	gtagccaaat	ggataaatgag	aacatgtata	aaataataaa	600
gaaataaaact	acaatcataa	aaagtaacta	aaatagccaa	ctgtcatgt	aaaggtatgt	660
agccaaactga	cag					673

```
<210> 124  
<211> 370  
<212> DNA  
<213> Homo sapiens
```

```
<400> 124
ggggagagca gagcagagcg tgaagggtgct gggaggccctg cctcaaagtggcaaaaaccc 60
acagcgcttc agagctgcgt tcatgttcta gttccctgcct ctgtgcctgagtgagaccagaa 120
aaccaggcca ctcaaaaagcc tcttgcgtgt gctctctatg aatggaggct ggggcaagggg 180
caggaccctt gggcctcagg cgagaagaag cagatttacc ctcagcttcc ttccctgtctg 240
tggcattggc tgtgccccggg attttaggag ctttgcctt ctcatccgaaagcacctc 300
taacgcgaac ctccttcgc gcantatagc tgcaaagatg aaccgtcttt gaattgtaca 360
aaagcttatgg 370
```

<210> 125  
<211> 896  
<212> DNA  
<213> *Homo sapiens*

<400> 125  
cacaagacat agcagcagag gtgcacagcg ctcagcagt acctcgcatg caccgaggct 60  
ggaccccgga accaaatctc cctggctcca cctttcacaa gctgcgcgaa ggggacaagt 120  
cctgccacct ataaggctcc gtttccatgt ctatacactg ggttccctag ctcacgggac 180  
tgtcgggta attgagttag ttaacgtcta gggagcacct gtgacatgco aacacagtgc 240  
tgtcatttct gctgttgc atttttctgc atcttttattt gtaaggattt gaaagaatgt 300  
acagttggaa acctgtatgat ctcaaggcaga aaatatcttt tcataacgct gagcatgaat 360  
gacatgagaa tccatgtctg aagtggaaatc gtatggatct gaagaatggt tgggtccagc 420  
cctggtgaa tgggtgcga aggagggagg atgagagcca gacgtttcag tctgggtgac 480  
cctgccaccc agagccacct tccattaact gagggttcca ggctccctc cggggccatt 540  
gccactaaag ctcagctaaa gtctaaaaaa ggacacattc ggagccaaago aacaggcaca 600  
gccccatgtta ggaatgtttc tgcaatggaa aaataaaaaa ccagaaaagga agtgtgtggg 660  
cctaattcgta catgttttac aacattttac tgcaatgtat gacatttctg tgagcacaag 720  
attagccctt gtatTTTTTt ctgggaagta taaaagactt tttttttctt tcttttggtt 780  
ttcaatttct ctctagagga attaaaaacc ggatatttcc atcttaaagt tcttgagcaa 840  
qtctqtcaqq qtqccatat ttcttaccc tttccctctca gcatacqaaqt qctatc 896

<210> 126  
<211> 998  
<212> DNA  
<213> *Homo sapiens*

```
<400> 126
cacaagacat agcagcagag gtgcacagcg ctcagcagt acctcgcatg caccgaggct 60
ggaccccgga accaaatctc cctggctcca cctttcacaa gctgcgcgaa ggggacaagt 120
cctgccacct ataaggctcc gtttccatgt ctatacactg gggttcctag ctcacggac 180
tgtcggggta attgagttag ttaacgtcta gggagcacct gtgacatgcc aacacagtgc 240
tgtcatttct gctgttgtcc attttctgc atcttattt gtaaggattt gaaagaatgt 300
acagttggaa acctgtatgat ctcaagcaga aaatatctt tcataaacgct gagcatgaat 360
gacatgagaa tccatgtctg aagtgaaatc gtatggatct qaaqaatqqt tggtgccacg 420
```

cctgggtgaa	tggggtgcga	aggagggagg	atgagagcca	gacgtttcag	tctgggtgac	480
cctgccaccc	agagccacct	tccattaact	gaggggtcca	gggctccctc	caggccactt	540
gccactaaag	ctcaaaaaaa	gtctaaaaaa	ggacacattc	ggagccaagc	aacaggcaca	600
gccccatgtta	ggaatgtttc	tgcaatggaa	aaatacaaaa	ccagaaaagga	agtgtgtggg	660
cctaattcgta	catgttttac	aacattttac	tgcaatgtat	gacatttctg	tgagcacaag	720
attagcccttg	gtatTTTTT	ctggaaagta	taaaagactt	ttttttctt	tcttttttgtt	780
ttcaattttct	ctctagagga	attnaaaaacc	ggatatttcc	atcttaaagt	tcttgagcaa	840
gtctgtcaag	gtgtccatat	ttcttaccct	gttcctctca	gcatcgaagt	gctatctctg	900
ttacactctat	gtttgctgtt	cacaatggag	tactaatgaa	atagcaaaat	taagctaccg	960
gcatgggtgct	aataactgaa	actaaaaatc	ggttggqg			998

<210> 127  
<211> 838  
<212> DNA  
<213> *Homo sapiens*

<220>  
<221> unsure  
<222> (100)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (112)  
<223> a, c, q or t

<220>  
<221> unsure  
<222> (134)  
<223> a, c, q or t

<220>  
<221> unsure  
<222> (151)..(152)  
<223> a, c, q or t

<220>  
<221> unsure  
<222> (161)  
<223> a, c, q or t

<220>  
<221> unsure  
<222> (164)  
<223> a, c, q or t

gtgtacagtc aggttatatac tttaaaaatac ctattcgta tatattaata tgtagaca 838

<210> 128  
<211> 5542  
<212> DNA  
<213> *Homo sapiens*

<220>  
<221> unsure  
<222> (5379)  
<223> a, c, g or t

<220>  
<221> unsure  
<222> (5382)  
<223> a, c, q or t

<220>  
<221> unsure  
<222> (5391)..(5392)  
<223> a, c, g or t

<400> 128  
cacaacccg gaagcggtc gcgtggagtg aaggcttac cactggcggt gagtttcgct 60  
ctgccttgg aataatctgc acttcccagg tccccggcgc ttetggccct gggacgtggg 120  
atccccacgg acctggaaat tctcgctgt ctteccctca cccagagcaa attgagacgt 180  
cccgagaa gaccaaggca gcctattggg cttccaggg aatcacatgg gaatcagcca 240  
cacgtcatc ctcctcacct cagaacatct cagaataact tggtaaatgg tctcccactg 300  
tgagccttag tgagccacc tgtaacataag aggctcgcc cctgagctct acaatcctgt 360  
gtccagttgt ctccctcagct gtctcctggg tcatcaaacg ggcattcccc ccttcagggt 420  
tccacagtg gcttctaaa ccccaaaca catttccttg cagtctgcac atctcagatg 480  
agggtacta cgtacttccg gaaacggccg aacttgacag catgtatTTT aaatttgtga 540  
aataaattac ttatTTTgt aagtgtttaa ttataatataa agagaaaa tttagatgtat 600  
acgtgaaaag agtgagaaga tacatcaactt ccaattttgt ttgtttgtt gttttttgt 660  
gaggaattt cacttctgt gctgaggctg gagtgcataa ccatgatatac agctcactgc 720  
aacctctgac tcctgggatc aaggattct ctttcctcag actccccgagt agctgggatc 780  
acagtcgact ttcaaaattc tttaaggatt gattccctaa gactcatgtt atgtgaagaa 840  
gcagctcaga agaggaaagg aaaggagcca ggcattggc ttccctcaggg acgcttgcact 900  
ttcaggatg tggcttataga atttctcattt gcaagatggaa aatgcctgaa cccttcgcaag 960  
agggcttgc acaggaaagt gatgttggag aactacagga acctggaaagc tggtggatatac 1020  
tcttccaaac gcatgtatgaa ggaggtcttg tcaacaggc aaggcaatac agaagtgtatc 1080  
cacacagggc catttcaaaat atatcaaaatg tattcacattt gagatTTTtg cttccaggaa 1140  
attgagaaag aaattcatgt tattgaggat cagtgtcaag aagatgaaag aaatggccat 1200  
gaagcacccca tgacaaaaat aaaaaaggttt actggtagca cagaccaaca tgatcagagg 1260  
catgctgaa acaaggctt taaatgtca gttggatcaa gcttttattt acatctgcct 1320  
gaactccaca taattcagat caaaggtaaa attggtaatc aatttgagaa gtcattaccgt 1380  
gatgtccct cggttcaac atccccaaaga atttctcta ggccccaaat ccatttttct 1440  
aataactatg ggaataattt cccgaatttt tcaactactcc cacaaaaaaca ggaatatac 1500  
atgagagaaa aatcttcca atgtatgtt gatggcaaaag cctttaattt tagtctactc 1560  
ttaaggaaac accagatacc ccattttagga gacaaacaat ataaatgtga tigtatgtggc 1620  
aagctctta atcacaagca ataccttaca tgccatcgta gatgtccacat tggagagaaa 1680  
ccttacaatg gtaatgagtg tggaaagtcc ttcaatcgagg tatcatccct tacatggccat 1740  
cgtagacttcc acactgcagt aaaatctcactt aagtgtatg agtgtggcaaa gatcttgggt 1800  
caaaattccat cccttgcataat tcataaggca attcataactg gagaaaaaacc ttacaatgtgt 1860  
aatgaatgtt acaaaatgtt taatcagcaat tcaaaacccctt cactgtcatcg tagaattcat 1920  
actggagaga aacccatcaaa atgtgaagaaa tggacaaag ttttcagtcg gaaatcaacc 1980  
cttgcgtcac ataagagaat tcaatctggaa gagaaccat acaaaatgtaa ggtttgtgac 2040  
acagcttca catgaaattt tcaatcggtca agacataaaa gaattcacac tggagagaaaa 2100  
acttacaatg gtaatgagtg tggcaagacc ttcaatcgatc agtcatccct tigtatgtccat 2160  
catagacttcc atggggaga gaaatcttacaa aatgttaagg tctgtgacaa ggcttttgcc 2220

tggaaattcac acctggtaag acatactaga attcatagt gaggaaaacc ttacaagtgt 2280  
 aatgaatgtg ggaagactt tggtcaaaaat tcagatcttc taattcataa gtcaattcat 2340  
 actggagagc aacttacaa atatgaagaa tgtgaaaagg ttttcagtt tgatcaacc 2400  
 cttgagacac ataagataat tcacaccgga gagaaacccat acaaatgtaa gttttgtgac 2460  
 aaggctttg cgtgtcattc ctatctggca aaacatacta gaattcatag tgagagaaaa 2520  
 ccttacaagt gtaatgagt cagcaagacc ttccgtctga ggtcataacct tgcagccat 2580  
 cgccaggttc atagtggta gaaacccat aagtgtaat agtgcagcaa gacccctcagt 2640  
 cagaggtcat accttcattt ccatcgtaga cttcatagtg gtgagaaacc ttacaagtgt 2700  
 aatgagtgtg gcaagaccc cagtcacaag ccattccctt ttcaccatcg tagacttcat 2760  
 actggagaga aatcttacaa atgtacgggt tgcacaagg ctttcgtcgc taattcatac 2820  
 ctggcaagac ataccagaat tcacactgca gagaaacccat acaatgtaa tgaatgtggg 2880  
 aaggcttttta atcaacaatc acaacttca cttcatcata gaattcatgc tgcccggaaaa 2940  
 ctttacaat gtgaaacatg tgacaaagtt ttcagtcgc aatcacaccc taaaagacat 3000  
 aggagaattc atcctggaaa gaaaccatac aatgttaagg tttgtgacaa gacttttggg 3060  
 agtgattcac acctgaaaca acatactggc cttcacactg gagagaaacc ttacaagtgt 3120  
 aatgagtgtg gcaaaagcct tagcaagcag tcaacactta ttcaccatca ggcagttcat 3180  
 ggtgttaggaa aacttgacta atgtatgtat tgccaaaggg tccatgttgcg cgtcacaacc 3240  
 attgcaatc attggagaat ctataatgaa taaagatcta acaatgtaa taaatgtggc 3300  
 aaattttca gacatcatc atacattgca gttcattgac acactcatac tgagagaaaa 3360  
 ctttacaat gtcatgactg tggcaaggc ttcagtcgc cttcatcata tgcacccat 3420  
 aggagaattc atacaggaga gaaacccatc atgtgtgatg attgtggca accctttact 3480  
 tcatgttccac accttcattt acatcgaga atccctactg gacagaaatc ttacaatgt 3540  
 cagaagtgtg gcaaggctt gaggccggg tcaactccctt cagaacatca gaaaattcat 3600  
 ttttggata actgttccca atgcagttag tatagcaaac catcaagcat taattgacac 3660  
 tagagtcaatg tcagcatgtt cttggatggg acttaacattt gagttgaagc ctaatttgc 3720  
 attaaatgtt ttatgtttag aggactgggc caggcacatg ggctcacacc tgaatctga 3780  
 gagctttggg aggccagcac cggtagatca cttgaactcc cagccatcaga tgatccaccc 3840  
 acctccggcct cccaaatgtc tgggattaca ggcgtgagcc tccgcacccg gccaagat 3900  
 accatttcaat gtagagatc ttcttacatg aaactgaccc aaacaatcta ataaaaatcta 3960  
 atttttactt ttaaatcaaa atgtggggg gggaaaccat ctccctctt aacatgacag 4020  
 catatatatac ttaaatatata aagcttaat atgtcaatg aatttgttctt ttacaatccc 4080  
 agcaacacaa tgaagactaa gcaaaaggaa aagaacacatc tatcaacaaa agaaaaatgt 4140  
 ctctatcctc tttatcaaca aactacatat ttacaaatgtt gaaatgttat agaacaacta 4200  
 tgataaacac agatattta tagtaaaccg aagaaagcca cccacacaga gctttaaaa 4260  
 tcatttgcag gtttaagcat agtttacaa aagtgtatc gcaatatgt cacgtccaca 4320  
 ctgtctataa aacaaaaaaa aagctaaaga ggattgtaca gttgtctatg gatatccatc 4380  
 ggggatttgtt acctgtaccg tccccccata cccaaatcg tgcacatctca actcccttag 4440  
 ctcttcagaa cccatggta tgaaaatggg gtcgtcttta ctcgggttc agattctgcc 4500  
 aatgtgttac ttccctgtt catgtgtttt cagatgcaaa accccgcacat aggagggtt 4560  
 acatgacaac tgcgttccac agatgtggg tgacaaatgtt ttcaacatcc ttctccaatg 4620  
 gcttcccaac aaacaatgtt atcaagaagc taatgcctat attaataaaa atactctgt 4680  
 ttttacatac atatgtatca gcaatgttca catattaata tataacgaat aggtat 4740  
 aagatataac ctgactgtac acacagcaat ctaaaaatcc cactctacca cacagggtt 4800  
 gtatgccatt tcacttcaac aaacataaaa agtttctgcc ctatagttt aagttaaaata 4860  
 tatccacccaa atacaacaaa ttctgtcaca tctgtaaagg tagatgacat attatacatg 4920  
 gacacaacta acaatcaaataa aacactctac atacacacca aatttttttt aaaaataaag 4980  
 gtttacactt ctattgttca aagattgtttt tcaccatatt ttaacattca tatattctgt 5040  
 atgttcatat atgtgtatgg tgggtgtttc tacataccta gggaaattcag atgttattca 5100  
 agacgcttat ctattattca tacagcagtt aatggtctc cagctctatc caggcacc 5160  
 acagcccaat aaacacacca agggacaagc caccgattag gttggaaataa gaaaaataa 5220  
 tacaaaaatg tacatttttataaaaaattt gtttagacaa agacaatctc attttttttaga 5280  
 actcccgaaac cccaaacaaa accaagaaaa ccctcaaaaat caaaacccatc aagcacacaa 5340  
 agatgtaac tctattggca acaatgattt tacatttgcnc cnccaaaatg nnctttccca 5400  
 aaaatatgtac agaaattgtt tattttataa tttttgtat atttatcttc tagatacaat 5460  
 tatatatctt gcatcaacca aataaaatccc attttaaacat ggcatacgaa ttctactgt 5520  
 caaactaaag tgtttatgtcc ct 5542

&lt;210&gt; 129

&lt;211&gt; 2948

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (389)..(412)

&lt;223&gt; a, c, g or t

&lt;400&gt; 129

gcctgtaca ggcatcgagt tagtggctc ccactcggtt ggccgcggca ggatataaaat 60  
 cccggcgcgg gccccctgctg tggctcctct ccctgcacac tcaggagagg gagcttcctt 120  
 ctaaaagacct ttctttatc tgaagccgca cagcccgca ggctgtgctg acttggtgaa 180  
 ggcagcagcg gcagagcagc ctgagcagca gcctgagcag gaaaactgtct ggggtgggga 240  
 gggcagggtgt ctgcagcccc tgagaagaag gcccctgggg gccccagacc ctggcatcg 300  
 ttccaggggag gtctctagcc gccccagccct gcaccatgtg ggcccccaagg tgcggccgg 360  
 tctggtctcg ctgggagcag gtggcagcnn nnnnnnnnnn nnnnnnnnnn nnccgggtgc 420  
 ccccgcgaaag cctggcgctg ccccccattcc gctattccca cgccggcattc tgccccaacg 480  
 acatgaatcc caacctctgg gtggacgcac agagcacctg caggccggag tggagacgg 540  
 accaggagtg tgagacccat gagaagtgtc gccccaaacgt atgtggacc aagagctgcg 600  
 tggccggcccg ctacatggac gtggaaaggga agaaggggcc agtggcattc cccaaggagg 660  
 ccacatgtga ccacttcattt tgtctgcagc agggctctga gtgtgacatc tggatggcc 720  
 agccccgtgtg taagtgcaaa gaccgctgtg agaaggaggcc cagcttacc tgcgcctcg 780  
 acggcctcac ctactataac cgctgctaca tggatgcca ggcctctcc aaaggcatca 840  
 cactggccgt tgtaacctgc cgctatcact tcacctggcc caacaccaggcccccagcac 900  
 ctgagaccac catgcacccc agcacagcc ccccaagagac ccctgagctg gacatggcg 960  
 tcctctgcgtc gtcacaaac cgtgtgcacc agtcggtcac catgggttag acagttagtt 1020  
 tcctctgtga tgggtgggc cggggccggc ctgagatcac ctgggagaag cagttggagg 1080  
 atcgggagaa tgggtcatg cggggcaacc atgtgcgtgg caacgtgggt gtcaccaaca 1140  
 ttggccagct ggtcatcata taacggccag actgcaggat gctggatct acacctgcac 1200  
 gtggccggaa cgtggctggg tggctctgaga ggctgattt cgcgtgtcg atggtcagg 1260  
 gtcacatcgac atgcagccag catcagagag cagggccaaat ggcacggctt tccggccggc 1320  
 cgagtgcctg aaggccccccag acagtggagat ctgtggcgaa gagcagaccc gtcggcactt 1380  
 cgatgcccag gccaacaact gcctgacccat cacttcggc cactggcacc gtaaccta 1440  
 ccacttttagg acctatgagg cctgcatttgc ggcctgcattt ggcggccggc tggccgcgt 1500  
 cagcctgccc gcccctgcaagg gggccctgcaa agcctacgcg cctcgctggg ctacaaacag 1560  
 ccagacggggc cagtgcoaattt ctttgtcta tgggtggctgc gagggcaatg gcaacaactt 1620  
 tgagagccgt gaggcctgtg aggagtgcgtt ccccttcccc agggggaaacc agcgcgtgtc 1680  
 ggcctgcaag cctcggoaga agctcgattt cagttctgtt cgcagcgact ttgtcatcct 1740  
 gggccgagtc tctgagctga ccgaggagcc tgactcggtt cgccgcctgg tgactgtgaa 1800  
 tgaggctcta aaggatgaga aaatgggcctt caagttctg ggccaggagc cattggaggt 1860  
 cactctgttt cacgtggact gggcatgccc ctggcccaac gtgaccgtga gcgagatgcc 1920  
 gtcacatcata atgggggagg tggacggcgatg catggccatg ctgcggcccg atagctttgt 1980  
 gggcgcatcg agtggccggcc gggtcaggaa gtttcgttag gtcacatcgaca agaagacctg 2040  
 tgacgtcttc aaggagttt ttggcttgca ctgaagcccccc ccacccctcc ctggcccttc 2100  
 cctggcccttc ttccacccat ccaccccaat gcctctcagc aaactggcg aggtcagatt 2160  
 agacaggctt gggacagccag gggaaacatca accgcacgtt cacagaaaaaa gcccacagaag 2220  
 gtcacatcgatc agcatctatt ctttgggttc aataagggtt tcacatcttt tttagctgag 2280  
 ggggacaaga ggagaagtc gttggacacat ggaagttact cgtgaccacc agcttgcata 2340  
 gatattctcc tcctcccttc actggccccc caccctggc tctccctgtt accctccct 2400  
 agccagtctc ccagcaaggg tttaagagat ggcgcgtgt tgctggtcac agaagtggtt 2460  
 gaatggattt gcttgcaag ggggttaggtg gggagagata ggagggccca ggactcatg 2520  
 ggcacacccctt cccacagccct cctcgatttc tggatggcata ggcacactcg agttaggggc 2580  
 atggggcaata gcaagctggc ggcagactcc agcccgatcat atgacttgcc ctgaatggaa 2640  
 gtcgtgaaa cgggtgcctt tgggtgggtt tggcttgcc tctggggccca ccacggcacc 2700  
 agcagaatac gtatttcctt tccttggctg cattggttt tcgtatcgatg tcagttcaac 2760  
 tcagtggatg ttctctgaat gcttaaactg tctggagttt ctgtctgtatg gatgggtgtc 2820  
 ttccatcatgc cactggcttc cttggacata gtcagacaa aagccccccggg atctgcaatc 2880  
 tctctgagtc tctgtttccatctgtctc ctgtctgccc tggataactca ctccctcacct 2940  
 tcctgcac 2948

&lt;210&gt; 130

&lt;211&gt; 3063

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 130

caggtgtccc accgtgccag akacgctgcc taaaactgctt ccagcttc ttttttttt 60  
 ccccccctct gcaataagtc tgtgatcagc cacgggacag aggcgccagc agcctgcctg 120  
 tgacaggcat caggtagct ggctccact cgggtggcgc gcccaggata taaatccggg 180  
 cgccggcccc tcgtgtgct cctccctg cacactcagg agagggagct tccttctaaa 240  
 gacctttctt ttatctgaag cgcacagcc cggcaggctg tgctgacttg gtggaggcag 300  
 cagcggcaga gcagccttag cagcagctg agcaggaaac ctgctgggt ggggagggca 360  
 ggtgtctgca gcccctgaga agaaggccct ggtgggcccc agaccctggc atcgttcag 420  
 gggaggtctc tagccgcccc agcctgcacc atgtgggccc caagggtgtc cccggtctgg 480  
 tctcgctggg agcaggtggc agcgtctgtc ctgctgtgc tactgtctgg ggtgccccgg 540  
 cgaagcctgg cgctgccccc catccgctat tcccacgccc gcatctgccc caacgacatg 600  
 aatcccaacc tctgggtgga cgcacagagc acctgcagggc gggagtgtga gacggaccag 660  
 gagtgtgaga cctatgagaa gtgtgcccc aacgtatgtg ggaccaagag ctgcgtggcg 720  
 gcccgcata tggacgtgaa agggagaag ggcccagtgg gcatgccaag ggaggccaca 780  
 tgtgaccact tcatgtgtc gcagcagggc tctgatgtg acatctgggta tgccagcccc 840  
 gtgtgtaaat gcaaagaccg ctgtgagaag gagcccagct ttacctgcgc ctccggacggc 900  
 ctcacctaact ataaccgtcg ctacatggat gccgaggcct gctccaaagg catcacactg 960  
 gcgcgtttaa cctgcgccta tcacttcacc tggcccaaca ccagcccccc agcacctgag 1020  
 accaccatgc accccagcac agcctccca gagaccctgt agctggacat ggcggtccct 1080  
 ggcgtctca acaaccgtgt gcaccagtcg gtcaccatgg gtgagacagt gagtttctc 1140  
 tgtgatgtgg tggccgccc cccggtctgag atcacctggg agaagcagtt ggaggatcgg 1200  
 gagaatgtgg tcatgcgccc caaccatgtg cgtggcaacg tgggtggcac caacattgcc 1260  
 cagctggtca tcatataaag cccagactgc aggatgtctgg gatctacacc tgacacgtgcc 1320  
 cgaacgtgg ctgggtgtcc tgagaggctg atttcccgct gtcggatgtt caggggtcat 1380  
 caggcatgca gccagcatca gagagcagcc ccaatggcac ggctttcccg gcccggcaggt 1440  
 gcctgaagcc cccagacagt gaggactgtg gcaagagagca gaccgcgtgg cacttcgtat 1500  
 cccaggccaa caactgcctg accttcaccc tccggccactg ccacccgtaaat ctcacccact 1560  
 tttagaccta tgaggcctgc atgtggcct gcatgagcgg gccgctggcc gctgtcagcc 1620  
 tggccgcctt gcagggggccc tgcaaaaggctt acggcgtctg ctgggtttac aacagccaga 1680  
 cgggcccagtgc ccagtcctt gtctatggtg gtgcggaggg caatggcaac aactttgaga 1740  
 gccgtgaggc ctgtgaggag tcgtgccccct tccccagggg gaaccagcgc tgcggccct 1800  
 gcaaggcctcg gcagaagtc gttaccagct tctgtcgca gcaactttgtc atccctggcc 1860  
 gagtcctctga gctgaccggag gagcctgact cggggccggc cctgggtact gtggatgagg 1920  
 tcctaaagga tgagaaaatg ggcctcaagt tcctggccca ggagccattt gagggtcactc 1980  
 tgcttcacgt ggactggca tggccctgc ccaacgtgac cgtgagcgtt atgcgcctca 2040  
 tcatcatggg ggaggtggac ggccgcattgg ccatgtctgg ccccgatagc ttgtggcgg 2100  
 catcgagtgc cccgggggtc aggaagctt gtcggatgtt gcaacaagaag acctgtgacg 2160  
 tcctcaagga gtttcttggc ttgcaactgaa gccccccaccc cctccctgc ccctccctgg 2220  
 ccttccttcca cctatccacc ccaatgcctc tcagccaaact gggcgagggtc agattagaca 2280  
 ggcttgggac agcaggaaaa catcaaccga cgtgtccacag aaaaagccac agaaggcttc 2340  
 agatcagcat ctattcttg ggttcaataa ggggttcata tcttttttag ctgaggggg 2400  
 caagaggaga agtcagtgaa cacatggaaat ttactcgtga ccaccagttt gtcagat 2460  
 tctccctcctc ccctcactgg ccccacaccc ctggctctcc cagtcaccct cccctagcca 2520  
 gtctccctcg aagggtttaa gagatggccg ctgtgtgtct gtcacaggaa gtgttgaatg 2580  
 gattggcttgc caaagggggtt aggtggggag agataggagg gcccagggtc tcatgggaca 2640  
 ccttccttccac agcctccctcg attgtctgtt gcaaggccca ctcggagttt ggggcatggg 2700  
 caatagcaag ctggccggcag agtccagcccc agcatatgtt gtccttgc gttggatgtc 2760  
 tggaaacgggtt gctttttgggtt ggtggctggc ttgcctctgtt ggcaccacacg gcaaccaggc 2820  
 aatacgtatt tcttccttcc tggctcattt gtttgcgtt gtagttcagt tcaactcgtt 2880  
 ggtgttttc tgaatgttta aactgtctgg agtttctgtc tgatggatgg tgcgtttca 2940  
 tatgccactg gcttccttgg acatagatca gacaaaagcc cccggatctg caatctctt 3000  
 gagtcctctgtt ttcctcatct gtcctctgtc tgccctggat actcacttcc cacccctctg 3060  
 cac 3063

&lt;210&gt; 131

&lt;211&gt; 904

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 131

ggagggccag gactcatggg acaccttcc cacagcctcc tcgattgctg tgagcagagg 60  
 ccaactcgag ttagggcat gggcaatagc aagctggcgg cagagtccag cccagcatat 120  
 gacttgcctt gaatggaaacg tgctgaaacg ggtgccttgc ggtgggtgc ggcttcctc 180  
 tgaggcccacc acggcacccag cagaatacgt atttcttc cttggctgca ctgggttgta 240  
 gatcttagttc agttcaactc agtggatgtt ctctgaatgc ttactgggtg ccaggaccac 300  
 agagagatgt tagtcactgc ccagttctta gagccccaaac acagataccc tcatcccagg 360  
 gccccccagac acacccctcc gctggactca caactgtctg gagtttctgt ctgtatggatg 420  
 gtgtgccttc atatgcact ggcttccttgc gacatagatc agacaaaagc cccgggatct 480  
 gtttggtagc aggagaaatg aagaagatg aaaaagcagg cagggaaagg ggttagtaaag 540  
 gactgagaga ggagggaggt ggctggagaa ggaaaaggaa cattgctcgat tgctcccatc 600  
 tggggcggc ctcaggaacc cacgggaacc tggaggagg ctctttgtga gacctgggca 660  
 aaggatgggg cagctcgatc atgattttt tggatggatc ggcttcctgt gtgatcctgg 720  
 ccctccggcc gctagagaga ggattggaa accccactgt cagctctgca totgccccca 780  
 ctaccctcct ctgccttatt ctgtccctgc ccctccaagc tgaagaaggt cttgtgggg 840  
 cgtcctcatt ttttcctcaa atataaggag gaagatacca attaaaagct catagtatca 900  
 atgc 904

&lt;210&gt; 132

&lt;211&gt; 442

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; unsure

&lt;222&gt; (393)

&lt;223&gt; a, c, g or t

&lt;400&gt; 132

cactaccata gtggggaggg gtattcataa ctgttggca tgccagggaa ttcaagggtcc 60  
 ccaggtagtc tacactggaa atatggagg agccttgc ccacctgata gagatgaaag 120  
 tcccaggtac ctactcaatc tctgtacac cccagcagga aagttagggt aacttggtag 180  
 aggctggta ggggtggcacc ccactcagcc tatgctggca taggcagagg tggggacaca 240  
 gttcttctg tgggtgttag ctggagtaga acagttacag tatacaagtt ttctgttcta 300  
 cttagttgcc ccttcctgg tcttttgc aaggagagga ggctttatattt atttattatt 360  
 ttattttttgc tcttactcac tggcattctg ggntgcttgt tcttcagctc caagtctgag 420  
 atatatggat ccaaaaagaaaa ac 442

&lt;210&gt; 133

&lt;211&gt; 530

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 133

aatggtcaag aaaccttgc tggtaagaaa gtttaagctt tgaaaccttgc gaacaacaac 60  
 ttcattttca catgacttgc caccttaat catctaattt accatgataa ggtgccttgg 120  
 tcaatataaa atctagaaaat atagatataat tataactctgat tattaaacttag gaattataaaa 180  
 tggtaatggat tcttgcattt aaaaatatttgc tgaaactaaa atgattaataa 240  
 cattaaataaa atcaaaaatttgc tattttttgc gtctggaaat gcattttcat attccatattt 300  
 taagtgtgtat ttaagcgact gtttccttgc atgtcattt ttttatatggaa aaatgccttc 360  
 attgtctgaa agcattttac tgagttccgc ggtttgtat tggacaaaac tgagcacaat 420  
 ttctcatct gcaaaaattt tactgctaat ttgttgcataa gtttagctaat taaataattt 480  
 ttgtataaaaaa cgaaaatataa tttgggtggaa aacgctaaac tggcagatattt 530

&lt;210&gt; 134

<211> 300  
<212> DNA  
<213> Homo sapiens

<220>  
<221> unsure  
<222> (289)  
<223> a, c, g or t

&lt;400&gt; 134

gctcgaggct gctaacagag aagccctca tcctgtacga ccagtgcaga gaaacgatcc 60  
cctcgaatgc ttccctagtgg agttaagaaa tttttgttg atcgtgcctt tgaactaagg 120  
tcatttaagt atacaacaga tgccctctg agggaaacag acttataaag tcaggaacac 180  
agaagggacc taatggttt cttaggggtgg cgcattaagt tcatacgcaat ttaactcctt 240  
tcaatgctaa acaaaaacaat gacgcattt gatgcgcaat aaaaacttnt caaaaacaatc 300

&lt;210&gt; 135

&lt;211&gt; 696

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 135

cttagaatct ttctctgcag caggctcggtt ttctccctca aattcctctg tggtttggcta 60  
agaacaatct gtttttccctaa cacttgtcaa gttgtcgaa attccataatg cccatttcattg 120  
ttctttccaa ggatttagcag agcactcctc gcttgcctt catcacactc cctccgcaca 180  
tggggtaaaa attacatttg agtggaaaccc tggctatcga tgcctgtaaa atggagaact 240  
ttggcgagac tcacttcccc gggtaaagt gggaaacagg cctaaaaaac aggctgagc 300  
atcttaatg atgtgcagaa agagaggggc ctctgcccc acggccagat gtacacagct 360  
gctaacagag aagccctca tcctgtacga ccagtgcaga gaaacgatcc cctcgaatgc 420  
ttccttagtgg agttaagaaa tttttgttg atcgtgcctt tgaactaagg tcatttaagt 480  
atacaacaga tgccctctg agggaaacag acttataaag tcaggaacac agaagggacc 540  
taatggttt cttaggggtgg cgcattaagt tcatacgcaat ttaactcctt tcaatgctaa 600  
acaaaacaat gacgcattt gatgcgcaat aaaaacttgc taaaacaatc aaaaaaaaaa 660  
aaaaaaaaaaaa aaaaaaaaaatc tgcgtcgca agaata 696

&lt;210&gt; 136

&lt;211&gt; 376

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 136

agtctctaaa aatcttgcca taggatttgg tctatacttt taaaaaccac tctttttca 60  
tgataaagcc cttcaacttg ctctaaaagg caacatagga agagagagac gatgcaggcc 120  
agtccctctcc aaataaggca aaacccagct ttatTTTtag taatgacttt cccaaactgca 180  
agagggcaca agtccatgtat ccagcattac agaaacccac caacttccag aaaagttca 240  
acaactcata aagactcaca tgtgcatgca gacacaaaaga cccatttttag ggaagaggcc 300  
ccaaagacata gtctgaagcc ccagctggc actttctcc atgacaactc ttcagccagc 360  
ctgggacagt gcaacc 376

&lt;210&gt; 137

&lt;211&gt; 1141

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 137

ttggcacgag gagtctctaa aaatcttgcc ataggatttg gtctatactt taaaaacca 60  
ctcttttttc atgataaagc cttcaactt gctctaaaag gcaacatagg aagagagaga 120  
cgatgcaggc cagtcctctc caaataaggc aaaacccagc tttatTTta gtaatgactt 180

tcccaactgc aagagggcac aagtccatga tccagcatta cagaaaaccca ccaacttcca 240  
gaaaagtttc aacaactcat aaagactcac atgtgcattgc agacacaaaag acccatttta 300  
gggaagaggc cccaaagacat agtctgaagc cccagctggg gcccatttc catgacaact 360  
cttcagccag cctggacagt gcaacccttg agtaacccca gctttgctta actgggacaa 420  
ccccaccttc ctcatcctcc tggagaatag cagttttgtt ttttcctgtat gtttgcattggg 480  
cccgacatca gaggatcctc gaaagtata ttccctggga aatctgacca aaccgtaaga 540  
acgaaaagac tattggctaa ctttgtggag accactgaga gctcagtcct cagcagagga 600  
gctggaggga aagagacatt ggaataacttc actgtgatg tccacccgt cattctttc 660  
atctgtataa actgtggctg gttcacttta accctgagca ggagctgcct atgaaaagagg 720  
atggctggag tcagatgcct gggactctt ctggtaagt cgggagctct cagtgcctgc 780  
tgactcatct gtaaaatggg gataaacgtca ggatgagcta ataacgcga agccagaaaag 840  
gctgatgcca tctctgttcc caatatgatt ttatggcct ccaagatggt gtccttagaa 900  
tctttctctg cagcaggctc gttttctcc tcaaattcct ctgtgtttgg ctaagaacaa 960  
tctgttttc ctacacttgt caagttgctc gaaaattccta atgcccattc atgttctttc 1020  
caaggatttag cagagcactc ctcgttgctc tttcatcaca ctccctccgc acatggggta 1080  
aaaattacat ttgagtggaa ccctggctat cgatgcctgt aaaatggaga ctttggcgag 1140  
a 1141

<210> 138  
<211> 14  
<212> PRT  
<213> Homo sapiens

<400> 138  
Met Gly Tyr Tyr Val Ser Asp Val Leu Leu Asp Leu Val Phe  
1 5 10

<210> 139  
<211> 18  
<212> PRT  
<213> Homo sapiens

<400> 139  
Met Phe Leu Ser Ser Val Leu Tyr Cys Ser Leu Leu Ser Tyr Leu His  
1 5 10 15  
Leu Ser

<210> 140  
<211> 449  
<212> PRT  
<213> Homo sapiens

<400> 140  
Leu Phe Pro Arg Leu Glu Tyr Gly Gly Thr Ile Leu Ala Tyr Cys Asn  
1 5 10 15

Leu His Leu Pro Gly Ser Ser Asn Pro Pro Thr Ser Ala Ser Gln Val  
20 25 30

Ala Gly Thr Arg Asp Val Cys His His Thr Trp Leu Val Cys Val Cys  
35 40 45

Val Cys Val Cys Val Cys Val Cys Val Cys Val Glu Met Arg Phe His  
50 55 60

Tyr Val Ser Gln Ala Gly Leu Glu Leu Leu Ser Ser Ser Asp Pro Pro

65	70	75	80
Ile Ser Ala Ser Gln Ser Ala Gly Ile Ile Gly Ile Ser His Cys Thr			
85		90	95
Trp Pro Trp His Asp Ser Phe Ile Ser Pro Gly Ala Glu Leu Pro Thr			
100		105	110
Phe Ala Tyr Thr Trp Pro Gly Arg Pro Lys Ile Pro Leu Thr Ile Leu			
115	120		125
Leu Leu Tyr Pro Gly Pro Gly Asp Val Leu Val Ala Phe Arg Thr Glu			
130	135		140
Leu Tyr Tyr Ala Ser Pro Ser Arg Gln Pro Gly Ala Ser Asp Thr Ala			
145	150	155	160
Arg Glu Ser Trp Gly Asn Gly Ala Val Pro Asp Phe Leu His Lys Glu			
165		170	175
Trp Leu Ile Phe Cys Pro Phe Ser Asn Gln Ser His Leu Trp Thr Thr			
180		185	190
Lys Ser Lys Trp Ala Glu Val Pro His Pro Gly Arg Arg Ala Glu Leu			
195	200		205
Pro Ala Met Lys Glu Gln Lys Ala Ala Asn Glu Asn Ser Gly Ser Val			
210	215	220	
Thr Glu Pro Ser Ser Ser Ala Ser Ile Leu His Ala Arg Trp Asp Val			
225	230	235	240
Tyr Phe Leu Ile Asn Ala Leu Ile Tyr Phe Leu Arg Gln Ser Leu Arg			
245		250	255
Ser Val Ala Gln Ala Gly Val Gln Trp Cys Ser Gly Ala Asp Leu Gly			
260		265	270
Ser Leu Gln Pro Leu Pro Pro Gly Phe Lys Ala Phe Pro Cys Leu Ser			
275	280		285
Leu Leu Ser Ser Trp Asp Tyr Arg Ser Leu Pro Pro Cys Pro Ala Asn			
290		295	300
Phe Phe Val Phe Leu Ile Glu Thr Gly Phe His His Ile Ser Gln Ile			
305	310	315	320
Ser Ile Ser Ala Pro Cys Asp Pro Pro Ala Ser Ala Ser Gln Ser Ala			
325		330	335
Gly Ile Thr Gly Met Ser His Cys Ala Gln Pro Asp Val Tyr Tyr Tyr			
340		345	350
Val Ser Gly Tyr Ile Gly Lys Gln Asp Arg Cys Tyr Leu Phe Phe Phe			
355	360	365	
Phe Phe Phe Glu Thr Glu Ser Arg Thr Val Ala Gln Ala Gly Arg			
370	375	380	
Leu Glu Arg Ser Gly Ala Ile Ser Thr Arg Arg Ser Leu Gln Pro Leu			
385	390	395	400

Pro Pro Gly Leu Lys Arg Phe Ser Cys Leu Ser Leu Leu Ser Ser Trp  
405 410 415

Asp Tyr Arg Cys Thr Pro Pro Arg Leu Ala His Phe Cys Thr Phe Ser  
420 425 430

Arg Asp Gly Val Ser Pro Cys Trp Ser Gly Trp Ser Leu Ser Pro Asp  
435 440 445

Leu

<210> 141

<211> 11

<212> PRT

<213> Homo sapiens

<400> 141

Met Ile Ala Ile Phe Leu Ser Phe Leu Phe Phe  
1 5 10

<210> 142

<211> 40

<212> PRT

<213> Homo sapiens

<400> 142

Met Asp Ala Lys Gln Asn Val Glu Lys Thr Tyr Cys Pro Ala Leu Ser  
1 5 10 15

Gly Ser Phe Gln Asp Ser Met Ile Tyr Trp Glu Arg Ser Asn Ser Leu  
20 25 30

Pro Leu Pro Ala Thr Cys Lys Pro  
35 40

<210> 143

<211> 17

<212> PRT

<213> Homo sapiens

<400> 143

Met Asp Gly Phe Val Lys Asp Gln Ala Thr Ser Ser Leu Pro Leu Ala  
1 5 10 15

Thr

<210> 144

<211> 24

<212> PRT

<213> Homo sapiens

<400> 144

Met Ala Ser Lys Pro Asn Leu Leu Tyr Ile Leu His Tyr Cys Val Pro  
1 5 10 15

Asp Thr Ala Asn Ser Ile Asn Glu  
20

<210> 145  
<211> 20  
<212> PRT  
<213> Homo sapiens

<400> 145  
Met Ser Cys Ser Ser Ser Thr Gly Ala Gly Lys Tyr Asn Leu Lys Gly  
1 5 10 15

Glu Ala Asn Leu  
20

<210> 146  
<211> 107  
<212> PRT  
<213> Homo sapiens

<400> 146  
Tyr Tyr Phe Tyr Tyr Tyr Phe Phe Leu Arg Glu Ser Leu Thr Leu Ser  
1 5 10 15

Leu Gly Leu Glu Cys Ser Gly Val Thr Met Ala His Gln Thr Ile Asn  
20 25 30

Ile Pro Gly Ser Ser Asn Ser Pro Val Val Val Gly Thr Thr Gly Ala  
35 40 45

Cys His Asn Ala Trp Leu Ile Phe Val Phe Leu Val Glu Thr Gly Leu  
50 55 60

His His Val Gly Gln Ala Gly Leu Gly Leu Leu Ala Ser Ser Asp Leu  
65 70 75 80

Ser Ala Leu Ala Ser Pro Ser Ala Gly Ile Ile Gly Leu Ser His Cys  
85 90 95

Thr Gln Gln Lys Thr Asn Phe Leu Lys Gln Asn  
100 105

<210> 147  
<211> 18  
<212> PRT  
<213> Homo sapiens

<400> 147  
Met Arg Ser Asn Phe Lys Lys Asn Ile Pro Ser Leu Glu Leu Phe Asn  
1 5 10 15

Met Ser

<210> 148  
<211> 99

55

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 148

Leu Phe Ser Phe Ala Arg Gln Asp Val Ser Met Leu Pro Arg Leu Glu  
1 5 10 15

Tyr Ser Gly Gly Ile Ile Ala His Cys Lys Leu Asp Val Leu Asp Ser  
20 25 30

Ser Glu Leu Thr Ala Leu Thr Ser Gln Ile Ala Gly Thr Thr Gly Val  
35 40 45

His His His Ala Arg Leu Ile Phe Thr Met Phe Met Gln Met Gly Ser  
50 55 60

Cys Ser Val Ala Gln Ala Cys Leu Lys Leu Leu Ala Ser Asp Asp Pro  
65 70 75 80

Pro Ala Phe Gly Ser Gln Ser Ala Gly Ile Ala Asp Val Ala His His  
85 90 95

Ala Gln Pro

&lt;210&gt; 149

&lt;211&gt; 64

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 149

Met Ser Val Ser Val Leu Pro Val Gln Pro Pro Thr Gly Leu Leu Trp  
1 5 10 15

Gly Arg Ser Pro Pro Gly Ser Pro Ala Glu Leu His Gly Leu Pro Cys  
20 25 30

Leu Thr Arg Asp Asn Arg Asp Phe Gly Ser Pro Ser Ala Asp Ala Phe  
35 40 45

Val Leu Phe Leu Ile Arg Ser Arg Thr Arg Val Gly Arg Arg Val Met  
50 55 60

&lt;210&gt; 150

&lt;211&gt; 23

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 150

Met Val Glu Ser Gly Ile Glu Pro Glu Asn Ser Asp Ser Arg Leu Ser  
1 5 10 15

Cys Phe Ser His Arg Ala Val  
20

&lt;210&gt; 151

&lt;211&gt; 27

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 151

Met Ile Gln Arg Leu Leu Arg Gly His Asn Cys Ile Ser Ile Pro Asn  
1 5 10 15Leu Phe Tyr Asn Glu Arg Ile Tyr Arg Ile His  
20 25

&lt;210&gt; 152

&lt;211&gt; 26

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 152

Met Pro Ser Ala Trp Lys Val Glu Asp Ser Gly Ile Arg Glu Arg Phe  
1 5 10 15Arg Pro Gly Glu Met Glu Gly Ser Gly Thr  
20 25

&lt;210&gt; 153

&lt;211&gt; 16

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 153

Met Gln Val Trp Ser Gly Ile Phe Pro Asp Arg Gly Cys Cys Ser Cys  
1 5 10 15

&lt;210&gt; 154

&lt;211&gt; 61

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 154

Met Phe Met Trp His Arg Val Ala Asn Cys Leu Ser Leu Phe Val Ser  
1 5 10 15Gln Asn Asp Phe Ala Asp Val Leu Gly Gln Ala Ser Pro Gly Trp Gln  
20 25 30Pro Gly Ala Ala Val Lys Phe Ser Leu Thr Asn Ser Leu Pro Pro Phe  
35 40 45Pro His His Gly Thr Leu Val Leu Cys Val Thr Thr Val  
50 55 60

&lt;210&gt; 155

&lt;211&gt; 69

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 155

57

Met Pro Cys Trp Lys Leu Leu Met Asn Arg Ala Trp Ser Leu Thr Leu  
 1               5               10               15

Gly Gly Gln Val Ile Tyr Arg Gly Asn Asp Asn Val Asn Pro Gly Pro  
 20               25               30

Trp Gly Ala Gly Ser Val Val Lys Glu Thr Gln His Thr Gln Gly Trp  
 35               40               45

Asp Pro Thr Gln Ala Lys Glu Gly Ser Thr Pro Ser Pro Asp Val Cys  
 50               55               60

Trp Asn Lys Glu Lys  
 65

<210> 156

<211> 51

<212> PRT

<213> Homo sapiens

<220>

<221> UNSURE

<222> (7)

<400> 156

Met Lys Lys Lys Arg Phe Xaa Tyr Asn Ile Lys Ile Leu Val Asn Ser  
 1               5               10               15

Trp Leu Glu Leu Tyr Ser Glu Ile Thr Val Phe Lys Lys Asp Arg Pro  
 20               25               30

Leu Pro Leu Ser Leu Trp Leu Met Ala Leu Ile Ile Thr Arg Ile Pro  
 35               40               45

Lys Met Ser  
 50

<210> 157

<211> 126

<212> PRT

<213> Homo sapiens

<400> 157

Met Lys Leu Leu Ser Arg Lys Met Trp His Ser Leu Leu Gly Gly Gly  
 1               5               10               15

Trp Gly Gly Gly Lys Arg Glu Gly Arg Cys Pro Gln Leu Pro Pro Arg  
 20               25               30

Ser Ile Asn Lys Lys Arg Ile Asp Pro Pro Ala Pro Phe Asn Ser Pro  
 35               40               45

Pro Glu Leu Pro Pro Asn Ser Val Lys Thr Cys Gly Phe Asp Tyr Ser  
 50               55               60

Asp Glu Asn Asn Gly Cys Ser Val Glu Ile Cys Arg Ala His Thr His  
 65               70               75               80

Met Ile Ser Lys Ser Asn Ser Val Ala Thr Val Pro Ile Arg Lys Thr

58

85

90

95

His Gln Ala His Lys Arg Asp Pro Phe Ile Gln Arg Ser Leu Cys Ile  
100 105 110

Pro Ile Ser Thr His Ser Thr Cys Ile Phe Lys Pro Ile Ser  
115 120 125

<210> 158  
<211> 84  
<212> PRT  
<213> Homo sapiens

<220>  
<221> UNSURE  
<222> (21)

<220>  
<221> UNSURE  
<222> (35)

<220>  
<221> UNSURE  
<222> (45)

<220>  
<221> UNSURE  
<222> (48)

<220>  
<221> UNSURE  
<222> (52)

<220>  
<221> UNSURE  
<222> (58)

<220>  
<221> UNSURE  
<222> (61)

<400> 158

Met Lys Arg Pro Pro Val Leu Leu Gln Glu Lys Pro Pro Glu Gly Asn  
1 5 10 15

Gly Ala Val Ala Xaa Trp Pro Val Val Thr Pro Arg Arg Gly Arg Gly  
20 25 30

Gln Gly Xaa Leu Gly Pro Gln Asn Ile Val Pro Val Xaa Ser Phe Xaa  
35 40 45

Ala Gly Leu Xaa Leu Leu Arg Ser Leu Xaa Gly Ser Xaa Leu Asn Ser  
50 55 60

Leu Leu Ser Ala Ser Trp Ala Val Val Ser Gly His Arg Leu Leu Leu  
65 70 75 80

Thr Ser Pro Pro

<210> 159  
<211> 23  
<212> PRT  
<213> Homo sapiens

<220>  
<221> UNSURE  
<222> (20)

<400> 159  
Met Asp Ser Ala Lys Leu Gly His Ile Cys Tyr Thr Asp Asp Thr Ser  
1 5 10 15  
  
Leu Asp Val Xaa Ala Gln Thr  
20

<210> 160  
<211> 50  
<212> PRT  
<213> Homo sapiens

<400> 160  
Met Ile Asn Phe Ala Phe Val Val Cys His Lys Thr Thr Val Thr Val  
1 5 10 15

Ser Leu Gln Leu Lys Ile Ile Gly Tyr Ala Thr Pro Glu Gly Asn Gln  
20 25 30

His Ser Lys Cys Ile Pro Ser Ile Val Phe Ile Ile Cys Glu Arg Met  
35 40 45

Ser His  
50

<210> 161  
<211> 57  
<212> PRT  
<213> Homo sapiens

<400> 161  
Met Met Pro Thr Asp Asn Leu Leu Met Ile Ser Ser Ile Leu Lys Asp  
1 5 10 15

Val Cys Lys Thr Gln Pro Leu Arg Lys Asp Ser Tyr His Cys Ser His  
20 25 30

Arg His Pro Pro Gln Ser Tyr Thr Phe Pro Phe His Pro Pro Lys Gln  
35 40 45

Ile Ile Gln His Ile Tyr Phe Ile Leu  
50 55

<210> 162  
<211> 10  
<212> PRT  
<213> Homo sapiens

60

<400> 162  
Met Gly Ser Glu Arg Gly Ile Cys Gly Tyr  
1 5 10

<210> 163  
<211> 39  
<212> PRT  
<213> Homo sapiens

<400> 163  
Met Leu Ser Arg Ser Ile Gln Asn Phe Asn Phe Lys Pro Ser Ser Arg  
1 5 10 15

Ser Leu Leu Cys Tyr Leu Pro Ser Arg Pro Thr Thr Pro Val Ile Gln  
20 25 30

Leu Ile His Ala Gln Ile Leu  
35

<210> 164  
<211> 77  
<212> PRT  
<213> Homo sapiens

<220>  
<221> UNSURE  
<222> (4)

<400> 164  
Met Ala Lys Xaa Trp Leu Val Gly Asp Val Lys Arg Arg Pro Pro Asp  
1 5 10 15

Gly Thr Ile Ser Gln Cys Gly Ala Pro Arg His Trp Ser His Ile Ala  
20 25 30

Asn Ser Asn Pro Gly Pro Ala His Gly Leu Trp Val Met Leu Ile Thr  
35 40 45

Tyr Phe Pro Arg Leu Leu Phe Pro Ser Cys Lys Val Trp Ile Thr Ile  
50 55 60

Ala Pro Val Ser Pro Gly Cys Gly Glu Asp Tyr Met Ser  
65 70 75

<210> 165  
<211> 72  
<212> PRT  
<213> Homo sapiens

<220>  
<221> UNSURE  
<222> (10)..(30)

<400> 165  
Met Leu Ile Leu Ile Ala Ser Lys Phe Xaa Xaa Xaa Xaa Xaa Xaa Xaa  
1 5 10 15

Xaa Ile Ala

61

20

25

30

Ser Ser Leu Val Ser Ser Leu Asp Leu Asn Glu Asn Ile Ser Val Tyr  
35 40 45

Phe Thr Thr Lys Tyr Glu Leu Ala Ser Gly Cys Ala Leu Phe Tyr Phe  
50 55 60

Tyr Thr Glu Cys Phe Lys Thr Asn  
65 70

&lt;210&gt; 166

&lt;211&gt; 57

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 166

Met Ser Cys Ser Val Leu Leu Arg Lys Cys Tyr Asn Arg Ala Asp Gln  
1 5 10 15

Phe His His Val Phe Ile Ile Thr Ile Leu Arg Trp Ala Leu Asn Thr  
20 25 30

Ala Gln Gln Ala Cys His Phe His Leu Ile Ser Ser Ala Thr His Phe  
35 40 45

Leu Leu Glu Leu Ala Ser Ser Asn Leu  
50 55

&lt;210&gt; 167

&lt;211&gt; 121

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 167

Met Thr Pro Leu Leu Pro Gly Gly Glu Gln Leu Arg Glu Asn Trp Arg  
1 5 10 15

Ala Gln Thr Thr Gln Leu Gly Arg Gly Gly Leu Met Glu Pro Arg  
20 25 30

Ala Leu Arg Ala Ser Pro Gly Ser Ser Pro Pro Ala Pro Pro Leu Pro  
35 40 45

Glu Ser Pro Ser Leu Ser Trp Cys Ala Gly Arg Thr Cys Ala Ala Ala  
50 55 60

Ala Gly Gly Gly Cys Thr Ser Gly Arg Glu Leu His Ala His Trp Glu  
65 70 75 80

Gln Pro Met His Arg Pro Pro Arg Cys Ala Gln Val Ser Gly Ala Ser  
85 90 95

Gly Lys Glu Glu Lys Ala Ala Val Ser Ala Leu Ser Leu Ser Leu Met  
100 105 110

Pro Val Trp Asn Pro Thr Asp Glu Leu  
115 120

<210> 168  
<211> 17  
<212> PRT  
<213> Homo sapiens

<400> 168  
Met Gly Glu Val Val Tyr Leu Phe Lys Val Pro Cys Leu Val Tyr Thr  
1 5 10 15

His

<210> 169  
<211> 47  
<212> PRT  
<213> Homo sapiens

<400> 169  
Met Ser Asn Tyr Tyr Ser Phe Ile Ile Asn Leu Asn Ser Phe Gln Ile  
1 5 10 15  
  
Arg Ala Thr Pro Ser Pro Cys Pro Leu Phe Gln Glu Tyr Phe Gly Ser  
20 25 30

Ser Trp Phe Phe Val Ser Pro Tyr Asp Asp Phe Thr Ile His Leu  
35 40 45

<210> 170  
<211> 33  
<212> PRT  
<213> Homo sapiens

<400> 170  
Met Lys Ala Ile Gln Ile Glu Glu Phe Phe Ala Ser Leu Leu Thr Gly  
1 5 10 15  
  
Pro Gly Val Leu Asp Asn Phe Leu Ser Lys Glu Glu Lys Asn Ile Phe  
20 25 30

His

<210> 171  
<211> 49  
<212> PRT  
<213> Homo sapiens

<400> 171  
Met Asp Ala Cys Leu Gly Asp Cys Gln Pro Gln Gly Arg Ser Ile Asp  
1 5 10 15  
  
Leu Lys Tyr Glu Gln Thr Asp Asp Phe Ile Ile Met Thr Leu Ala Gln  
20 25 30  
  
Asn Arg Asn Phe Gly Thr Glu Lys Asn Lys His Met Glu Phe Leu Lys  
35 40 45

Gly

<210> 172  
<211> 56  
<212> PRT  
<213> Homo sapiens

<400> 172  
Met Ser Leu Lys His Asn Asn Ile Ile Phe Tyr Ser Gln Glu Glu Leu  
1 5 10 15  
Ile His Asp Arg Ile Ile Ser Leu Ala Ile Leu Tyr Ser Tyr Phe Val  
20 25 30  
Leu Phe Ser Ser Phe Pro Leu Pro Phe Asp Asp Gln Phe Leu Tyr Lys  
35 40 45  
Thr His Arg Tyr Ile Pro Phe Ile  
50 55

<210> 173  
<211> 79  
<212> PRT  
<213> Homo sapiens

<400> 173  
Met Gly Glu Ile Gln Val Asp Leu Asn Cys His His Gln Ser Arg Pro  
1 5 10 15  
Arg Arg Arg Leu Leu Ser Arg Met Tyr Thr Trp Pro Leu Phe Ala Val  
20 25 30  
Ala Val Leu Leu Leu Arg Gly Glu Pro Ile Tyr Val Cys Leu Phe  
35 40 45  
Leu Leu Ser Leu Ala Ala Gln Gln Asn Pro Val Ile Tyr Met Asn Lys  
50 55 60  
Phe Leu Glu Val Lys Arg Asp Glu Lys Phe Thr Lys Ser Pro Thr  
65 70 75

<210> 174  
<211> 30  
<212> PRT  
<213> Homo sapiens

<400> 174  
Met Val Leu Lys Gly Met Asn Ile Thr Glu Ile Glu Cys Phe Leu Gln  
1 5 10 15  
Val Glu Arg Leu His Ser Leu Ala Gly Thr Phe Cys Pro Ile  
20 25 30

<210> 175  
<211> 73  
<212> PRT

<213> Homo sapiens

<400> 175

Met Ala Gly Ala Gly Gly Gln His His Pro Pro Gly Ala Ala Gly Gly  
1 5 10 15

Ala Ala Ala Gly Ala Gly Ala Ala Val Thr Ser Ala Ala Ala Ser Ala  
20 25 30

Gly Pro Gly Glu Asp Ser Ser Asp Ser Glu Ala Glu Gln Glu Gly Pro  
35 40 45

Gln Lys Leu Ile Arg Lys Val Ser Thr Ser Gly Gln Ile Arg Thr Lys  
50 55 60

Gly Phe Ile Met Leu Ala Arg Leu Val  
65 70

<210> 176

<211> 33

<212> PRT

<213> Homo sapiens

<220>

<221> UNSURE

<222> (22)

<400> 176

Met Glu Ile Trp Leu Leu Ala Leu Ala Phe Lys Lys Leu Ser Arg Arg  
1 5 10 15

Phe Tyr Val Gln Pro Xaa Leu Gly Thr Thr Val Leu Gly Asn Ile Arg  
20 25 30

Arg

<210> 177

<211> 22

<212> PRT

<213> Homo sapiens

<400> 177

Met Leu Phe Ser Ile Leu Pro His Lys Gly Tyr Ile Leu Lys Asp Ile  
1 5 10 15

Trp Leu Leu Asn Leu Asn  
20

<210> 178

<211> 45

<212> PRT

<213> Homo sapiens

<220>

<221> UNSURE

<222> (21)

65

&lt;400&gt; 178

Met	Leu	Leu	Lys	Gly	Ser	Asn	Ser	Lys	Val	Ser	Arg	Glu	Tyr	Ser	Ala
1				5					10					15	

Thr	Phe	His	Lys	Xaa	Thr	Glu	Gln	Ser	Ser	Arg	Asn	Phe	Phe	Arg	Ala
	20					25				30					

Gly	Ile	Ala	Leu	Pro	Pro	Arg	Ile	Leu	Thr	Arg	Phe	Ser			
	35					40				45					

&lt;210&gt; 179

&lt;211&gt; 38

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (21)...(22)

&lt;400&gt; 179

Met	Val	Ala	Thr	Leu	Trp	Leu	Asn	Asn	Phe	Phe	Arg	Asn	His	Lys	Asn
1				5					10				15		

Ala	Val	Lys	Asp	Xaa	Xaa	Lys	Arg	Leu	Lys	Ala	Ile	Leu	His	Ser	Leu
	20						25				30				

Val Tyr Met Lys Gly Asn

35

&lt;210&gt; 180

&lt;211&gt; 65

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 180

Ser	Trp	Cys	Ser	Gly	Leu	Met	Pro	Ser	Val	Leu	Asn	Ser	Ile	Ser	Cys
1			5					10				15			

Val	Pro	Gly	Lys	Gly	Arg	Gly	His	Ser	Leu	Glu	Trp	Phe	Pro	Gly	Glu
	20						25				30				

Lys	Ser	Gln	Ser	Asn	Leu	Cys	Ser	Ser	Phe	Leu	Asn	Lys	Asn	Arg	Arg
		35				40					45				

Gln	Asn	Lys	Gly	His	Arg	Asp	Lys	Gly	Leu	Leu	Thr	Arg	Leu	Ala	Asn
	50				55				60						

Gln

65

&lt;210&gt; 181

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 181

Met	Ala	Phe	Gly	Ile	Tyr	Gln	Cys	Leu	Gly	Met	Phe				
1				5				10							

<210> 182  
<211> 23  
<212> PRT  
<213> Homo sapiens

<220>  
<221> UNSURE  
<222> (21)

<400> 182  
Met Leu Leu Thr Pro Gln Pro Trp Phe Phe Lys Val Ile Phe Val Asn  
1 5 10 15  
Tyr Lys Val Arg Xaa Tyr Lys  
20

<210> 183  
<211> 29  
<212> PRT  
<213> Homo sapiens

<400> 183  
Met Tyr Lys Ile Arg Lys Ser Arg Pro Glu Glu Asp Ser His Cys Leu  
1 5 10 15  
Gln Arg Thr Ala Lys Gly Lys Gly Phe Lys Ile Phe Asn  
20 25

<210> 184  
<211> 58  
<212> PRT  
<213> Homo sapiens

<400> 184  
Met Leu Phe Leu Val Ser Ala Ala Leu Ser Ser Ser Leu Thr Asp Asn  
1 5 10 15  
Cys Arg Ala Gln Val Gly Arg Lys Asn Ser Val Cys Leu Leu Gly Ser  
20 25 30  
Ala Ser Ala Pro Val Ser Asn Thr Gly Val Thr Gly Gly Leu Leu Asn  
35 40 45  
Val Lys Tyr Lys Gly Ser Ser Phe Ser Leu  
50 55

<210> 185  
<211> 21  
<212> PRT  
<213> Homo sapiens

<400> 185  
Met Gln Cys Gln Gln Leu Gly Phe Ser Glu Ile Ile Ser Arg Leu Gln  
1 5 10 15  
Ser Asn Gln Ile Ser

<210> 186  
<211> 16  
<212> PRT  
<213> Homo sapiens

<400> 186  
Met Lys Val Glu Arg Gln Phe Glu Ala Arg Ser Leu Thr Asp Ser Leu  
1 5 10 15

<210> 187  
<211> 104  
<212> PRT  
<213> Homo sapiens

<400> 187  
Gln Ile Val Asn Phe Phe Phe Leu Arg Trp Ser Leu Ala Leu Val  
1 5 10 15

Thr Gln Ala Gly Val Gln Trp Pro Asp Leu Ser Ser Leu Gln Pro Leu  
20 25 30

Pro Pro Gly Phe Lys His Phe Ser Cys Leu Ser Leu Pro Ser Ser Ala  
35 40 45

Asp Leu Ser His Val Pro Leu Cys Pro Ala Asn Phe Ala Asn Phe Phe  
50 55 60

Val Glu Met Gly Ser His Cys Val Thr Gln Ala Gly Leu Ala Val Leu  
65 70 75 80

Ala Ala Ser Asp Ser Leu Thr Leu Ala Pro Gln Ser Ala Gly Ile Ile  
85 90 95

Gly Met Ser His Gly Ala Cys Pro  
100

<210> 188  
<211> 41  
<212> PRT  
<213> Homo sapiens

<400> 188  
Met Asp Arg Asp Leu Arg Pro Ala Pro Arg Asp Thr Lys Asp Gly Ser  
1 5 10 15

Ser Val Ala Ser Ser Pro Asn Ser Ile Cys Pro Cys Leu Ala Arg Cys  
20 25 30

Arg Glu Asp Phe Pro Thr Gln Glu Lys  
35 40

<210> 189  
<211> 39  
<212> PRT  
<213> Homo sapiens

&lt;400&gt; 189

Met Cys Leu Lys Gln Ile Leu Leu Glu Phe Pro Lys Arg Leu Asp Ile  
1 5 10 15

Ile Asn Thr Phe Met Tyr Thr Trp His Pro Thr Arg Ala Val Cys Phe  
20 25 30

Tyr Lys Lys Trp His Lys Asn  
35

&lt;210&gt; 190

&lt;211&gt; 53

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 190

Phe Ser Ser Leu Met Lys Val Ile Thr Asp Trp Ala Gln Trp Leu Thr  
1 5 10 15

Pro Val Ile Pro Val Leu Trp Glu Val Ala Val Val Gly Ala Leu Glu  
20 25 30

Ala Arg Ser Leu Arg Pro Ala Trp Glu Thr Ala Thr Pro Phe Pro Phe  
35 40 45

Ala Lys Lys Lys Lys  
50

&lt;210&gt; 191

&lt;211&gt; 44

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 191

Met Lys Ala Leu Cys Arg Leu Ser Val Leu Gln Met Leu Val Met Gly  
1 5 10 15

Met Val Val Met Arg Lys Val Met Pro Val Thr Met Arg Arg Gly Asp  
20 25 30

Ala Val Asn Ser Ile His Pro Val Leu Gly Lys Tyr  
35 40

&lt;210&gt; 192

&lt;211&gt; 53

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 192

Met Ser Leu Ser Leu Asp Ser Leu Ser Ser Ile Cys Leu Ile Val Asp  
1 5 10 15

Leu Leu Asn Phe Ser Tyr Met Glu Phe Thr Glu Arg Leu Glu Cys Glu  
20 25 30

Asp Gln His Phe Ser Ser Asn Leu Val Ser Phe Gln Ala Met Ile Ser  
35 40 45

Ser Asp Ile Leu Pro  
50

<210> 193  
<211> 124  
<212> PRT  
<213> Homo sapiens

<400> 193  
Met Arg Phe Leu Leu Pro Ala Ala Glu Lys Arg Lys Glu Asn Ser Ala  
1 5 10 15

Gly Ala Pro Leu Ala Ser Pro Arg Val Thr Thr Met Phe Ser His Asp  
20 25 30

Arg Gln Thr Gly Ala Leu Leu Leu Cys Asp Pro Pro Arg Ala Ala Glu  
35 40 45

Ser Ile Leu Ile His Leu Gly Thr Pro Ala Gln Glu Glu Pro Gly Pro  
50 55 60

Ser Pro Phe Arg Asp Val Asp Pro Leu Arg Gly Glu Phe Ser Ser Val  
65 70 75 80

Asp Ser Asp Leu Leu Arg Leu Thr Ser Leu Gly Asn Pro Ala Ile Ala  
85 90 95

Val Gly Asn Gln Val Ala Ala Trp Ala His Met Ala Ser Arg Arg Leu  
100 105 110

Arg Leu Thr Ser Lys Arg His Ser Gln Arg Arg Lys  
115 120

<210> 194  
<211> 44  
<212> PRT  
<213> Homo sapiens

<400> 194  
Met Phe Gln Arg Ile Ser Val Phe Ser Pro Ala Ile Thr Asn Lys Ser  
1 5 10 15

Ser Gly Phe Ala Val Pro Pro Cys Lys Asn Tyr Lys Met Ala Glu Asn  
20 25 30

Asn Ala Cys Phe Ile Ile Leu Val Lys Trp Ser Thr  
35 40

<210> 195  
<211> 27  
<212> PRT  
<213> Homo sapiens

<400> 195  
Met Val Arg Arg His Ile Gly Ser Ala Val Arg Trp Pro Leu Phe Phe  
1 5 10 15

70

Ser Asn Trp Ser Pro Tyr Ala Ser Cys Cys Asn  
20 25

<210> 196  
<211> 31  
<212> PRT  
<213> Homo sapiens

<400> 196  
Met Thr Lys Ile Cys Phe Leu Asn Pro Thr Leu Ala Phe Lys Lys Ile  
1 5 10 15

Gln Ser Lys Ile Phe Arg Leu Phe Leu Lys Asp Glu Lys Ala Ala  
20 25 30

<210> 197  
<211> 25  
<212> PRT  
<213> Homo sapiens

<400> 197  
Met Tyr Met His Tyr Arg Asp Arg Lys Thr Gln Phe Asn Ile Lys Asn  
1 5 10 15

Asn Ile Ser Leu Leu Asn Asn Ala Val  
20 25

<210> 198  
<211> 82  
<212> PRT  
<213> Homo sapiens

<220>  
<221> UNSURE  
<222> (80)

<400> 198  
Met Gly Met Val Ala Gly Ala Pro Thr Ala Trp Asn Pro Glu Asp Lys  
1 5 10 15

Gly Cys Ile Leu Leu Gly Arg Gln Ser Tyr Glu Leu Asp Ala Met Trp  
20 25 30

Pro Leu Gly Ala Leu Cys Arg Thr Ala Thr Ile Pro Ala Leu Leu Asp  
35 40 45

Gly Glu Ser Glu Ala Leu Arg Ser Asp Glu Asn Gln Trp Gln Ser Gln  
50 55 60

Met Tyr His Phe Ser His Thr Leu Thr Phe Phe Cys Phe Val Pro Xaa  
65 70 75 80

Phe Phe

<210> 199  
<211> 46

71

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 199

Met Pro Leu Arg Ser Lys Leu Val Asn Ile His Leu Phe Leu Thr Thr  
1 5 10 15

Ala Thr Val Phe Ser Leu Tyr Thr Asn Tyr Thr Ala Ser Lys Phe Ser  
20 25 30

Ser Phe Pro Ala Ser Asn Gln Glu Phe Asn Met Glu Val Gln  
35 40 45

&lt;210&gt; 200

&lt;211&gt; 74

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 200

Met Gln Val Gln Arg Pro Thr Ser Trp Gly His Ile Ser Thr Ala Phe  
1 5 10 15

Arg Ala Ala Pro Glu Ser Ser Arg Ser Phe Leu Ser Leu Leu Gln Thr  
20 25 30

Phe Phe Glu Lys Trp Thr Phe His Pro His Val Pro Ser Val Trp Leu  
35 40 45

Arg Lys Ser Thr Ser Gly Pro Trp Glu Gly Pro Gly Lys Pro Phe Pro  
50 55 60

Leu Ser Leu Trp Cys Val Gly Ile Asn Leu  
65 70

&lt;210&gt; 201

&lt;211&gt; 150

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 201

Met Asn Gly Lys Thr Gln Cys Lys Ala Pro Asn Asp Ser Val Arg Ser  
1 5 10 15

Val Val Gly Arg Thr Asn Thr Trp Ile His Arg Thr Glu Ile Asp Asn  
20 25 30

Leu Ala Cys Asp Glu Leu Lys Ala Asp Ile Leu Asn Trp Trp Arg Lys  
35 40 45

Glu Tyr Leu Leu Ile Ile Gly Ile Thr Ala Phe Leu Phe Leu Phe Arg  
50 55 60

Gly Ala Ile Leu Lys Asp Lys Gln Pro Thr Gly Lys Leu Gly Gln His  
65 70 75 80

Asn Thr Asn Arg Gln Cys Thr Val Glu Ile Tyr Lys Trp Pro Ile Asn  
85 90 95

Met Glu Met Phe Asp Phe Val Arg Asn Gln Gly Asn Ser Ser Glu Asn

72

100

105

110

Lys Val Leu Ser Ile Thr Arg Leu Val Lys Thr Lys Gln Asn Asn Leu  
 115                   120                   125

Ser Ile Leu Ile Pro Leu Thr Val Gly Lys Gly Leu Glu Lys Trp Val  
 130                   135                   140

Leu Leu Trp Arg Val Asn  
 145                   150

&lt;210&gt; 202

&lt;211&gt; 33

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 202

Met Ala Ala Arg Leu Pro Thr Leu Thr Arg Tyr Lys Phe Ser Ser Leu  
 1                   5                   10                   15

Gly Ser Trp Tyr Lys Ser Gln Pro Phe Gln Leu Val Met Asn Glu Arg  
 20                   25                   30

Ala

&lt;210&gt; 203

&lt;211&gt; 68

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (9)

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (23)

&lt;220&gt;

&lt;221&gt; UNSURE

&lt;222&gt; (42)

&lt;400&gt; 203

Met Gln His His Phe Ser Leu His Xaa Pro Cys Arg Asp Leu Pro Gly  
 1                   5                   10                   15

Ala Gln Lys Lys Lys Asp Xaa Ile Cys Cys Ser Gln Glu Met Leu His  
 20                   25                   30

Ile Val His Leu Pro Ala Ser Tyr Arg Xaa Tyr Lys Tyr Glu Ser Thr  
 35                   40                   45

Asn Ser Leu Gly Phe Asn Asn Val Thr Tyr Ile Tyr His Lys Val Ala  
 50                   55                   60

Ile Pro Asp His  
 65

<210> 204  
<211> 34  
<212> PRT  
<213> Homo sapiens

<400> 204  
Met Thr Ala Ser Leu Cys Leu Gln Pro Lys Pro Leu Leu Ser Thr Asn  
1 5 10 15  
Pro Tyr Ala His Gly Ala Glu Thr Ala Gln Pro Ser Val Lys Glu Pro  
20 25 30  
Gly Phe

<210> 205  
<211> 115  
<212> PRT  
<213> Homo sapiens

<400> 205  
Leu Ala Ala Ile Tyr Gly Phe Leu Ser Phe Phe Phe Phe Phe Phe  
1 5 10 15  
Ala Asp Lys Val Ser Leu Ser Pro Arg Leu Glu Ala Cys Asn Gly Thr  
20 25 30  
Ile Thr Ala His Gly Ser Phe Asp Phe Leu Gly Ser Gly Asp Pro Pro  
35 40 45  
Thr Ser Ala Ser Ala Ile Ala Gly Thr Gly Ala His His His Ile Ala  
50 55 60  
Leu Leu Phe Val Phe Phe Val Glu Val Gly Ser Arg Tyr Val Ala Gln  
65 70 75 80  
Ala Ala Leu Gln Leu Leu Arg Ser Gly Asp Leu Pro Ala Ser Ala Ser  
85 90 95  
Gln Ser Thr Gly Ile Thr Gly Thr Ser His Cys Ser Trp Pro Tyr Met  
100 105 110  
Val Leu Phe  
115

<210> 206  
<211> 28  
<212> PRT  
<213> Homo sapiens

<400> 206  
Met Phe Ala Ser Tyr Lys Leu Asn Asn Tyr Ser Tyr Pro Val Leu Val  
1 5 10 15  
Leu Tyr Ala Thr Leu Phe Pro His His Met Ile Phe  
20 25

<210> 207  
<211> 68  
<212> PRT  
<213> Homo sapiens

<400> 207  
Met Ser Leu Ser Pro Ile Tyr Phe Asn Ala Ser Phe Val Ile Ser Glu  
1 5 10 15

Tyr Met Ser Asn Phe Tyr Phe Asn Ser Thr Cys His Leu Cys Tyr Glu  
20 25 30

Asp Trp Lys Pro Ser Phe Ser Pro Gly Leu Gly Glu Ala Lys Cys Phe  
35 40 45

Thr Tyr Leu Glu Cys Leu Cys His Ser Asn Phe Gln Leu Val Cys Asn  
50 55 60

Cys Ser Phe Asn  
65

<210> 208  
<211> 39  
<212> PRT  
<213> Homo sapiens

<400> 208  
Met Asn Glu Tyr Val Asn Glu Cys Leu Asn Glu Trp Ser Gly Met Asn  
1 5 10 15

Pro Val Ser Pro Val Leu Cys Pro Pro Leu Ile His Ser Val Thr Leu  
20 25 30

Gly Arg Thr Phe Asn His Ser  
35

<210> 209  
<211> 45  
<212> PRT  
<213> Homo sapiens

<400> 209  
Met Pro Phe Pro Ser His Ser Leu Leu His Phe Phe Pro Pro Glu  
1 5 10 15

Arg Leu Ser Ser Gly Pro Tyr Glu Ile Ala Ser Ile Gln Leu Phe Phe  
20 25 30

Ile Leu Lys Gly Asp Asn Ser Ile Ser Phe Asn Leu Asn  
35 40 45

<210> 210  
<211> 70  
<212> PRT  
<213> Homo sapiens

<400> 210  
Leu Gly Ser Leu Gln Pro Pro Pro Gly Phe Lys Ala Phe Ser Cys

75

1 5 10 15

Leu Ser Leu Pro Ser Ser Trp Asp His Ala Arg Pro Pro Ala Cys Leu  
20 25 30

Ala Lys Phe Cys Ile Phe Ser Lys Asp Arg Val Ser Pro Cys Trp Pro  
35 40 45

Gly Trp Ser Ala Thr Ala Asp Leu Val Ile Arg Pro Pro Leu Pro Pro  
50 55 60

Lys Val Leu Gly Leu Gln  
65 70

&lt;210&gt; 211

&lt;211&gt; 24

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 211

Met Leu Asn Cys Leu Phe Cys Ile Leu Ala Ile Val Lys Ser Ala Thr  
1 5 10 15

Asn Arg Ile Ala Asn Val Ser Ser  
20

&lt;210&gt; 212

&lt;211&gt; 492

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 212

Thr Lys Phe Ile Lys Leu Ser Lys Tyr Lys Asn Ile Ile Lys Lys Ser  
1 5 10 15

Ala Ala Phe Leu Tyr Ile Ser Asn Tyr Leu Lys Met Lys Phe Lys Lys  
20 25 30

Ile Pro Ser Thr Ala Leu Ala Phe Glu Val Asn Leu Thr Lys Lys Leu  
35 40 45

Lys His Leu Thr Phe Tyr Ser Lys Glu His Tyr Thr Asn Ala Val Thr  
50 55 60

His Lys Trp Asn Asn Ile Thr His Ser Ala Thr Gly Ile Phe Asn Ser  
65 70 75 80

Ala Ile Phe Val Leu His Lys Met Ile Cys Arg Tyr Asn Ala Thr Ser  
85 90 95

Ile Lys Ile Pro Val Thr Tyr Phe Ile Asp Ile Phe Lys Lys Ala Tyr  
100 105 110

Leu Lys Phe Ile Trp Tyr His Lys Thr Pro Ala Ile Ala Lys Ala Ile  
115 120 125

Lys Thr Lys Glu Gly Ile Thr Pro Asp Phe Glu Ile His Tyr Lys Thr  
130 135 140

Val Val Thr Lys Thr Val Cys His Leu Asn Lys Asn Arg Asp Ile Gly  
 145                    150                    155                    160  
  
 Gln Trp Ser Arg Arg Lys Arg Glu Gln Lys Tyr Ile Ser Val Phe Thr  
 165                    170                    175  
  
 Ala Asn Ala Phe Ala Ile Gln Val Thr Phe Phe Ala Gly Lys Asn  
 180                    185                    190  
  
 Ser Ile Phe Asn Lys Ala Cys Leu Glu Asn Phe Met Ser Thr Cys Arg  
 195                    200                    205  
  
 Lys Lys Lys Ala Asp Pro His Leu Thr Pro Tyr Val Lys Ile Asn Ser  
 210                    215                    220  
  
 Lys Ala Ile Ser His Leu Asn Val Arg Pro Lys Thr Leu Lys Leu Leu  
 225                    230                    235                    240  
  
 Tyr Gln Lys Ile Glu Ala Lys Pro His Asn Ile Gly Leu Gly Ser Lys  
 245                    250                    255  
  
 Phe Phe Asp Leu Thr Ala Ile Ser Gln Asp Thr Lys Gly Arg Thr Ser  
 260                    265                    270  
  
 Gln Ser Asp His Phe Lys Leu Lys Ser Cys Cys Thr Glu Ser Asp Thr  
 275                    280                    285  
  
 Ala Thr Glu Val Thr Thr Lys Lys Arg Glu Lys Ile Phe Ala Asn Tyr  
 290                    295                    300  
  
 Thr Cys Asp Lys Gly Leu Ile Ala Lys Ile Tyr Thr Lys Leu Lys Ala  
 305                    310                    315                    320  
  
 Gln Tyr Asn Lys Asn Lys Ala Leu Leu Lys Ile Ser Ser Ala Asn Lys  
 325                    330                    335  
  
 Tyr Phe Ser Arg Lys Tyr Ile His Met Ala Asn Ala Tyr Ile Ala Lys  
 340                    345                    350  
  
 Cys Ser Met Ser Ile Ile Thr Lys Lys Ala Ser Gln Lys Arg Lys Asn  
 355                    360                    365  
  
 Lys Thr Arg Arg Tyr Gln Leu Ile Pro Val Arg Met Thr Leu Ile Lys  
 370                    375                    380  
  
 Lys Lys Lys Arg Trp Ala Arg Cys Glu Glu Lys Gly Arg Leu Ala His  
 385                    390                    395                    400  
  
 Cys Trp Phe Glu Cys Lys Ala Arg Gln Pro Leu Ala Lys Thr Lys Ala  
 405                    410                    415  
  
 Arg Phe Leu Lys Lys Leu Lys Leu Pro Cys His Thr Ala Ile Ala Leu  
 420                    425                    430  
  
 Leu Asp Ile Tyr Pro Lys Gln Ile Lys Ser Glu Ala Arg Asn Ile Cys  
 435                    440                    445  
  
 Asn Ser Val Tyr Ala Leu Phe Thr Ile Ala Lys Ile Gln Asn Lys Ser  
 450                    455                    460  
  
 Leu Thr Ser Asn Glu Ala Met Lys Thr Met Trp Ala Ile Tyr Thr Thr

77

465

470

475

480

Glu Tyr Tyr Phe Ala Asn Lys Lys Ile Pro Phe Leu  
485 490

&lt;210&gt; 213

&lt;211&gt; 37

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 213

Met Met Leu Pro Pro Asn Leu Glu Asn Thr Gly Ser His Ile Ser Pro  
1 5 10 15

Glu Trp Arg Phe Met Arg Arg Asn Thr Asn Glu Lys Lys Lys Trp Ser  
20 25 30

Met Lys Pro Glu Leu  
35

&lt;210&gt; 214

&lt;211&gt; 67

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 214

Met Cys His Glu Leu Trp Pro Cys Leu Tyr Phe Tyr Phe Asn Arg Asn  
1 5 10 15

His Leu Phe Lys Gln Lys Val Leu His Leu Asn Cys His Asn Cys Val  
20 25 30

Cys Val Ile Asn Ile Ser Tyr Phe Ile Gln Ala Gln Pro Thr Leu Ala  
35 40 45

Phe Ile Asn Ala His Asn Gln Glu Ile Asn Leu Ile Leu Thr Lys Asn  
50 55 60

Tyr Pro Ser  
65

&lt;210&gt; 215

&lt;211&gt; 12

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 215

Met Ser His Asn Ile Asp Leu Leu Gly Lys Asp Phe  
1 5 10

&lt;210&gt; 216

&lt;211&gt; 39

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 216

Met Arg Glu Cys Gly Glu Ser Ile Cys Pro Ser Leu Ala Gly His Arg

78

1

5

10

15

Leu Ser Arg Gly Ala Val Glu Val Glu Thr Thr Gln Asp Ser Glu Ser  
20 25 30

Pro Gln Val His Pro Gly Pro  
35

&lt;210&gt; 217

&lt;211&gt; 89

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 217

Met Leu Leu Ser Cys Cys Ser Gln Asn Gln Lys Met Ala Ser Arg Ser  
1 5 10 15

Ala Gln Ser Ser Gln Glu Gln Met Leu Arg Val Thr Leu Glu Ser Phe  
20 25 30

Cys Cys Leu His Ile Gln Thr Ile Thr Ile Ser Leu Ile Ser Leu Leu  
35 40 45

Tyr Ile Phe His Met Cys Pro Leu Leu Ser Ile Cys Thr Leu Ile Ser  
50 55 60

Glu Gly His Gln His Leu Ser Ser Glu Cys Leu Gln Tyr Leu Leu Thr  
65 70 75 80

Gly His Gln Ala Ser Ser Phe Ala Pro  
85

&lt;210&gt; 218

&lt;211&gt; 56

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 218

Met Asp Cys Thr Ala Val Gly Arg Gly Thr Arg Arg Ala Ser Ala Pro  
1 5 10 15

Thr Cys Glu Arg Arg Pro Arg Gly Leu Arg Cys Arg Arg Pro Val Ala  
20 25 30

Pro Pro Pro Arg Ala Leu Ser Ala Val Asn Leu Gly Arg Arg Arg Trp  
35 40 45

Gly Ser Gly Lys Arg Arg Ala Gln  
50 55

&lt;210&gt; 219

&lt;211&gt; 36

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 219

Ala Ala Ala Ala Pro Pro Ala Pro Pro His His Gly Ala Ala Ala  
1 5 10 15

Pro Pro Pro Gly Gln Leu Ser Pro Ala Ser Pro Ala Thr Ala Ala Pro  
20 25 30

Pro Ala Pro Ala  
35

<210> 220  
<211> 85  
<212> PRT  
<213> Homo sapiens

<400> 220  
Met Ala Gly Pro Arg Cys Pro Arg Lys Gly Arg Thr Asn Thr Cys Val  
1 5 10 15

Cys Ser Ala Asn Pro Leu Glu Ala Val Gln Lys Pro Leu Ala Ala Gly  
20 25 30

Pro Thr Arg Arg Gly Gly Trp Asp Pro Ala Gly Ala Gly Ala Ala  
35 40 45

Trp Leu His Gly Leu Tyr Ser Val Tyr Thr Ala Gly Gly Arg Gly Gly  
50 55 60

Arg Leu Arg Phe Leu Arg Tyr Gln Ser Arg Arg Phe Gly His Leu Arg  
65 70 75 80

Ala Pro Ala Ala Gly  
85

<210> 221  
<211> 376  
<212> PRT  
<213> Homo sapiens

<400> 221  
Met Met Ala Ser Tyr Pro Glu Pro Glu Asp Ala Ala Gly Ala Leu Leu  
1 5 10 15

Ala Pro Glu Thr Gly Arg Thr Val Lys Glu Pro Glu Gly Pro Pro Pro  
20 25 30

Ser Pro Gly Lys Gly Gly Gly Gly Gly Thr Ala Pro Glu Lys  
35 40 45

Pro Asp Pro Ala Gln Lys Pro Pro Tyr Ser Tyr Val Ala Leu Ile Ala  
50 55 60

Met Ala Ile Arg Glu Ser Ala Glu Lys Arg Leu Thr Leu Ser Gly Ile  
65 70 75 80

Tyr Gln Tyr Ile Ile Ala Lys Phe Pro Phe Tyr Glu Lys Asn Lys Lys  
85 90 95

Gly Trp Gln Asn Ser Ile Arg His Asn Leu Ser Leu Asn Glu Cys Phe  
100 105 110

Ile Lys Val Pro Arg Glu Gly Gly Glu Arg Lys Gly Asn Tyr Trp

80

115 120 125

Thr Leu Asp Pro Ala Cys Glu Asp Met Phe Glu Lys Gly Asn Tyr Arg  
 130 135 140

Arg Arg Arg Arg Met Lys Arg Pro Phe Arg Pro Pro Pro Ala His Phe  
 145 150 155 160

Gln Pro Gly Lys Gly Leu Phe Gly Ala Gly Gly Ala Ala Gly Cys  
 165 170 175

Gly Val Ala Gly Ala Gly Ala Asp Gly Tyr Gly Tyr Leu Ala Pro Pro  
 180 185 190

Lys Tyr Leu Gln Ser Gly Phe Leu Asn Asn Ser Trp Pro Leu Pro Gln  
 195 200 205

Pro Pro Ser Pro Met Pro Tyr Ala Ser Cys Gln Met Ala Ala Ala Ala  
 210 215 220

Ala Ala Ala Ala Ala Ala Ala Ala Gly Pro Gly Ser Pro Gly  
 225 230 235 240

Ala Ala Ala Val Val Lys Gly Leu Ala Gly Pro Ala Ala Ser Tyr Gly  
 245 250 255

Pro Tyr Thr Arg Val Gln Ser Met Ala Leu Pro Pro Gly Val Val Asn  
 260 265 270

Ser Tyr Asn Gly Leu Gly Gly Pro Pro Ala Ala Pro Pro Pro Pro  
 275 280 285

His Pro His Pro His Pro His Ala His His Leu His Ala Ala Ala Ala  
 290 295 300

Pro Pro Pro Ala Pro Pro His His Gly Ala Ala Ala Pro Pro Pro Gly  
 305 310 315 320

Gln Leu Ser Pro Ala Ser Pro Ala Thr Ala Ala Pro Pro Ala Pro Ala  
 325 330 335

Pro Thr Ser Ala Pro Gly Leu Gln Phe Ala Cys Ala Arg Gln Pro Glu  
 340 345 350

Leu Ala Met Met His Cys Ser Tyr Trp Asp His Asp Ser Lys Thr Gly  
 355 360 365

Ala Leu His Ser Arg Leu Asp Leu  
 370 375

&lt;210&gt; 222

&lt;211&gt; 19

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 222

Met Gln Tyr Phe Ser Leu Pro Val Leu Thr Leu Leu Met Val Pro Phe  
 1 5 10 15

Ile Phe Ile

<210> 223  
<211> 30  
<212> PRT  
<213> Homo sapiens

<400> 223  
Met Pro Leu Lys His Ile Lys Phe Lys Asn Leu Phe Leu Leu Ala Leu  
1 . . . . . 5 . . . . . 10 . . . . . 15

Glu Ile Leu Trp Asn Phe Thr Trp Asn Leu Ile Leu Gly Arg  
20 . . . . . 25 . . . . . 30

<210> 224  
<211> 52  
<212> PRT  
<213> Homo sapiens

<400> 224  
Met Leu Ile Met Lys Glu Thr His Glu Gln Leu Ser Glu Glu Ser Gly  
1 . . . . . 5 . . . . . 10 . . . . . 15

Glu Val Gly Met Ile Ser Glu His Arg Gly Gly Ser Pro Ala Trp Gly  
20 . . . . . 25 . . . . . 30

Leu Pro Asn Pro Asp Ala Gln Lys Phe Leu Ser Arg Pro His Tyr Thr  
35 . . . . . 40 . . . . . 45

Gly Met Ile Asp  
50

<210> 225  
<211> 52  
<212> PRT  
<213> Homo sapiens

<400> 225  
Met Gly Leu Asn Pro Gly Val Cys Leu Glu Pro Gln Leu Val Cys Asp  
1 . . . . . 5 . . . . . 10 . . . . . 15

Thr Asp His His Phe Leu Lys Thr Ile Tyr Lys Asn Lys Thr Arg Cys  
20 . . . . . 25 . . . . . 30

Met Lys Phe Arg Phe Trp Lys Lys Val Gln Val Phe Met Asn Ile Ser  
35 . . . . . 40 . . . . . 45

Glu Leu Pro Lys  
50

<210> 226  
<211> 19  
<212> PRT  
<213> Homo sapiens

<220>  
<221> UNSURE

<222> (14)

<220>

<221> UNSURE  
<222> (18)

<400> 226

Met Asp Asn Glu Asn Gln Asn Ile Lys Lys Glu Lys Lys Xaa Lys Lys  
1 5 10 15

Lys Xaa Lys

<210> 227

<211> 75

<212> PRT

<213> Homo sapiens

<400> 227

Phe Phe Phe Leu Arg Gln Ser Leu Ala Leu Ser Pro Arg Leu Glu Cys  
1 5 10 15

Ser Gly Ala Ile Ser Ala His Cys Lys Leu Arg Leu Pro Gly Ser Cys  
20 25 30

His Phe Pro Ala Ser Ala Ser Gln Val Ala Glu Thr Thr Gly Thr Arg  
35 40 45

His Asn Ala Arg Val Ile Phe Cys Ile Leu Val Glu Thr Gly Phe His  
50 55 60

Arg Val Ser Gln Asp Gly Leu Asp Leu Leu Thr  
65 70 75

<210> 228

<211> 95

<212> PRT

<213> Homo sapiens

<400> 228

Met Arg Arg Ala Lys Ala Pro Lys Ile Arg Gly Thr Ala Asn Ala Thr  
1 5 10 15

Asp Arg Lys Lys Ala Glu Gly Lys Ser Ala Ser Ser Arg Leu Arg Pro  
20 25 30

Arg Gly Pro Ala Leu Ala Pro Ala Ser Ile His Arg Glu His Thr Gln  
35 40 45

Glu Ala Phe Glu Trp Pro Gly Phe Leu Val Ser Leu Ala Gln Arg Gln  
50 55 60

Glu Leu Glu His Glu Arg Ser Ser Glu Thr Leu Trp Val Leu Pro Thr  
65 70 75 80

Leu Arg Gln Ala Ser Gln His Leu His Ala Leu Leu Cys Ser Pro  
85 90 95

&lt;210&gt; 229

&lt;211&gt; 98

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 229

Met Val Gly Ala Ser Pro Gly Gly Met Gly Cys Glu Gly Gly Arg Met  
1 5 10 15

Arg Ala Arg Arg Phe Ser Leu Gly Asp Pro Ala Thr Gln Ser His Leu  
20 25 30

Pro Leu Thr Glu Gly Ser Arg Ala Pro Ser Gly Pro Leu Ala Thr Lys  
35 40 45

Ala Gln Leu Lys Ser Gln Lys Gly His Ile Arg Ser Gln Ala Thr Gly  
50 55 60

Thr Ala His Val Arg Asn Val Ser Ala Met Glu Lys Tyr Lys Thr Arg  
65 70 75 80

Lys Glu Val Cys Gly Pro Asn Arg Thr Cys Leu Ser Thr Phe Tyr Cys  
85 90 95

Asn Val

&lt;210&gt; 230

&lt;211&gt; 84

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 230

Met Asp Thr Thr Asn Asn Gln Ile Asn Leu Tyr Ile His Thr Lys Phe  
1 5 10 15

Phe Leu Lys Ile Lys Val Asn Thr Ser Ile Ser Lys Arg Leu Phe Ser  
20 25 30

Pro Tyr Phe Asn Ile His Ile Phe Cys Met Phe Ile Tyr Val His Gly  
35 40 45

Gly Cys Phe Tyr Ile Pro Arg Lys Phe Arg Cys Tyr Ser Arg Arg Leu  
50 55 60

Ser Ile Ile His Thr Ala Val Lys Trp Ser Pro Ala Leu Ser Arg His  
65 70 75 80

Pro Thr Ala Gln

&lt;210&gt; 231

&lt;211&gt; 924

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 231

Gly Arg Leu Thr Phe Arg Asp Val Ala Ile Glu Phe Ser Leu Ala Glu  
1 5 10 15

Trp Lys Cys Leu Asn Pro Ser Gln Arg Ala Leu Tyr Arg Glu Val Met  
           20                 25                 30

Leu Glu Asn Tyr Arg Asn Leu Glu Ala Val Asp Ile Ser Ser Lys Arg  
           35                 40                 45

His Asp Glu Gly Gly Leu Val Asn Arg Ala Arg Gln Tyr Arg Ser Asp  
       50                 55                 60

Pro His Arg Asp Ile Ala Lys Ile Ser Lys Leu Ser His Trp Arg Phe  
       65                 70                 75                 80

Leu Leu Pro Gly Asn Ala Glu Arg Asn Ser Ala Tyr Ala Val Ser Val  
       85                 90                 95

Ser Arg Arg Glu Arg Asn Gly His Glu Ala Pro Met Thr Lys Ile Lys  
      100                105                110

Lys Leu Thr Gly Ser Thr Asp Gln His Asp His Arg His Ala Gly Asn  
      115                120                125

Lys Pro Ile Lys Asp Gln Leu Gly Ser Ser Phe Tyr Ser His Leu Pro  
      130                135                140

Glu Leu His Ile Ile Gln Ile Lys Gly Lys Ile Gly Asn Gln Phe Glu  
      145                150                155                160

Lys Ser Thr Ser Asp Ala Pro Ser Val Ser Thr Ser Gln Arg Ile Ser  
      165                170                175

Pro Arg Pro Gln Ile His Ile Ser Asn Asn Tyr Gly Asn Asn Ser Pro  
      180                185                190

Asn Ser Ser Leu Leu Pro Gln Lys Gln Glu Val Tyr Met Arg Glu Lys  
      195                200                205

Ser Phe Gln Cys Asn Glu Ser Gly Lys Ala Phe Asn Cys Ser Ser Leu  
      210                215                220

Leu Arg Lys His Gln Ile Pro His Leu Gly Asp Lys Gln Tyr Lys Cys  
      225                230                235                240

Asp Val Cys Gly Lys Leu Phe Asn His Lys Gln Tyr Leu Thr Cys His  
      245                250                255

Arg Arg Cys His Thr Gly Glu Lys Pro Tyr Lys Cys Asn Glu Cys Gly  
      260                265                270

Lys Ser Phe Ser Gln Val Ser Ser Leu Thr Cys His Arg Arg Leu His  
      275                280                285

Thr Ala Val Lys Ser His Lys Cys Asn Glu Cys Gly Lys Ile Phe Gly  
      290                295                300

Gln Asn Ser Ala Leu Val Ile His Lys Ala Ile His Thr Gly Glu Lys  
      305                310                315                320

Pro Tyr Lys Cys Asn Glu Cys Asp Lys Ala Phe Asn Gln Gln Ser Asn  
      325                330                335

85

Leu Ala Arg His Arg Arg Ile His Thr Gly Glu Lys Pro Tyr Lys Cys  
340 345 350

Glu Glu Cys Asp Lys Val Phe Ser Arg Lys Ser Thr Leu Glu Ser His  
355 360 365

Lys Arg Ile His Thr Gly Glu Lys Pro Tyr Lys Cys Lys Val Cys Asp  
370 375 380

Thr Ala Phe Thr Trp Asn Ser Gln Leu Ala Arg His Lys Arg Ile His  
385 390 395 400

Thr Gly Glu Lys Thr Tyr Lys Cys Asn Glu Cys Gly Lys Thr Phe Ser  
405 410 415

His Lys Ser Ser Leu Val Cys His His Arg Leu His Gly Gly Glu Lys  
420 425 430

Ser Tyr Lys Cys Lys Val Cys Asp Lys Ala Phe Ala Trp Asn Ser His  
435 440 445

Leu Val Arg His Thr Arg Ile His Ser Gly Gly Lys Pro Tyr Lys Cys  
450 455 460

Asn Glu Cys Gly Lys Thr Phe Gly Gln Asn Ser Asp Leu Leu Ile His  
465 470 475 480

Lys Ser Ile His Thr Gly Glu Gln Pro Tyr Lys Tyr Glu Glu Cys Glu  
485 490 495

Lys Val Phe Ser Cys Gly Ser Thr Leu Glu Thr His Lys Ile Ile His  
500 505 510

Thr Gly Glu Lys Pro Tyr Lys Cys Lys Val Cys Asp Lys Ala Phe Ala  
515 520 525

Cys His Ser Tyr Leu Ala Lys His Thr Arg Ile His Ser Gly Glu Lys  
530 535 540

Pro Tyr Lys Cys Asn Glu Cys Ser Lys Thr Phe Arg Leu Arg Ser Tyr  
545 550 555 560

Leu Ala Ser His Arg Arg Val His Ser Gly Glu Lys Pro Tyr Lys Cys  
565 570 575

Asn Glu Cys Ser Lys Thr Phe Ser Gln Arg Ser Tyr Leu His Cys His  
580 585 590

Arg Arg Leu His Ser Gly Glu Lys Pro Tyr Lys Cys Asn Glu Cys Gly  
595 600 605

Lys Thr Phe Ser His Lys Pro Ser Leu Val His His Arg Arg Leu His  
610 615 620

Thr Gly Glu Lys Ser Tyr Lys Cys Thr Val Cys Asp Lys Ala Phe Val  
625 630 635 640

Arg Asn Ser Tyr Leu Ala Arg His Thr Arg Ile His Thr Ala Glu Lys  
645 650 655

Pro Tyr Lys Cys Asn Glu Cys Gly Lys Ala Phe Asn Gln Gln Ser Gln

86

660

665

670

Leu Ser Leu His His Arg Ile His Ala Gly Glu Lys Leu Tyr Lys Cys  
 675                   680                   685

Glu Thr Cys Asp Lys Val Phe Ser Arg Lys Ser His Leu Lys Arg His  
 690                   695                   700

Arg Arg Ile His Pro Gly Lys Lys Pro Tyr Lys Cys Lys Val Cys Asp  
 705                   710                   715                   720

Lys Thr Phe Gly Ser Asp Ser His Leu Lys Gln His Thr Gly Leu His  
 725                   730                   735

Thr Gly Glu Lys Pro Tyr Lys Cys Asn Glu Cys Gly Lys Ala Phe Ser  
 740                   745                   750

Lys Gln Ser Thr Leu Ile His His Gln Ala Val His Gly Val Gly Lys  
 755                   760                   765

Leu Asp Ala Cys Asn Asp Cys His Lys Val Phe Ser Asn Ala Thr Thr  
 770                   775                   780

Ile Ala Asn His Trp Arg Ile Tyr Asn Glu Ala Arg Ser Asn Lys Cys  
 785                   790                   795                   800

Asn Lys Cys Gly Lys Phe Phe Arg His His Ser Tyr Ile Ala Val His  
 805                   810                   815

Ala His Thr His Thr Gly Glu Lys Pro Tyr Lys Cys His Asp Cys Gly  
 820                   825                   830

Lys Val Phe Ser Gln Ala Ser Ser Tyr Ala Lys His Arg Arg Ile His  
 835                   840                   845

Thr Gly Glu Lys Pro His Met Cys Asp Asp Cys Gly Lys Ala Phe Thr  
 850                   855                   860

Ser Cys Ser His Leu Ile Arg His Gln Arg Ile Pro Thr Gly Gln Lys  
 865                   870                   875                   880

Ser Tyr Lys Cys Gln Lys Cys Gly Lys Val Leu Ser Pro Arg Ser Leu  
 885                   890                   895

Leu Ala Glu His Gln Lys Ile His Phe Ala Asp Asn Cys Ser Gln Cys  
 900                   905                   910

Ser Glu Tyr Ser Lys Pro Ser Ser Ile Asn Ala His  
 915                   920

<210> 232  
<211> 322  
<212> PRT  
<213> Homo sapiens

<220>  
<221> UNSURE  
<222> (291)..(299)

<400> 232

87

Met Leu Ala Ala Cys Leu Met Thr Pro Asp His Pro Thr Ala Gly Asn  
 1 5 10 15

Gln Pro Leu Arg Thr Pro Ser His Val Pro Gly Thr Cys Arg Cys Arg  
 20 25 30

Ser Gln His Pro Ala Val Trp Ala Leu Tyr Asp Asp Gln Leu Gly Asn  
 35 40 45

Val Gly Asp His His Val Ala Thr His Met Val Gly Pro His Asp His  
 50 55 60

Ile Leu Pro Ile Leu Gln Leu Leu Pro Gly Asp Leu Arg Pro Gly  
 65 70 75 80

Pro Ala His His Ile Thr Glu Glu Thr His Cys Leu Thr His Gly Asp  
 85 90 95

Arg Leu Val His Thr Val Val Glu Gln Arg Arg Asp Arg His Val Gln  
 100 105 110

Leu Arg Gly Leu Trp Gly Gly Cys Ala Gly Val His Gly Gly Leu Arg  
 115 120 125

Cys Trp Gly Ala Gly Val Gly Pro Gly Glu Val Ile Ala Ala Gly Tyr  
 130 135 140

Asn Gly Gln Cys Asp Ala Phe Gly Ala Gly Leu Gly Ile His Val Ala  
 145 150 155 160

Ala Val Ile Val Gly Glu Ala Val Arg Gly Ala Gly Lys Ala Gly Leu  
 165 170 175

Leu Leu Thr Ala Val Phe Ala Leu Thr His Gly Leu Ala Ile Pro Asp  
 180 185 190

Val Thr Leu Arg Ala Leu Leu Gln Thr His Glu Val Val Thr Cys Gly  
 195 200 205

Leu Leu Gly His Ala His Trp Ala Leu Leu Pro Phe His Val His Val  
 210 215 220

Ala Gly Arg His Ala Ala Leu Gly Pro Thr Tyr Val Gly Ala Ala Leu  
 225 230 235 240

Leu Ile Gly Leu Thr Leu Leu Val Arg Leu Thr Leu Pro Pro Ala Gly  
 245 250 255

Ala Leu Cys Val His Pro Glu Val Gly Ile His Val Val Gly Ala Asp  
 260 265 270

Ala Gly Val Gly Ile Ala Asp Gly Arg Gln Arg Gln Ala Ser Arg Gly  
 275 280 285

His Pro Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys His Leu Leu Pro  
 290 295 300

Ala Arg Pro Glu Pro Ala Thr Pro Trp Gly Pro His Gly Ala Gly Trp  
 305 310 315 320

Gly Gly

&lt;210&gt; 233

&lt;211&gt; 503

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 233

Glu	Cys	Glu	Thr	Tyr	Glu	Lys	Cys	Cys	Pro	Asn	Val	Cys	Gly	Thr	Lys
1					5					10				15	

Ser	Cys	Val	Ala	Ala	Arg	Tyr	Met	Asp	Val	Lys	Gly	Lys	Lys	Gly	Pro
							20			25			30		

Val	Gly	Met	Pro	Lys	Glu	Ala	Thr	Cys	Asp	His	Phe	Met	Cys	Leu	Gln
							35			40			45		

Gln	Gly	Ser	Glu	Cys	Asp	Ile	Trp	Asp	Gly	Gln	Pro	Val	Cys	Lys	Cys
						50			55			60			

Lys	Asp	Arg	Cys	Glu	Lys	Glu	Pro	Ser	Phe	Thr	Cys	Ala	Ser	Asp	Gly
					65		70			75			80		

Leu	Thr	Tyr	Tyr	Asn	Arg	Cys	Tyr	Met	Asp	Ala	Glu	Ala	Cys	Ser	Lys
							85			90			95		

Gly	Ile	Thr	Leu	Ala	Val	Val	Thr	Cys	Arg	Tyr	His	Phe	Thr	Trp	Pro
					100			105			110				

Asn	Thr	Ser	Pro	Pro	Ala	Pro	Glu	Thr	Thr	Met	His	Pro	Ser	Thr	Ala
						115			120			125			

Ser	Pro	Glu	Thr	Pro	Glu	Leu	Asp	Met	Ala	Val	Pro	Ala	Leu	Leu	Asn
						130			135			140			

Asn	Arg	Val	His	Gln	Ser	Val	Thr	Met	Gly	Glu	Thr	Val	Ser	Phe	Leu
						145			150			155			160

Cys	Asp	Val	Val	Gly	Arg	Pro	Arg	Pro	Glu	Ile	Thr	Trp	Glu	Lys	Gln
						165			170			175			

Leu	Glu	Asp	Arg	Glu	Asn	Val	Val	Met	Arg	Pro	Asn	His	Val	Arg	Gly
						180			185			190			

Asn	Val	Val	Val	Thr	Asn	Ile	Ala	Gln	Leu	Val	Ile	Tyr	Asn	Ala	Arg
						195			200			205			

Leu	Gln	Asp	Ala	Gly	Ile	Tyr	Thr	Cys	Thr	Ala	Arg	Asn	Val	Ala	Gly
						210			215			220			

Val	Leu	Arg	Ala	Asp	Phe	Pro	Leu	Ser	Asp	Gly	Gln	Gly	Ser	Ser	Gly
						225			230			235			240

Met	Gln	Pro	Ala	Ser	Glu	Ser	Ser	Pro	Asn	Gly	Thr	Ala	Phe	Pro	Ala
							245		250			255			

Ala	Glu	Cys	Leu	Lys	Pro	Pro	Asp	Ser	Glu	Asp	Cys	Gly	Glu	Glu	Gln
							260		265			270			

Thr	Arg	Trp	His	Phe	Asp	Ala	Gln	Ala	Asn	Asn	Cys	Leu	Thr	Phe	Thr
-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----	-----

89

275

280

285

Phe Gly His Cys His Arg Asn Leu Asn His Phe Glu Thr Tyr Glu Ala  
 290                   295                   300

Cys Met Leu Ala Cys Met Ser Gly Pro Leu Ala Ala Cys Ser Leu Pro  
 305                   310                   315                   320

Ala Leu Gln Gly Pro Cys Lys Ala Tyr Ala Pro Arg Trp Ala Tyr Asn  
 325                   330                   335

Ser Gln Thr Gly Gln Cys Gln Ser Phe Val Tyr Gly Gly Cys Glu Gly  
 340                   345                   350

Asn Gly Asn Asn Phe Glu Ser Arg Glu Ala Cys Glu Glu Ser Cys Pro  
 355                   360                   365

Phe Pro Arg Gly Asn Gln Arg Cys Arg Ala Cys Lys Pro Arg Gln Lys  
 370                   375                   380

Leu Val Thr Ser Phe Cys Arg Ser Asp Phe Val Ile Leu Gly Arg Val  
 385                   390                   395                   400

Ser Glu Leu Thr Glu Glu Pro Asp Ser Gly Arg Ala Leu Val Thr Val  
 405                   410                   415

Asp Glu Val Leu Lys Asp Glu Lys Met Gly Leu Lys Phe Leu Gly Gln  
 420                   425                   430

Glu Pro Leu Glu Val Thr Leu Leu His Val Asp Trp Ala Cys Pro Cys  
 435                   440                   445

Pro Asn Val Thr Val Ser Glu Met Pro Leu Ile Ile Met Gly Glu Val  
 450                   455                   460

Asp Gly Gly Met Ala Met Leu Arg Pro Asp Ser Phe Val Gly Ala Ser  
 465                   470                   475                   480

Ser Ala Arg Arg Val Arg Lys Leu Arg Glu Val Met His Lys Lys Thr  
 485                   490                   495

Cys Asp Val Leu Lys Glu Phe  
 500

&lt;210&gt; 234

&lt;211&gt; 89

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 234

Met Phe Leu Phe Leu Leu Gln Pro Pro Pro Ser Ser Leu Ser Pro Leu  
 1                   5                   10                   15

Leu Pro Pro Ser Leu Pro Ala Phe Ser Ser Ser Phe Ile Ser Pro Ala  
 20                   25                   30

Thr Lys Gln Ile Pro Gly Leu Leu Ser Asp Leu Cys Pro Arg Lys Pro  
 35                   40                   45

Val Ala Tyr Glu Ser Thr Pro Ser Ile Arg Gln Lys Leu Gln Thr Val

90

50

55

60

Val Ser Pro Ala Glu Gly Cys Val Trp Gly Pro Trp Asp Glu Gly Ile  
65                   70                   75                   80

Cys Val Gly Ala Leu Arg Thr Gly Gln  
85

<210> 235

<211> 29

<212> PRT

<213> Homo sapiens

<400> 235

Met Gly Gly Ala Leu Leu Pro Pro Asp Arg Asp Glu Ser Pro Arg Tyr  
1                   5                   10                   15

Leu Leu Asn Leu Cys Asn Thr Pro Ala Gly Lys Leu Gly  
20                   25

<210> 236

<211> 38

<212> PRT

<213> Homo sapiens

<400> 236

Met Pro Ser Leu Ser Glu Ser Ile Leu Leu Ser Ser Glu Val Cys Asp  
1                   5                   10                   15

Trp Thr Lys Leu Ser Thr Ile Phe Ser Ser Ala Asn Asn Leu Leu Leu  
20                   25                   30

Ile Cys Cys Lys Val Ser  
35

<210> 237

<211> 33

<212> PRT

<213> Homo sapiens

<400> 237

Met Leu Pro Ser Gly Val Lys Lys Phe Phe Val Asp Arg Ala Phe Glu  
1                   5                   10                   15

Leu Arg Ser Phe Lys Tyr Thr Thr Asp Val Pro Leu Arg Glu Thr Asp  
20                   25                   30

Leu

<210> 238

<211> 88

<212> PRT

<213> Homo sapiens

<400> 238

Met Gin Ala Ser Pro Leu Gln Ile Arg Gln Asn Pro Ala Leu Phe Leu

91

1	5	10	15
Val Met Thr Phe Pro Thr Ala Arg Gly His Lys Ser Met Ile Gln His			
20	25	30	
Tyr Arg Asn Pro Pro Thr Ser Arg Lys Val Ser Thr Thr His Lys Asp			
35	40	45	
Ser His Val His Ala Asp Thr Lys Thr His Phe Arg Glu Glu Ala Pro			
50	55	60	
Arg His Ser Leu Lys Pro Gln Leu Gly Thr Phe Leu His Asp Asn Ser			
65	70	75	80
Ser Ala Ser Leu Gly Gln Cys Asn			
85			

1

94